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RESUMEN
INTRODUCCIÓN   
La enfermedad de Huntington (EH) es una enfermedad con herencia autosómica dominante causada 
por una mutación en el gen IT15, que codifica la proteína huntingtina (HTT). Esta proteína presenta 
una amplia expresión células de mamíferos y, aunque su función exacta no es totalmente conocida, 
se sabe que está relacionada con la modulación de procesos celulares tales como transcripción 
génica, señalización celular, metabolismo energético y neurogénesis. La mutación consiste en una 
expansión excesiva del tracto de poliglutamina localizado en el extremo N-terminal de la proteína, 
lo cual afecta a su plegamiento y actividad normales, y lleva a la alteración de una serie de procesos 
celulares y la aparición de eventos citotóxicos (ej. Formación de agregados de la huntingtina 
mutada (mHTT), desregulación transcripcional, reducción de los niveles de BDNF, excitotoxicidad, 
alteraciones en la función mitocondrial, alteraciones en la degradación proteica y autofagia, estrés 
oxidativo, activación glial y respuesta inflamatoria). Todos estos eventos son causados bien por 
pérdida o por ganandia de función de la mHTT, la cual resulta ser tóxica y provocar la degeneración 
de subpoblaciones neuronales específicas localizadas en los ganglios basales, especialmente las 
neuronas medianas espinosas, y también en la corteza cerebral (neuronas piramidales). Además, en 
fases avanzadas de la enfermedad otras regiones cerebrales se ven también afectadas, tales como la 
substantia nigra, el tálamo y el hipocampo.
Dependiendo de la longitud de la cola de poliglutamina, losprimeros síntomas aparecen generalmente 
como problemas cognitivos y psiquiátricos, al os que les siguen los trastornos motores característicos, 
los cuales tienen dos componentes principales: en primer lugar movimientos involuntarios o corea, 
los cuales comienzan temprano en el transcurso de la enfermedad; y en segundo lugar la incapacidad 
para realizar movimientos voluntarios, que incluye bradicinesia y falta de coordinación. Los 
trastornos mentales acaban llevando a demencia en fases avanzadas, y los síntomas se desarrollan 
inexorablemente hasta el desenlace fatal de la enfermedad, generalmente 15-20 años después de la 
aparición de los síntomas motores.
Actualmente no existe ningún tratamiento efectivo para la EH, y los pocos tratamientos aprobados 
están centrados en el control de los síntomas. No existen aún terapias efectivas dirigidas a retrasar o 
detener el proceso degenerativo. Por este motivo, muchos compuestos centrados en la prevención 
o reducción del daño cerebral en pacientes de EH están ahora en investigación.
En las últimas décadas los compuestos cannabinoides sido evaluados como potenciales agentes 
neuroprotectores en muchas enfermedades neurodegenerativas, entre ellas la EH. El denominado 
sistema cannabinoide endógeno SCE está implicado en una serie de procesos fisiológicos que 
ayudan al mantenimiento o la recuperación de la homeostasis e integridad celular ante un daño 
agudo o crónico. Por lo tanto, los diferentes elementos del SCE (receptores cannabinoides, 
endocannabinoides y sus enzimas de síntesis y degradación) ofrecen nuevas e interesantes dianas 
terapéuticas para el desarrollo de fármacos neuroprotectores. Los pacientes de EH presentan 
alteraciones en varios componentes de este sistema a lo largo de la enfermedad, principalmente una 
reducción en la señalización de receptores CB
1
 en las neuronas medianas espinosas del estriado (lo 
cual es un evento temprano en la patología) y un aumento en los niveles de CB
2
 en células gliales del 
estriado y la corteza cerebral (lo cual está relacionado con una respuesta inflamatoria). También se 
han descrito alteraciones en los niveles de endocannabinoides y enzimas de síntesis y degradación, 
que pueden alterar las acciones de los endocannabinoides sobre sus receptores. Por lo tanto, la 
manipulación farmacológica de este sistema podría ser terapéuticamente relevante en la EH, debido 
a la capacidad de los cannabinoides para actuar sobre muchas vías de señalización  implicadas 
en la supervivencia celular, y por tanto limitar los distintos eventos citotóxicos que se dan en la 
enfermedad. De hecho, cannabinoides con distintos perfiles farmacológicos, tales como agonistas 
CB
1
, agonistas CB
2
 y cannabinoides antioxidantes, han sido ya estudiados en modelos preclínicos 
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que representan distintos eventos patogénicos que ocurren en los cerebros de los pacientes de EH 
(ej. Excitotoxicidad, inflamación y estrés oxidativo) y han mostrado resultados muy prometedores. 
OBJETIVOS
La hipótesis principal de esta Tesis Doctoral es que compuestos fitocannabinoides, de manera 
individual o en combinación, y con un perfil farmacológico de amplio espectro, pueden representar 
una opción prometedora para abordar los múltiples procesos citotóxicos implicados en la patología 
de la EH.
Para demostrar esta hipótesis, el objetivo global de esta Tesis es progresar en el desarrollo de una 
terapia neuroprotectora basada en fitocannabinoides en la EH. Este objetivo global será dividido en 
3 objetivos específicos, que serán presentados como 3 capítulos diferentes:
Capítulo 1: Evaluación preclínica de fitocannabinoides como agentes modificadores de la 
enfermedad en modelos animales de la EH.
En este capítulo evaluamos en primer lugar la combinación 1:1, equivalente al Sativex, de extractos 
botánicos enriquecidos en Δ9-THC and CBD, en un modelo de degeneración estriatal aguda en 
rata, generado por la inducción de eventos inflamatorios y activación de la apoptosis provocada 
por la inyección intraestriatal de malonato. El tratamiento con Sativex redujo el volumen de edema 
estriatal generado tras la lesión, atenuó la muerte celular y activación glial en el estriado y revertió la 
expresión de marcadores pro-inflamatorios. También pudimos demostrar que este efecto protector 
incluía la activación de receptores CB
1
, pero sobre todo CB
2
.
A continuación, evaluamos el tratamiento crónico con la misma combinación de fitocannabinoides 
en el modelo transgénico de ratón R6/2. El tratamiento con Sativex no produjo una mejoría en la 
coordinación motora pero sí atenuó el grado de “clasping”, lo cual es un marcador de distonia, en 
estos animales. También atenuó las deficiencias metabólicas observadas en los cerebros de estos 
animales, e indujo mejoría en algunos marcadores metabólicos relacionados con déficit energético, 
fallo mitocondrial y deterioro neuronal.
Por último, analizamos el potencial neuroprotector del fitocannabinoide CBG en un modelo agudo 
en ratón que cursa con activación glial y daño oxidativo, producido por la inyección de 3NP. El 
tratamiento con CBG mejoró parcialmente varios déficit motores causados por la toxina, impidió casi 
con totalidad la neurodegeneración estriatal, atenuó la activación microglial y revirtió los cambios 
en marcadores de inflamación y oxidación en los estriados de estos animales. A continuación, 
evaluamos los efectos del tratamiento crónico con CBG en ratones R6/2. El tratamiento produjo 
una pequeña mejoría en la coordinación motora y redujo el número de agregados estriatales de 
mHTT en este modelo. Asimismo, revirtió el incremento en  la expresión génica de CB
2
 y reducción 
BDNF y PPARγ, así como de otros marcadores de la patología. Puesto que el CBG presenta muy 
baja afinidad por receptores cannabinoides, sugerimos que la activación del receptor nuclear PPARγ 
podría explicar en parte este efecto neuroprotector.
Los resultados de este Capítulo están incluidos en las siguientes publicaciones:
 Valdeolivas, S., Satta, V., Pertwee, R.G., Fernandez-Ruiz, J. & Sagredo, O. (2012) Sativex-like 
combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory 
model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci, 3, 400-406.
 Valdeolivas, S., Sagredo, O., Delgado, M., Pozo, M.A. & Fernandez-Ruiz, J. (2017) Effects of a 
Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental 
Model of Huntington’s Disease. Int J Mol Sci, 18.
 Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M.L., Munoz, E. & Sagredo, O. (2015) 
Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 
3-nitropropionate-lesioned mice. Neurotherapeutics, 12, 185-199.
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Capítulo 2: Evaluación del Sativex en un ensayo clínico piloto con pacientes de EH.
Los resultados preclínicos obtenidos de modelos celulares y animales sobre la evaluación del 
potencial neuroprotector de los cannabinoides en EH apoyan la validación de formulaciones 
de cannabinoides con un amplio espectro farmacológico en estudios clínicos. En este Capítulo, 
presentamos los resultados de un ensayo piloto en fase II, doble ciego, aleatorizado, cruzado y 
controlado con placebo en pacientes de EH tratados con Sativex, que se llevó a cabo en el Hospital 
Ramón y Cajal de Madrid. El objetivo principal del estudio, que era la seguridad y tolerabilidad del 
Sativex por los pacientes se cumplió, pero no obstante el tratamiento ofreció ninguna mejoría a nivel 
motor ni cognitivo. Además tampoco se observaron cambios en los biomarcadores examinados con 
el tratamiento, excepto un incremento en los niveles de expresión génica de CB
2
 en los linfocitos 
de los pacientes, durante la fase de tratamiento con Sativex, lo cual se interpretó como una posible 
respuesta protectora y antiinflamatoria. A la vista de los resultados, proponemos la realización de 
estudios adicionales, con un mayor número de pacientes y en particular con una duración mayor del 
tratamiento para confirmar si el Sativex puede producir un beneficio clínico en los pacientes de EH.
Los resultados de este Capítulo están incluidos en la siguiente publicación:
 Lopez-Sendón Moreno, J.L., Garcia Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., Garcia 
Ribas, G., Alonso Arias, M.A., Garcia de Yebenes, M.J., Tolon, R.M., Galve-Roperh, I., Sagredo, O., 
Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., Garcia-Bermejo, M.L., Fernandez Ruiz, J., Guzman, M. 
& Garcia de Yebenes Prous, J. (2016) A double-blind, randomized, cross-over, placebo-controlled, 
pilot trial with Sativex in Huntington’s disease. J Neurol, 263, 1390-1400.
Capítulo 3: Estudio de algunos de los mecanismos implicados en el efecto de compuestos 
cannabinoides en modelos experimentales de EH.
En este capítulo nos propusimos estudiar con profundidad algunos de los posibles mecanismos 
implicados en el efecto protector de los cannabinoides. Nos centramos principalmente en el efecto 
antioxidante, y la posible activación de NRF2 y la consecuente respuesta antioxidante. Con este 
objetivo, evaluamos la combinación equivalente al Sativex de extractos botánicos de Δ9-THC and 
CBD, en comparación con estos fitocannabinoides por separado, en un modelo celular de EH de 
neuroblastos de ratón (células STHdhQ7/Q7 and STHdhQ111/Q111). En primer lugar se expuso a estas células 
a agentes que producían distintos tipos de daño celular que ocurren en el cerebro de pacientes de 
EH: glutamato (excitotoxicidad), malonato (daño mitocondrial) y peróxido de hidrógeno (H
2
O
2
, daño 
oxidativo). En todos los casos esta exposición llevó una elevada muerte celular, pero sólo se observó 
un efecto protector de los fitocannabinoides ante el daño por peróxido de hidrógeno. CBD y, sobre 
todo, Sativex, protegieron ambas líneas celulares frente ante la exposición a H
2
O
2
, aunque este 
efecto era mucho más modesto en las células STHdhQ111/Q111 que en las STHdhQ7/Q7. Junto a este efecto 
neuroprotector se observó un incremento en la expresión génica de la enzima HO-1, por lo que a 
continuación estudiamos el posible papel de la vía NRF2/ARE en esta acción de los fitocannabinoides. 
Nuestros resultados no han podido confirmar la participación de NRF2/ARE en este proceso, por lo 
que serán necesarios más experimentos para descifrar los posibles mecanismos implicados en esta 
neuroprotección a las células estriatales ante el daño oxidativo ejercida por el Sativex y CBD.
El segundo objetivo específico en este capítulo consistía en estudiar si los endocannabinoides, en 
particular el 2-AG, proporcionan neuroprotección en la EH, utilizando el modelo de malonato. A 
diferencia de lo esperado, observamos que la inhibición de la MAGL, lejos de resultar neuroprotectora, 
agravaba el daño estriatal, mientras que la inhibición de la DAGL producía el efecto opuesto. Pudimos 
explicar este inesperado resultado mediante la regulación a la alza de la enzima COX-2 inducida por 
el malonato, la cual contribuía a la conversión del 2-AG en prostaglandin-gliceril-esters, derivados 
de este endocannabinoide que son altamente neurotóxicos. Utilizando la línea celular M-213, 
demostramos que la inducción de COX-2 y consiguiente generación de estos derivados oxigenados 
del 2-AG contribuía a la muerte neuronal, mientras que la inhibición de COX-2 o el bloqueo de las 
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dianas de estos derivados reducía la neurotoxicidad.
Los resultados de este Capítulo están incluidos en las siguientes publicaciones:
 Valdeolivas, S., Rodriguez-Cueto, C. Sagredo, O. and Fernández-Ruiz, J. Study of the 
involvement of NRF2-KEAP1/ARE signaling in the antioxidant effect of phytocannabinoids against 
hydrogen peroxide in a cellular model of Huntington’s disease. (Datos preliminares no publicados).
 Valdeolivas, S., Pazos, M.R., Bisogno, T., Piscitelli, F., Iannotti, F.A., Allara, M., Sagredo, O., Di 
Marzo, V. & Fernandez-Ruiz, J. (2013) The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, 
rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a 
potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death Dis, 4, e862.
CONCLUSIONES
Los resultados obtenidos en esta Tesis Doctoral nos permiten concluir que:
 1. El tratamiento con CBG protege a las neuronas estriatales y mejora el deterioro neurológico 
en el modelo de daño oxidativo estriatal por 3NP, actuando específicamente en la mejora de la 
respuesta antioxidante y la reducción de la activación glial. Estos efectos no están mediados por 
receptores cannabinoides, y podrían deberse a una acción sobre receptores PPAR.
 2. El CBG también proporciona neuroprotección en el modelo transgénico R6/2, en este caso, 
mediante la reducción de la acumulación de agregados de huntingtina, y actuando de manera positiva 
en la expresión de determinadas neurotrofinas y genes relacionados con desregulación transcripcional 
en la EH. De nuevo, estos efectos eran independiendtes de receptores cannabinoides. 
 3. La combinación equivalente al Sativex de extractos botánicos de fitocannabinoides protege 
a las células estriatales en el modelo de malonato de inflamación aguda y apoptosis, actuando 
específicamente sobre la reducción de la glía reactiva y mejorando el apoyo neurotrófico. Este efecto 
implica la activación de receptores CB
1
 y CB
2
.
 4. La combinación equivalente al Sativex de extractos botánicos de fitocannabinoides también 
mejora algunas alteraciones motoras y corrige deficiencias metabólicas y marcadores relacionados 
con déficit energético y daño mitocondrial en el modélo transgénico de EH R6/2.
 5. El Sativex es seguro y bien tolerado por pacientes de EH, como muestran los resultados de 
un ensayo clínico piloto en fase II realizado en una cohorte de pacientes sintomáticos tempranos.
 6. No obstante, el Sativex no ha demostrado ningún benedicio clínico en escalas motoras 
ni cognitivas, así como en biomarcadores de la enfermedad, salvo el aumento en la expresión de 
receptores CB
2
, lo cual podría suponer una respuesta protectora. El corto tiempo de tratamiento 
aplicado en este ensayo sugiere la necesidad de establecer periodos de tratamiento más largos para 
futuros estudios clínicos.
 7. Utilizando una estrategia in vitro, demostramos (células STHdhQ7/Q7 y STHdhQ111/Q111), 
demostramos que los efectos neuroprotectores ante el daño oxidativo ejercidos por el CBD en forma 
de extracto botánico, en solitario o combinado con Δ9-THC como en el Sativex, podrían implicar una 
cierta activación de la señalización mediada por NRF2, aunque parece necesaria la contribución de 
otros mecanismos celulares adicionales.
 8. Al contrario de lo esperado, las células STHdhQ111/Q111 no son más vulnerables al daño 
oxidativo, y que la acción de la vía de señalización activada por NRF2 en estas células es limitada.
 9. La inhibición de la biosíntesis de 2-AG en ratas lesionadas con malonato, al contrario de 
lo esperado, previene la degeneración de las neuronas estriatales, mientras que la inhibición de la 
degradación de 2-AG agrava el daño estriatal.
Resumen
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 10. Utilizando este modelo in vivo y una estrategia in vitro (células M-213) demostramos 
que este resultado podía explicarse por la regulación a la alza de la enzima COX-2, el aumento en los 
niveles de 2-AG y su transformación mediante esta enzima en prostaglandil-gliceril-esters, los cuales 
son altamente neurotóxicos.
Todos estos resultados apoyan el potencial neuroprotector de compuestos fitocannabinoides con un 
amplio espectro farmacológico en modelos experimentales de EH. Estos hallazgos preclínicos sugieren 
la necesidad de realizar más estudios para dilucidar los mecanismos de neuroprotección de los 
fitocannabinoides, así como la necesidad de evaluar formulaciones multi-diana de fitocannabinoides, 
como el Sativex en ensayos clínicos con periodos de tratamiento más prolongados.
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SUMMARY
INTRODUCTION
Huntington’s disease is an inherited autosomal dominant disease caused by a mutation in the IT15 
gene that encodes the protein huntingtin (HTT). This protein is widely expressed in mammalian cells 
and, although its exact function still remains unclear, it appears to be related to the modulation 
cell processes such as gene transcription, cell signaling, energy metabolism and neurogenesis. The 
mutation consists in an excessive expansion of the polyglutamine tract of the protein located in its 
N-terminal domain, which alters protein folding and activity and leads to the disturbance of many 
cellular processes and the appearance of many cytotoxic events (e.g. aggregation of mutant HTT 
(mHTT), transcriptional dysregulation, reduced BDNF levels, excitotoxicity, altered mitochondrial 
function, alterations in protein degradation and autophagy, oxidative stress, glial activation and 
inflammatory responses). All these events are caused by either loss-of-function or gain-of-function 
in mHTT, which results to be toxic and elicit the degeneration of selective neuronal subpopulations 
in the basal ganglia, specifically the medium spiny neurons (MSNs), and also in the cerebral cortex 
(pyramidal cells). In addition, in advanced phases of the disease, other brain regions  are also 
affected, such as substantia nigra, thalamus and hippocampus. 
Depending on the length of the poliglitamine tract, its earliest symptoms often appear as cognitive 
and neuropsychiatric issues and are followed by characteristic motor disorders, which have two 
major components: firstly involuntary movements or chorea, beginning early in course of the 
pathology; and second the impairment of voluntary movements, which include bradykinesia and 
lack of coordination. Signs and symptoms develop inexorably, leading mental issues generally to 
decline into dementia, until the fatal outcome of the disease, generally around 20 years after the 
appearance of motor impairment. 
To date, there is no effective treatment to cure HD, and the very few treatments approved are 
focused on ameliorating the symptoms. No effective therapies designed to delay or stop the 
neurodegenerative process are available yet. Therefore, there is an unmet need for neuroprotective 
strategies aimed at preventing or reducing brain damage in HD patients, and several agents are 
currently under research.
In the last decades, cannabinoid compounds have emerged as potential neuroprotective agents 
in many neurodegenerative diseases, including HD. The so-called endocannabinoid system (ECS) 
is involved in a wide variety of physiological processes that help to maintain or recover cell 
homeostasis and integrity after acute or chronic damage. Therefore, the different elements of the 
SCE (cannabinoid receptors, endocannabinoids and their synthesizing and degradative enzymes) 
offer interesting new therapeutic targets for the development of neuroprotective drugs. HD patients 
show alterations in various components of this system during the progression of the disease, mainly 
a dysregulation of CB
1
 receptors signaling in the MSNs in the striatum (which occurs early in the 
pathology) and an upregulation of CB
2
 receptors in glial elements of striatal and cortical areas 
(which is related to inflammatory responses). Alterations in the levels of endocannabinoids and 
synthesizing and degradative enzymes have also been reported and may alter the endocannabinoid 
actions at their receptors. Therefore, the pharmacological manipulation of this system may be 
therapeutically relevant for HD because of the capability of cannabinoids to act on many signaling 
pathways involved in cell survival then limiting the different cytotoxic events that occur in the disease. 
Indeed, cannabinoids with different pharmacological profiles, such as CB
1
 agonists, CB
2
 agonists and 
antioxidant cannabinoids, have already been tested in preclinical models that resemble different 
pathogenic events that occur in the brains of HD patients (such as excitotoxicity, inflammation and 
oxidative stress), showing very promising results. 
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18
AIMS
The main hypotheses of this Doctoral Thesis is that phytocannabinoids, alone or in combination, 
ensuring a broad-spectrum profile, may represent a promising option to arrest the multiple cytotoxic 
processes involved in HD pathology.
To prove this hypotheses, the global aim of this Thesis is to progress in the development of a 
phytocannabinoid-based neuroprotective therapy in HD. This global objective will be divided into 3 
specific aims, which will be presented as 3 different chapters:
Chapter 1: Preclinical evaluation of phytocannabinoids as disease modifiers in animal models of 
HD.
In this chapter we first evaluated the Sativex-like 1:1 combination of botanical extracts enriched 
with Δ9-THC and CBD in a rat model of acute striatal degeneration generated by the induction of 
inflammatory events and activation of the apoptotic machinery elicited by the intrastriatal injection 
of malonate. The treatment with Sativex reduced the volume of striatal edema after the lesion, 
attenuated the striatal cell loss and glial activation and reversed the increase in expression of pro-
inflammatory markers. We also demonstrated that CB
1
, but mainly CB
2
 receptors were involved in 
this neuroprotective effect.
Next, we evaluated the chronic treatment with the same Sativex-like combination of phytocannabinoids 
in the transgenic R6/2 mouse model. Sativex did not produce an improvement in motor coordination 
but attenuated clasping behavior, which is a marker of dystonia, in these animals. It also attenuated 
metabolic deficiencies found in the brain of these mice, as well as it improved some prognostic 
markers related to energy deficit, mitochondrial failure and neuronal deterioration.
Last, we analyzed the neuroprotective potential of the phytocannabinoid CBG in a mouse model of 
oxidative damage and calpain activation produced by the injection of 3NP. CBG partially improved 
some motor deficits caused by the toxin, completely prevented striatal cell loss, attenuated microglial 
activation and reversed the changes in markers of inflammation and oxidative damage in the striata 
of these mice. Next, we evaluated the effects of chronic treatment with CBG in R6/2 mice. CBG 
produced a modest improvement in motor coordination and reduced the number of striatal mHTT 
aggregates in this model. It also partially reversed the increase in CB
2
 and decrease in BDNF and 
PPARγ striatal gene expression, as well as other markers reflecting HD pathology. Since CBG has very 
low affinity for cannabinoid receptors, we propose that the activation of PPARγ may underlie this 
neuroprotective effect.
The results of this chapter are included in the following publications:
 Valdeolivas, S., Satta, V., Pertwee, R.G., Fernandez-Ruiz, J. & Sagredo, O. (2012) Sativex-like 
combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory 
model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci, 3, 400-406.
 Valdeolivas, S., Sagredo, O., Delgado, M., Pozo, M.A. & Fernandez-Ruiz, J. (2017) Effects of a 
Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental 
Model of Huntington’s Disease. Int J Mol Sci, 18.
 Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M.L., Munoz, E. & Sagredo, O. (2015) 
Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 
3-nitropropionate-lesioned mice. Neurotherapeutics, 12, 185-199.
Chapter 2: Evaluation of Sativex in a pilot clinical trial with patients of HD.
The preclinical results obtained from animal and cellular models about the evaluation the potential 
neuroprotective effect of cannabinoids in HD support the validation of broad-spectrum cannabinoid 
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formulations in clinical studies. In this Chapter, we present the results of a double-blind, randomized, 
cross-over, placebo-controlled pilot clinical trial with Sativex in patients with HD, that was performed 
at “Hospital Ramón y Cajal”, Madrid. The primary endpoint of this study, which was the safety and 
tolerability of Sativex by the subjects was achieved, but it did not show any improvement in motor 
performance and cognitive and psychiatric measures. Besides, no change was observed in the 
biomarkers examined, except for an increase in CB
2
 expression in the patients’ lymphocytes during 
Sativex-treatment phase, which was interpreted as a possible cytoprotective and antiinflamatory 
response. Additional studies, with more subjects and in particular, longer treatment duration are 
proposed to further evaluate if Sativex can produce a clinical benefit in HD patients.
The results of this chapter are included in the following publication:
 Lopez-Sendon Moreno, J.L., Garcia Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., Garcia 
Ribas, G., Alonso Arias, M.A., Garcia de Yebenes, M.J., Tolon, R.M., Galve-Roperh, I., Sagredo, O., 
Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., Garcia-Bermejo, M.L., Fernandez Ruiz, J., Guzman, M. 
& Garcia de Yebenes Prous, J. (2016) A double-blind, randomized, cross-over, placebo-controlled, 
pilot trial with Sativex in Huntington’s disease. J Neurol, 263, 1390-1400.
Chapter 3: Study of some of the molecular mechanisms involved in the effect of cannabinoid 
compounds in experimental models of HD.
In this chapter we aimed to deeply study some of the possible mechanisms involved in the protective 
effect of cannabinoids. We focused particularly in the antioxidant effect and the possible involvement 
of NRF2 activation and promotion of antioxidant response. To this aim, we tested the Sativex-like 
combination of Δ9-THC and CBD botanical extracts compared with each phytocannabinoid used 
individually in a HD cellular model of conditionally immortalized murine striatal neuroblasts (STHdhQ7/
Q7 and STHdhQ111/Q111 cells). Firstly, we exposed these cells to agents that produced different cytotoxic 
events that occur in HD brains: glutamate (excitotoxicity), malonate (mitochondrial damage) and 
hydrogen peroxide (oxidative damage). An important extent of cell death was confirmed in all cases, 
but results showed that protection with phytocannabinoids was only significant against hydrogen 
peroxide insult. CBD, but mainly Sativex, protected both cell lines against H
2
O
2
, although this effect 
was much more modest in STHdhQ111/Q111 than in STHdhQ7/Q7 cells. This effect was accompanied by an 
increase of HO-1 gene expression, so next we tested the possible involvement of NRF2/ARE pathway 
in this phytocannabinoid-mediated neuroprotection. Our results did not confirm a role of NRF2/ARE 
in this process, so further research will be needed to dissect the potential mechanisms involved in 
the CBD and Sativex –mediated neuroprotection against oxidative damage in striatal cells.
A second specific objective in this chapter consisted in exploring whether endocannabinoids, 
in particular 2-AG, provide some type of tonic protection in HD, using the malonate model. 
Unexpectedly, we observed that inhibiting MAGL, rather than being neuroprotective, aggravated 
striatal damage, whereas the opposite happened with DAGL inhibition. This unexpected result 
was explained through a malonate-induced COX-2 up-regulation which contributes to convert 
2-AG in prostaglandin-glycerol-esters. Such derivatives were highly neurotoxic. Using in vitro tools, 
M-213 cells, we demonstrated the induction of COX-2 and the generation of the 2-AG oxygenated 
derivatives, as well as that inhibition of COX-2 or the blockade of the targets for these derivatives 
reduced the neurotoxicity.
The results of this chapter are included in the following publications:
 Valdeolivas, S., Rodriguez-Cueto, C. Sagredo, O. and Fernández-Ruiz, J. Study of the 
involvement of NRF2-KEAP1/ARE signaling in the antioxidant effect of phytocannabinoids against 
hydrogen peroxide in a cellular model of Huntington’s disease. (Datos preliminares no publicados).
 Valdeolivas, S., Pazos, M.R., Bisogno, T., Piscitelli, F., Iannotti, F.A., Allara, M., Sagredo, O., Di 
Marzo, V. & Fernandez-Ruiz, J. (2013) The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, 
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rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a 
potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death Dis, 4, e862.
CONCLUSIONS
The results obtained in this Doctoral Thesis allow us to conclude that:
 1. CBG protects striatal neurons and improves neurological decline  in the 3NP model of acute 
striatal oxidative damage, by acting specifically on improving antioxidant defenses and reducing 
glial reactivity, and these effects are exerted by cannabinoid receptor-independent mechanisms, 
presumably by acting at the PPARs.
 2. CBG also exerts neuroprotection in the transgenic R6/2 model, in this case, by reducing the 
accumulation of huntingtin aggregates and acting positively on specific neurotrophins and specific 
genes related to HD transcriptional dysregulation. Again the effects are cannabinoid receptor-
independent. 
 3. The Sativex-like combination of phytocannabinoid botanical extracts protects striatal cells 
in the malonate model of acute inflammatory and apoptotic damage, acting specifically on limiting 
glial reactivity and improving neurotrophic support. This effect involves the activation of both CB
1
 
and CB
2
 receptors. 
 4. The Sativex-like combination of phytocannabinoid botanical extracts also improves some 
motor deficits and corrects the metabolic deficiencies and prognostic markers related to energy 
deficit and mitochondrial failure in the R6/2 transgenic model of HD.
 5. Sativex is safe and well-tolerated in HD patients as shown in a pilot Phase II clinical trial 
conducted in a cohort of early symptomatic HD patients.
 6. However, Sativex did not exert any clinical benefit in motor and cognitive scales and also 
in different biomarkers, other than an elevation in the levels of CB
2
 receptors that could be an 
endogenous protective response. The short time used for the active treatment in this clinical trial 
suggests the need to consider longer periods of treatment in future clinical studies.
 7. Using in vitro strategies (STHdhQ7/Q7 and STHdhQ111/Q111 cells), we could demonstrate that 
the protective effects of CBD against oxidative damage in the form of botanical extract, alone or 
combined with Δ9-THC as in Sativex, may involve a certain activation of the NRF2 signaling, although 
the contribution of additional cellular mechanisms appears to be necessary.
 8. Contrarily to the expected result, STHdhQ111/Q111 cells are not more vulnerable to the 
oxidative insult, and the contribution of NRF2 signaling in these cells is rather limited. 
 9. The inhibition of 2-AG biosynthesis in malonate-lesioned rats, contrarily to the expected 
result, preserves striatal neurons from death, whereas the inhibition of 2-AG degradation aggravates 
striatal damage.
 10. Using this in vivo model and also an in vitro strategy (M-213 cells), we could demonstrate 
that such unexpected result was facilitated by the up-regulation of COX-2 enzyme, the increase in 
2-AG availability, and its transformation by this enzyme into prostaglandin-glyceryl-esters, which are 
highly neurotoxic.
Our results support the neuroprotective potential of broad-spectrum phytocannabinoid compounds 
in different experimental models of HD. These preclinical findings suggest the need of more studies 
to elucidate the mechanisms of neuroprotection by phytocannabinoids, as well as the need for the 
evaluation of a multi-target phytocannabinoid formulation, such as Sativex, in additional clinical 
studies with HD patients but using longer periods of treatment.
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ABBREVIATIONS
2-AG 2-Arachidonoylglycerol
2-OG 2-Oleylglycerol
3-NT 3-Nitrotyrosine
8-OHDG 8-hydroxydeoxyguanosine
AA Arachidonic acid
ACEA Arachidonoyl-2-chloroethylamide
AD Alzheimer’s disease
AEA Anandamide or N-arachidonoylethanolamine
AIDS Acquired immune deficiency syndrome
ALS Amyotrophic lateral sclerosis
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ASO Antisense oligonucleotide
ATF2 Activating transcription factor 2
ATP Adenosine triphosphate
BDNF Brain derived neurotrophic factor
cAMP Cyclic adenosine monophosphate
CB1 Cannabinoid receptor type 1
CB2 Cannabinoid receptor type 2
CBC Cannabichromene
CBD Cannabidiol
CBDA Cannabidiolic acid
CBDV Cannabidivarin
CBG Cannabigerol
CBN Cannabinol
CBP CREB binding protein
CBR Cannabinoid receptor
CNS Central nervous system
COX Ciclooxigenase
CREB cAMP response element binding protein
CSF Cerebrospinal fluid
DA Dopamine
DAG Diacylglycerol
DAGL Diacylglycerol lipase
DALN Desacetyllevonantradol
DNA Desoxyribonucleic acid
DSE Depolarization-induced supression of excitation
DSI Depolarization-induced supression of inhibition
ECB Endocannabinoid
ECS Endocannabinoid system
EMA European Medicines Agency
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ERK Extracellular signal-regulated kinase
FAAH Fatty acid amide hydrolase
FDA Food and Drug Administration
FLAT FAAH-like anandamide transporter
GABA γ-Aminobutyric acid
GP Globus Pallidus
GPe External segment of the globus pallidus
GPi Internal segment of the globus pallidus
GPCR G protein-coupled receptor
HD Huntington’s disease
HDAC Histone deacetylase
HO1 Heme oxygenase 1
HTT Huntingtin
IL Interleukin
iNOS Inducible nitric oxid synthase
IP3 Inositol triphosphate
JNK c-Jun N-terminal protein kinase
liso-PI Lysophosphatidylinositol
LOX Lipooxigenase
LTD Long term synaptic depression
MAGL Monoacylglycerol lipase
MAPK Mitogen-activated protein kinase
mHTT Mutant huntingtin
MSN Medium spiny neuron
NADA N-Arachidonoyldopamine
NADPH Reduced nicotinamide adenine dinucleotide phosphate
NAGly N-Arachidonoylglycine
NAPE N-Arachidonoyl phosphatidylethanolamine
NF-κB Nuclear factor kappa-licht-chain-enhancer of activated B cells
NHR Nuclear hormone receptor
NMDA N-methyl-D-aspartate 
NO Nitric oxide
NOS Nitric oxide synthase
NPY Neuropeptide-Y
NRF2 Nuclear factor (erythroid-derived 2)-like 2
OEA Oleylethanolamide
PA Phosphatidic acid
PD Parkinson’s disease
PDE10A Phosphodiesterase 10A
PEA Palmithoylethanolamide
PET Positron emission tomography
PGE2 Prostaglandin E2
Abbreviations
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PG-G Prostaglandin-glycerol-ester
PI Phosphoinositide
PI3K Phosphatidylinositol 3-kinase
PIP2 Phosphatidylinositol biphosphate
PKA Protein kinase A
PKC Protein kinase C
PLA1 Phospholipase A1
PLC Phospholipase C
PLD Phospholipase D
polyQ Polyglutamine
REST RE1-Silencing transcription factor
PPAR Peroxisome proliferator-activated receptor
RNA Ribonucleic acid
RNAi Interfering RNA
RNS Reactive nitrogen species
ROS Reactive oxygen species
RXR Retinoid X receptor
SEA stearoylethanolamide
SNc Substantia nigra pars compacta
SNr Substantia nigra pars reticulata
SS Somatostatin
SSCI Substrate-selective COX-2 inhibitor
STN Subthalamic
TGF Transforming grouth factor
TNF Tumor necrosis factor
TRP Transient receptor potential
VMAT2 Vesicular monoamine transporter 2
Δ9-THC Δ9-tetradydrocannabinol
Δ9-THCA Δ9-tetradydrocannabinolic acid
Δ9-THCV Δ9-tetradydrocannabivarin
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Huntington’s disease (HD) is a devastating 
neurological disorder that currently has no cure. 
Along this Introduction, we will review the main 
aspects of this disease and its current therapies. 
This will be followed by a description of the 
alterations observed in the endocannabinoid 
system in relation with the disease and how 
different cannabinoid compounds, because of 
their neuroprotective potential, can modify the 
course of the disease, what makes them good 
potential therapies for HD.
HUNTINGTON’S DISEASE
Epidemiology and clinical features
 Huntington’s disease is a hereditary, 
autosomal dominant disorder caused by a 
mutation in the exon 1 of the huntingtin (HTT) 
gene (reviewed in THDCRG, 1993). With a 
prevalence of 10.6 to 16.7 affected individuals 
per 100,000 in the Western populations (Evans 
et al., 2013; Fisher & Hayden, 2014), it is the 
most common monogenic neurological disorder. 
First clinically described by George Huntington 
in 1872 (Huntington, 2003), the symptoms 
of this disease usually begin as cognitive and 
neuropsychiatric issues, such as attention 
problems, decreased learning, depression and 
irritability (Peavy et al., 2010; Thompson et al., 
2012). As the disease progresses, the typical 
motor disorders arise (although sometimes 
they precede cognitive impairment), which 
have two major components: the first one is the 
involuntary movements or chorea, beginning 
early in the course of the pathology; the second 
is the impairment of voluntary movements, 
which include incoordination and bradykinesia. 
This last component is more frequent in the 
juvenile-onset disease, but also appears in the 
late phases of the adult illness (Morreale, 2015). 
Signs and symptoms develop inexorably until 
the fatal outcome of the disease, which occurs 
around 15-20 years after motor impairment 
onset (Ross et al., 2014).
Etiology and genetics
 As introduced above, HD is caused by 
a mutation in the HTT gene (IT15). This gene is 
located at chromosome 4p16.3 and encodes 
the protein huntingtin, whose normal function 
is not completely understood yet, although 
it appears to be related to modulation of cell 
processes like apoptosis, energy metabolism 
and neurogenesis (Reiner et al., 2003; Cattaneo 
et al., 2005). This protein has a molecular weight 
of 348 KDa and contains a polyglutamine (polyQ) 
tract in its N-terminal domain (THDCRG, 1993).
The mutation consists in an excessive number of 
CAG repeats in the IT15 gene, which results in an 
expansion of the polyQ tract that affects protein 
folding and activity. Population not affected by 
the disease contain 6-35 CAG repeats; between 
36 and 39 repeats, the mutation shows reduced 
penetrance, with some subjects developing HD 
and others living without showing any clinical 
sign. When the tract is expanded to 40 or more 
repeats, the mutation is highly penetrant and 
inevitably leads to the onset of motor symptoms. 
The length of the polyQ tract is inversely 
proportional to the age at onset (Duyao et al., 
1993)1993 and, importantly, this is determined 
by the allele with the longer CAG repeat in a 
completely dominant manner (Lee et al., 2012). 
Therefore, juvenile-onset individuals will have a 
higher number of repeats (usually more than 60) 
than adult-onset subjects (40-50).
Mutant huntingtin and mechanisms of 
neurodegeneration
 Huntingtin is ubiquitously expressed in 
human tissues, with high levels of expression in 
the central nervous system (CNS). Interestingly, 
this protein is present in high levels in cortical 
pyramidal neurons in layers III, V and VI that 
project to striatal neurons (Hedreen et al., 1991; 
Strong et al., 1993; Fusco et al., 1999). Forms of 
the protein are found in the cytoplasm and in the 
nucleus, and it can change its location between 
these compartments. Shortly after the cloning 
of HTT gene in 1993, huntingtin was proved to 
be essential for the embryonic development 
of the CNS (Duyao et al., 1995). In vitro and in 
vivo studies have shown its pro-survival and 
anti-apoptotic role (Rigamonti et al., 2000). It 
has also been demonstrated its involvement in 
synaptic activity (Smith et al., 2005) as well as in 
the production and axonal and vesicle transport 
of the neurotrophin brain-derived neurotrophic 
factor (BDNF). 
Despite what is already known about wild type 
HTT function, it remains unclear why a single 
mutation in this protein leads to the selective 
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neurodegeneration of a specific population of 
neurons in the striatum: the medium spiny 
neurons (MSNs). In this context, hypotheses 
about “loss of function” and “gain of function” 
have emerged and it appears that both 
conditions may contribute to the pathogenesis. 
On the one hand, the loss of normal function of 
wild type HTT could contribute to the selective 
vulnerability of these cells and to their 
degeneration. For example, mutant huntingtin 
(mHTT) loses the capability to retain RE1-
Silencing Transcription factor (REST) factor in 
the cytoplasm, then allowing its translocation 
to the nucleus, where it inhibits BDNF gene 
expression (Zuccato et al., 2003). On the other 
hand, the single mutation in the HTT gene 
would mean the acquisition of new toxic 
functions that also contribute to cell death. For 
instance, mHTT binds to CREB binding protein 
(CBP), retaining it in the cytosol and thus 
counteracting its acetylase activity on specific 
histones (Jiang et al., 2006).  (Figure 1. Di 
Prospero & Tagle, 2000).
A high amount of data indicates that the 
fragmentation of the mHTT protein is a key 
early step in the pathogenic mechanism of 
HD. HTT is translated to produce full-length 
huntingtin and an amino-terminal HTT exon-
1 fragment, as a result of aberrant splicing. 
Additional protein fragments can be generated 
after proteolytic cleavage of full-length mHTT. 
These fragments translocate to the nucleus, 
where they are retained by self-association, 
oligomerization and aggregation, leading to 
the formation of nuclear inclusions that can 
interfere in the transcriptional machinery. 
Fragments can oligomerize and aggregate in 
the cytoplasm as well. The dysregulation of the 
cellular proteostasis network that occurs during 
the disease exacerbates this aggregation, and 
this finally results in an amount of cellular 
impairments (reviewed in Bates et al., 2015). 
mHTT aggregates are abundant in the cerebral 
cortex, mainly in layers V and VI, even before 
the onset of neurodegeneration. Surprisingly, 
they are not so abundant in the striatum, the 
Huntingtin
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Figure 1. mHTT loss and gain of function of hypotheses. Poliglutamine repeat expansion can lead to a toxic gain of 
function through various mechanisms: A, it may activate an inflammatory response, leading to the release of cytokines 
and other factors such as nitric oxide, thus exerting a toxic effect; B, it may interfere with energy metabolism triggering 
oxidative stress; C, it can be abnormally cleaved, creating fragments that aggregate in the nucleus, thus inducing 
apoptotic processes and transcriptional dysregulation; D, it may form aggregates with itself and other proteins, thus 
also inducing apoptosis and trascriptional dysregulation; E, it may sequester other proteins, including WT HTT, thereby 
creating a dominant negative effect while also conferring loss of function (adapted from Di Prospero & Tagle. 2000)
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most affected structure in the disease, although 
they can be found in the MSNs. The number of 
aggregates in the cortex is directly related to the 
length of the poly-Q tract and therefore inversely 
related to the age at onset, which confirms its 
involvement in the etiology of the symptoms. 
However, there are studies that suggest that large 
inclusions are not correlated with cell death and 
might even be neuroprotective (Arrasate et al., 
2004). Interestingly, recent reports hypothesize 
that a cell-to-cell transmission of aggregates 
between cells can occur in HD, suggesting a 
prion-like propagation (Frost & Diamond, 2010). 
Among the cellular and molecular mechanisms 
involved in the onset and progression of HD, 
we can cite the following (reviewed in Zuccato 
et al., 2010. See Figure 2): aberrant proteolysis 
and aggregation of mHTT; transcriptional 
dysregulation; reduced BDNF synthesis 
and transport; excitotoxicity, which is the 
first pathological mechanism that leads to 
corticostriatal dysfunction; altered mitochondrial 
function, mainly affecting the mitochondrial 
complex II; oxidative stress; alterations in protein 
degradation and autophagy; and glial activation, 
together with inflammatory responses. For a 
description of some of these mechanisms, see 
Box 1.
All these cytotoxic events result finally in the 
degeneration, specifically and in a greater extent, 
of the MSNs in the striatum. This neuronal loss 
is however not exclusive of this structure, as will 
be discussed in the next sections.
Neuropathology of HD
 The main neuropathological hallmark 
of the disease, as can be seen in Figure 3, is a 
progressive, bilateral atrophy of the striatum and 
the cerebral cortex (de la Monte et al., 1988). 
The striatum belongs to the basal ganglia, whose 
function is related to the control of movement, 
therefore the degeneration of this area is directly 
involved in the motor disturbances observed in 
HD patients. (for an overview of the basal ganglia 
organization and pathways, see Box 2). 
The majority of neurons in the striatum 
(approximately 95%) are the medium spiny 
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Figure 2. Mechanisms of mHTT toxicity and therapeutic targets under investigation. Most recent therapeutic strategies 
for HD include mHTT lowering, immunomodulation, BDNF, autophagy, chaperone and metabolic enhancers, histone 
deacetylase, PDE10A and kynurenine 3 monooxygenase (KMO) inhibition and modulation of signalling pathways such 
as mitogen-activated protein kinases (MAPK), p38 and c-Jun N-terminal kinase (JNK). Adapted from Bates et al., 2016.
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 BOX 1. Pathogenic mechanisms in HD 
Among the pathogenic mechanisms that contribute to neurodegeneration in HD, three will be 
described in this Doctoral Thesis: excitotoxicity, neuroinflammation and oxidative stress. 
Excitotoxicity 
Excitotoxicity is a pathological process initiated by an excessive exposure to glutamate, normally 
caused by an overactivation of N-methyl-D-aspartate (NMDA) and α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors. This leads to an uncontrolled influx of Ca2+ that activates 
phospholipases, endonucleases and proteases such as calpain, which are involved in the damage of 
cell components such as cytoskeleton, DNA and membrane, and definitely provoke cell death (Manev 
et al., 1989).  
Early studies in presymptomatic HD brains showed increased expression of NMDA receptors in the 
MSNs, which were found to die earlier than interneurons (Graveland et al., 1985). Studies in rodents 
showed that striatal injection of NMDA receptor agonists results in the selective death of MSNs (Beal 
et al., 1991; Schwarcz et al., 2010).  In HD, mHTT alters neurotransmitter release and the activity of 
extrasynaptic glutamatergic receptors, especially the NR2B subunit of NMDA (Zeron et al., 2002). 
mHTT also alters the crosstalk between NMDA and D1/D2 receptors, thus resulting in the selective 
death of MSNs containing such dopaminergic receptors (Andre et al., 2010). Moreover, mHTT inhibits 
the expression of mitochondrial transcriptional activators, which alters mitochondrial biogenesis and 
respiration and reduces its capacity to buffer intracellular Ca2+ (Cui et al., 2006). These and other 
processes contribute to the specific vulnerability of MSNs to excitotoxic damage (Estrada Sanchez et 
al., 2008).  
Neuroinflammation 
Astrocytes are the most abundant cells in the brain. They contribute to the cellular homeostasis, 
acting as a trophic support for the neurons, helping in the maintenance of the blood brain barrier and 
modulating synaptic transmission, but are also involved in the release of certain cytokines and 
chemokines (Dong & Benveniste, 2001). Microglial cells, on the other hand, are the resident immune 
cells in the brain (Ransohoff & Perry, 2009). The activation of glial cells as a consequence of an 
inflammatory event leads to the release of cytotoxic mediators, such as cytokines (e.g., Tumor 
necrosis factor(TNF)-α, Interleukin(IL)-6, IL-1β), nitric oxide (NO) and reactive oxygen species (ROS)). 
This process is initially associated with a protective role, eliminating death cells and then allowing 
damage repair, but a sustained activation of microglia and astrocytes leads finally to an impairment 
in neuronal homeostasis that drives to cell death. 
There is evidence that the expression of mHTT alters the normal function of glial cells, resulting in a 
pro-inflammatory, overactivated state (Crotti & Glass, 2015). Microglial and astroglial activation has 
been reported in postmortem brains, and inflammatory mediators are increased in the brain and 
blood of HD patients (e.g. IL-6, IL-10, TNF-α), and also in the cerebrospinal fluid (CSF) (e.g. 
complement factors such as C1QC, C2 and C3). Although this immune activation starts years before 
the onset of symptoms, it is still not clear wether the inflammatory mechanisms are cause or 
consequence of the neurodegenerative process (Rocha et al., 2016). 
Oxidative stress 
Both acute and chronic brain damage trigger the accumulation of toxic elements, such as ROS and 
reactive nitrogen species (RNS), which can harm membrane lipids, proteins and the DNA, thus leading 
to neural death. This process is called oxidative stress, and starts usually as a consequence of an 
imbalance between the activity of endogenous antioxidant elements (e.g., catalase, heme-oxygenase, 
superoxide dismutase, glutation) and the oxidative mediators. 
Studies in postmortem HD brains show increased levels of components of oxidative processes, such 
as of 8-hydroxydeoxyguanosine (8-OHDG, a marker of DNA oxidation), 3-nitrotyrosine (3-NT, a protein 
nitration product) and lipofucsin (marker of lipid peroxidation) among others. Moreover, an elevation 
of inducible nitric oxide synthase (iNOS) is observed in microglia surrounding dying neurons. This is 
not only a process restricted to the CNS, since markers of oxidative damage have been observed also 
in serum, plasma and CSF of patients (Browne & Beal, 2006). They have been used as biomarkers for 
the different antioxidant therapies that have already been tested in animal models, and some of them 
in patients (Gil-Mohapel et al., 2014). 
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neurons (MSNs), which are γ-aminobutyric acid 
(GABA)-ergic projection neurons that reach 
mainly the globus pallidus (GP) and the substantia 
nigra pars reticulata (SNr). These are the earliest 
and most severely affected striatal cell type 
during HD (Graveland et al., 1985). Other striatal 
neurons, such as those interneurons being 
positive for somatostatin (SS), nicotinamide 
adenine dinucleotide phosphate (NADPH) 
and neuropeptide-Y (NPY) that modulate the 
function of the MSNs, are unaffected until late 
stages of the disease (Ferrante et al., 1985). Large 
cholinergic neurons are also preserved until late 
phases (Cicchetti & Parent, 1996). This selective 
vulnerability of MSNs has been proposed to 
be due to: differential expression of  certain 
glutamate receptors in these neurons compared 
to interneurons, which would make them more 
vulnerable to excitotoxicity (Ferrante et al., 1987; 
Zeron et al., 2001); a special sensitivity to energy 
deficit in these cells, which would mean a higher 
susceptibility to mitochondrial damage (Beal 
et al., 1993; Gu et al., 1996); and an extreme 
dependency of BNDF by the MSNs, which make 
them specially affected by the reduction in BDNF 
levels caused by mHTT (Zuccato et al., 2003; 
Gauthier et al., 2004).. Moreover, different MSN 
subtypes show different vulnerability: MSNs 
that express encephalin and D
2
 receptors and 
project to the external segment of the GP (GPe, 
“indirect pathway”) are the most vulnerable 
and first to degenerate, which is related to 
the development of chorea; MSNs hat express 
dynorphin, substance P and D
1
 receptors and 
project to the internal segment of the GP (GPi) 
and SNr (“direct pathway”) degenerate later, 
with correlates with the appearance of akinesia 
and rigidity and, in general, a more parkinsonian 
clinical status (Reiner et al., 1988; Albin et al., 
1990).
Although the main structure that experiences 
neurodegeneration in HD is the striatum, other 
brain regions are also affected. As indicated 
before, cortical degeneration has been seen 
in HD brains, especially in advanced phases in 
adult-onset patients (40-50 CAG repeats) or 
earlier (even before the occurrence of chorea) in 
juvenile-onset patients (>60 CAG repeats). Such 
cortical degeneration means mainly a significant 
loss of pyramidal cells in the primary motor 
cortex (layers V, VI and III), which is involved 
in corticostriatal pathways (de la Monte et al., 
1988). The appearance of cortical degeneration 
also in early phases suggests that this process 
is not secondary, but parallel to striatal atrophy 
(Hedreen et al., 1991). The extent of cortical 
volume loss correlates with the level of striatal 
atrophy and the number of polyglutamine 
repeats, which suggests a relation in the 
disease processes between these two regions 
(van Dellen et al., 2005). In late stages of the 
disease, neuronal loss and atrophy have also 
been described in other brain structures such 
as globus pallidus, substantia nigra, subthalamic 
nucleus, thalamus, hippocampus and cerebellum 
(Vonsattel et al., 2008; Waldvogel et al., 2015). 
Most dramatic changes in HD happen in the brain, 
but degeneration of peripheral tissues has been 
recently reported as well. Some of these non-
brain abnormalities include weight loss, skeletal 
muscle wasting, insulin sensitivity, testicular 
degeneration, gastrointestinal disorders and 
cardiac issues (van der Burg et al., 2009).
Current therapeutic strategies and clinical trials
 Huntington’s disease is caused by a 
single mutation in one gene. However, there 
is a bunch of molecular mechanisms involved 
in the pathogenesis, which makes the search 
for an effective therapy very difficult. Despite 
all the efforts and the extensive research 
performed since the description of the disease, 
Figure 3. Atrophy of the striatum in HD. (A) Frontal section 
through the right basal forebrain of a representative 
control individual. (B) Frontal section through the right 
basal forebrain of a HD patient. Note the loss of deep 
white matter (1), the narrowed corpus callosum (CC) 
(2) and widened third ventricle (3). The atrophy of the 
caudate nucleus (C) (4) and putamen (PU) (5) are also 
remarkable. AC, anterior commissure; PA, pallidum; PU, 
putamen. Taken from Rüb et al., 2009.
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BOX 2. Basal ganglia organization and pathways  
  
 
 
 
The inhibition of SNr inputs leads to a disinhibition of the thalamic glutamatergic neurons, that project back 
to cortical areas, then resulting in the activation of the movement. In the indirect pathway, excitatory 
output from the cortex activates striato-pallidal MSNs, which project indirectly to the SNr through the GPe 
and STN. The inhibition of the GABA-ergic neurons in the GPe by the activation of GABA-ergic MSNs leads 
to a disinhibition of the STN, which projects glutamatergic signals to the SNr, activating GABA-ergic neurons 
that project to the thalamus, thus resulting in an inhibition of the thalamic glutamatergic neurons that reach 
cortical areas, and this results in the inhibition of movement. 
It is interesting to mention that the activation of movement exerted by the direct pathway and the 
inhibition mediated by the indirect pathway are regulated by nigrostriatal dopaminergic neurons, which 
enhance movement activation by acting on D1 receptors located at MSNs of the direct pathway, or cause 
the opposite effect by acting on inhibitory D2 receptors located at MSNs of the indirect pathway.  
According to this model, an adequate balance between the direct and indirect pathway would result in a 
normal control of the movement. In HD, as also happens in other basal ganglia disorders (e.g. Parkinson’s 
disease -PD-), this balance is broken and leads to the appearance of motor symptoms. As explained above, 
MSNs that express D2 receptors and project to the GPe are the earliest affected in HD. This would mean an 
alteration of the indirect pathway that would lead to the exacerbation of the movement.  Conversely, as 
the disease progresses, striato-nigral MSNs that express D1 receptors and project to the GPi degenerate, 
which would affect the direct pathway and ultimately inhibit the thalamic projections to the cortex, 
resulting in a decreased activation of the movement (Han et al., 2010). These two phases correspond 
respectively to the early and intermediate grades of the disease, characterized by choreic movements, and 
to late grades which are more akinetic and resemble parkinsonian symptoms. 
Although this canonical view is widely accepted, recent findings have revealed that the circuitry might be 
much more complex, with the participation of other neurotransmitters, such as serotonin, acetylcholine, 
neuropeptides, etc. Thus, these two pathways would be structurally and functionally intertwined, and 
MSNs might either activate or inhibit movement depending on the form of synaptic plasticity expressed at 
a certain moment (Calabresi et al., 2014). 
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The basal ganglia are a group of nuclei involved in 
the control of movement and located 
subcortically at the base of the forebrain. The 
term involves the striatum (caudate nucleus and 
putamen), globus pallidus (internal segment -Gpi- 
and external segment -Gpe), the subthalamic 
nucleus (STN), and the substantia nigra (pars 
compacta -SNc- and pars reticulata -SNr).  
The basal ganglia are integrated in a forebrain 
loop that forms a cortical/basal 
ganglia/thalamus/cortical circuit (Figure 4). The 
main afferent projection to the striatum comes 
from glutamatergic cortical neurons, but it also 
receives projections from other areas: 
glutamatergic inputs from the thalamic nuclei and 
dopaminergic signals from the SNc which are the 
regulatory components in the circuit. The 
canonical model of basal ganglia function states 
that two pathways, direct and indirect, form by 
different populations of MSNs that project to 
distinct output structures. Thus, in the direct 
pathway, cortical glutamatergic projections 
activate MSNs, that project to the SNr and GPi. 
MSNs are GABA-ergic, so they inhibit SNr neurons 
that are also GABA-ergic and project to the 
ventrolateral nucleus of the thalamus. 
Figure 4. Schematic representation of the basal ganglia 
direct/indirect pathway classical model, and location of CB1 and 
TRPV1 receptors in the involved structures. Arrows indicate 
excitatory signalling, blunted arrows indicate inhibitory 
signalling. DA, dopamine. Adapted from Calabresi et al., 2014. 
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it still has no cure and very few therapies have 
passed the clinical evaluation. The majority of 
drugs approved for HD patients are focused 
on ameliorating the primary symptomatology 
(such as psychiatric agents, cognitive enhancers 
and motor modulators). However, no therapies 
designed to delay or stop the progression of 
the neurodegenerative process are available 
(Pidgeon & Rickards, 2013). The ultimate desired 
goal is to find a therapy that can be proved to 
show disease modification (preventing, slowing 
or even reverting the curse of the pathology), 
together with the characterization of biomarkers 
that give early signs of therapeutic success of a 
drug in pre-symptomatic patients.
Currently, there are several therapeutic agents 
being pre-clinically and clinically evaluated, mostly 
acting on the previously mentioned molecular 
processes affected by the pathology. These 
strategies include: drugs against excitotoxicity, 
strategies to increase BDNF, stimulators of 
huntingtin clearance and autophagy enhancers, 
drugs against mitochondrial dysfunction 
and antioxidants, drugs targeting gene 
transcription (e.g. histone deacetylase (HDAC) 
inhibitors), modulators of synaptic function 
(e.g. Phosphodiesterase(PDE)10A inhibitors), 
immunomodulators and anti-inflammatory 
agents, mHTT lowering strategies (e.g. Antisense 
oligonucleotides (ASO), interfering RNA (RNAi), 
zinc fingers). Stem cell therapies are also under 
investigation as a neurorepair strategy.
For an overview of some of the last clinical trials 
performed and currently ongoing, see Table 1.
CANNABINOIDS AND THE 
ENDOCANNABINOID SYSTEM
 The term “cannabinoid” has been 
used traditionally to name the psychoactive 
components of the Cannabis sativa. Nowadays, 
cannabinoids can be classified into 3 categories: 
phytocannabinoids, or natural components 
of the plant; endocannabinoids, endogenous 
molecules present in animal tissues and organs, 
Drug 
Mechanism of 
action 
Study ID / 
Identifier 
Sponsor 
Phase and 
Status 
References 
IONIS-HTTRx 
Antisense 
oligonucleotide  
ISIS-443139-CS1 / 
NCT02519036 
Ionis 
Pharmaceuticals 
Phase I/IIa. 
Recruiting 
(Kordasiewicz et al., 
2012) 
PF-02545920  
(MP-10) 
PDE10A  inhibitor NCT02197130 Pfizer 
Phase II. 
Completed 
(Wilson et al., 2015) 
Selisistat  
(SEN0014196) 
Sirt1 inhibitor 
(inhibition of 
HDACs) 
NCT01521585 Siena Biotech 
Phase II. 
Completed 
(Sussmuth et al., 2015) 
Deutetrabenazine 
(SD-809) 
Vesicular 
Monoamine 
Transporter 2 
(VMAT2) inhibitor 
First-HD / 
NCT01795859 
Teva 
Pharmaceutical 
Industries  
Phase III.  
Completed 
(Group et al., 2016) 
Pridopidine 
Dopaminergic 
stabilizer 
(functional 
antagonism of D2) 
PRIDE-HD / 
NCT02006472 
Teva 
Pharmaceutical 
Industries 
Phase II.  
Completed 
(Shannon, 2016) 
Laquinimod Immunomodulator 
LEGATO-HD / 
NCT02215616 
Teva 
Pharmaceutical 
Industries 
Phase II. 
Recruiting 
(Dobson et al., 2016) 
VX15/2503 
Monoclonal 
antibody against 
semaphorin 4D 
SIGNAL-HD / 
NCT02481674 
Vaccinex 
Phase II. 
Ongoing 
(Southwell et al., 2015) 
Cellavita Stem cell therapy 
SAVE-DH / 
NCT02728115 
Azidus Brasil 
Phase I. 
Approved 
(Kerkis et al., 2015) 
Triheptanoin 
Brain energy 
metabolism 
enhancer 
TRIHEP3 / 
NCT02453061 
INSERM 
Phase II. 
Recruiting 
(Adanyeguh et al., 
2015) 
 
Table 1. Recent clinical trials on HD.
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and able to bind cannabinoid receptors; and 
synthetic cannabinoids, compounds generated 
in the laboratory that have facilitated the study 
of the so-called endocannabinoid system (ECS), 
whose characteristics and mechanisms will be 
briefly reviewed along this second part of the 
introduction.
Preparations of the plant Cannabis sativa (e.g. 
marijuana and hashish) have been used during 
centuries for both recreational and medicinal 
purposes. The first written description found 
about medicinal cannabis dates around 2350 B.C 
and belongs to the Old Kingdom in Memphis, 
Egypt. There are evidences that prove its use as 
a drug also in India, the ancient Persia, medieval 
Arab countries and China, where it was used for 
numerous indications, such as pain, seizures, 
asthma and loss of appetite. However, it was 
not until the 19th century (1839), in Europe, 
when O’Shaughnessy described its use for 
the treatment of tetanus in India, and since 
then it started being used as muscle relaxant 
and antispasmodic. After all these anecdotal 
evidences, the medicinal use of cannabis was 
reduced at the beginning of the 20th century, 
which hampered significantly the study of its 
applications (Ligresti et al., 2016).
The key events in the study of cannabinoids 
occurred in 1963 and 1964, with the isolation 
and characterization for the first time of 
the two major constituents of the plant, 
cannabidiol (CBD) (Mechoulam & Shvo, 1963) 
and Δ9-tetrahydrocannabinol (Δ9-THC) (Gaoni & 
Mechoulam, 1964) respectively. The evidence 
of a psychoactive effect of Δ9-THC boosted 
the search for endogenous mediators of its 
action. Due to its lypophilic nature, it was 
believed to interact nonspecifically with the 
lipids on the plasma membrane (Lawrence & 
Gill, 1975). However, in 1988 the first receptor 
for cannabinoids was discovered, which was 
formerly called cannabinoid receptor type-1 (CB
1
) 
(Devane et al., 1988). The second main receptor 
of this system was described in 1993, and was 
called cannabinoid receptor type-2 (CB
2
) (Munro 
et al., 1993). The finding of these receptors 
encouraged the search for their endogenous 
ligands. Thus, the first endocannabinoids 
described were the arachidonoylethanolamine 
(AEA), or anandamide (Devane et al., 1992) and 
the 2-arachidonoylglycerol (2-AG) (Mechoulam 
et al., 1995). 
The cannabinoid receptors, their endogenous 
ligands and the enzymes involved in their 
synthesis and degradation constitute what we 
call the ECS, a signaling system involved in many 
physiological and pathological processes. For 
this reason, it has become in the last decades 
an important potential target for the design and 
development of new therapies.
Cannabinoid receptors
 As introduced above, two cannabinoid 
receptors (CBR) have been already cloned and 
described: CB
1
 and CB
2
 receptors (Figure 5). 
They belong to the G protein-coupled receptors 
(GPCRs), which have 7 transmembrane domains 
and are coupled to G proteins. They share a global 
homology of 44%, which increases up to 68% 
between the transmembrane domains (Montero 
et al., 2005)2005, and are widely expressed in all 
vertebrates and also in invertebrates (Elphick, 
2012).
CB
1
 receptor 
The CB
1
 receptor was firstly characterized by 
radiometric methods firstly in neuroblastoma 
cell line membranes and furtherly in rat brain 
membranes (Devane et al., 1988), and then 
cloned in rat (Matsuda et al., 1990)1990 and later 
in humans (Gerard et al., 1991)1991. Importantly, 
its crystal structure has been determined very 
recently (Hua et al., 2016). The expression of CB
1
 
is particularly abundant in the central nervous 
system (CNS). Indeed, it is considered the most 
abundant metabotropic receptor in the brain. 
The brain areas where its presence is higher 
are the basal ganglia (SNc, GP and striatum), 
hippocampus, cerebral cortex and cerebellum, 
regions that underlie some of the observed 
effects of cannabinoids, including alterations 
in memory and cognition, learning and motor 
behavior. Its expression is more moderate in the 
amygdala, nucleus accumbens, hypothalamus 
and brainstem (Herkenham et al., 1991). 
Besides this wide distribution in different brain 
areas it can be expressed in different neuronal 
types, including GABAergic, glutamatergic and 
serotoninergic. They are located predominantly 
on presynaptic terminals, but they have been 
also found postsynaptically, and in glial cells and 
neuronal progenitors as well (Howlett et al., 
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2002; Aguado et al., 2005).
From a cellular perspective, CB
1
 receptors are 
mainly expressed at the plasma membrane, 
but recent studies applying advanced imaging 
techniques have provided evidence of 
differential activation-dependent distribution of 
these receptors (Dudok et al., 2015), as well as 
mitochondrial localization (Benard et al., 2012). 
Besides its broad distribution in the CNS, CB
1
 is 
also expressed in a high number of peripheral 
tissues, such as heart, spleen, liver, skeletal 
muscle and gastrointestinal and genitourinary 
systems (Galiegue et al., 1995; Mackie, 2005). 
CB
2
 receptor
The second cannabinoid receptor was firstly 
described in spleen (Munro et al., 1993). It 
is widely expressed particularly in immune 
tissues such as thymus, tonsils, mast cells and 
blood cells, including all kind of immune cells 
(macrophages, polymorphonuclear neutrophils, 
monocytes, T cells and B cells) (Galiegue et al., 
1995; Schatz et al., 1997). 
Apart from the immune system, this receptor 
has also been described in other peripheral 
tissues, including the gastrointestinal system 
(Wright et al., 2008), bone cells (Ofek et al., 
2006), pulmonary endothelial cells (Zoratti et al., 
2003), fibroblasts of cirrhotic liver (Julien et al., 
2005) and cardiomyocytes (Shmist et al., 2006).
CB
2
 receptor has been typically described as the 
“peripheral” cannabinoid receptor, since at first 
it was not found in any CNS structure (Lynn & 
Herkenham, 1994). However, in the last years 
it has been proved to be expressed in the CNS, 
mainly associated with astroglial and microglial 
cells that become activated in pathologies that 
curse with inflammation (Benito et al., 2003; 
Nunez et al., 2004; Cabral & Griffin-Thomas, 
2009). The presence of CB
2
 in neuronal cells is 
a controversial topic that has been discussed 
in the last few years, maybe due to the lack of 
specificity of the available antibodies to date 
(Atwood & Mackie, 2010). Nonetheless, some 
recent studies have shown their expression 
in neurons of the basal ganglia (Lanciego et 
al., 2011), cerebellum (Rodriguez-Cueto et al., 
2014), hippocampus (Brusco et al., 2008)2008 
and brainstem (Van Sickle et al., 2005), among 
others.
Non-cannabinoid receptors activated by 
cannabinoids
 Some of the effects of cannabinoid 
compounds cannot be totally explained by the 
activation of CB
1
 and CB
2
 receptors. Therefore, 
there must be other molecular targets for 
both endocannabinoids and plant-derived 
phytocannabinoids. Recent studies have proved 
that cannabinoid compounds can activate other 
receptors, such as other GPCRs, ion channels and 
nuclear hormone receptors (NHRs) (Alexander, 
2015). 
There are orphan GPCRs that are widely 
expressed in the CNS and are activated by the 
action of fatty acid-derived lipids, including 
certain endocannabinoids among them, despite 
their limited structural similarity to CB
1
 and CB
2
. 
One of them is GPR18, whose endogenous ligand 
has been suggested to be N-arachidonoylglycine 
(NAGly), an active derivative of AEA that does 
not activate neither CB
1
 nor CB
2
. Other ligands of 
this receptor, with less affinity, could be Δ9-THC 
and AEA (McHugh et al., 2012). The cannabinoid-
like receptor GPR119 is proposed to be activated 
by the AEA and 2-AG analogs oleylethanolamide 
(OEA) and 2-oleoylglycerol (2-OG), respectively 
(Overton et al., 2006; Hansen et al., 2011). 
Lastly, GPR55 is the receptor proposed for the 
endogenous lipid lysophosphatidilinositol, but 
can also be activated by Δ9-THC, HU-210, noladin 
eter, AM-251 and SR141716A (Henstridge et al., 
2010).
Direct effects of cannabinoids on ion channels 
have also been reported. Mainly, on the transient 
receptor potential channels (TRPs), membrane 
channels that mediate the transmission of 
somatosensory stimuli (e.g. pressure, pain and 
temperature). TRPV1 is activated by AEA, CBD 
and Δ9-THC; these last two phytocannabinoids 
are also agonists of TRPV2, TRPA1 and TRPM8. By 
the activation of these channels, cannabinoids 
are suggested to act as pronociceptive agents, in 
contrast to the antinociceptive effects mediated 
by CB
1
 and CB
2 
(reviewed in De Petrocellis et al., 
2011). Furthermore, CBD and Δ9-THC have also 
shown to inhibit voltage-gated calcium channels, 
such as Cav3 (Ross et al., 2008).
Lastly, cannabinoids can act also on peroxisome 
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proliferators-activated receptors (PPARs). These 
are nuclear receptors that, once activated, 
heterodimerize with the retinoid X receptor 
(RXR), and act as transcription factors involved in 
inflammation, cell differentiation and regulation 
of lipid metabolism. To mention a few, PPARα is 
activated by AEA, OEA, palmithoylethanolamide 
(PEA), noladin eter and the synthetic compound 
WIN55-212,2; PPARγ is activated by WIN55-
212,2 and Δ9-THC. Although most of the 
PPAR-mediated effects of these compounds 
have not been elucidated yet, it is suggested 
that some analgesic, anti-inflammatory and 
neuroprotective effects of cannabinoids may 
be partly mediated by the activation of these 
receptors (Sun & Bennett, 2007; O’Sullivan, 
2016). 
Endocannabinoids
 The endogenous compounds that 
bind cannabinoid receptors are called 
endocannabinoids (ECBs). These are 
lipid molecules derived from long chain 
polyunsaturated fatty acids. 
The first endocannabinoid to be described, 
the so-called anandamide (AEA) (Devane et 
al., 1992), was purified from porcine brain. 
It is found in in the CNS but with lower levels 
of expression than other endocannabinoids 
(Bisogno et al., 1999), mainly in hippocampus 
and striatum (where CB
1
 expression is elevated), 
but also in brainstem and spinal cord (where CB
1
 
expression is not so high). In the periphery it is 
found in spleen, heart, testis and uterus (Felder 
et al., 1996). Pharmacologically, AEA binds to 
both cannabinoid receptors CB
1
 and CB
2
 as a 
partial agonist, but it can activate GPR55 (Ryberg 
et al., 2007), TRPV1 (Toth et al., 2009) and PPAR 
receptors (Sun & Bennett, 2007), as well as 
inhibit 5-HT3A receptors (Xiong et al., 2008).
The second main endocannabinoid, the so-called 
2-arachidonoylglycerol (2-AG), was isolated 
in 1995 from dog intestine (Mechoulam et al., 
1995).  It is the most abundant endocannabinoid 
in the brain, with the highest expression in brain 
stem, striatum and hippocampus, but also found 
in the brain cortex and cerebellum (Bisogno et 
al., 1999). Peripherally, it is expressed in spleen, 
liver, lung, kidney and pancreas (Mechoulam et 
al., 1995) (Kondo et al., 1998). It behaves as a 
full agonist of both CB
1
 and CB
2
 receptors, and 
can also bind to GPR55 (Ryberg et al., 2007) and 
TRPV1 (Zygmunt et al., 2013).
Other compounds have been identified as 
potential endogenous ligands of cannabinoid 
receptors, such as O-arachidonoylethanolamine 
(or virhodamine), N-arachidonoyldopamine 
(NADA) and noladin ether (Pacher et al., 2006). 
Other molecules do not bind cannabinoid 
receptors but have cannabimimetic activity, and 
exert an “entourage” effect on main 
endocannabinoids, enhancing their action (Ho 
et al., 2008) or avoiding their inactivation, 
presumably due to the fact that they share the 
same hydrolytic enzymes with AEA and 2-AG. 
These are, among others, PEA, OEA, 
stearoylethanolamide (SEA), 2-linoleylglycerol 
(2-LG) and 2-OG (Conti et al., 2002; Maccarrone 
et al., 2002). See in Figure 5 the structure of 
various endocannabinoids.
Synthesis and release of endocannabinoids
 Unlike classic water-soluble 
neurotransmitters, which are synthesized 
and stored in vesicles before being released, 
endocannabinoids are synthesized “on 
demand”. This means that certain physiological 
stimuli (usually an increase in the intracellular 
concentration of Ca2+) trigger their production 
from lipid precursors localized on the inner layer 
of the plasmatic membrane, and are released 
immediately after that (Piomelli, 2003). Since 
the most studied synthesis and degradation 
pathways of endocannabinoids are the ones for 
AEA and 2-AG, they will be briefly explained in 
this and the following section.
The main synthesis route of AEA starts 
with the activation of a Ca2+-inducible 
AEA
2-AG
Figure 5. Chemical structure of the endocannabinoids AEA 
and 2-AG.
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N-acyltransferase that transfers arachidonic 
acid (AA) to phosphatidylethanolamine to form 
N-arachidonoyl phosphatidylethanolamine 
(NAPE). This is then hydrolyzed by a specific 
phospholipase, Ca2+-inducible as well, NAPE-PLD, 
thus producing phosphatidic acid (PA) and AEA 
(Di Marzo et al., 1994). Additional mechanisms 
of AEA production have been recently proposed 
(Liu et al., 2008). Furthermore, other studies 
suggest that the synthesis of AEA can also be 
Ca2+-independent (Leung et al., 2006), as well as 
induced by the activation of certain dopamine, 
glutamate and acetlcholine receptors (Piomelli, 
2003).
The biosynthesis of 2-AG is also Ca2+-inducible 
and is produced from diacylglycerols (DAGs). 
These molecules can be generated either 
from the hydrolysis of phosphoinositides (PI) 
by a phospholipase C (PLC), or PA by the PA 
phosphohydrolase. DAGs are then hydrolyzed 
by a DAG-lipase (DAGL), thus producing 
2-AG. An alternative pathway involves the 
formation of the intermediate 2-arachidonoyl-
lysophosphatidylinositol (liso-PI) from PI by the 
phospholipase A1 (PLA1), and the action of the 
liso-PLC to generate 2-AG (Piomelli, 2003).
Inactivation of endocannabinoids
 Once released to the synaptic cleft, 
ECBs exert their action through the binding 
to cannabinoid or non-cannabinoid receptors 
(as explained before) and are then rapidly 
transported back inside the cell to be degraded 
once ECB signal needs to be terminated. Since 
they are lipid molecules, they can pass through 
the membrane by passive diffusion, a process 
that might be facilitated by a selective transport 
system. Indeed, the existence of an AEA-specific 
transporter has been postulated: the fatty 
acid amide hydrolase (FAAH)-like anandamide 
transporter (FLAT) would be an inactive cytosolic 
form of FAAH enzyme that would bind AEA 
and facilitate its reuptake, although it is not 
expressed in all tissues, so it cannot be proposed 
as a global intracellular endocannabinoid carrier 
(Leung et al., 2013).
Back inside the cell, endocannabinoids are 
inactivated and degraded by specific enzymes. 
Anandamide is hydrolyzed by the FAAH enzyme, 
producing AA and ethanolamine (Cravatt et al., 
1996). FAAH is not specific, but it uses other 
N-acylethanolamines as substrates, even 2-AG. 
It is located mainly postsynaptically and its 
distribution correlates with the presence of AEA 
and CB
1
 receptor (Egertova et al., 2003). 2-AG is 
mainly degraded (although it also a substrate of 
FAAH) by the enzyme monoacylglycerol lipase 
(MAGL), thus producing AA and glycerol (Dinh 
et al., 2002). It is expressed presynaptically, and 
in brain regions in which CB
1
 receptor is highly 
expressed as well. Other enzymes that can 
hydrolyze 2-AG, namely ABDH6 and ABDH12, 
have been identified (Savinainen et al., 2012). 
Last, AEA and 2-AG can be inactivated not only 
by hydrolysis, but also by oxidation by other 
enzymes involved in lipid metabolism, such as 
lipooxigenases (LOXs) and ciclooxigenases (COXs). 
But the reactions catalyzed by these enzymes 
generate a high amount of new biologically 
active molecules. The products of COX-2 activity 
have generated much more interest in the last 
years. This isoform, inducible by inflammatory 
stimuli in the brain, can oxygenate both AEA 
and 2-AG. The oxygenation of AEA produces 
prostamides such as prostaglandin E
2
 (PGE
2
)-
ethanolamide, a metabolite that exerts its 
action by the binding to PGE
2
 receptors. On the 
other hand, the oxygenation of 2-AG generates 
PGE
2
-glyceryl esters, metabolites that do not act 
via cannabinoid receptors and that have been 
suggested recently to play a role in inflammation 
and excitotoxicity in the brain (Sang et al., 2007; 
Woodward et al., 2008; Valdeolivas et al., 2013) .
Pharmacology of the cannabinoid system
 Since the first description of Δ9-THC, 
an important part of the cannabinoid research 
started to focus on the generation of analogous 
molecules with better pharmacological profile 
than this natural compound. In addition, 
this prompted the search for new synthetic 
molecules that could manipulate the ECS, in 
order to better understand its physiological 
activity. The compounds that are currently used 
for the modulation of the ECS can be classified 
as cannabinoid receptors agonists, cannabinoid 
receptors antagonists and endocannabinoid 
tone modulators, which will be reviewed in 
this section (see Figure 6: chemical structure of 
synthetic cannabinoids).
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Cannabinoid receptor agonists
Cannabinoid receptors agonists are compounds 
that bind and activate either CB
1
, or CB
2
, or both 
receptors, with more or less affinity and potency. 
They can be classified by their chemical structure.
Classic cannabinoids
The group of classic cannabinoids involves 
dibenzopyrene derivatives, which include 
both natural constituents of cannabis or 
phytocannabinoids (e.g. Δ9-THC, Δ8-THC, 
cannabinol (CBN)) and synthetic cannabinoids. 
These include mainly synthetic analogs Δ9-
THC, being HU-210 the most potent and widely 
characterized, which presents both affinity for 
CB
1
 and CB
2
 (Ottani & Giuliani, 2001). Other Δ9-
THC derivatives include nabilone (Cesamet) and 
the selective CB
2
 agonist JWH-133 (Huffman, 
2005), among others. For more information on 
phytocannabinoids, see Box 3.
Non-classic cannabinoids
Non-classic cannabinoids are bicyclic and tricyclic 
Δ9-THC analogs that lack the pyran ring. The main 
representative of this group is CP-55,940, which, 
like Δ9-THC, is a non-selective agonist of CB
1
 
and CB
2
, but has around 5 times more potency. 
Other examples would be CP-22,244, CP-50,556 
(levonantradol) and desacetyllevonantradol 
(DALN) (Howlett et al., 1988).
Aminoalkylindoles
This group includes molecules with a chemical 
structure derived from pravadoline, quite 
different from the groups previously mentioned. 
The most widely used is WIN55,212-2, whose 
affinity is higher for CB
2
 than for CB
1
 and has a 
faster activity than Δ9-THC (D’Ambra et al., 1992). 
Other aminoalkylindoles to mention, derived 
from WIN55,212-2 and CB
2
-selective are JWH-
015 and L-768,242 (Huffman, 2005).
Eicosanoids 
These cannabimimetic compounds include 
derivatives of AA, thus their structures are 
similar to the endocannabinoids AEA and 2-AG. 
One of these molecules is methaanandamide 
(AM-356), an AEA analog that is more CB
1
-
selective and, in particular, more resistant to 
FAAH-mediated metabolism (Abadji et al., 1994). 
Other compounds in this group are arachidonoyl-
2-chloroethylamide (ACEA) (Hillard et al., 1999) 
and O-1812 (Di Marzo et al., 2001).
Cannabinoid receptor antagonists
The generation of compounds that selectively 
block CB
1
 or CB
2
 receptors, together with the 
development of knock-out models for these 
receptors, has been a crucial tool for the 
study of the endocannabinoid signaling. The 
first discovered CB1-selective antagonist is 
SR141716A or “rimonabant” (Rinaldi-Carmona 
et al., 1994). Other molecules derived from 
SR141716A are AM-251 (Gatley et al., 1996) and 
JWH-133HU210
CP 55,940 WIN55,212_2 ACEA
Figure 6. Chemical structure of synthetic cannabinoid agonists.
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BOX 3. Phytocannabinoids  
More than 100 cannabinoid compounds have been identified in Cannabis sativa, in different amounts. 
These plant-derived natural compounds are called phytocannabinoids. The most abundant in cannabis are 
Δ9-THC and CBD, and of the tens of compounds left in variable amounts, only a few have generated 
pharmaceutical interest so far: cannabichromene (CBC), CBG, cannabidivarin (CBDV), Δ9-
tetrahydrocannabivarin (Δ9-THCV), Δ9-tetrahydrocannabinolic acid (Δ9-THCA) and cannabidiolic acid 
(CBDA). For the purpose of this Doctoral Thesis, we will focus in this Box on Δ9-THC, CBD and CBG (See 
Figure 7). 
 
 
The main constituent of the plant, and accountable for its psychoactive effects, is Δ9-THC. This 
phytocannabinoid is a high-affinity, partial agonist of both CB1 and CB2, so most of it central effects are due 
to this cannabinoid receptor activation, but it has shown activity on other receptors as well. For example, 
it is suggested to activate GPR55 and GPR18. It acts as an allosteric modulator of 5-HT3A serotonin receptors, 
and glycine receptors. Regarding vanilloid receptors, it can activate TRPV2, TRPA1 and inhibit TRPM8. Δ9-
THC can also act as an inhibitor of ion channels, such as Cav3, Kv1.2 and voltage-gated sodium channels. 
This variable pharmacological activity allows Δ9-THC to alter many different central and peripheral 
processes, but due to the activation of cannabinoid receptors, it has shown positive effects on analgesia, 
food intake, nociception, emesis, inflammation, anxiety, sleep and modulation of neuronal excitability 
among others, besides the neuroprotective effects on neurodegeneration that will be addressed on further 
sections. Nevertheless, the activation of CB1 receptor is also the main reason for the appearance of 
psychotropic effects, the development of tolerance and dependence, as well as the risk of psychiatric and 
cardiovascular complications, which have limited its application in therapy (Costa, 2007). 
CBD is the most abundant non-psychoactive phytocannabinoid, which has aroused the interest for its 
therapeutic potential in the last years. It is usually called an “atypical cannabinoid”, since it does not elicit 
the classic CB1-mediated cannabinoid “tetrad” (catalepsy, analgesia, hypolocomotion, hypothermia), 
unlike Δ9-THC. It has been reported classically to have very low affinity for cannabinoid receptors, although 
recent studies suggest its activity as an allosteric inhibitor of CB1 and week inverse agonist of CB2. In 
addition, it can increase the endocannabinoid levels by inhibiting FAAH enzyme. CBD also acts as a partial 
agonist of GPR18 and antagonist of GPR55. It can activate TRPV1, TRPV2 and TRPA1, as well as antagonize 
TRPM8. Like Δ9-THC, it shows positive allosteric modulation of glycine receptors. CBD can activate PPARγ 
and 5-HT1A (in this case presumably acting as an allosteric modulator), as well as inhibit the metabolism of 
AA. Moreover, due to its chemical structure, it has an interesting antioxidant profile. Because this moderate 
activity exhibited on a wide number of molecular targets CBD is currently investigated for its potential 
therapeutic properties on anxiety, psychosis, depression, epilepsy, emesis, inflammatory disorders, 
arthritis, neurodegeneration and cancer, among others (see Pisanti et al., 2017 for review). 
CBG was isolated and synthesized in 1964 (Gaoni & Mechoulam, 1964) and has been much less studied 
than the other previous phytocannabinoids so far. Like CBD, it does not induce psychoactive effects, since 
it has negligible activity at the CB1 receptor and appears also inactive at CB2 (Granja et al., 2012). It has been 
reported to act as a TRPM8 antagonist and TRPV1 and TRPA1 agonist (Borrelli et al., 2014). CBG can also 
activate α2 adrenergic receptors and inhibit 5-HT1A (Cascio et al., 2010). 
For a deeper insight on the pharmacology and therapeutic potential of phytocannabinoids, see a review in 
Ligresti et al., 2016. 
 
 
 
 
 
CBD CBG∆9-THC
Figure 7. Chemical structure of the phytocannabinoids ∆9-THC, CBD and CBG. 
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SR147778 or “surinabant” (Rinaldi-Carmona et 
al., 2004). Rimonabant is the most widely used 
CB
1
 antagonist for basic research and was one 
of the first cannabinoid-related compounds to 
be commercialized (named Acomplia) for the 
treatment of obesity and metabolic syndrome 
(Topol et al., 2010), but had to be withdrawn 
in 2008 due to serious secondary effects 
that included depressive/suicidal behavior. 
Nowadays, it is accepted that this might be 
provoked by the capacity of these compounds 
to behave as inverse agonists, thus not only 
attenuating the effects of cannabinoid receptors, 
but also inducing the contrary effects (Pertwee, 
2010). Peripherally-restricted antagonists (not 
crossing the blood-brain barrier) or neutral 
antagonists are being developed to avoid these 
issues (Kirilly et al., 2012).
Among CB
2
-selective antagonists, the most used 
are SR144528, a rimonabant analog (Rinaldi-
Carmona et al., 1998), and the aminoalkylindole 
AM-630 (Howlett et al., 2002). 
Endocannabinoid tone modifiers
Besides the direct activation/inhibition of 
cannabinoid receptors, other mechanisms 
have been described to enhance or decrease 
endocannabinoid signaling. For example, a new 
pharmacological approachment to the study of 
the endocannabinoid system that is currently 
increasing is the search for potential allosteric 
modulators. That is, compounds that do not bind 
to the orthosteric binding site of the receptor but 
to allosteric sites, searching thus for a different 
action than the subsequent to the classical 
activation, or for the reduction of secondary 
effects derived from orthosteric binding. Some 
of these compounds are ORG27569 and the 
endogenous molecule lipoxin A4, which are 
positive allosteric modulators, and PSNCBAM-1, 
which is a negative allosteric modulator (reviewed 
in Morales et al., 2016). These are selective for 
CB
1
, but there is research in progress trying to 
generate CB
2
 allosteric modulators as well.
Other way to alter the levels of endocannabinoids 
is by the inhibition of the enzymes involved in 
their synthesis or, in particular, their degradation. 
Regarding the metabolism of AEA, some of the 
most used FAAH inhibitors are URB-597, OL-135, 
OL-92 and PF-750, which enhance the actions 
of ECBs, particularly AEA, at their receptors. 
Regarding 2-AG, DAGL inhibitors have been 
synthesized, such as O-3841 and OMDM188. To 
block 2-AG degradation, MAGL-inhibitors such 
as OMDM169 and JZL184 are used (reviewed in 
Di Marzo, 2009).
Last, another way to enhance the action of 
endocannabinoids would be the inhibition of 
their reuptake to the cell. Although the existence 
of the anandamide transporter, as explained 
before, is still controversial, a few inhibitors 
of endocannabinoid-reuptake have been 
synthesized, such as UCM707, UCM119, AM404, 
OMDM1 and OMDM2 (reviewed in Glaser et al., 
2005).
Cannabinoid receptor-coupled signaling
 As introduced in previous sections, 
cannabinoid receptors are membrane proteins 
with 7 transmembrane domains, coupled to 
G-proteins in the inner face of the cellular 
membrane (see Turu & Hunyady, 2010 for 
review). 
The activation of CB
1
 receptor leads to the 
recruitment and activation of three different 
types of G-proteins: Gαi/o, Gαs and Gαq. The 
activation of Gαi/o induces the inhibition of the 
adenylyl cyclase (AC), reducing the production 
of cyclic adenosine monophosphate (cAMP) and 
thus the activity of cAMP-dependent protein 
kinase (PKA), which participates in the control 
of many biological processes, representing the 
major intracellular signaling pathway associated 
with the CB
1
 receptor (Figure 8). The activation of 
this subunit has been also reported to modulate 
the function of Ca2+ channels, as well as different 
K+ channels (reviewed in Howlett et al., 2002). In 
certain cells, the activation of CB
1
 can cause the 
increase of cAMP levels through Gαs. This occurs 
after the treatment with pertussis toxin, which 
maintains Gαi/o inactive (Abadji et al., 1999). The 
coupling to Gαq induces the activation of the 
membrane protein phospholipase C (PLC), which 
hydrolyzes the phosphatidylinositol biphosphate 
(PIP2), producing inositol triphosphate (IP3) and 
DAG, both products involved in the release of 
Ca2+ from the endoplasmic reticulum and the 
activation of protein kinase C (PKC) (Lauckner et 
al., 2005).
On the other hand, the released βγ subunits 
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can induce several pathways. They can activate 
the mitogen-activated protein kinases (MAPK) 
p38, c-Jun N-terminal protein kinase (JNK) (Liu 
et al., 2000; Rueda et al., 2000), extracellular 
signal-regulated kinase (ERK) (Galve-Roperh 
et al., 2002) and phosphatidylinositol 3-kinase 
(PI3K) - Akt pathways (Molina-Holgado et al., 
2002), involved in cellular differentiation and 
death. Cannabinoid ligands can also modulate 
other pathways involved in cell proliferation and 
survival, such as ceramide biosynthesis (involved 
in apoptosis and cell-cycle arrest) (Guzman et 
al., 2001) and the modulation of nitric oxide 
synthase (NOS) enzymes (Stefano et al., 2000; 
Esposito et al., 2006).
Regarding CB
2
 receptor, it has only been reported 
to couple Gαi/o, and thus lead to the activation 
of MAPK and PI3K pathways. Moreover, CB
2
 
activation can lead to the increase of intracellular 
Ca2+, not through the activation of ion channels, 
but by the activation of the PLC pathway (Zoratti 
et al., 2003).
Last, the research on the formation and activity 
of cannabinoid receptor dimers has increased 
in the last few years. Homomers of CB
1
 and 
CB
1
-CB
2
 and CB
2
-GPR55 heteromers have been 
reported (Wager-Miller et al., 2002; Callen 
et al., 2012; Balenga et al., 2014), as well as 
with other receptors, such as D
2
, A2a, 5-HT
2A
 
and OX-1 (Carriba et al., 2007; Pinna et al., 
2014; Vinals et al., 2015; Imperatore et al., 
2016). The formation of these receptors can 
affect the canonical signaling of cannabinoid 
receptors alone and it can also influence the 
pharmacological management of the different 
receptors being part of a specific heteromer. 
Moreover, their presence and activity has been 
reported to be affected in certain pathologies. 
This has enhanced their interest as potential 
therapeutic targets, and thus prompted further 
investigation on this topic (Franco et al., 2013).
Physiological role of the ECS
 The wide expression of the ECS 
throughout all kind of tissues and organs 
indicates its crucial value as a modulator of 
multiple physiological processes in the body. 
Although its components are present mostly 
in the nervous system, endocannabinoids and 
cannabinoid receptors have been found also in 
peripheral organs, such as the immune system, 
liver, kidney, muscle and bones, among others. 
For an overview of the distribution of the ECS 
in the periphery and potential cannabinoid 
therapies for related pathologies, see Table 2.
Figure 8. CB1 and CB2 receptors-mediated signalling. ATF2, ctivating transcription factor 2; ATP, adenosine triphospate; 
CREB, cAMP response element binding protein; PKA, protein kinase A. Arrows indicate activation, blunted arrows 
indicate inhibition. Adapted from Andre & Gonthier, 2010.
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The ECS as a neuromodulator system in the CNS
The most important function of the 
endocannabinoids in the CNS is their action 
as modulators of synaptic transmission by 
acting retrograde signaling system. This action 
is mostly mediated by the activation of CB
1
 
receptor, which is the most abundant GPCR 
in the brain, although recent evidence also 
situates CB
2
 receptor in a similar function in 
specific synapses and/or CNS areas (Stempel et 
al., 2016). As explained previously, CB
1
 is mainly 
located at presynaptic terminals, while the 
enzymes for the synthesis of endocannabinoids 
are found postsynaptically. The depolarization of 
the postsynaptic membrane, as a consequence 
of an increase of Ca2+ entry to the cell stimulates 
the synthesis of endocannabinoids, which are 
released “backwards” to the synaptic cleft and 
activate presynaptically-located CB
1
 receptors. If 
the neurotransmitter whose release is inhibited 
is glutamate this effect is called depolarization-
induced suppression of excitation (DSE); if it 
is GABA, it is called depolarization-induced 
suppression of inhibition (DSI). In both cases, 
the role of the ECS is clearly protective, since it 
is addressed to maintain synapse homeostasis, 
attenuating both excessive neuronal excitation 
(glutamate) or inhibition (GABA). Retrograde 
cannabinoid signaling has also been reported 
to be involved in long term synaptic depression 
(LTD). This form of synaptic plasticity is followed 
by a low frequency, long patterned stimulus, 
which leads to a CB
1
-dependent, long-lasting 
decrease of neurotransmitter release, mainly 
as a consequence of a decrease in postsynaptic 
receptor density (see Castillo et al., 2012 for a 
deep review).
The synaptic modulation by the ECS can be 
exerted also by non-retrograde signaling. 
For example, postsynaptic AEA produced as 
a consequence of the synaptic activation of 
metabotropic glutamate receptors can instead 
act on postsynaptic TRPV channels, which 
have shown to trigger LTD in the dentate gyrus 
through a Ca2+ -dependent endocytosis of 
AMPA receptors (Chavez et al., 2010). Also, an 
intracellular CB
2
 activation at pyramidal cells 
of the medial prefrontal cortex produces an 
autocrine inhibition (den Boon et al., 2012).
It has been widely proved in the last years that 
not only neurons, but also glial cells can play a 
 
Peripheral 
organ 
Related pathologies Potential therapies 
Cardiovascular 
system 
Cardiomyopathies, heart failure, atherosclerosis, stroke 
CB1 antagonists (peripheral) 
CB2 agonists 
Gastrointestinal 
tract 
Irritable bowel syndrome, inflammatory bowel disease, 
gastric ulcer 
CB1 agonists (peripheral) 
CB2 agonists 
FAAH inhibitors 
MAGL inhibitors 
Obesity, metabolic syndrome CB1 antagonists (peripheral) 
Liver Fatty liver disease 
CB1 antagonists (peripheral) 
CB2 agonists 
Muscle Muscular dystrophy CB1 antagonists 
Bone Osteoporosis CB2 agonists 
Skin Atopic dermatitis, prurigo, uremic itch PEA 
Kidney Diabetic and other neprhopathies and tubulopathies 
CB1 antagonists (peripheral) 
CB2 agonists 
Reproductive 
system 
Infertility 
Δ9-THC 
PEA 
Immune system 
Immune-mediated 
diseases 
Multiple sclerosis Δ9-THC, CB2 agonists 
Arthritis CBD, CB2 agonists 
Allergic asthma Δ9-THC, CBN 
Table 2. Localization and therapeutic potential of the ECS in the periphery (Adapted from Croxford & Yamamura, 2005; 
Maccarrone et al., 2015).
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direct role in synaptic plasticity. Astrocytes have 
been reported recently not only to act as support 
agents, but be direct interplayers in the synaptic 
communication between neurons, what has 
been called the “tripartite synapse” (Covelo & 
Araque, 2016). Endocannabinoids can also act 
on this astrocyte-neuron communication. The 
activation of astroglial CB
1
 receptors leads to an 
influx of Ca2+ through activation of PLC, and this 
ends in the release of glutamate by astrocytes 
that acts on neurons (Navarrete et al., 2014). On 
the other hand, among the widely known roles of 
microglial cells, they can also prune developing 
synapses and thus regulate synaptic function 
and plasticity (Hong et al., 2016). Interestingly, 
recent reports show that microglial-AEA, 
released in vesicles, is able to act presynaptically 
on GABAergic neurons (Gabrielli et al., 2015). 
For an overview of the neuromodulatory activity 
of the endocannabinoid system, see Figure 9.
Since the ECS is located in many structures along 
the CNS, and modulates both inhibitory and 
excitatory transmission, it is involved in all kind of 
neurobiological processes that include cognitive 
function, anxiety, motor control and nociception, 
among others. Likewise, dysregulations of the 
ECS have been documented in the pathologies 
related to all of these processes, which turns 
it into a potential therapeutic target for these 
conditions. An overview of the presence of the 
ECS and its potential applications is presented in 
Table 3.
Cannabinoids and neuroprotection
One key function of the ECS in the nervous 
system is the regulation of the homeostasis, 
integrity and survival of neurons and glial 
cells. This is especially important, since all 
neurodegenerative disorders and acute brain 
damage curse with cell loss and the capability of 
replacement of neural cells is very limited. 
Indeed, the ECS has been reported to 
be altered in brain pathologies, and the 
pharmacological manipulation  of this system 
has provided potential therapeutic approaches 
in different models of acute brain damage and 
neurodegenerative diseases. These include 
ischemia (Hillard, 2008), brain trauma (Shohami 
et al., 2011), Alzheimer’s disease (Aso & Ferrer, 
2014), Huntington’s disease (Sagredo et al., 
2012), Parkinson’s disease (More & Choi, 2015), 
multiple sclerosis (Pryce & Baker, 2012) and 
amyotrophic lateral sclerosis (Pryce & Baker, 
Presynaptic 
terminal
ER
ER
ER
NAPE NAPE-PLD
NAPE
AEA
EMT
DAG PLC
AA AA
Gly     EtNH2
DAGL
AA
Gly 2-AG
2-AG
2-AG
FAAH
Ca2+    Ca2+
Ca2+ Ca2+
Ca2+
Ca2+Ca
2+
Ca2+
Ca2+
Ca2+
AEA
NAPE-PLD
PKA
MAGL
Metabotropic
receptors (e.g., mGluR)
CB2
CB1
NMDAR
AMPAR
TRPV1
Strong activation
Neurotransmitter
Cytokines
Glutamate
Exosomes
Postsynaptic 
terminal
Microglia
AEA   AEA
AEA
AEA
Astrocyte
Figure 9. Neuromodulatory activity of the endocannabinoid system at the tripartite synapse. Black arrows indicate 
stimulation, and red blunted arrows indicate inhibition. Dotted black arrows indicate enzymatic transformation. Taken 
from Ligresti et al., 2016.
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2015). When considering the manipulation 
of the ECS as a neuroprotective strategy it is 
important to take into account the following: 
endogenous protective responses (such as 
enhanced endocannabinoid generation or 
up-regulation of CB
2
 receptors) should be 
enhanced by pharmacological treatments, as 
they represent an adaptive response aimed at 
restoring cell and tissue homeostasis; however, 
dysregulated responses (such as elevated FAAH 
and MAGL or reduced CB
1 
receptor signaling) 
should be corrected by pharmacological 
treatments, as they represent a maladaptive 
mechanism eventually contributing to disease 
symptoms and progression.
Among the multiple cellular mechanisms 
involved in the neuroprotective role of 
cannabinoids, that can be cannabinoid receptors 
–dependent or not, three will be reviewed for 
their relevance for the purpose of this Doctoral 
Process 
Functions 
assigned to the 
ECS 
Location of 
ECS elements 
Pathologies for the 
application of cannabinoids 
References 
Motor control 
Stimulation of 
movement at low 
doses; inhibition at 
high doses 
Basal ganglia, 
cerebellum 
HD, multiple sclerosis (MS)*, 
PD, Tourette syndrome, 
dyskinesia 
(Fernandez-Ruiz et al., 
2011; Muller-Vahl, 2013) 
Cognitive 
processes 
Motivation, 
emotion, reward 
system 
Brain cortex, 
limbic system 
Addiction, psychiatric disorders (Laviolette & Grace, 2006) 
Learning and 
Memory 
Memory extinction, 
effects on LTP and 
LTD 
Hippocampus 
Memory impairment disorders 
(Alzheimer’s disease (AD), post-
traumatic stress syndrome) 
(Maroof et al., 2013; 
Neumeister et al., 2015) 
Stress and 
anxiety 
Anxiolytic effect 
Central 
amygdala, 
paraventricular 
hypothalamic 
nucleus 
Anxiety, psychiatric disorders 
(Rubino et al., 2015; Lee et 
al., 2016) 
Sleep 
Regulation of sleep 
and sleep-wake 
cycles 
Anterior and 
lateral 
hypothalamus 
Sleep disorders (insomnia, 
somnolence) 
(Prospero-Garcia et al., 
2016) 
Pain 
Spinal and supra-
spinal analgesia 
Brain and spinal 
areas involved 
in nociception, 
sensory nerve 
terminals 
Neuropathic pain 
(Romero-Sandoval et al., 
2015; Maldonado et al., 
2016) 
Neuronal 
development 
Normal neural 
differentiation and 
proliferation during 
development 
Embryonic stem 
cells, neuronal 
progenitors 
Epilepsy, possible interest in 
neuro-repair 
(Dow-Edwards & Silva, 
2017; Rosenberg et al., 
2017) 
Body 
temperature 
Regulation of body 
temperature 
Hypothalamic 
nuclei 
Unknown (Rawls & Benamar, 2011) 
Appetite and 
food intake 
Regulation of 
appetite and energy 
balance 
Hypothalamic 
nuclei and 
limbic areas 
Increase of appetite in AIDS 
and cancer patients; decrease 
of appetite in obesity patients 
(Gatta-Cherifi & Cota, 
2015; Ostadhadi et al., 
2015) 
Emesis 
Vomit and nausea 
control 
Area postrema 
Reduction of nausea and vomit 
in cancer patients 
(Rock & Parker, 2016) 
Neuroendocrine 
regulation 
Adenohypophyseal 
hormones release 
Mediobasal 
hypothalamus 
Unknown (Pagotto et al., 2006) 
 Table 3. Overview of the physiological processes of the CNS in which the ECS is involved, and potential applications of 
endocannabinoid modulators in related pathologies. *Although MS is not a motor disorder in nature, those symptoms 
that are treated with cannabinoids (e.g. spasticity) may be interpreted as motor symptoms.
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Thesis: attenuation of excitotoxicity, oxidative 
stress and neuroinflammation, three neurotoxic 
events introduced previously that are strongly 
related to each other, as well as present among 
most neurodegenerative disorders (Figure 10).
Cannabinoids and excitotoxicity
Cannabinoids can act as antiexcitotoxic agents 
through different mechanisms. As explained 
previously, the release of cannabinoids activates 
CB
1
 receptors present in presynaptic glutamatergic 
terminals, thus inhibiting glutamate release and 
reducing excitotoxicity. CB
2
 may be also involved 
in this action, as HU-210 has proved to act as 
antiexcitotoxic in a manner dependent of both 
cannabinoid receptors (Docagne et al., 2007). 
Moreover, certain cannabinoids, such as the 
synthetic HU-211 and anandamide can directly 
antagonize NMDA receptors (Feigenbaum et 
al., 1989; Hampson et al., 1998). In addition, 
cannabinoid agonists can also directly act on 
postsynaptic terminals by closing voltage-gated 
channels to prevent Ca2+ entry and the activation 
of Ca2+ dependent damaging pathways.
Cannabinoids and neuroinflammation
Cannabinoids can have a double effect on 
neuroinflammation, reducing the production 
of pro-inflammatory cytokines and stimulating 
the release of anti-inflamatory and pro-survival 
mediators, such as transforming growth 
factor(TGF)-β and IL-10 by glial cells (reactive 
microglia and activated astrocytes). Interestingly, 
CB
2
 is typically overexpressed in these cells in 
neuroinflammatory events, and thus the anti-
inflammatory effects mediated by cannabinoids 
are proposed to be mediated mostly by the 
action on this receptor. However, some studies 
indicate that CB
1
 agonists are also effective 
in this sense. Other cannabinoids can act by a 
cannabinoid receptor-independent manner, for 
example by activating PPAR nuclear receptors, in 
particular PPAR-γ, and inhibiting Nuclear factor 
kappa-licht-chain-enhancer of activated B cells 
(NFκB) (Fernandez-Ruiz et al., 2010).
Cannabinoids and oxidative stress
Certain cannabinoids, because of its chemical 
Ca2+
ROS
PRE-SYNAPTIC NEURON
POST-SYNAPTIC NEURON
ASTROCYTE
REACTIVE MICROGLIA
CB1 receptor
CB2 receptor
NMDA receptor
Excitotoxicity
Oxidative
stress
Inflammation
NO
Glutamate release
TNF-α
Il1-β
Cannabinoids
Figure 10. Schematic view of the main mechanisms of neuroprotection by cannabinoids that may be translated to HD.
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structure that includes a phenolic ring (such 
as CBD, Δ9-THC, CBG, dexanabinol) can act as 
ROS scavengers and thus attenuate oxidative 
damage. It has been clasically accepted that 
cannabinoid action on oxidative damage was 
only due to this receptor-independent activity, 
but recent studies have suggested that their 
antioxidant action might also be mediated by 
the action on PPAR receptors and transcription 
factors, such as Nuclear factor (erythroid-
derived 2)-like 2 (NRF2) and NFκB. Moreover, 
AEA, which is not a ROS scavenger by structure, 
has shown to reduce oxidative stress, maybe by 
the activation of CB
1
. Therefore, the involvement 
of cannabinoid receptors on the antioxidant 
properties of cannabinoids cannot be ruled out 
(Fernandez-Ruiz et al., 2015).
CANNABINOIDS AND HUNTINGTON’S 
DISEASE
 One of the neurological disorders that 
has been more intensively investigated for the 
development of a cannabinoid therapy, mainly 
addressed to delay disease progression, is HD. 
Indeed, some clinical trials have been conducted 
with different cannabinoid formulations, one of 
them included as a part of this Doctoral Thesis.
Endocannabinoid signaling in the basal ganglia
 As explained before, CB
1
 receptors are 
highly expressed throughout the basal ganglia. 
Indeed, they are located in the presynaptic 
terminals of striatonigral and striatopallidal 
neurons, the two major neural subpopulations 
that degenerate in HD, which belong to the so-
called direct and indirect pathways respectively, 
and are both GABAergic. Intrinsic striatal neurons 
do not contain CB
1
, with the exception of some 
parvalvumin-positive GABAergic interneurons 
and a few cholinergic neurons. CB
1
 receptors are 
also located in the terminals of glutamatergic 
cortico-striatal projection neurons and also 
in those that project from the subtalamic 
nucleus to the substantia nigra. However, nigro-
striatal dopaminergic neurons do not express 
CB
1
, but TRPV1 instead. This receptor is also 
involved, as explained in previous sections, in 
 
BOX 4. Clinical development of cannabinoid drugs 
Years of preclinical research have lead finally to the approval of some cannabinoid drugs, based on synthetic 
compounds or on phytocannabinoids, for different indications. 
Cesamet: Constituted by the synthetic Δ9-THC analog nabilone. It was originally approved in Canada in 1981 
and by the FDA (Food and Drug Administration) in 1985, for the treatment of nausea and vomiting in 
patients undergoing cancer treatment (Ware et al., 2008). It is currently being evaluated for chronic pain 
as well (Tsang & Giudice, 2016). 
Marinol: Constituted by synthetic Δ9-THC, not obtained from the plant and named dronabinol. Originally 
approved by the FDA) for nausea (1985) and for the stimulation of appetite (1992). It has been also 
approved in Canada for cancer-related nausea and vomiting (1988) (May & Glode, 2016) and for AIDS-
related anorexia (2000) (Badowski & Perez, 2016).  
Acomplia: Constituted by the CB1 inverse agonist rimonabant, or SR141716A. As explained in previous 
sections, it was initially approved by the European Medicine Association (EMA) in 2006 for the treatment 
of obesity and metabolic syndrome (Topol et al., 2010). It was finally withdrawn from market in 2008 due 
to negative psychiatric side effects reported during follow-up studies. 
Sativex: Mouth spray composed by a 1:1 combination of Δ9-THC and CBD botanical extracts, but contains 
other phytocannabinoids in minimal amounts. It was approved to treat MS-related spasticity in 11 countries 
in Europe, besides Canada (where it is also approved for neuropathic and oncologic pain) and Israel (Patti 
et al., 2016). In the US, the FDA granted in 2014 “Fast Track” designation to Sativex for the treatment of 
pain in cancer patients (Johnson et al., 2013). It is currently being evaluated for chronic non-cancer or 
neuropathic pain (Topol et al., 2010; Russo et al., 2016). 
Epidiolex: The last available cannabinoid medicine is an oral solution of pure CBD. It received orphan 
designation by the FDA in 2013 and the EMA in 2014 for the treatment of infantile epilepsies (Lippiello et 
al., 2016) such as Dravet syndrome and Lennox-Gastaut syndrome (Hussain et al., 2015; Devinsky et al., 
2016). 
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endocannabinoid signaling, and is present in the 
striatum and globus pallidus as well.
The presence of CB
1
 receptor, mainly 
presynaptically, in all these areas enables its 
ligands to directly or indirectly modulate the 
activity of the neurotransmitters involved 
in the function of the basal ganglia. Thus, 
cannabinoids can, by retrograde signaling, 
inhibit GABA or glutamate release depending on 
the neuronal-type, in a CB
1
-dependent manner, 
while cannabinoids that are TRPV1 agonists 
may directly reduce dopamine release. Al these 
effects result in the inhibition of motor activity 
(see Fernandez-Ruiz, 2009 for review) (Figure 4).
As regards to CB
2
 receptors, they have not 
been found in significant levels in motor areas, 
except for certain neuronal populations in the 
cerebellum (Rodriguez-Cueto et al., 2014) and 
substantia nigra (Garcia et al., 2015), as well as 
in perivascular microglia (Nunez et al., 2004). 
However, their expression in the basal ganglia 
is exacerbated in pathological conditions, which 
suggests an important role of these receptors in 
the modulation of motor disorders. 
The levels of endocannabinoids such as AEA 
and 2-AG are also higher in the basal ganglia, 
especially in the substantia nigra and globus 
pallidus (Giuffrida et al., 2000). 
Alterations of the ECS in Huntington’s disease
Autoradiographic and immunohistochemical 
studies in post-mortem tissues reveal a 
downregulation in the expression of CB
1
 
receptors in the MSNs, both in human samples 
of HD patients (Glass et al., 2000), transgenic 
mice (McCaw et al., 2004) and in neurotoxin-
generated models (Lastres-Becker et al., 
2002a). This downregulation occurs early in the 
pathology, before the appearance of clinical 
symptoms, which indicates that this event is one 
of the most relevant neurochemical alterations of 
these neurons, and potentially a key pathogenic 
factor in this pathology (Blazquez et al., 2011). 
Interestingly, this decrease of CB
1
 levels has 
been reported recently to occur also in NPY/
nNos-expressing striatal interneurons (Horne 
et al., 2013), while it does not occur in the 
glutamatergic corticostriatal projection neurons 
(Chiodi et al., 2012; Chiarlone et al., 2014).
Conversely, the expression of CB
2
 receptors has 
been found to be strongly increased in human 
striatal and cortical samples, some transgenic 
models (Palazuelos et al., 2009; Bouchard et al., 
2012) and in inflammatory acute models of the 
disease (Sagredo et al., 2009), and such elevation 
has been situated in vascular endothelium of 
postmortem samples (Dowie et al., 2014) and 
in glial elements in animal models (activated 
astrocytes and reactive microglia).
On the other hand, alterations in the levels of 
endocannabinoids and the enzymes involved 
in their metabolism have also been reported. 
Although, these alterations vary in one way or 
another depending on the brain structure in the 
case of human tissues, and between different 
models of the disease (see Morera-Herreras 
et al., 2016 for review). It is important to 
remark that some controversial data have been 
recorded with the endocannabinoid inactivating 
enzymes, in particular FAAH, and this may have 
an important influence in pharmacological 
treatments targeting the endocannabinoid 
system, as suggested by Dowie et al., 2010. 
For example, FAAH levels have been found to 
change in opposite directions in HD, decreasing 
in human lymphocytes (Battista et al., 2007) and 
increasing its activity in lymphocytes of genetic 
murine models like R6/2 mice (Bari et al., 2013). 
Regarding the caudate-putamen, FAHH levels 
have been reported to be increased both in 
postmortem human tissue and in the striatum 
of R6/1 and R6/2 mice (Blazquez et al., 2011), 
which is accompanied by reduced levels of 
endocannabinoids (Bisogno et al., 2008).
All these described alterations in the 
components of the endocannabinoid system in 
the brains of HD patients and in animal models 
suggest first that losses of CB
1
 receptor signaling 
may be a pathogenic event, thus facilitating the 
development of excitotoxicity or other neurotoxic 
events, so that it should be pharmacologically 
corrected by the treatment with selective CB
1
 
agonists, also useful to reduce chorea. They also 
suggest that the elevated levels of CB
2
, rather 
than being a pathogenic event, appears more 
an endogenous protective response that should 
be potentiated by pharmacological treatment. 
Therefore, the collected evidences suggest that 
both CB
1
 and CB
2
 receptors could be interesting 
pharmacological targets in HD. Thus, considering 
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these premises, the manipulation of classic 
cannabinoid receptors could mean a potential 
strategy to attenuate cell death and alleviate 
motor symptoms in this disease. However, this 
possibility also demands to investigate the status 
of the endocannabinoid hydrolyzing enzymes, 
whose inhibition may be protective or harmful 
depending on the cellular context
Therapeutic potential of cannabinoids in 
Huntington’s disease
Different approaches have been followed so far 
in the preclinical evaluation of cannabinoids as 
disease modifiers in HD. Firstly, the hypokinetic 
activity of CB
1
 agonists or compounds able 
to enhance the endocannabinoid tone (e.g. 
inhibition of ECB inactivation) suggested that 
they could be efficient anti-hyperkinetic, and 
thus symptom-relieving agents. In this sense, 
positive results have been obtained in acute 
models of the disease (Lastres-Becker et al., 
2002b). However, the Δ9-THC analog nabilone 
was clinically evaluated for its action on motor 
symptoms, and contradictory results were 
reported (Muller-Vahl et al., 1999; Curtis & 
Rickards, 2006), although the last clinical 
trial performed with this compound showed 
improvements in various motor and cognitive 
parameters (Curtis et al., 2009). Interestingly, 
the inhibition of ECB inactivation was effective 
against choreic movement in preclinical 
models, but their effects were not CB
1
-receptor 
dependent, but involved the action of TRPV1 
receptors (Lastres-Becker et al., 2003), so these 
receptors could be another potential target for 
the management of motor symptoms in HD.
Another therapeutical approach would be to 
prevent or delay the progressive cell death 
that occurs in the brains of HD patients. The 
neuroprotective and neuromodulator effect of 
cannabinoid compounds makes them interesting 
as potential disease modifiers. Along the last 
years, several preclinical studies have shown the 
protective capability of cannabinoids against brain 
damage in different models of HD. For example, a 
non-selective agonist, the phytocannabinoid Δ9-
THC, showed positive results in a mouse model 
of excitotoxicity and in R6/2 transgenic mice 
(Palazuelos et al., 2009; Blazquez et al., 2011) 
and both CB
1
 and CB
2
 receptors were proposed 
to be involved in this effect. CB
2
 agonists have 
also provided neuroprotection in inflammatory 
models (Sagredo et al., 2009). Moreover, non-
cannabinoid receptor dependent mechanisms 
have been reported to be also contributing to 
this neuroprotection. The phytocannabinoids 
Δ9-THC and CBD alone, but particularly in a 
1:1 combination, proved to be effective in a 
rat model of oxidative damage, in a manner 
that was not dependent on neither CB
1
 nor 
CB
2
 activation, but presumably because of the 
potent intrinsic antioxidant properties of these 
phytocannabinoids (Sagredo et al., 2011). 
Indeed, CBD had been evaluated in a clinical 
trial many years before, unfortunately without 
benefits on symptoms or disease progression 
(Consroe et al., 1991).
In conclusion, several cannabinoid compounds, 
with different pharmacological profiles, have 
been evaluated and proved efficiency as 
neuroprotective agents in different models of HD. 
Despite the promising results at the preclinical 
level, further evidences are needed to move to 
the clinical field. Given the multi-target profile of 
cannabinoids as well as the evidence collected 
with individual cannabinoids in preclinical 
models, it appears that the combination of 
some of these compounds may result in a broad-
spectrum treatment that can approach various 
of the many neuropathological events that 
occur in the brains of the patients, making them 
interesting novel therapeutic strategies for HD.
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 Huntington’s disease is a devastating neurodegenerative disorder that currently has no 
cure and for which only a few therapies against specific motor and psychiatric symptoms are 
available yet, so there is an urgent need for new medicines than can delay the progression of the 
neurodegenerative process. Since the discovery of alterations of different elements of the ECS in HD 
patients,  there has been a huge increase in the research studies performed to evaluate the potential 
of cannabinoid compounds as symptom relieving and disease modifying therapies in this disease. 
Cannabinoids have proven to prevent various deleterious events that take place in the brains of HD 
patients and that are involved in the neurodegenerative process, such as excitotoxicity, oxidative 
stress and inflammation. Our hypotheses is that phytocannabinoids, alone or in combination, but 
always with a broad-spectrum profile, may represent a promising option to approach the multiple 
cytotoxic processes involved in HD neuropathology. In order to obtain robust evidences that support 
these compounds, a deep preclinical evaluation must be developed, from different cellular and 
animal models to finally reach the evaluation in patients.
In this context, the global aim of this Thesis is to validate the neuroprotective potential of 
phytocannabinoids in Huntington’s disease. 
This global objective will be divided into 3 specific aims, which will be represented in this Thesis as 
3 different chapters:
 1. Preclinical evaluation of phytocannabinoids as disease modifiers in animal models of 
HD. The different cytotoxic events that lead to striatal neurodegeneration can be reproduced by 
different experimental models. We used acute models of neuroinflammation and oxidative stress, as 
well as a transgenic murine model of HD. The selected phytocannabinoids were the 1:1 Sativex-like 
combination of Δ9-THC-BDS and CBD-BDS, as well as CBG administered in pure form.
 2. Evaluation of  Sativex in a pilot clinical trial with patients of HD. The results obtained from 
preclinical studies supported the evaluation of this 1:1 combination of Δ9-THC and CBD botanical 
extracts present in Sativex. This was conducted with subjects recruited at “Hospital Universitario 
Ramón y Cajal”, Madrid.
 3. Study of some of the molecular mechanisms involved in the effect of cannabinoid 
compounds in experimental models of HD. To this aim, we used first a model of knock-in HD cell lines 
that were exposed to different cytotoxic agents and treated with the Sativex-like combination of Δ9-
THC-BDS and CBD-BDS, as well as each phytocannabinoid alone. In a second study, we investigated 
the status of the endocannabinoid signaling in experimental models of HD, paying emphasis in 2-AG 
and its metabolism, and we explored how changes in the availability of this endocannabinoid may 
alter its effects from the expected protective action towards an increase in striatal damage.
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CHAPTER 1
Preclinical evaluation of phytocannabinoids as disease modifiers in animal models 
of HD.
In this Chapter we evaluated the neuroprotective potential of phytocannabinoids in different animal 
models of HD.
First, we evaluated the effect of the 1:1 combination of botanical extracts enriched with Δ9-THC 
and CBD, which are the main constituents of Sativex, in rats lesioned with the complex II inhibitor 
malonate. This model is characterized by an acute striatal degeneration by mechanisms that involve 
apoptosis and glial activation. The treatment with Sativex was able to reduce the volume of striatal 
edema caused by the lesion. It also partially attenuated the striatal cell loss and the microglial and 
astroglial activation caused by the lesion, and completely prevented the increase in expression of 
the pro-inflammatory marker iNOS. Our results also supported the involvement of CB
1
, but mainly 
CB
2
 receptors in these effects.
In the next paper, we evaluated the same Sativex-like combination of Δ9-THC and CBD botanical 
extracts by a daily treatment from 4th to 12th week of age in the transgenic R6/2 mouse model. This 
model is characterized by an early and fast development of motor symptoms as well as a marked 
striatal atrophy. To analyze the effect of Sativex in these mice, we evaluated the extent of motor 
disturbances, the brain metabolic activity by positron emission tomography (PET) imaging and 
the levels of brain metabolic markers by H+-MRS. Sativex did not produce any recovery in rotarod 
performance, but clearly attenuated clasping behavior, thus improving dystonia in these animals. 
It also attenuated the reduction in brain metabolic activity and recovered the changes in some 
metabolic markers of energy failure and neuronal deterioration observed in these animals.
In the last paper, we analyzed the neuroprotective potential of pure CBG in mice lesioned with the 
complex II inhibitor 3NP. In this model the acute striatal cell death is associated with calpain activation, 
mitochondrial dysfunction and oxidative stress. CBG partially improved some motor deficits caused 
by the toxin, completely reverted striatal cell loss and attenuated the microglial activation. It also 
reverSed the changes in markers of inflammation and oxidative stress in the striata of these mice. 
Next, we evaluated the effects of CBG in the transgenic mouse model R6/2. CBG produced a modest 
improvement in motor performance measured by the rotarod test. It also partially reversed the 
increase in CB
2
 and decrease in BDNF and PPARγ striatal gene expression, as well as other markers of 
HD pathology. Last, it reduced the number of mHTT aggregates in the striata of these mice. This work 
was performed in collaboration with the group led by Eduardo Muñoz at “Universidad de Córdoba”.
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Sativex-like Combination of Phytocannabinoids is Neuroprotective in
Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s
Disease: Role of CB1 and CB2 Receptors
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ABSTRACT: We have investigated whether a 1:1 combination of botanical extracts enriched in either
Δ9-tetrahydrocannabinol (Δ9-THC) or cannabidiol (CBD), which are the main constituents of the
cannabis-based medicine Sativex, is neuroprotective in Huntington’s disease (HD), using an
experimental model of this disease generated by unilateral lesions of the striatum with the
mitochondrial complex II inhibitor malonate. This toxin damages striatal neurons by mechanisms that
primarily involve apoptosis and microglial activation. We monitored the extent of this damage and the
possible preservation of the striatal parenchyma by treatment with a Sativex-like combination of
phytocannabinoids using different histological and biochemical markers. Results were as follows: (i)
malonate increased the volume of edema measured by in vivo NMR imaging and the Sativex-like
combination of phytocannabinoids partially reduced this increase; (ii) malonate reduced the number
of Nissl-stained cells, while enhancing the number of degenerating cells stained with FluoroJade-B, and
the Sativex-like combination of phytocannabinoids reversed both effects; (iii) malonate caused a
strong glial activation (i.e., reactive microglia labeled with Iba-1, and astrogliosis labeled with GFAP)
and the Sativex-like combination of phytocannabinoids attenuated both responses; and (iv) malonate increased the expression of
inducible nitric oxide synthase and the neurotrophin IGF-1, and both responses were attenuated after the treatment with the
Sativex-like combination of phytocannabinoids. We also wanted to establish whether targets within the endocannabinoid system
(i.e., CB1 and CB2 receptors) are involved in the beneficial effects induced in this model by the Sativex-like combination of
phytocannabinoids. This we did using selective antagonists for both receptor types (i.e., SR141716 and AM630) combined with
the Sativex-like phytocannabinoid combination. Our results indicated that the effects of this combination are blocked by these
antagonists and hence that they do result from an activation of both CB1 and CB2 receptors. In summary, this study provides
preclinical evidence in support of a beneficial effect of the cannabis-based medicine Sativex as a neuroprotective agent capable of
delaying signs of disease progression in a proinflammatory model of HD, which adds to previous data obtained in models
priming oxidative mechanisms of striatal injury. However, the interest here is that, in contrast with these previous data, we have
now obtained evidence that both CB1 and CB2 receptors appear to be involved in the effects produced by a Sativex-like
phytocannabinoid combination, thus stressing the broad-spectrum properties of Sativex that may combine activity at the CB1
and/or CB2 receptors with cannabinoid receptor-independent actions.
KEYWORDS: Phytocannabinoids, cannabidiol, Δ9-tetrahydrocannabinol, CB1 and CB2 receptors, Huntington’s disease, malonate,
basal ganglia, neurodegeneration, neuroprotection
Huntington’s disease (HD) is an inherited neurodegener-ative disorder characterized by motor abnormalities,
cognitive dysfunction, and psychiatric symptoms.1 The primary
cause of the disease is a mutation in the huntingtin gene
consisting of a CAG triplet repeat expansion translated into an
abnormal polyglutamine tract in the amino-terminal portion of
this protein that becomes toxic for striatal and cortical neuronal
subpopulations.2 At present, there is no specific pharmacother-
apy to alleviate motor and cognitive symptoms and/or to
arrest/delay disease progression in HD. Thus, even though a
few compounds have produced encouraging effects in
preclinical studies (i.e., minocycline, coenzyme Q10, unsatu-
rated fatty acids, inhibitors of histone deacetylases) none of the
findings obtained in these studies have yet led on to the
development of an effective medicine.3 Importantly, therefore,
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following on from an extensive preclinical evaluation using
different experimental models of HD, clinical tests are now
being performed with cannabinoids. The preclinical studies
with cannabinoids demonstrated preservation of striatal
neurons by several agonists against different cytotoxic stimuli
that operate in HD pathogenesis,4,5 effects that were exerted
through multiple mechanisms of action, some of which involve
the activation of CB1 and/or CB2 receptors and others of which
do not. For example, cannabinoids with antioxidant profile, that
is, Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol
(CBD), protected striatal neurons against toxicity caused by
the mitochondrial complex II inhibitor 3-nitropropionic acid
(3NP) that primes oxidative injury.6,7 However, the activity of
Δ9-THC at the CB1 and CB2 receptors enables this
phytocannabinoid to induce neuroprotection in other exper-
imental models, for example, the transgenic mouse model of
HD, R6/2, in which the effects of Δ9-THC are likely produced
through the activation of CB1 receptors
8 and possibly through
the activation of CB2 receptors too, as selective agonists of this
receptor type preserved striatal neurons in this genetic model9
and also in malonate-lesioned rats,10 a model priming pro-
inflammatory events. Selective agonists of CB1
8,11 and CB2
9
receptors also preserved striatal neurons in in vitro or in vivo
excitotoxic models. By contrast, other studies showed no effects
in R6/1 mice using Δ9-THC, the synthetic agonist HU-210 and
the inhibitor of the endocannabinoid metabolism URB597.12
All these data suggest that the evaluation of cannabinoids as
disease-modifying agents in patients should be necessarily
conducted with a broad-spectrum cannabinoid or with
combinations of various cannabinoids with different and
complementary pharmacological profiles. Sativex, a cannabis-
based medicine recently licensed for the treatment of spasticity
and pain in multiple sclerosis patients,13,14 has an appropriate
profile for HD as it can activate CB1 and CB2 receptors due to
the presence of Δ9-THC, but it can also exert cannabinoid
receptor-independent antioxidant properties due to Δ9-THC
and, in particular, to CBD.15 We recently initiated some
experiments with the combination of Δ9-THC and CBD
botanical extracts present in Sativex in those animal models of
HD, in which individual cannabinoid agonists have proved to
be effective,6−11 with the objective of determining whether this
mixture also works in these models. We have just published the
first data obtained in rats subjected to 3NP intoxication,16 a
model priming, as mentioned above, calpain activation and
oxidative injury as major cytotoxic mechanisms, and in which
pure Δ9-THC6 and CBD7 administered separately, have already
been found to display neuroprotective properties. The Sativex-
like combination of phytocannabinoids also preserved striatal
neurons from death caused by 3NP intoxication, and this effect
was, as expected, independent of CB1 and CB2 receptors.
16
These findings prompted us to extend our research to rats
lesioned with malonate, an acute model of HD in which striatal
damage is produced primarily by apoptosis and glial activation/
inflammatory events and in which selective CB2 receptor
agonists have been shown to be effective.10 To this end, we
lesioned rats with an intrastriatal injection of malonate and used
these animals for two different sets of experiments. First, we
examined the neuroprotective effects of a 1:1 combination of
botanical extracts of Δ9-THC and CBD, a combination that
approximates to the 1.0:0.93 mixture of these extracts that is
present in Sativex. The level of neuroprotection was evaluated
by measuring the following parameters: (i) the volume of
edema measured by in vivo NMR imaging; (ii) the number of
Nissl- and FluoroJade B-stained cells which correlate with the
number of surviving and degenerating cells, respectively, in the
striatal parenchyma; (iii) the presence of reactive microgliosis,
by using Iba-1 immunohistochemistry, and astrogliosis labeled
with GFAP immunostaining; and (iv) the expression of various
biochemical markers that have been found previously to be
altered in this and other HD models, i.e. inducible nitric oxide
synthase (iNOS), the neurotrophin IGF-1 and the CB1
receptor.8,10,16,17 In the second set of experiments, we explored
whether the neuroprotective effects observed in this model with
the combination of Δ9-THC and CBD present in Sativex
involved the activation of CB1 receptors, CB2 receptors, or
both, using selective antagonists for these two receptors
(SR141716 and AM630, respectively). For this second set of
experiments, we monitored the number of Nissl-stained cells,
since this constitutes a very selective and sensitive marker of
malonate damage in the striatal parenchyma.
■ RESULTS AND DISCUSSION
Only a few clinical studies have been performed to determine
whether cannabinoid compounds are efficacious in HD, and the
results they have yielded are rather controversial.18−21 Possibly,
the reason for such controversy is that these clinical studies
concentrated more on HD symptoms rather than on disease
progression. Recent animal studies, however, have demon-
strated that combinations of different cannabinoids or the use
of a broad-spectrum cannabinoid may delay disease progression
by preserving striatal neurons from death in different animal
models of HD, thus stressing again the need for new clinical
studies directed now at testing whether the neuroprotective
effects that certain cannabinoids induce in experimental models
of HD8−11,16 are also produced in HD patients. As mentioned
in the introduction, we recently initiated some experiments
with a 1:1 combination of the Δ9-THC and CBD botanical
extracts that are present in Sativex in those animal models of
HD, in which individual cannabinoid agonists have been found
to be protective,6−11 with the objective to determine whether
this mixture also works in these models. We used first rats
subjected to 3NP intoxication, a model priming calpain
activation and oxidative injury as major cytotoxic mechanisms,
and in which pure Δ9-THC6 and pure CBD7 administered by
themselves, had displayed neuroprotective properties. The
Sativex-like combination of phytocannabinoids also protected
striatal neurons from death caused by 3NP intoxication and its
effects were, as expected, independent of CB1 and CB2
receptors.16 In this Article,16 we already presented preliminary
evidence that the Sativex-like combination of phytocannabi-
noids might also work in additional models of HD, as it was
capable to attenuate malonate-induced iNOS up-regulation in
rats lesioned with this neurotoxin, but this was the only
parameter analyzed in these rats.16 The goal of the present
study was to corroborate the potential of Sativex-like
combination of phytocannabinoids in this model of HD, in
which striatal damage is primarily produced by apoptosis and
glial activation/inflammatory events,10 by measuring different
histopathological and biochemical parameters that have been
more directly related to striatal degeneration in this HD model.
Effects of Phytocannabinoids on Malonate-Induced
Striatal Damage. The first objective was to establish that we
could produce the characteristic striatal damage associated with
the local administration of malonate.10 As expected, the
administration of malonate damaged the striatal parenchyma
as indicated by the increased edema volume recorded in in vivo
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NMR imaging (F(2,19) = 8.86, p < 0.005; see Figure 1), the
reduction in the number of surviving cells determined by Nissl
staining (F(2,10) = 6.36, p < 0.05; see Figure 2), the increase in
the level of degenerating cells determined by FluoroJade B
staining (F(2,10) = 32.87, p < 0.0005; see Figure 2), and the
extent of reactive microgliosis labeled with Iba-1 immunohis-
tochemistry (F(2,12) = 4.652, p < 0.05; see Figure 3) and
astrogliosis labeled with GFAP immunohistochemistry (F(2,11)
= 9.25, p < 0.01; see Figure 3). Malonate toxicity also affects the
expression of different markers related to inflammation (i.e.,
iNOS: F(2,11) = 5.78, p < 0.05) and neurotrophins (i.e., IGF-1:
F(2,15) = 4.41, p < 0.05) (see Figure 4). These changes,
although characteristic of a specific experimental model of HD,
have also been found in HD patients using CSF, blood cell, and
post-mortem brain samples,22,23 thus supporting the idea that
glial activation associated with inflammatory events is part in
the pathogenic process that occurs in HD patients. Lastly,
malonate toxicity is also associated with a reduction in the
expression of CB1 receptors (F(2,25) = 4.863, p < 0.05; see
Figure 4) an effect largely related to HD pathogenesis in
different animal models.6,8,16
The administration of a 1:1 combination of Δ9-THC- and
CBD-enriched botanical extracts that are present in Sativex
attenuated, to a different extent, all these malonate-induced
changes. For example, it slightly reduced the volume of edema
measured with in vivo NMR imaging procedures 24 h after
Figure 1. Volume of edema measured by in vivo NMR imaging procedures in the caudate-putamen of rats subjected to unilateral lesions with
malonate and receiving two injections of Δ9-THC- and CBD-enriched botanical extracts combined in a Sativex-like ratio 1:1 (total cannabinoid dose
equivalent to 3 mg/kg weight), or vehicle (Tween 80-saline). Details in the text. The 1:1 mixture Δ9-THC- and CBD-enriched botanical extracts is
referred to as Sativex in this figure. Values are expressed as means ± SEM for 5−6 animals per group. Data were subjected to one-way analysis of
variance followed by the Student−Newman−Keuls test (*p < 0.05, **p < 0.005 compared with controls). Representative in vivo NMR images for
each experimental group are included in the left panel.
Figure 2. Nissl and FluoroJade B staining measured in the caudate-putamen of rats subjected to unilateral lesions with malonate and receiving two
injections of Δ9-THC- and CBD-enriched botanical extracts combined in a Sativex-like ratio 1:1 (total cannabinoid dose equivalent to 3 mg/kg
weight), or vehicle (Tween 80-saline). Details in the text. The 1:1 mixture Δ9-THC- and CBD-enriched botanical extracts is referred to as Sativex in
this figure. Values correspond to percent over the contralateral nonlesioned side and are expressed as means ± SEM for 5−6 animals per group. Data
were subjected to one-way analysis of variance followed by the Student−Newman−Keuls test (*p < 0.05, **p < 0.01, ***p < 0.005 compared with
controls; #p < 0.05 compared with malonate + vehicle). Representative Nissl- and FluoroJade B-stained microphotographs for each experimental
group are included in the left panel. Magnification = 20×.
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malonate application and 24 h before animal death (Figure 1).
These in vivo results correlated well with the data obtained
after the histopathological analysis of animal brains. For
example, the treatment with a Sativex-like combination of
phytocannabinoids increased the number of Nissl-stained cells
that had been reduced by malonate (see Figure 2), while
reducing the high number of degenerating cells stained with
FluoroJade-B (see Figure 2). In a similar way, the Sativex-like
combination of phytocannabinoids attenuated the activation of
glial elements caused by malonate (i.e., reactive microglia
labeled with Iba-1, and astrogliosis labeled with GFAP; see
Figure 3), which was particularly abundant and generalized
along the whole striatal parenchyma in this experimental model.
Lastly, the Sativex-like combination of phytocannabinoids
attenuated the malonate-induced up-regulatory responses in
iNOS (already described in ref 16) and IGF-1 gene expression
in the striatal parenchyma (see Figure 4), whereas it partially
recovered the malonate-induced reduction in CB1 receptors
(see Figure 4). These findings support the notion that the
combination of both phytocannabinoid-botanical extracts may
be effective as a neuroprotective therapy in malonate-lesioned
rats as it was previously found when individual cannabinoid
agonists (i.e., HU-308) were used in the same HD model.10 In
this study,10 however, we found that CBD administered alone
was not active against malonate-induced striatal damage, but,
according to the present data, its combination with Δ9-THC
resulted in highly positive effects presumably by enhancing the
activity of this last phytocannabinoid at the CB1 and CB2
receptors (see below). The rationale for such combination has
been largely discussed in previous reviews.24
Involvement of CB1 and/or CB2 Receptors in the
Beneficial Effects of Phytocannabinoids on Malonate-
Induced Striatal Damage. In our previous study that used an
experimental model of HD that primes oxidative injury and
calpain activation as major causes of striatal damage, we
detected protective effects of the Sativex-like combination of
phytocannabinoids, that seemed to result from the antioxidant
and cannabinoid receptor-independent properties of both
phytocannabinoids rather than from any interaction with CB1
and/or CB2 receptors. We wanted to see if this was also the
case in the experimental model of HD used in the present
study. To this end, we conducted additional experiments with
selective antagonists for CB1 and CB2 receptor types, that is,
SR141716 and AM630, respectively, combined with the
Sativex-like mixture of phytocannabinoids. The same or similar
antagonists had been already tested after being administered
alone in the same animal model of HD, showing no effect in
the case of CB2 receptor blockade
10 or even aggravating striatal
damage in the case of SR141716.25 In our present study, the
blockade of CB1 receptors with SR141716 or the blockade of
CB2 receptors with AM630 reversed the phytocannabinoid-
induced decrease in the ability of malonate to attenuate Nissl-
staining of cells (F(5,23) = 6.11, p < 0.005; see Figure 5).
Interestingly, this reversal was no greater when both antagonists
were administered together (see Figure 5). However, it is
important to note that, although SR141716 and AM630, both
separately and together, reversed the effects of the Sativex-like
combination of Δ9-THC- and CBD-enriched botanical extracts,
the lowest number of Nissl-stained cells was observed after the
treatment with AM630, administered alone or in combination
with SR141716. This finding, together with our previously
published data showing that CB2 receptors underwent an up-
regulation in glial elements located in the striatal parenchyma
after malonate,10 whereas CB1 receptors underwent a down-
regulation in the same animal model in the present study (see
Figure 4) and also in other models of HD,8,16 suggests that
even though Δ9-THC can activate both CB1 and CB2 receptors,
the CB2 receptor plays a greater role than the CB1 receptor in
the protection from malonate-induced striatal damage that the
Δ9-THC- and CBD-enriched botanical extracts produce.
Figure 3. Iba-1 and GFAP immunostainings measured in the caudate-putamen of rats subjected to unilateral lesions with malonate and receiving two
injections of Δ9-THC- and CBD-enriched botanical extracts combined in a Sativex-like ratio 1:1 (total cannabinoid dose equivalent to 3 mg/kg
weight), or vehicle (Tween 80-saline). Details in the text. The 1:1 mixture Δ9-THC- and CBD-enriched botanical extracts is referred to as Sativex in
this figure. Values correspond to percent over the contralateral nonlesioned side and are expressed as means ± SEM for 3−4 animals per group. Data
were subjected to one-way analysis of variance followed by the Student−Newman−Keuls test (*p < 0.05, **p < 0.01 compared with controls; #p <
0.05 compared with malonate + vehicle). Representative Iba-1 and GFAP immunostained microphotographs for each experimental group are
included in the left panel. Magnification = 20×.
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■ CONCLUSION
Collectively, this study provides preclinical evidence in support
of a beneficial effect of the cannabis-based medicine Sativex as a
neuroprotective agent capable of delaying disease progression
in a proinflammatory model of HD, which adds to previous
data obtained in models priming oxidative mechanisms of
striatal injury. However, the interest here is that, in contrast to
these previous data, we have now obtained evidence that both
CB1 and CB2 receptors are likely to be involved in Sativex
effects, thus stressing the broad-spectrum properties of this
medicine that may combine activity at the CB1 and/or CB2
receptors with cannabinoid receptor-independent actions.
Moreover, our previous data showing that, in this proin-
flammatory model of HD, CB2 receptors were up-regulated
10
whereas CB1 receptors were down-regulated (also demon-
strated here), as well as our observation that the protective
effect of the Sativex-like combination of Δ9-THC- and CBD-
enriched botanical extracts could be blocked by the selective
CB2 receptor antagonist AM630, suggest that CB2 receptors
play a particularly important role in this protective effect, a
hypothesis that is also in concordance with the previous
literature (see ref 26 for review). Lastly, given that HD is a
disorder that is currently poorly managed in the clinic, the
present data obtained with malonate-lesioned rats, together
with previously published data obtained using an oxidative
model of HD,16 provide a strong justification for mounting
clinical trials with cannabinoids that produce positive effects in
these preclinical models of HD.
■ MATERIALS AND METHODS
Animals and Surgery. Adult (12 week old; 350−400 g) male
Sprague−Dawley rats (Harlan Ibeŕica, Barcelona, Spain) were used for
the experiments. Animals were housed in a room with controlled
photoperiod (08:00−20:00 light) and temperature (22 ± 1 °C) with
free access to standard food and water. All experiments were
conducted according to local and European rules (directive 86/609/
EEC) and approved by the “Comite ́ de Experimentacioń Animal” of
our university. Rats were subjected to unilateral lesions of the striatum
with the complex II inhibitor malonate, following a procedure
described previously.10 Rats were injected stereotaxically (coordinates:
+0.8 mm anterior, +2.9 mm lateral from the bregma, −4.5 mm ventral
from the dura mater) into the left striatum with 2 M malonate
(dissolved in PBS 0.1 M, pH = 7.4) in a volume of 1 μL. The
contralateral striatum of each animal remained unaffected, when data
generated in this experimental model are expressed as percent of the
lesioned side over the corresponding nonlesioned side.
Treatments and Sampling. We followed the same procedure
used in previous studies with cannabinoids in malonate-lesioned
rats.10,25 Thus, 30 min before and 2 h after the intrastriatal injection of
malonate, animals were treated with combinations of botanical extracts
enriched with either Δ9-THC, kindly provided by GW Pharmaceut-
icals Ltd., Cambridgeshire, U.K. (Δ9-THC botanical extract contains
67.1% Δ9-THC, 0.3% CBD, 0.9% cannabigerol, 0.9% cannabichro-
mene, and 1.9% other phytocannabinoids) or CBD, also provided by
GW Pharmaceuticals Ltd., Cambridgeshire, U.K. (CBD botanical
extract contains 64.8% CBD, 2.3% Δ9-THC, 1.1% cannabigerol, 3.0%
cannabichromene, and 1.5% other phytocannabinoids). The total dose
of cannabinoid administered was always 4.63 mg/kg (equivalent to 3
mg/kg of pure CBD + Δ9-THC), a dose within the range of effective
doses of both compounds when they were administered in pure form
in this and other experimental models of HD.8−11 This was also the
effective dose in our previous study with Sativex-like combination of
phytocannabinoids in another HD model.16 Cannabinoids were
prepared in Tween 80-saline solution (1:16) and they were
administered i.p. Malonate-lesioned rats administered with vehicle,
as well as sham-operated animals, were also included in this
experiment. In a further experiment, rats injected with malonate,
following the same procedure described above, and also injected with
the 1:1 combination of Δ9-THC- and CBD-enriched botanical extracts
used in the previous experiment, were coadministered (10 min before
each injection of Sativex-like combination) with the CB1 receptor
antagonist SR141716 (1 mg/kg), kindly provided by Sanofi-Aventis
(Montpellier, France) or the CB2 receptor blocker AM630 (1 mg/kg),
purchased from Tocris (Biogen Cientif́ica, Madrid, Spain), both
prepared in Tween 80-saline (1:16). In both experiments, animals
were killed 48 h after the administration of malonate and their brains
were rapidly removed, the two striata dissected and frozen separately
in 2-methylbutane cooled in dry ice, and stored at −80 °C for
subsequent qRT-PCR analysis. Animals to be used for histological
analysis were transcardially perfused with saline followed by fresh 4%
paraformaldehyde [in 0.1 M phosphate buffered-saline (PBS)], and
their brains were collected and postfixed overnight at 4 °C, and then
immersed in antifreeze solution and stored at −20 °C for Nissl and
FluoroJade B staining and immunohistochemical analysis. In all
experiments, at least 5−6 animals were used per experimental group.
Figure 4. Gene expression for iNOS, IGF-1, and CB1 receptors
measured in the caudate-putamen of rats subjected to unilateral lesions
with malonate and receiving two injections of Δ9-THC- and CBD-
enriched botanical extracts combined in a Sativex-like ratio 1:1 (total
cannabinoid dose equivalent to 3 mg/kg weight), or vehicle (Tween
80-saline). Details in the text. The 1:1 mixture Δ9-THC- and CBD-
enriched botanical extracts is referred to as Sativex in this figure.
Values correspond to percent over the contralateral nonlesioned side
and are expressed as means ± SEM for 5−6 animals per group. Data
were subjected to one-way analysis of variance followed by the
Student−Newman−Keuls test (*p < 0.05 compared with controls; #p
< 0.05 compared with malonate + vehicle).
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In Vivo NMR Imaging Procedures. In the first experiment
consisting of injections of Sativex-like combinations of phytocannabi-
noids to malonate-lesioned rats, animals from the three experimental
groups were used, at 24 h after malonate lesion and 24 h before animal
death, for in vivo NMR imaging studies in which the volume of striatal
edema was calculated. Experiments were performed at the Nuclear
Magnetic Resonance Centre of Complutense University (Madrid,
Spain) using a BIOSPEC BMT 47/40 (Bruker, Ettlingen, Germany)
operating at 4.7 T, equipped with a 12 cm actively shielded gradient
system. Rats were anesthetized with oxygen:isoflurane and sub-
sequently placed in prone position inside a cradle. The animal head
was immobilized and placed underneath a 4 cm surface coil. A
respiration sensor was used to control the animals. First global
shimmer was assessed, and then three gradient-echo scout images in
axial, sagittal, and coronal directions were acquired (TR/TE = 100/3.2
ms, matrix = 128 × 128). A 3D fast spin−echo experiment with axial
slice orientation was subsequently performed using the following
acquisition parameters: TR = 3000 ms, effective TE = 86.5 ms, NA =
2, FOV = 2.56 × 2.56 × 1.28 cm3, matrix size = 256 × 128 × 32. The
reconstructed matrix size was 256 × 256 × 32. The total time of the
acquisition experiment was 27 min.
Histological Analyses. Coronal brain sections (25 μm thick) were
obtained with a vibratome and collected as floating slices at the level of
the caudate-putamen. They were used for Nissl (see details in ref 27)
and FluoroJade B (see details in ref 10) staining, which permitted
determination of the effects of particular treatments on cell number,
and for immunohistochemical analysis of Iba-1, a marker of microglial
cells, and GFAP, a marker of astrocytes. For immunohistochemistry,
sections were incubated overnight at 30 °C with (i) monoclonal antirat
Iba-1 antibody (Wako, Neuss, Germany) used at 1:300, or (ii)
monoclonal antirat GFAP (Sigma-Aldrich, Madrid, Spain) used at
1:400. After incubation with the corresponding primary antibody,
sections were washed in 0.1 M PBS and incubated for 2 h at 37 °C
with a mouse highly cross-adsorbed AlexaFluor 488 secondary
antibody (Invitrogen, Carlsbad, CA) for GFAP immunostaining, and
with a rabbit biotinylated secondary antibody (Sigma-Aldrich, Madrid,
Spain) followed by incubation for 2 additional hours with streptavidin
488 (Molecular Probes, Paisley, U.K.) for Iba-1 immunostaining. Both
secondary antibodies were used at 1:200. Negative control sections
were obtained using the same protocol with omission of the primary
antibody. All sections for each immunohistochemical procedure were
processed at the same time and under the same conditions. A Nikon
Eclipse 90i confocal microscope and a Nikon DXM 1200F camera
were used for slide observation and photography, and all image
processing, including cell counting, was done using ImageJ, the
software developed and freely distributed by the U.S. National
Institutes of Health (Bethesda, MD). For this purpose, multiple
sections, selected from levels located approximately 200 μm from the
middle of the lesion, were obtained from each brain and used to
generate a mean value per subject.
Real Time qRT-PCR Analysis. Total RNA was isolated from
striata using RNATidy reagent (AppliChem. Inc., Cheshire, CT). The
total amount of RNA extracted was quantitated by spectrometry at 260
nm and its purity from the ratio between the absorbance values at 260
and 280 nm, whereas its integrity was confirmed in agarose geles. After
genomic DNA was removed (to eliminate DNA contamination),
single-stranded cDNA was synthesized from 1 μg of total RNA using a
commercial kit (Rneasy Mini Quantitect Reverse Transcription,
Qiagen, Izasa, Madrid, Spain). The reaction mixture was kept frozen
at −20 °C until enzymatic amplification. Quantitative RT-PCR assays
were performed using TaqMan Gene Expression Assays (Applied
Biosystems, Foster City, CA) to quantify mRNA levels for IGF-1 (ref
Rn99999087_m1), iNOS (ref Rn00561646_m1), or CB1 receptor (ref
Rn00562880_m1), using β-actin expression (ref Rn00667869_m1) as
an endogenous control gene for normalization. The PCR assay was
performed using the 7300 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA), and the threshold cycle was calculated
by the instrument’s software (7300 Fast System, Applied Biosystems,
Foster City, CA).
Statistics. Data were assessed by one-way ANOVA, followed by
the Student−Newman−Keuls test.
■ AUTHOR INFORMATION
Corresponding Author
*Telephone: 34-913941450. Fax: 34-913941691. E-mail:
onintza@med.ucm.es (O.S.); jjfr@med.ucm.es (J.F.-R.).
Author Contributions
#Both authors have contributed equally to this work.
Author Contributions
▽Both authors shared the senior authorship of this study.
Author Contributions
O.S., R.G.P., and J.F.-R. designed the experiments included in
this Article, which were conducted by S.V. and V.S. and
supervised by O.S. and J.F.-R. J.F.-R. wrote the different
versions of the manuscript, which were revised by the other
Figure 5. Nissl staining measured in the caudate-putamen of rats subjected to unilateral lesions with malonate and receiving two injections of Δ9-
THC- and CBD-enriched botanical extracts combined in a Sativex-like ratio 1:1 (total cannabinoid dose equivalent to 3 mg/kg weight), selective
antagonists for the CB1 (SR141716) and/or the CB2 (AM630) receptor, or vehicle (Tween 80-saline). Details in the text. The 1:1 mixture Δ9-THC-
and CBD-enriched botanical extracts is referred to as Sativex in this Figure. Values correspond to percent over the control group and are expressed as
means ± SEM for 5−6 animals per group. Data were subjected to one-way analysis of variance followed by the Student−Newman−Keuls test (*p <
0.05, **p < 0.01 compared with controls; #p < 0.05 compared with malonate + Sativex).
ACS Chemical Neuroscience Research Article
dx.doi.org/10.1021/cn200114w | ACS Chem. Neurosci. 2012, 3, 400−406405
Results - Chapter 1
65
authors. All authors have approved the final version for
submission.
Funding
This work has been supported by grants from CIBERNED
(CB06/05/0089), MICINN (SAF2009/11847), CAM (S2011/
BMD-2308), and GW Pharmaceuticals Ltd. These agencies had
no further role in study design, the collection, analysis, and
interpretation of data, in the writing of the report, or in the
decision to submit the paper for publication.
Notes
The authors declare the following competing financial
interest(s):Authors have formal links with GW Pharmaceuticals
that funds some of their research.
■ ACKNOWLEDGMENTS
Authors are indebted to Yolanda Garciá-Movellań for
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striatal type 1 cannabinoid receptors is a key pathogenic factor in
Huntington’s disease. Brain 134, 119−136.
(9) Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C.,
Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., Fernańdez-
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Abstract: Several cannabinoids afforded neuroprotection in experimental models of Huntington’s
disease (HD). We investigated whether a 1:1 combination of botanical extracts enriched in either
∆9-tetrahydrocannabinol (∆9-THC) or cannabidiol (CBD), which are the main constituents of the
cannabis-based medicine Sativex®, is beneficial in R6/2 mice (a transgenic model of HD), as it was
previously shown to have positive effects in neurotoxin-based models of HD. We recorded the
progression of neurological deficits and the extent of striatal deterioration, using behavioral, in vivo
imaging, and biochemical methods in R6/2 mice and their corresponding wild-type mice. The mice
were daily treated, starting at 4 weeks after birth, with a Sativex-like combination of phytocannabinoids
(equivalent to 3 mg/kg weight of pure CBD + ∆9-THC) or vehicle. R6/2 mice exhibited the
characteristic deterioration in rotarod performance that initiated at 6 weeks and progressed up
to 10 weeks, and elevated clasping behavior reflecting dystonia. Treatment with the Sativex-like
combination of phytocannabinoids did not recover rotarod performance, but markedly attenuated
clasping behavior. The in vivo positron emission tomography (PET) analysis of R6/2 animals at
10 weeks revealed a reduced metabolic activity in the basal ganglia, which was partially attenuated
by treatment with the Sativex-like combination of phytocannabinoids. Proton nuclear magnetic
resonance spectroscopy (H+-MRS) analysis of the ex vivo striatum of R6/2 mice at 12 weeks revealed
changes in various prognostic markers reflecting events typically found in HD patients and animal
models, such as energy failure, mitochondrial dysfunction, and excitotoxicity. Some of these changes
(taurine/creatine, taurine/N-acetylaspartate, and N-acetylaspartate/choline ratios) were completely
reversed by treatment with the Sativex-like combination of phytocannabinoids. A Sativex-like
combination of phytocannabinoids administered to R6/2 mice at the onset of motor symptoms
produced certain benefits on the progression of striatal deterioration in these mice, which supports the
interest of this cannabinoid-based medicine for the treatment of disease progression in HD patients.
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1. Introduction
Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by
motor alterations (chorea followed by akinesia), but also cognitive dysfunction and psychiatric
symptoms [1]. HD is primarily caused by a mutation in the huntingtin gene consisting of a CAG
triplet repeat expansion translated into an abnormal polyglutamine tract in the N-terminus of this
protein, which becomes toxic for striatal and cortical neuronal subpopulations [2]. The available
pharmacotherapy to alleviate HD symptoms is poor (e.g., tetrabenazine for chorea), whereas there
are no available treatments able to arrest/delay disease progression in HD. In recent years,
several compounds (e.g., minocycline, coenzyme Q10, unsaturated fatty acids, inhibitors of histone
deacetylases) have been investigated and produced encouraging effects in preclinical studies, but none
of the findings obtained in these studies have yet led to the development of an effective medicine [3].
Continuing on from an extensive preclinical evaluation using different experimental models of HD,
clinical tests are now being performed with cannabinoids [4]. Such preclinical evaluation demonstrated
preservation of striatal neurons by several cannabinoid agonists against different cytotoxic stimuli that
operate in HD pathogenesis [5,6]. These beneficial effects were exerted through multiple mechanisms
of action, some of which involve the activation of CB1 and/or CB2 receptors and others of which do
not. For example, cannabinoids with an antioxidant profile (i.e., ∆9-tetrahydrocannabinol (∆9-THC),
cannabidiol (CBD), or cannabigerol (CBG)) protected striatal neurons against oxidative injury caused
by the mitochondrial complex II inhibitor 3-nitropropionic acid (3NP), and this occurred through effects
that were CB1/CB2 receptor-independent [7–9]. Given its activity at the CB1 and CB2 receptors, ∆9-THC
was also investigated with positive results in other experimental models, for example, R6/2 mice,
a transgenic mouse model of HD [10]. The effects of ∆9-THC in these mice are likely produced through
the activation of CB1 receptors [10], but they could also involve the activation of CB2 receptors,
as selective agonists of this receptor type preserved striatal neurons in this genetic model [11] and
also in malonate-lesioned rats [12], a model priming apoptotic death and glia-driven inflammation.
Selective agonists of CB1 [10,13] and CB2 [11] receptors also preserved striatal neurons in in vitro
or in vivo excitotoxic models, whereas other authors did not find any beneficial effect in R6/1 mice
using ∆9-THC, the synthetic agonist HU-210, and the inhibitor of the endocannabinoid metabolism
URB597 [14].
The data collected from these studies support the interest of evaluating cannabinoids as
disease modifiers in HD in patients, but they also suggest that this should be done with a
broad-spectrum cannabinoid. As an alternative, a combination of cannabinoids having complementary
pharmacological effects would also be adequate. Such a profile can be found in Sativex,
a cannabis-based medicine which has been licensed for alleviating specific symptoms (spasticity, pain)
in patients affected by multiple sclerosis [15,16]. ∆9-THC present in Sativex may activate CB1/CB2
receptors and exert receptor-independent antioxidant effects, which would be markedly enhanced
by CBD also present in Sativex [17]. A few years ago, we initiated experiments with the Sativex-like
combination of these two phytocannabinoids in different animal models of HD. We used those
models in which individual cannabinoids had been active [7,8,10–13]. We worked first with rats
subjected to 3NP intoxication [18], in which calpain activation and oxidative injury are important
cytotoxic mechanisms. In this model, the administration of pure ∆9-THC [7] or pure CBD [8]
displayed neuroprotective properties. We found that, using the Sativex-like combination of these
two phytocannabinoids, striatal neurons were also preserved against the 3NP intoxication and,
again, we found that such a neuroprotective effect was CB1/CB2 receptor independent [18]. Next,
we conducted similar studies in a second model of HD, rats unilaterally-lesioned with malonate,
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in which activation of the apoptotic machinery and glial activation/inflammatory events were
responsible for the striatal damage. We had previously described that selectively activating the
CB2 receptor resulted in a reduction of the striatal damage [12], whereas this was aggravated after
CB1 receptor blockade [19]. The Sativex-like combination of phytocannabinoids also preserved
striatal neurons from death caused by malonate, and this effect was dependent on both CB1 and
CB2 receptors [20].
These positive effects prompted us to extend our research to transgenic mouse models of HD,
specifically the R6/2 mice, which are frequently used for the evaluation of potential neuroprotective
compounds that warrant investigation at the clinical level. To this end, we subjected R6/2 mice to
daily treatment with Sativex-like combination of phytocannabinoids (equivalent to 3 mg/kg weight
of pure CBD + ∆9-THC) or with vehicle. Treatments commenced at 4 weeks and were prolonged up
to 12 weeks after birth, the age at which animals were euthanized. The progression of neurological
deficits (e.g., rotarod performance) was recorded during the treatment period, whereas additional
motor markers (e.g., clasping behavior) were recorded just before animals were euthanized together
with the in vivo imaging analysis of local metabolic activity using positron emission tomography
(PET). Once euthanized, brains were collected and the striatum dissected and used for ex vivo proton
magnetic resonance spectroscopy (H+-MRS) analysis, which provides a series of detectable biomarkers
reflecting: (i) oxidative damage (e.g., reduced glutation/creatine ratio (GSH/Cre)); (ii) energy failure
(e.g., elevated lactate/N-acetyl-aspartate ratio (Lac/NAA), reduced NAA/choline ratio (NAA/Cho));
(iii) excitotoxicity (e.g., increased glutamate/NAA ratio (Glu/NAA)); and (iv) other events typically
found in HD (e.g., taurine/Cre ratio (Tau/Cre), Tau/NAA ratio, all of them being relatively prognostic
for brain integrity/damage) [21–26].
2. Results
2.1. Behavioral Analysis of R6/2 Mice Treated with the Sativex-Like Combination of Phytocannabinoids
Despite the possibility of differences by gender in disease progression and treatment responses
in R6/2 mice, our experiment was conducted exclusively in males to avoid a potential influence
of ovarian steroid fluctuations when using females. Compared to wild-type animals, R6/2 mice
exhibited a characteristic loss of weight gain that was initiated at 9 weeks of age and deteriorated
at 10–11 weeks and up to 12 weeks of age when animals were euthanized (age: F(8,200) = 279.1,
p < 0.0001; genotype/treatment: F(2,200) = 4.497, p < 0.05; interaction: F(16,200) = 10.64, p < 0.0001;
Figure 1A). This loss of weight has been widely reported in R6/2 mice [9,10] and also in other
transgenic models of HD [27,28]. In parallel, there was a deterioration in rotarod performance that
was already evident at the age of 6 weeks after birth, then occurring before the loss of weight,
and reaching its maximum at the last age analyzed (10 weeks after birth) (age: F(5,139) = 21.57,
p < 0.0001; genotype/treatment: F(2,139) = 187.3, p < 0.0001; interaction: F(10,139) = 15.30, p < 0.0001;
Figure 1B). The treatment with the Sativex-like combination of phytocannabinoids did not produce
any recovery in both rotarod performance and weight gain (Figure 1A,B). By contrast, the Sativex-like
combination of phytocannabinoids was highly effective in attenuating clasping behavior detected in
R6/2 mice at the age of 10 weeks (F(2,17) = 13.88, p < 0.0005; <95% confidence intervals for wild-type
mice, and R6/2 animals treated with vehicle or Sativex-like combination of phytocannabinoids were 0,
1.12. and 0.04, respectively; >95% confidence intervals were 0, 2.88, and 1.53, respectively; Figure 1C),
a response that reflects dystonia and is absent in wild-type animals. The statistical relevance of
these differences was confirmed using different post-hoc assays (Student-Newman-Keuls, Tukey,
and Bonferroni), all reaching similar statistics.
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Figure 1. Weight gain (A), rotarod performance (B), and clasping behavior (C) in R6/2 mice treated 
from the age of 4 weeks after birth with ∆9-tetrahydrocannabinol (∆9-THC)- and cannabidiol (CBD)-
enriched botanical extracts combined in a Sativex®-like ratio 1:1 (4.5 mg/kg equivalent to 3 mg/kg of 
pure CBD + ∆9-THC), or vehicle (Tween 80-saline), and the corresponding wild-type animals. Details 
in the text. Values are expressed as means ± SEM for six to eight animals per group. Data were 
subjected to one- (clasping) or two-way (rotarod and weight) analysis of variance followed by the 
Student-Newman-Keuls test (* p < 0.05, *** p < 0.005 compared with wild-type mice; ## p < 0.01 
compared to R6/2 mice treated with vehicle).  
2.2. In Vivo Imaging Analysis of Regional Brain Metabolic Activity in R6/2 Mice Treated with the Sativex-
Like Combination of Phytocannabinoids 
The PET analysis with [18F]-fluoro-deoxy-glucose ([18F]FDG) of R6/2 mice proved a reduced 
metabolic activity in the whole brain at 10 weeks (F(2,14) = 4.609, p < 0.05; Figure 2A). Such reduction 
was also evident in those brain areas more affected in R6/2 mice such as the caudate-putamen (F(2,14) 
= 4.593, p < 0.05; Figure 2B) and the globus pallidus (F(2,14) = 4.794, p < 0.05; Figure 2C), but it was 
also present in the cerebral cortex, cerebellum, amygdala, hypothalamus, and other forebrain regions 
(data not shown). In all cases, the reduction in regional metabolic activity in the R6/2 mice was 
attenuated by treatment with the Sativex-like combination of phytocannabinoids (Figure 2A–C). In 
the case of the whole brain, the difference between R6/2 mice treated with vehicle and treated with 
the Sativex-like combination of phytocannabinoids reached statistical significance (<95% confidence 
intervals for wild-type mice, and R6/2 animals treated with vehicle or Sativex-like combination of 
phytocannabinoids were 12.99, 10.01, and 10.79, respectively; >95% confidence intervals were 18.57, 
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Figure 1. Weight gain (A), rotarod performance (B), and clasping behavior (C) in R6/2mice treated from
the age of 4 weeks after birth with ∆9-tetrahydrocannabinol (∆9-THC)- and cannabidiol (CBD)-enriched
botanical extracts combined in a Sativex®-like ratio 1:1 (4.5 mg/kg equivalent to 3 mg/kg of pure
CBD + ∆9-THC), or vehicle (Tween 80-saline), and the corresponding wild-type animals. Details in
the text. Values are expressed as means ± SEM for six to eight animals per group. Data were
subjected to on - (clasping) or two-way (rotarod and weight) analysis of variance followed by the
Student-Newman-Keuls test (* p < 0.05, *** p < 0.005 compared with wild-type mice; ## p < 0.01
compared to R6/2 mice treated with vehicle).
2.2. In Vivo Imaging Analysis of Regional Brain Metabolic Activity in R6/2 Mice Treated with the Sativex-Like
Combination of hytocannabinoids
The PET analysis with [18F]-fluoro-deoxy-glucose ([18F]FDG) of R6/2 mice proved a reduced
metabolic activity in the whole brain at 10 weeks (F(2,14) = 4.609, p < 0.05; Figure 2A). Such reduction
was also evident in those brain areas more affected in R6/2 mice such as the caudate-putamen
(F(2,14) = 4.593, p < 0.05; Figure 2B) and the gl bus pallidus (F(2,14) = 4.794, p < 0.05; Figure 2C), but it
was also pres nt in the c rebral cortex, c rebellu , amygdala, hypoth lamus, and other forebrain
regions (d ta not shown). In all cases, the reductio in regional m tabolic activity in the R6/2 mice
was attenuated by treatment with the Sativex-like combination of phytocannabinoids (Figure 2A–C).
In the case of the whole brain, the difference between R6/2 mice treated with vehicle and treated with
the Sativex-like combination of phytocannabinoids reached statistical significance (<95% confidence
intervals for wild-type mice, and R6/2 animals treated with vehicle or Sativex-like combination of
phytocannabinoids were 12.99, 10.01, and 10.79, respectively; >95% confidence intervals were 18.57,
12.80, and 19.12, respectively; Figure 2A), but in the case of the caudate-putamen and globus pallidus,
the effect was evident only in the loss of statistical significan e when compared to wild-type animals
(caudate-putame : <95% confidence intervals for wild-type mice, and R6/2 animals reated with
vehicle or Sativex-like combination of phytocannabinoids were 13.95, 10.19, and 10.52, respectively;
>95% confidence intervals were 20.56, 13.56, and 20.27, respectively; Figure 2B; globus pallidus:
<95% confidence intervals for wild-type mice, and R6/2 animals treated with vehicle or Sativex-like
combination of phytocannabinoids were 13.98, 10.48, and 10.86, respectively; >95% confidence intervals
were 20.53, 13.51, and 20.14, respectively; Figure 2C). Effects similar to the caudate-putamen and the
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globus pallidus by the treatment with the Sativex-like combination of phytocannabinoids were also
evident in the cerebellum (data not shown), other Central Nervous System (CNS) structure that has
been related to the control of motor activity. In other brain regions (e.g., septum nuclei, amygdala)
the differences between R6/2 mice treated with vehicle or with the Sativex-like combination of
phytocannabinoids were statistically significant (data not shown), as for the whole brain, but these
regions are not related to the control of movement but to emotional and cognitive processes which,
although also affected in HD patients, were not reproduced in R6/2 mice. Representative PET images
for the three groups investigated are included in Figure 2D.
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Figure 2. In vivo glucose metabolic rates measured by positron emission tomography (PET) analysis
in the whole brain (A), caudate-putamen (B), and globus pallidus (C), including representative PET
images in (D) of R6/2 mice (at 10 weeks after birth) treated from the age of 4 weeks after birth
with ∆9-THC- and CBD-enriched botanical extracts combined in a Sativex®-like ratio 1:1 (4.5 mg/kg
equivalent to 3 mg/kg of pure CBD + ∆9-THC), r vehicle (Tween 80-saline), and the corresponding
wild-type animals. Details in the text. Values correspond to standard uptake value (SUV) and are
expressed as means± SEM of five subjects per group and age. Data were subjected to one-way analysis
of variance followed by the Student-Newman-Keuls test (* p < 0.05 compared with wild-type mice;
# p < 0.05 compared to R6/2 mice treated with vehicle).
2.3. H+-MRS Analysis of Several Markers of Brain Integrity in R6/2 Mice Treated with the Sativex-Like
Combination of Phytocannabinoids
The H+-MRS analysis of the post-mortem striatum of R6/2 animals at 10 weeks after birth
demonstrated important changes in specific markers of HD pathology. For example, we found an
elevation in Lac/NAA ratio (F(2,14) = 10.99, p < 0.005; Figure 3A), which is an indirect marker of
a possibl energy deficit an mitochondrial dysfunction due to el vated Lac g nerati n, a result
also foun by other authors [24,25], and/or reduced NAA l vels possibly reflecting neuronal
dysfunction/damage [24]. Lowered NAA levels also may reflect mitochondrial dysfunction,
as this metabolite is synthesized in mitochondria [24]. This elevation tended to be reduced,
although modestly (without reaching statistical significance) by the treatment with the Sativex-like
combination of phytocannabinoids (Figure 3A). However, this treatment completely recovered the
reduction in NAA/Cho ratio found in R6/2 mice (F(2,12) = 11.62, p < 0.005; (<95% confidence
intervals for wild-type mice, and R6/2 animals treated with vehicle or Sativex-like combination
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of phytocannabinoids were 0.84, 0.55, and 0.88, respectively; >95% confidence intervals were 1.16, 0.72,
and 1.26, respectively; Figure 3B), which is also a potential predictive marker of energy failure [24,25].
We also found an elevation in Glu/NAA ratio (F(2,14) = 24.81, p < 0.0001), which potentially reflects
excitotoxicity [21–23,26], but this response was not altered by the treatment with the Sativex-like
combination of phytocannabinoids (Figure 3C). The H+-MRS analysis also revealed elevated Tau/Cre
(F(2,14) = 4.572, p < 0.05; Figure 3D) and Tau/NAA (F(2,14) = 30.08, p < 0.0001; Figure 3E) ratios in
R6/2 mice. Elevated Tau levels—presumably reflecting an endogenous protective response, as well
as changes in cell volume regulation, and being frequently associated with lower Cre concentrations
potentially reflecting reduced energy availability—have been found in HD patients using metabolomic
analysis [29] and in other mouse models of HD [26]. These changes were attenuated by the
treatment with the Sativex-like combination of phytocannabinoids, in particular for Tau/NAA ratio
(<95% confidence intervals for wild-type mice, and R6/2 animals treated with vehicle or Sativex-like
combination of phytocannabinoids were 0.76, 2.00, and 0.94, respectively; >95% confidence intervals
were 1.24, 2.34, and 1.81, respectively; Figure 3E) and, to a lesser extent (only losing statistical
significance with respect to wild-type mice), for Tau/Cre ratio (<95% confidence intervals for wild-type
mice, and R6/2 animals treated with vehicle or Sativex-like combination of phytocannabinoids were
0.70, 1.28, and 0.93, respectively; >95% confidence intervals were 1.30, 1.37, and 1.35, respectively;
Figure 3D). No changes were noted in GSH/Cre ratio (F(2,14) = 1.583, ns), potentially reflecting
oxidative damage [30], in R6/2 mice compared to wild-type animals, which agrees with the poor
oxidative stress response described in these mice [9]; treatment with the Sativex-like combination of
phytocannabinoids did not modify this ratio (Figure 3F).
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Figure 3. Lactate/N-acetyl-aspartate (Lac/NAA) (A); NAA/ choline (Cho) (B); glutamate (Glu)/NAA
(C); Tau/Cre (D); Tau/NAA (taurine/creatine) (E); and (reduced glutation) GSH/Cre (F) ratios measured
by proton nuclear magn tic resonance sp ct scopy (H+-MRS) analysis in the striatum of R6/2 mice
(at 12 weeks after birth) treated from the age of 4 weeks after birth with ∆9-THC- and CBD-enriched
botanical extracts combined in a Sativex®-like ratio 1:1 (4.5 mg/kg equivalent to 3 mg/kg of pure
CBD + ∆9-THC), or vehicle (Tween 80-saline), and the corresponding wild-type animals. Details in the
text. Values are expressed as means ± SEM of five animals per group. Data were subjected to one-way
analysis of variance followed by the Student-Newman-Keuls test (* p < 0.05, ** p < 0.01, *** p < 0.005
compared with wild-type mice; ## p < 0.01, ### p < 0.005 compared to R6/2 mice treated with vehicle).
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3. Discussion
Only a few clinical studies have been performed to determine whether cannabinoid compounds
have beneficial effects in HD [31–34]. These clinical studies concentrated more on HD symptoms
(e.g., choreic movements, behavioral disturbances) rather than on disease progression. Recent animal
studies, however, have demonstrated that using a broad-spectrum cannabinoid or, alternatively,
combinations of cannabinoids having complementary profiles, it is possible to delay the progression
of the disease and to preserve the integrity of striatal neurons, and this has been found in different
animal models of HD [8–13]. Such observations demand new clinical studies directed at testing
in patients these disease-modifying properties demonstrated by certain cannabinoids. To provide
more support to this idea, we recently demonstrated neuroprotective effects, using the Sativex-like
combination of ∆9-THC and CBD botanical extracts, in rats subjected to 3NP intoxication [18] and also
in malonate-lesioned rats [20], two classic experimental in vivo models of HD in which striatal damage
is caused by different primary mechanisms (e.g., calpain activation/oxidative injury, apoptosis/gial
activation/inflammation, respectively).
In the present study, we used R6/2mice, a genetic model which is frequently used in the preclinical
evaluation of novel therapies for HD because of the rapid disease progression of these animals,
and in which different cannabinoids administered individually, including ∆9-THC but not CBD,
were shown to be active [10,11]. Our results suggest certain benefits with the Sativex-like combination
of phytocannabinoids in R6/2 mice in line with those observed in neurotoxin-based models [18,20].
In our hands, the mixture of both phytocannabinoids attenuated clasping behavior, which represents a
classic motor symptom found in these mice, although it was inactive against the progressive worsening
in rotarod performance. This lack of Sativex benefits in mouse rotarod performance was relatively
surprising, as we have previously found that this parameter, being markedly reduced in R6/2 mice,
was attenuated by the treatment with pure ∆9-THC [10]. In our opinion, it is not a problem of
insufficient dose, as we have preliminary and unpublished data indicating that higher doses (5 and
10 mg/kg) for the Sativex-like combination of phytocannabinoids led to the same lack of improvement.
We do not consider that this improvement may be elicited by increasing the number of subjects in both
experimental groups, as they were relatively homogeneous with their progressing lines for the rotarod
performance showing a high overlapping. In order to find an explanation it is better to look at other
studies that have also described no improvement in rotarod performance but beneficial effects in other
behavioral parameters and recovery at the neuropathological level. This was the case of our previous
study with the phytocannabinoid CBG, which proved a poor and statistically non-significant recovery
in the worsened rotarod response typical of R6/2 mice, but it produced a much more marked reduction
in the presence of mutant huntingtin aggregates as well as an increase in different prosurvival factors
(e.g., neurotrophins) [9]. Similar findings derive from a study in R6/1 mice, a similar genetic HD
model, although with a less aggressive phenotype due to a shorter CAG repeat length in the transgene,
in which authors were unable to find rotarod improvements with ∆9-THC, despite some benefits found
in other behavioral parameters such as motor responses in exploratory tests [14].
The benefits we found in clasping behavior with the Sativex-like combination of
phytocannabinoids had a biochemical correlate in the improvement of metabolic activity recorded
in the basal ganglia using in vivo imaging PET analysis, as well as in different H+-MRS indices,
potentially reflecting energy failure and neuronal deterioration. It is true that we did not observe
any improvement in excitotoxicity and oxidative stress markers measured with H+-MRS with the
Sativex-like combination of phytocannabinoids, despite the potential of this combination against
both processes. This can be possibly explained by the fact that excitotoxic damage and, in particular,
oxidative stress are not particularly relevant cytotoxic processes in R6/2 mice, as found here and as has
been described before in other studies [9,35]. On the other hand, it would have been interesting to have
data of animal survival after the treatment with the Sativex-like combination of phytocannabinoids,
but this was not possible once the animals were euthanized for collecting tissues for H+-MRS analysis.
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Collectively, the improvement in some behavioral and neurochemical parameters that have been
found here in R6/2 mice after the Sativex-like combination of phytocannabinoids, together with
the data obtained in neurotoxin-based models [18,20], fueled the interest in the clinical evaluation
of Sativex as a disease-modifying therapy in HD patients. In fact, such clinical evaluation was
initiated before our present experiment in R6/2 mice was concluded, and it was derived from the
collaboration of a group of Spanish neurologists, GW Pharmaceuticals (the British pharma company
that developed Sativex), and various groups of basic researchers including us. The clinical study
was developed in a small population of HD patients (all of them early symptomatic), designed as a
crossover trial with two different treatment patterns: (i) placebo (12 weeks), washout period (4–6 weeks),
and Sativex (12 weeks); and (ii) Sativex (12 weeks), washout period (4–6 weeks) and placebo (12 weeks).
The dosing of Sativex®/placebo was 12 sprays/day. The primary endpoint was safety of Sativex in HD
patients, whereas the secondary endpoint was to obtain any evidence of slower disease progression
in the patients during the active treatment phases. We observed that Sativex, in concordance with
previous data obtained in control subjects, patients of other pathologies, and laboratory animals
(reviewed in [36]), was safe in HD patients. However, we were unable to detect any evidence of
slower disease progression [4]. It is possible that the efficacy of Sativex constituents needs periods
of treatments longer than the relatively short 12 weeks used in this clinical trial. A similar situation
happened with creatine, which was also a very active neuroprotective compound in preclinical studies
in HD [37,38], but failed when passed to clinical validation [39]. Authors concluded that the duration
of the study was the critical factor as one year, a treatment period longer than in our study with
Sativex [4], was considered not sufficiently long to have clinically detectable impact in HD patients [39].
With the aim of progressing in this direction, we are presently designing a novel initiative that will
attempt to recruit a higher population of HD patients, to involve different hospitals in Europe, and to
work with more than one Sativex dosing regimen and longer treatment periods.
4. Materials and Methods
4.1. Animals
R6/2 and wild-type mice, produced from initial breeders obtained from Jax (Jackson Laboratories,
Bar Harbor, ME, USA), were housed in rooms with controlled photoperiod (08:00–20:00 light) and
temperature (22 ± 1 ◦C) and with free access to standard food and water. Offspring were genotyped
for the transgene containing the mutated huntingtin following a procedure described previously [10].
Male R6/2 (160 ± 5 CAG repeats) and wild-type animals were used at the age of 4 weeks to record
disease progression and basal ganglia deterioration in pharmacological studies using a Sativex-like
combination of phytocannabinoids. All experiments were conducted according to local and European
rules (directive 86/609/EEC) and approved by the “Comité de Experimentación Animal” of our
university (CEA-UCM 56/2012; 8 March 2012).
4.2. Treatments and Sampling
Animals included in our pharmacological studies were treated with the 1:1 combination of
botanical extracts enriched with either ∆9-THC, kindly provided by GW Research Ltd., Cambridge,
UK (∆9-THC botanical extract contained 69.6% ∆9-THC, 0.3% CBD, 0.9% CBG, 0.9% cannabichromene,
and 1.9% other phytocannabinoids) or CBD, also provided by GW Research Ltd., Cambridge, UK
(CBD botanical extract contained 64.3% CBD, 2.3% ∆9-THC, 1.1% CBG, 3.0% cannabichromene,
and 1.5% other phytocannabinoids). The total dose of cannabinoid administeredwas always 4.5 mg/kg
(equivalent to 3 mg/kg of pure CBD + ∆9-THC), a dose within the range of effective doses of both
compounds when they were administered in pure form in this and other experimental models of
HD [10–13], and also close to the clinical uses of Sativex [4,36]. This was also close to the doses used
in our previous studies with Sativex-like combination of phytocannabinoids in other HD models,
although these studies used rats instead mice [18,20]. Cannabinoids were prepared in Tween 80-saline
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solution (1:16) and they were administered intraperitoneally (i.p.). R6/2 mice administered with
vehicle, as well as counterpart wild-type animals, were also included in this experiment. To include
an additional group of wild-type mice treated with Sativex would have been desirable. However,
due to the need to consider the new 3R recommendations on the use of experimental animals and
given that previous studies have reported no relevant differences between wild-type animals treated
with vehicle or with different cannabinoids [9–11], such a group was not included in our present study.
The treatment was initiated when animals were 4 weeks old (presymptomatic) and was repeated every
day up to the age of 12 weeks, the age at which the animals were euthanized after behavioral (rotarod
test analyzed weekly, and clasping analyzed at 10 weeks) and in vivo PET imaging (at 10 weeks)
analysis. Their brains were rapidly removed and the two striata dissected and stored immediately
at −80 ◦C for subsequent H+-MRS analysis. It would have been interesting to detect any possible
benefit of the Sativex-like combination of phytocannabinoids on animal survival, but this would have
demanded a separate experiment, which was not approved due to ethical concerns. In all experiments,
at least six animals were used per experimental group.
4.3. Behavioral Recording
All behavioral tests were conducted prior to drug injections to avoid acute effects of the compounds
under investigation, and they were carried out by researchers blinded to the treatment in each animal.
4.3.1. Rotarod Test
We used a LE8200 device (Panlab, Barcelona, Spain), with acceleration from 4 to 40 rpm. over a
period of 600 s. After a period of acclimation and training (first session: 0 rpm for 30 s; second and
third sessions: 4 rpm for 60 s, with periods of 10 min between sessions) mice were tested on one day
every week from week 4 of age, for four consecutive trials, with a rest period of approximately 20 min
between trials. The average of the last three trials per day was used for the statistical analysis.
4.3.2. Hindlimb Clasping
Mice were suspended by the tail, so that their body dangled in the air facing downward. Hindlimb
position was observed with the mice lifted by the tail for 30 s and animals were scored according
to the following scale: (i) score = 0 if the hindlimbs are consistently splayed outward, away from
the abdomen; (ii) score = 1 if one hindlimb is retracted toward the abdomen; (iii) score = 2 if both
hindlimbs are partially retracted toward the abdomen; and (iv) score = 3 if both hindlimbs are entirely
retracted and touching the abdomen.
4.4. In Vivo Analysis of Glucose Metabolism: [18F]FDG PET Imaging
To evaluate the regional brain metabolic activity, PET with the radiotracer [18F]-fluoro-
deoxy-glucose ([18F]FDG) was performed. Briefly, mice were fasted, to minimize the influence of
glycemia, for at least 12 h previous to be i.p. injected with approximately 11.1 MBq of [18F]FDG
(Instituto Tecnológico PET, Madrid, Spain). After an uptake period of 45 min, mice were scanned
with a small-animal hybrid PET/CT (computed tomography) device (Albira ARS scanner, Oncovision,
Valencia, Spain) under 2% isoflurane anesthesia. PET acquisition time was 30 min and it was
immediately followed by CT scanning. After reconstruction of the PET and CT images, these were
co-registered to a magnetic resonance image (MRI) template for the mouse brain, in which the brain
regions were delineated. To this aim, the CT image was first co-registered to the MRI template
and the mathematical transformation was saved. Then, this transformation was applied to its own
fused PET image. This step allows the right matching of the PET image with the mouse brain
MRI template. All these steps were carried out using PMOD 3.0 software (PMOD Technologies Ltd.,
Zurich, Switzerland). As an index of regional metabolic activity, we used the standard uptake
value (SUV), which is currently the most used quantification index using [18F]FDG PET imaging
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for small animals [40]. It represents the ratio of the regional radioactivity concentration measured
by the PET scanner and the actual injected dose (corrected for radiotracer decay at the time of the
injection) divided by the animal weight.
4.5. Proton Magnetic Resonance Spectroscopy (H+-MRS)
Ex vivo H+-MRS analysis has been demonstrated to provide metabolic information with higher
sensitivity and spectral resolution than in vivo magnetic resonance spectroscopy [21]. H+-MRS was
performed in the MRI Unit of the Instituto Pluridisciplinar (Universidad Complutense, Madrid,
Spain) using a Bruker AMX500 spectrometer and following previously described procedures [21,22].
The spectra generated were analyzed for Lac, NAA, Glu, GSH, Cre, Tau, and Cho, and several
ratios were calculated. They are relatively predictive of excitotoxicity (Glu/NAA), energy deficits
(Lac/NAA, NAA/Cho), oxidative damage (GSH/Cre), and other HD-acting neurotoxic events
(Tau/Cre, Tau/NAA), all being prognostic for brain integrity [21–26].
4.6. Statistics
Data were assessed by one- or two-way ANOVA, followed by the Student-Newman-Keuls,
Bonferroni, or Tukey tests as post-hoc assays, as required, using the GraphPad software (version 5.0,
GraphPad Software, Inc., La Jolla, CA, USA).
5. Conclusions
In summary, in line with the promising prospects generated by its beneficial effects in
neurotoxin-based models of HD, this study demonstrated that the Sativex-like combination of
phytocannabinoids improved some behavioral and neurochemical parameters, but not all, related to
the progression of striatal deterioration in R6/2 mice. This provides more evidence in support of its
potential for developing a future disease modifying therapy for HD patients, despite the recently failed
clinical evaluation of Sativex in a small population of patients. Higher dosage and longer treatments
periods may be important to reveal such potentialities in patients.
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Neuroprotective Properties of Cannabigerol
in Huntington’s Disease: Studies in R6/2 Mice
and 3-Nitropropionate-lesioned Mice
Sara Valdeolivas & Carmen Navarrete & Irene Cantarero &
María L. Bellido & Eduardo Muñoz & Onintza Sagredo
# The American Society for Experimental NeuroTherapeutics, Inc. 2014
Abstract Different plant-derived and synthetic cannabinoids
have shown to be neuroprotective in experimental models of
Huntington’s disease (HD) through cannabinoid receptor-
dependent and/or independent mechanisms. Herein, we stud-
ied the effects of cannabigerol (CBG), a nonpsychotropic
phytocannabinoid, in 2 different in vivo models of HD. CBG
was extremely active as neuroprotectant in mice intoxicated
with 3-nitropropionate (3NP), improving motor deficits and
preserving striatal neurons against 3NP toxicity. In addition,
CBG attenuated the reactive microgliosis and the upregulation
of proinflammatory markers induced by 3NP, and improved
the levels of antioxidant defenses that were also significantly
reduced by 3NP. We also investigated the neuroprotective
properties of CBG in R6/2 mice. Treatment with this
phytocannabinoid produced a much lower, but significant,
recovery in the deteriorated rotarod performance typical of
R6/2 mice. Using HD array analysis, we were able to identify
a series of genes linked to this disease (e.g., symplekin, Sin3a,
Rcor1, histone deacetylase 2, huntingtin-associated protein 1,
δ subunit of the gamma-aminobutyric acid-A receptor (GABA-
A), and hippocalcin), whose expression was altered in R6/2
mice but partially normalized by CBG treatment. We also
observed a modest improvement in the gene expression
for brain-derived neurotrophic factor (BDNF), insulin-
like growth factor-1 (IGF-1), and peroxisome proliferator-
activated receptor-γ (PPARγ), which is altered in these mice,
as well as a small, but significant, reduction in the aggregation
of mutant huntingtin in the striatal parenchyma in CBG-
treated animals. In conclusion, our results open new research
avenues for the use of CBG, alone or in combination with
other phytocannabinoids or therapies, for the treatment of
neurodegenerative diseases such as HD.
Key Words Phytocannabinoids . cannabigerol .
Huntington’s disease . inflammation . neuroprotection
Introduction
Huntington’s disease (HD) is an inherited neurodegenerative
disorder characterized by motor abnormalities, cognitive dys-
function, and psychiatric symptoms [1]. The primary cause of
the disease is a mutation in the huntingtin gene, which consists
of a CAG triplet repeat expansion translated into an abnormal
polyglutamine tract in the amino-terminal portion of this
protein that becomes toxic for striatal and cortical neuronal
subpopulations [2]. At present, there is no specific pharmaco-
therapy to alleviate motor and cognitive symptoms and/or to
arrest/delay disease progression in HD. Thus, even though a
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few compounds have produced encouraging results in preclin-
ical studies (i.e., unsaturated fatty acids, inhibitors of histone
deacetylases, coenzyme Q10, minocycline), none of the find-
ings obtained in these studies have yet led to the development
of an effective medicine [3]. Importantly, following on from
an extensive preclinical evaluation using different experimen-
tal models of HD (reviewed in [4] and [5]), clinical tests are
now being performed with cannabinoids. Using experimental
models that reproduce different cytotoxic stimuli that operate
in HD pathogenesis, for example rodents treated with mito-
chondrial toxins (e.g., inhibitors of mitochondrial complex II),
quinolinate-lesioned mice, or transgenic mice bearing mutated
forms of human huntingtin, preclinical studies with cannabi-
noids demonstrated preservation of striatal neurons [6–11].
The beneficial effects of cannabinoids were exerted through
multiple mechanisms of action, including cannabinoid recep-
tor type 1 (CB1) activation (e.g., excitotoxic models [8, 11]),
cannabinoid receptor type 2 (CB2) activation (e.g., inflamma-
tory models [10]), and CB1/CB2-independent mechanisms.
For example, cannabinoid receptor-independent effects were
induced by compounds with antioxidant profiles, such asΔ9-
tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), and
were particularly evident against the toxicity caused by the
mitochondrial complex II inhibitor 3-nitropropionic acid
(3NP), which primes oxidative injury [6, 7]. The combination
of botanical extracts enriched in these 2 phytocannabinoids,
similar to the formulation of the already approved cannabis-
based medicine, Sativex® (GW Pharmaceuticals, Salisbury,
UK) [12, 13], also preserved striatal neurons in rats subjected
to 3NP intoxication [14], a model priming, as mentioned
above, calpain activation and oxidative injury as major cyto-
toxic mechanisms and in which, as mentioned above, both
Δ9-THC [6] and CBD [7], administered separately, have al-
ready been found to display neuroprotective properties. These
effects of the Sativex®-like combination of phytocannabinoids
were also, as expected, independent of CB1 and CB2 recep-
tors [14], and attributed to the inherent antioxidant proper-
ties of both phytocannabinoids that may depend on their
particular chemical structure (reviewed in [15]). In addi-
tion, it has been suggested that Δ9-THC, and especially
CBD, may exert its neuroprotective effects by regulating
the activity of inducible transcription factors such as nucle-
ar factor kappa B (NF-κB), nuclear factor erythroid 2-
related factor 2 (Nrf-2), and peroxisome proliferator-
activated receptor (PPARγ) [16].
Cannabigerol (CBG) is another major phytocannabinoid
having a pharmacological profile relatively similar to Δ9-
THC and CBD in relation to its CB-independent activities.
CBG is nonpsychotropic and does not bind or activate CB1 or
CB2 [17, 18]. However, CBG is antioxidant [17, 18], as well
as anti-inflammatory, as it inhibits lipopolysaccharide-
induced (LPS) release of proinflammatory cytokines and pros-
taglandin E2 in primary microglial cells [19], activates
PPARγ [19], and attenuates murine colitis induced by
intracolonic administration of dinitrobenzene sulfonic acid
[20]. CBG also targets α-2 adrenergic receptors [21], and
serves as an antagonist of serotonin 5-hydroxytryptamine 1A
receptors (5HT1A) [21]. CBG has not been studied in HD but
its pharmacological profile (e.g., antioxidant and activator of
PPARγ) presents certain interest as a potential disease-
modifying agent in this disorder. This possibility prompted us
to extend our preclinical work with classic phytocannabinoids
in HD to CBG using first a neurotoxin-based model, 3NP-
lesioned mice. This is a model in which the death of striatal
neurons is predominantly associated with the occurrence of
mitochondrial dysfunction, calpain activation, and oxidative
stress [14, 22]; therefore, a model in which CBG may be
beneficial owing to its antioxidant and anti-inflammatory ac-
tivities. Moreover, we also wanted to study CBG in R6/2 mice,
a transgenic model of HD that reproduces a very aggressive
pathological phenotype and that is frequently used in preclin-
ical evaluation of potential neuroprotective compounds. Can-
nabinoids other than CBG are particularly active in this murine
model [8, 9]. To this end, we subjected 3NP-lesioned or R6/2
mice, and their respective controls, in two separate experiments
to daily treatments with CBG at a dose of 10 mg/kg. In the case
of 3NP-lesionedmice, the treatmentswere prolonged for 4 days
before the animals were euthanized and their brains collected
for further analysis. In the case of R6/2 mice, treatments began
at 4 weeks and were prolonged up to 10 weeks after birth, the
age at which animals were also euthanized and their brains
collected for further analysis. The progression of neurological
deficits (e.g., failed rotarod performance, altered locomotor
activity, clasping, dystonia) was recorded before (only in
R6/2 mice) and/or during (in both experiments) the treatment
period, whereas for the extent of the striatal damage, the brains
were analyzed using different histological parameters [e.g.,
Nissl staining; NeuN or dopamine- and cyclic adenosine
monophosphate-regulated phosphoprotein, Mr 32 kDA
(DARPP-32) immunostaining; reactive microgliosis deter-
mined with Iba-1 immunohistochemistry; astrogliosis labelled
with glial fibrillary acidic protein (GFAP) immunostaining],
and the expression of various biochemical markers related to
the endocannabinoid signaling system [e.g., CB1 and CB2,
fatty acid amide hydrolase (FAAH) and monoacylglycerol
lipase (MAGL) enzymes] or that have been found previously
to be altered in different HD models [e.g., the neurotrophins
brain-derived neurotrophic factor (BDNF) and insulin-like
growth factor-1 (IGF-1), the glutamate transporters GLT-1
and glutamate aspartate transporter (GLAST), DARPP-32,
some antioxidant enzymes, and proinflammatory enzymes
and cytokines] [2, 8–10, 14, 23]. The striatal samples from
both experiments were also analyzed with a specific HD
polymerase chain reaction (PCR) array system. We performed
an additional experiment conducted with CBG in striatal pro-
genitor cell lines STHdhQ7/Q7 and STHdhQ111/Q111 expressing
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endogenous wild-type and mutant huntingtin, respectively,
which was aimed at determining the effects of this
phytocannabinoid on PPARγ receptors (see Supplementary
Information).
Materials and Methods
Animals and Treatments
All animals used in this study were housed in a room with a
controlled photoperiod (08:00–20:00 light) and temperature
(22±1 °C) with free access to standard food and water. All
experiments were conducted according to local and European
rules (European Union directive 86/609/EEC) and approved
by the respective animal research ethic committees of our
universities (Universidad de Córdoba and Universidad
Complutense). To induce lesions of the striatum, 16-week-
old C57BL/6 male mice (Harlan Ibérica, Barcelona, Spain)
were subjected to seven intraperitoneal (i.p.) injections of
50 mg/kg 3NP [Sigma-Aldrich, St. Louis, MO, USA; one
injection each every 12 h prepared in phosphate-buffered
saline (PBS)]. 3NP-treated animals and their respective
nonlesioned controls (injected with PBS) were used for phar-
macological studies with CBG (THC Pharm GmbH, Frank-
furt, Germany). Treatments consisted of 4 i.p. injections every
24 h with CBG at a dose of 10 mg/kg, a dose within the range
of effective doses for phytocannabinoids in HD and other
disorders when they were administered in pure form [8–11,
14] or vehicle (0.2 % dimethyl sulfoxide plus 5 % bovine
serum albumin in PBS), with the first and the last injections
30 min before the first and the last injections of 3NP, respec-
tively. All animals were euthanized 12 h after the last injection
of 3NP. In a second experimental approach, we used a colony
of R6/2 and wild-type mice generated from initial breeders
obtained from Jackson Laboratories (Bar Harbor, ME, USA;
code: B6CBA-Tg(HDexon1)62Gbp/1 J; 160±5 repeat expan-
sions), which is presently available in our animal facilities.
The colony was maintained by back-crossing R6/2 males with
B6CBAF1/J females. Animals were subjected to genotyping
to confirm the presence of the transgene with the mutated
huntingtin (see details in [8] and [9]). Male R6/2 and wild-
type animals were used at the age of 4 weeks after birth, an age
at which motor symptoms have not appeared yet [8, 9]. Mice
were treated daily with i.p. injections of CBG (10 mg/kg) or
vehicle (Tween 80-saline, 1:16) up to the age of 10 weeks, at
which point the animals were euthanized (always 24 ho after
the last injection of CBG).
Sampling
Once euthanized, mice were dissected and their brains re-
moved. The right hemisphere was used to dissect the striatum,
which was frozen in 2-methylbutane cooled in dry ice and
stored at −80 °C for biochemical analyses [quantitative re-
verse transcription (qRT)-PCR, enzyme activities, array sys-
tem]. The left hemisphere was fixed in fresh 4 % paraformal-
dehyde (in 0.1 M PBS) for 36 h at 4 °C, followed by
cryoprotection in 30 % sucrose and storage at −80 °C for
staining and immunohistochemical analysis. In all experi-
ments, at least 6–8 animals were used per experimental group.
Evaluation of the Neurological Deterioration
Mice were subjected to different behavioral tests for determin-
ing their neurological status. In R6/2 mice, we evaluated
motor coordination in the RotaRod test, using a LE8200
device (Harvard Apparatus, Barcelona, Spain), with accelera-
tion from 4 to 40 r.p.m. over a period of 600 s. Mice were
tested on 1 day every week from week 4 of age, for 4
consecutive trials, with a rest period of approximately
20 min between trials. Data from the first trial were not used
in the statistical analyses. The first RotaRod performance, at
week 4, was established as basal performance. In 3NP-
lesioned mice, we evaluated the motor activity (ambulation
in an automated actimeter), the hindlimb clasping and dysto-
nia, and the truncal dystonia, following previously-described
procedures [24]. All behavioral tests were conducted prior to
drug injections to avoid acute effects of the compounds under
investigation.
Real-time qRT-PCR Analysis
Total RNA was isolated from striata using either SurePrep
RNA/Protein Purification Kit (Fisher Bioreagents, Madrid,
Spain) or RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden,
Germany). The total amount of RNA extracted was quantitat-
ed by spectrometry at 260 nm and its purity from the ratio
between the absorbance values at 260 and 280 nm. After
genomic DNA was removed (to eliminate DNA contamina-
tion), single-stranded complementary DNA was synthesized
from up to 1 μg of total RNA using Rneasy Mini Quantitect
Reverse Transcription (Qiagen) and the iScript cDNA Syn-
thesis Kit (Bio-Rad, Hercules, CA, USA). The reaction mix-
ture was kept at −20 °C until enzymatic amplification. In the
case of samples from R6/2 mice, quantitative RT-PCR assays
were performed using TaqMan Gene Expression Assays (Ap-
plied Biosystems, Foster City, CA, USA) to quantify mRNA
levels for CB1 (ref. Mm01212171_s1), CB2 (ref.
Mm02620087_s1), FAAH (ref. Mm00515684_m1), MAGL
(ref. Mm00449274_m1), IGF-1 (ref. Mm00439560_m1),
BDNF (ref . Mm04230607_s1) , DARPP-32 (ref .
Mm00454892_m1), GLT-1 (ref. Mm00441457_m1), GLAST
(ref. Mm00600697_m1), tumor necrosis factor (TNF)-α (ref.
Mm00443260_g1), and PPARγ (ref. Mm01184322_m1)
using glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
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expression (ref. Mm99999915_g1) as an endogenous con-
trol gene for normalization. The PCR assay was performed
using the 7300 Fast Real-Time PCR System (Applied
Biosystems) and the threshold cycle (Ct) was calculated
by the instrument’s software (7300 Fast System; Applied
Biosystems). The iQTM SYBR Green Supermix (Bio-Rad)
was used to quantify mRNA levels, in samples from 3NP-
lesioned mice, for cyclooxygenase (COX)-2, TNF-α, inter-
leukin (IL)-6, and inducible nitric oxide synthase (iNOS).
Real-time PCR was performed using a CFX96 Real-Time
PCR Detection System (Bio-Rad). The GAPDH house-
keeping gene was used to standardize the mRNA expres-
sion levels in every sample. Expression levels were calcu-
lated using the 2-ΔΔCt method. Sequences of oligonucleo-
tide primers are given in Table 1. The complementary DNA
samples were also used for an array analysis using the RT2
Profiler PCR Array Mouse HD (PAMM-123Z; Qiagen),
which has been designed with 84 HD-related genes, fol-
lowing the manufacturer’s instructions.
Measurement of Oxidative Stress Parameters
To determine different parameters related to oxidative stress
and antioxidant systems, the right striatum obtained from
3NP-lesioned and control mice was homogenized in 0.1 M
phosphate buffer (pH 7.4) using an Ultra-Turrax (IKA,
Staufen im Breisgau, Germany) for 30 s on ice. Homogenates
were cleared by centrifugation at 13,400 g at 4 °C and the
supernatants were collected. The protein content of the sam-
ples was determined using the Bradford assay. Catalase activ-
ity was assayed by the method described by Luck [25] in
which the breakdown of hydrogen peroxide (H2O2) is mea-
sured at 240 nm. Briefly, the assay mixture consisted of
12.5 mM H2O2 in 50 mM phosphate buffer (pH 7.0) and
0.05 ml of the supernatant of each striatal homogenate
(10 %), and the change in absorbance was recorded at
240 nm. Enzyme activity was calculated using the millimolar
extinction coefficient of H2O2 (0.07). The results are
expressed as percentage of the mean activity in the control
group. Superoxide dismutase (SOD) activity was assayed
according to the method described by Kono [26], wherein
the reduction of nitroblue tetrazolium chloride (NBT) was
inhibited by the SOD that was measured at 560 nm spectro-
photometrically. Briefly, the reaction was initiated by the
addition of 20 mM of hydroxylamine hydrochloride to the
mixture containing 1 mM of NBT and 0.1 ml of each striatal
homogenate. The results are expressed as percentage of the
mean activity in the control group. Reduced glutathione
(GSH) levels in each striatal homogenate were estimated
according to the method described by Ellman [27]. The tissue
samples (0.1 ml) were treated with trichloroacetic acid (10 %)
during 30 min at room temperature and then centrifuged at
600 g for 15 min. The supernatants were collected and incu-
bated with 6 mM 5,5’-dithiobis(2-nitrobenzoic acid)
(DTNB). DTNB and GSH react to generate 2-nitro-5-
thiobenzoic acid and glutathione disulfide (GSSG). Since 2-
nitro-5-thiobenzoic acid is a yellow-colored product, its deter-
mination at 412 nm is used as an index of GSH concentra-
tions, which are represented as percentage of mean levels
found in the control group.
Histological Analyses
Brains fixed in 4% paraformaldehyde and cryoprotected in 30%
sucrose were sliced (30-μm thick) with a cryostat at the level of
the caudate-putamen and collected on gelatin-coated slides for
immunohistochemical analysis of 1) EM48, a marker of mutant
huntingtin aggregates, using a monoclonal anti-mouse EM48
antibody (Millipore, Billerica, MA, USA) used at 1/400 (see
details in [28]); and 2) DARPP-32, a marker of striatal projection
neurons, using a monoclonal anti-mouse DARPP-32 antibody
(Cell Signaling Technology, Danvers, MA, USA) used at 1/300.
In the case of 3NP model, 5-μm-thick sections were used for
Cresyl-violet staining (see details in [29]) and for immunohisto-
chemical analysis of 1) NeuN, a marker of neurons, using a
monoclonal antimouse NeuN antibody (Millipore) used at 1/
100; 2) Iba-1, a marker of microglial cells, using a monoclonal
anti-mouse Iba-1 antibody (Millipore) used at 1/50; and 3)GFAP,
a marker of astrocytes, monoclonal antimouse GFAP antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) used at 1/50.
In all cases, sections were incubated overnight at 4 °C. After
incubation with the corresponding primary antibody, sections
were washed in 0.1 M PBS and incubated for 2 h at room
temperature with the appropriate biotin-conjugated antirat
(1:500; Millipore), biotin-conjugated antirabbit (1:300; Sigma/
Aldrich,Madrid, Spain) or goat antimouse (Millipore) secondary
antibodies. Reaction was revealed with the Vectastain® Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA). Negative
Table 1 List of mouse primer
sequences used in quantitative
polymerase chain reaction
Gene Forward Reverse
IL6 5’ -GAACAACGATGATGCACTTGC- 3’ 5’ -TCCAGGTAGCTATGGTACTCC- 3’
iNOS 5′ -AACGGAGAACGTTGGATTTG-3´ 5´-CAGCACAAGGGGTTTTCTTC-3´
COX-2 5´-TGAGCAACTATTCCAAACCAGC-3´ 5´-GCACGTAGTCTTCGATCACTATC-3´
TNFα 5’ -AGAGGCACTCCCCCAAAAGA-3’ 5’ -CGATCACCCCGAAGTTCCCATT-3’
GAPDH 5´-TGGCAAAGTGGAGATTGTTGCC-3´ 5´-AAGATGGTGATGGGCTTCCCG-3´
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control sections were obtained using the same protocol with
omission of the primary antibody. All sections for each immu-
nohistochemical procedure were processed at the same time and
under the same conditions. A Nikon Eclipse 90i microscope
and a Nikon DXM 1200 F camera (Nikon, Tokyo, Japan) were
used for slide observation and photography, and all image
processing was done using ImageJ (National Institutes of
Health, Bethesda. MD, USA). For this purpose, multiple sec-
tions, selected from levels located approximately 200 μm from
the middle of the lesion, were obtained from each brain and
used to generate a mean value per subject. In the case of the
quantification of EM48 and DARPP-32 immunostaining, three
30-μm-thick slices (at a distance of 360 μm each other) per
animal and 4 images at a magnification of 40× per each slice
were used. The number of aggregates, or of DARPP-32-stained
cells, was expressed as the mean value per field.
Cell Cultures and PPARγ Transcriptional Activity
Additional experiments were conducted in conditionally immor-
talized striatal progenitor cell lines STHdhQ7/Q7 expressing en-
dogenous wild-type huntingtin, and STHdhQ111/Q111 expressing
comparable levels of mutant huntingtin with 111 glutamines
[30]. Cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Lonza Ibérica, Barcelona, Spain) supple-
mented with 4 % fetal bovine serum and 4 % bovine growth
serum, 2 mM L-glutamine, and antibiotics. The cells were
grown at 33 °C in a humidified atmosphere containing 5 %
CO2. In 24-well plates, 10
5 cells/ml were cultured and transient-
ly co-transfected with the expression vector GAL4-PPARγ and
the luciferase reporter vector GAL4-luc using Roti®-Fect (Carl
Roth, Karlsruhe, Germany) following the manufacturer’s in-
structions. Twenty-four hours post-transfection, cells were treat-
ed with increasing concentrations of CBG for 6 h. Then, the
cells were lysed in 25mMTris-phosphate pH 7.8, 8mMMgCl2,
1 mM dithiothreitol, 1 % Triton X-100, and 7 % glycerol.
Luciferase activity was measured in the cell lysate using a
TriStar LB 941 multimode microplate reader (Berthold, Bad
Wildbad, Germany) and following the instructions of the Lucif-
erase Assay Kit (Promega, Madison, WI, USA). Protein
concentration was measured by the Bradford assay (Bio-
Rad). The background obtained with the lysis buffer
was subtracted in each experimental value and the spe-
cific transactivation expressed as a fold induction over
untreated cells. All the experiments were repeated at
least 3 times. Rosiglitazone was purchased from Cay-
man Chemical Company (Ann Arbor, MI, USA) and
used as a positive control in these in vitro experiments.
Statistics
Data were assessed by one- or two-way analysis of variance,
as required, followed by the Student–Newman–Keuls test.
Results
Study of Neuroprotective Effects of CBG in 3NP-lesioned
Mice
The intoxication of mice with 3NP resulted in a myriad of
neurological, biochemical, and histological effects that were
reminiscent of some aspects of HD pathology (reviewed in
[22]). For example, 3NP-treated mice exhibited high scores in
hindlimb clasping [F(3,26)=13.87; P<0.01], dystonia
[F(3,26)=10.55; P<0.01], and in general locomotor activity
[F(3,26)=18.742; P<0.01] compared with control animals
(Fig. 1). A similar tendency was seen for truncal dystonia,
but it was not statistically significant (Fig. 1). In these animals,
the administration of CBG improved the motor deficits typical
of 3NP-lesioned mice by reducing hindlimb clasping and
dystonia and general locomotor activity, but had no effect on
trunkal dystonia (Fig. 1).
The striatal parenchyma of these 3NP-treated animals
showed an important reduction in Nissl-stained cells
[>50%; F(3,8)=96.89,P<0.01], which indicates an important
degree of neuronal death caused by 3NP that was clearly
prevented by treatment with CBG (Fig. 2). Neuronal cell death
was confirmed by NeuN immunohistochemistry, which
proved a reduction of about 50 % in the immunolabelling
for this neuronal marker in the striatal parenchyma of 3NP-
lesioned mice [F(3,8)=92.46; P<0.01], which was paralleled
by a notable increase in GFAP [F(3,8)=83.984; P<0.01] and
Iba-1 [F(3,8)=112.267; P<0.01] immunostainings, indicating
the occurrence of astrogliosis and reactive microgliosis, re-
spectively (Fig. 3). NeuN immunostaining confirmed that
CBG treatment prevented 3NP-induced neuronal loss
(Fig. 3A). However, this treatment did not reduce the number
of GFAP-positive cells, which, in fact, experienced an in-
crease (Fig. 3B), and produced only a modest reduction in
the reactive microgliosis (Iba-1-positive cells) (Fig. 3C). The-
se observations were not unexpected as glial activation has
been reported to be very poor after 3NP intoxication in rodents
[6, 7, 14], oxidative injury and calpain activation being the key
cytotoxic events underlying neuronal death in this experimen-
tal model [22].
As microglia activation and astrogliosis were barely or not
affected by CBG, we were interested to investigate the mRNA
expression of specific proinflammatory markers. We show
that the expression of inflammatory enzymes, for example
COX-2 [F(3,8)=29.071; P<0.01 (Fig. 4A)] and iNOS
[F(3,8)=34.051; P<0.01 (Fig. 4D)], and the expression of
proinflammatory cytokines, for example TNF-α [F(3,8)=
53.869; P<0.01 (Fig. 4B)] and IL-6 [F(3,8)=6.091; P<0.05
(Fig. 4C)] were significantly upregulated in 3NP-lesioned
mice. CBG significantly attenuated the upregulation of all
the proinflammatory markers induced by 3NP (Fig. 4). Taken
together, these results suggest that CBG mediates its anti-
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inflammatory activity on activated microglia and not in the
signaling pathways that drive microglia cells from a resting
state to an activated state.
Next, we used the striatum of 3NP-lesioned mice for anal-
ysis of some biochemical markers related to oxidative stress
(e.g., catalase activity, SOD activity and GSH levels), which
are particularly affected in this model [22]. As expected, there
was a marked reduction in the activities of catalase [F(3,8)=
12.593; P<0.01 (Fig. 5A)] and, in particular, SOD [F(3,8)=
20.262; P<0.01 (Fig. 5C)], as well as in the levels of GSH
[F(3,8)=4.487; P<0.05 (Fig. 5B)] compared with controls.
CBG treatment recovered the activities of antioxidant en-
zymes, for example catalase, SOD-1, and the levels of GSH
were reduced in the striatum of 3NP-intoxicated mice (Fig. 5).
Collectively, these effects were compatible with an important
neuroprotective effect exerted by CBG against the striatal
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##P<0.01, ###P<0.001 when comparing 3NP group with 3NP +
cannabigerol (CBG) group
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Fig. 2 Systemic administration of 3-nitropropionic acid (3NP) leads to a
progressive and selective degeneration in the striatum. (Left) Cresyl violet
staining was performed on brain sections from control, cannabigerol
(CBG)-, 3NP-, and 3NP + CBG-treated mice. Low (left column) and
high magnification (right column) showing the selective loss of cells in
the striatum at day 5 (pale region, outlined). This lesion was not detect-
able in the group that received CBG. Images were acquired by using light
microscopy. (Right) Quantification of Nissl-positive cells in the mouse
striatum. Total average number of neurons (100× magnification) is
shown. Values are expressed as means ± SEM for 6–8 animals per group.
Data were subjected to one-way analysis of variance followed by the
Student–Newman–Keuls test. ***P<0.001 when comparing the control
group with the 3NP and CBG group. ###P<0.001 when comparing the
3NP group with the 3NP + CBG group
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damage caused by 3NP, which is also supported by the fact
that the phytocannabinoid was mostly inactive on these pa-
rameters when it was administered to nonlesioned control
animals (Figs 1–5).
Lastly, cDNA samples obtained from the striatum of ani-
mals lesioned with 3NP, their controls, and the 3NP-lesioned
mice that were treated with CBG were analyzed with a spe-
cific HD array that measured the mRNA expression of 84
genes related to HD (Table S1; see Supplementary Informa-
tion). Our purpose was to identify possible genes that, being
affected by 3NP insult reproducing the changes observed in
the human pathology, may be normalized by treatment with
CBG. Using this HD RT-PCR panel, we found only 2 genes,
Cd44 and Sgk1, to be significantly upregulated (>2-fold in-
duction or repression). Cd44 was induced in 3NP mice com-
pared with control mice (3.0-fold induction) and was signifi-
cantly downregulated in 3NP mice treated with CBG (−1.3-
fold repression). Sgk1 was induced in 3NP mice compared
with control mice (2.7-fold induction) and was also signifi-
cantly downregulated in 3NP mice treated with CBG (−1.41-
fold repression). Although, in general, these results confirm
that the molecular mechanisms underling HD physiopatholo-
gy are quite different in 3NP and R6/2 murine models (see
below), previous studies have confirmed the relation of these
two genes with HD and other neuroinflammatory disorders
[31, 32].
Study of Neuroprotective Effects of CBG in R6/2 Mice
We also investigated the neuroprotective properties of CBG in
a transgenic murine model of HD, the R6/2 mice, which
exhibit a very aggressive pathological phenotype that recapit-
ulates most of the cytotoxic mechanisms that operate in the
human pathology. Thus, compared with wild-type animals,
R6/2 mice exhibited a characteristic loss of weight that was
initiated at 8 weeks of age and that worsened at 10 weeks of
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Fig. 3 (Left panels) Photomicrographs of NeuN (10×)-, glial fibrillary
acidic protein (GFAP) (10×)-, and Iba1 (20×)-immunostained sections
through the coronal section of striatum of control and 3-nitropropionic
acid (3NP)-lesioned mice treated with vehicle or cannabigerol (CBG).
They show a significant loss of NeuN-positive cells in the striatum of
3NP-treated mice compared with controls. CBG treatment significantly
reduced 3NP-induced loss of striatal NeuN-positive cells. (Right panels)
Quantification of (A) NeuN-, (B) GFAP-, and (C) Iba1-positive cells in
the mouse striatum. Total average number of neurons, astrocytes (100×
magnification) and microglia (200× magnification) is shown. Values are
expressed as means ± SEM for 6–8 animals per group. Data were
subjected to one-way analysis of variance followed by the Student–
Newman–Keuls test. *P<0.05, **P<0.01, ***P<0.001 when compar-
ing the control group with the 3NP and CBG group. #P<0.05, ##P<0.01,
###P<0.001 when comparing the 3NP group with the 3NP + CBG group
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age when the animals were euthanized [F(15,180)=12.13;
P<0.01 (Fig. 6A)]. This loss of weight has been largely
reported in R6/2 mice and also in other transgenic models of
HD [7–9, 14]. Treatment with CBG was not effective in
recovering the characteristic loss of weight of R6/2 mice; it
produced an apparent worsening effect (Fig. 6A). In parallel to
the weight loss, R6/2 mice exhibited a deterioration in rotarod
performance that was already evident at the age of 5 weeks,
then occurring before the loss of weight, and that reached a
maximum at 9 weeks after birth [F(15,180)=4.208;
P<0.01), 1 week before animals were euthanized
(Fig. 6B). The administration of CBG produced a modest
recovery in this deteriorated rotarod performance, as re-
vealed the fact that the time in the rod of R6/2 mice treated
with CBG was always higher at all time points analyzed
compared with R6/2 mice treated with vehicle (Fig. 6B).
However, these differences were not statistically significant,
being evident only because of a different probability level
for both groups compared with wild-type animals at spe-
cific time points, for example 8 weeks (Fig. 6B).
The analysis of the postmortem striatum of R6/2 animals at
10 weeks after birth proved important changes in specific
markers of HD pathology, in particular, a profound reduction
in the expression of CB1 [F(3,29)=22.50; P<0.01 (Fig. 7A)],
as has been largely demonstrated in patients with HD [33], and
in this and other experimental models of HD [8, 14].
Upregulatory responses of CB2 have been also found in
previous studies [9, 10], and were also evident here, but to a
significantly lesser extent [F(3,26)=3.079; P<0.05 (Fig. 7B)],
and the same happened with expression of FAAH, which only
showed a nonsignificant trend towards a decrease [F(3,29)=
1.208; Fig. 7C), and therefore a much more moderate reduc-
tion than in previous studies in patients with HD [34]. How-
ever, the expression of MAGL had not previously been stud-
ied in R6/2 mice or other HD models, and proved to have a
marked downregulatory response [F(3,29)=23.02; P<0.01
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Fig. 5 Effect of cannabigerol (CBG) on antioxidant defenses in the
striatum of 3-nitropropionic acid (3NP)-treated and control mice. Estima-
tion of (A) catalase activity, (B) reduced glutathione (GSH) levels, and
(C) superoxide dismutase (SOD) activity. Data presented are the percent-
age of the vehicle-treated control group and are expressed as means ±
SEM for 6–8 animals per group. Data were subjected to one-way analysis
of variance followed by the Student–Newman–Keuls test. *P<0.05,
**P<0.01, ***P<0.001 when comparing the control group with the
3NP and CBG group. #P<0.05, ##P<0.01, ###P<0.001 when comparing
the 3NP group with the 3NP + CBG group
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(Fig. 7D)]. Treatment with CBG only affected the gene ex-
pression for CB2 with a small effect, which is reflected in the
loss of statistical significance for the differences observed
between wild-type animals and R6/2 mice when these mice
were treated with CBG (Fig. 7B).
We also found the expected responses in R6/2 for other
biochemical markers according to previous studies [8, 9, 35],
for example in the neurotrophins BDNF and IGF-1, the ex-
pression of which experienced in both cases showed a dra-
matic reduction [BDNF: F(3,28)=5.618 (P<0.05); IGF-1:
F(3,29)=6.42 (P<0.05) (Fig. 8A, B)], as previously described
[2, 8]. Treatment with CBG partially improved deficits in both
BDNF (Fig. 8A) and IGF-1 (Fig. 8B), but the effects were
modest and similar to the case of CB2 (e.g., loss of statistical
significance of the differences observed between wild-type
animals and R6/2 mice). R6/2 mice also exhibited deficits in
the glial glutamate transporters GLAST [F(3,31)=11.44;
P<0.01 (Fig. 8D)] and, in particular, GLT-1 [F(3,31)=27.85;
P<0.01 (Fig. 8C)], also in accordance with previous data [36],
but, in this case, there was no recovery by the treatment with
CBG (Fig. 8C, D).
We also quantified DARPP-32, a protein involved in do-
paminergic receptor signaling in striatal projection neurons,
which experienced a dramatic reduction in gene expression
[F(3,31)=18.79; P<0.01 (Fig. 9A)] and immunostaining
[F(3,18)=11.09; P<0.05; Fig. 9B)] in R6/2 mice, concordant
with the expected death of these neurons, and similar to
previous studies [37]. None of these reductions was reversed
by the treatment with CBG (Fig. 9A, B). We also found
changes in inflammation-related markers such as the PPARγ
receptors, which were downregulated in R6/2 mice [F(3,25)=
4.32; P<0.05 (Fig. 9C)], and the cytokine TNF-α, which
experienced a marked increase [F(3,23)=5.716; P<0.01
(Fig. 9D)], in agreement with previous studies [38]. However,
we did not find any changes in other proinflammatory param-
eters, such as the enzymes COX-2 or iNOS, and the cytokine
IL-1β (data not shown), although this lack of response has
been documented in the literature [39]. Treatment with CBG
partially reversed the downregulation of PPARγ in R6/2 mice
(Fig. 9C), being less effective against the increase in TNF-α,
although a certain trend towards an attenuation may be appre-
ciated in this parameter (Fig. 9D). In parallel to the increase in
PPARγ expression by CBG in these mice, we also found that
this phytocannabinoid dose-dependently activated PPARγ in
cultured striatal cells expressing endogenous wild-type and
mutant huntingtins (Figure S1; see Supplementary
Information).
We were able to detect the presence of immunoreactivity
for mutant huntingtin aggregates, labeled with EM48 anti-
body, in the striatal parenchyma of R6/2 mice (Fig. 10), al-
though our immunohistochemical analysis with GFAP and
Iba-1 did not reveal a marked glial activation (data not
shown), as found in some studies [40]. Interestingly, EM48
immunostaining was slightly, but significantly, reduced in R6/
2 mice treated with CBG (Fig. 10). Given that the number of
striatal neurons does not appear to be significantly altered by
treatment with CBG in R6/2 mice, according to the data
obtained for DARPP-32 immunostaining (Fig. 9b), we believe
that the reduction in EM48 immunostaining by CBG does not
reflect a reduction in the number of neurons but a decrease in
the number of mutant huntingtin aggregates in surviving
neurons, which may be a beneficial event.
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Fig. 6 (A) Weight gain and (B)
rotarod performance in R6/2 mice
treated from the age of 4 weeks
with cannabigerol (CBG) or
vehicle (Tween 80-saline). Values
are expressed asmeans ± SEM for
6–8 animals per group. Data were
subjected to one-way analysis of
variance followed by the Student–
Newman–Keuls test (*P<0.05,
**P<0.01, ***P<0.005
compared with wild-type animals
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We also used the cDNA samples obtained from the stria-
tum of R6/2 mice, their controls, and the transgenic mice that
were treated with CBG for analysis with a specific HD array.
Again, our purpose was to identify possible genes that, being
affected in R6/2 mice reproducing more accurately the chang-
es observed in the human pathology, may be normalized by
treatment with CBG. We found numerous genes up- or down-
regulated in R6/2 mice (Table S2; see Supplementary Infor-
mation), but 7 that have been frequently linked to this disease
given their role in the regulation of gene transcription (e.g.,
symplekin, Sin3a, Rcor1, histone deacetylase 2, and
huntingtin-associated protein 1), GABA transmission (e.g.
δ subunit of the GABA-A receptor), and calcium homeo-
stasis (e.g. hippocalcin), were found to be up- or down-
regulated in R6/2 mice (Fig. 11A), as has previously been
found in patients with HD or experimental models
[41–44]. Importantly, the expression of these 7 genes
was partially normalized by treatment with CBG
(Fig. 11B), with some cases, for example huntingtin-
associated protein 1, the increase found in R6/2 mice
being completely reversed by CBG and exhibiting even
lower expression levels than wild-type animals (Fig. 11B).
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Fig. 7 Gene expression for (A)
cannabinoid receptor type 1
(CB1) and (B) cannabinoid
receptor type 2 (CB2) receptors,
and (C) fatty acid hydrolase
(FAAH) and (D)
monoacylglycerol lipase
(MAGL)measured in the striatum
of R6/2 mice (10 weeks after
birth) treated from the age of
4 weeks with cannabigerol (CBG)
or vehicle (Tween 80-saline).
Values correspond to fold of
change over wild-type animals
and are expressed as means ±
SEM for 6–8 animals per group.
Data were subjected to one-way
analysis of variance followed by
the Student–Newman–Keuls test
(*P<0.05, **P<0.01,
***P<0.005 compared with
wild-type animals treated with
vehicle)
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Fig. 8 Gene expression for (A)
brain-derived neurotrophic factor
(BDNF), (B) insulin-like growth
factor (IGF)-1, (C) glutamate
transporter (GLT)-1, and (D)
glutamate aspartate transporter
(GLAST) measured in the
striatum of R6/2 mice (10 weeks
after birth) treated from the age of
4 weeks with cannabigerol (CBG)
or vehicle (Tween 80-saline).
Values correspond to fold of
change over wild-type animals
and are expressed as means ±
SEM for 6–8 animals per group.
Data were subjected to one-way
analysis of variance followed by
the Student–Newman–Keuls test
(*P<0.05, **P<0.01,
***P<0.005 compared with
wild-type animals treated with
vehicle)
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Discussion
Only a few clinical studies have been performed to determine
whether cannabinoid compounds are efficacious in HD, and
the results they have yielded are rather controversial [45–48].
Possibly, the reason for such controversy is that these clinical
studies concentrated more on HD symptoms rather than on
disease progression. However, recent animal studies have
demonstrated that combinations of different cannabinoids or
the use of a broad-spectrum cannabinoid may delay disease
progression by preserving striatal neurons from death in dif-
ferent animal models of HD, thus stressing the need for new
clinical studies directed at testing whether the neuroprotective
effects that certain cannabinoids induce in experimental
models of HD are also reproduced in patients with HD
[7–11]. This includes the evaluation of Δ9-THC and CBD,
separately or in a combination [6–9], Sativex®, which has
been found to be neuroprotective in different animal models of
HD [14, 49], and additional phytocannabinoids.
We were particularly interested in investigating whether
CBG, another major phytocannabinoid present in Cannabis
sativa, could be as effective a disease-modifying agent in HD.
We studied its effects in 2 experimental models of HD, and
found particularly positive results in the 3NP-lesioned mice
model, a model in which the death of striatal neurons is
dependent on mitochondrial damage, activation of calpain,
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Fig. 9 Gene expression for (A) dopamine- and cyclic adenosine
monophosphate-regulated phosphoprotein, Mr 32 kDA (DARPP-32),
(C) peroxisome proliferator-activated receptor (PPAR)γ, and (D) tumour
necrosis factor (TNF)-α, and (B) DARPP-32 immunostaining measured
in the striatum of R6/2 mice (10 weeks after birth) treated from the age of
4 weeks with cannabigerol (CBG) or vehicle (Tween 80-saline). Values
correspond to fold of change (gene expression) or percentage
(immunostaining) over wild-type animals and are expressed as means ±
SEM for 6–8 animals per group. Data were subjected to one-way analysis
of variance followed by the Student–Newman–Keuls test (*P<0.05,
**P<0.01, ***P<0.005 compared with wild-type animals treated with
vehicle)
R6/2 + CBGR6/2
Fig. 10 EM48 immunostaining (representative of mutant huntingtin
aggregates) in the striatum of R6/2 mice (at 10 weeks after birth) treated
from the age of 4 weeks with cannabigerol (CBG) or vehicle (Tween 80-
saline). The stainings were repeated in 5–6 animals per group. Magnifi-
cation=40×. Data were subjected to Student’s t test (***P<0.005 com-
pared with R6/2 mice treated with vehicle)
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and the generation of reactive oxygen species [14, 22]. In this
model, subchronic administration of CBG preserved striatal
neurons from 3NP-induced death presumably by regulating
pro-oxidant and proinflammatory responses induced by 3NP
intoxication. Importantly, the preservation of striatal neurons
and the improvement of their homeostasis by CBG resulted in
a significant improvement in the neurological deterioration
typical of this model. These positive effects found in the
3NP model of HD were also investigated in a transgenic
model of this disorder, the R6/2 mice, although the effects of
CBG were much more modest in this model compared with
the 3NP-lesioned mice. The most important observations in
R6/2 mice were obtained from the analysis of the
neurotrophins BDNF and IGF-1, and the PPARγ receptors,
the deficits of which are strongly indicative of the deteriora-
tion in the striatal function—deficits that were partially re-
versed by CBG. We also collected some evidence from the
data obtained with a specific HD array analysis, which
showed some important HD-related genes, the up- or
downregulatory responses of which were significantly atten-
uated by the treatment with CBG. Both types of responses are
strongly associated with patients with HD in whom BDNF
deficiency and alterations in symplekin [2], Sin3a, Rcor1,
histone deacetylase 2, huntingtin-associated protein 1, and
other genes related to the regulation of gene transcription have
been found to play a key role in HD pathogenesis [41–44].
The presence of mutant huntingtin aggregates in the striatal
parenchyma of R6/2 mice, another key event in human HD
pathogenesis, was slightly reduced by CBG in these mice. By
contrast, we did not obtain any evidence that CBG may
preserve striatal neurons from death in R6/2 mice, as revealed
by DARPP-32 immunostaining, but this fact appears to sup-
port the fact that the reduction in the number of mutant
huntingtin aggregates reflects a lower presence of these
aggregates in surviving neurons rather than a reduction due
to lower number of striatal neurons. Reduction in huntingtin
aggregation has been associated with a better striatal function,
and has been proposed as a therapeutic objective in this
disease [3].
In this study, we have not addressed the potential mecha-
nisms involved in the beneficial effects of CBG in both HD
models, something that will be done in follow-up studies. It is
important to note that the profile of CBG has been poorly
studied in relation to its therapeutic and pharmacological effects
and, in particular, to its mechanisms of action, which makes it
difficult to relate the effects found to specific targets and sig-
naling pathways. However, we assume that the effects are not
dependent on the activation of CB1 and/or CB2, given the poor
affinity of CBG for these classic cannabinoid receptors [17, 18].
LikeΔ9-THC and CBD, CBG also penetrates the blood–brain
barrier after i.p. delivery [50], and may target α-2 adrenergic
receptors and PPARγ receptors in the brain [19, 21]. It has been
shown that the expression of α-2 adrenergic receptors is in-
creased in the hypothalamus of transgenic rats for HD [51], but
antagonism rather than agonism is involved α-2 adrenergic
receptor-mediated neuroprotection [52], and therefore it is un-
likely that CBG alleviates HD symptoms and disease markers
by targeting this receptor. On the contrary, PPARγ agonists
such as thioglitazones have been shown to have a neuroprotec-
tive effect in in vitro and in vivo models of HD [53–55]. There
is strong evidence that mitochondrial dysfunction results in
neurodegeneration and may contribute to the pathogenesis of
HD. Studies over the last few years have implicated an im-
paired function of PPARγ co-activator-1α (PGC-1α), a master
co-regulator of mitochondrial biogenesis, metabolism, and an-
tioxidant defenses, in causing mitochondrial dysfunction in
HD. PPARγ agonists are neuroprotective, increase oxidative
phosphorylation capacity in mouse and human cells, and
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Fig. 11 Huntingdon’s disease (HD) array analysis showing the up- or
downregulatory responses of some genes specifically affected in the
striatum of (A) R6/2 compared with wild-type mice or (B) R6/2 mice
treated with CBG compared with wild-type mice. One microgram of
RNA was retrotranscribed and the resulting cDNA was analyzed in a
mouse HD polymerase chain reaction array. Five housekeeping genes
contained on the experimental system were used to standardize the
mRNA expression levels in every sample. Values correspond to number
of folds that a specific gene is up- or downregulated. Data were assessed
by the unpaired two-tailed Student’s t test. The 7 genes presented in (A)
were selected because the up- and downregulatory responses found
between R6/2 and wild-type mice were more than 2-fold higher, and
these differences were statistically significant in all cases, and also be-
cause these differences were reversed by the treatment with cannabigerol
(CBG) (*P<0.05, **P<0.01, ***P<0.005)
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enhance mitochondrial function [56]. In addition, it has also
been demonstrated that oral treatment with rosiglitazone
induced mitochondrial biogenesis in mouse brain [57]. There-
fore, we assume that the activation of PPARγ receptors may be
certainly the most feasible mechanism for CBG effects in HD,
in particular in 3NP-lesioned mice, although this would need to
be demonstrated in follow-up studies. We also consider that
these nuclear receptors may be also involved in the effects of
CBG in R6/2 mice. In support of this hypothesis, we have
found that CBG activated PPARγ in striatal cells expressing
endogenous wild-type and mutant huntingtins, an experimental
condition relatively comparable with the case of R6/2 mice.
However, low levels of PPARγ receptors are expected in the
striatum of these mice given their low levels of gene expression
found in our study. In fact, these presumably reduced PPARγ
receptor levels, together with the fact that CBG does not
activate CB1 and CB2 and that, in R6/2 mice, the role of
these receptors in mediating the neuroprotective effects
of cannabinoids is much more relevant [8, 9], might
explain that the effects found with CBG in R6/2 mice
have been much more modest compared with 3NP-
lesioned mice, suggesting the need to continue the stud-
ies in R6/2 mice using combinations of CBG with other
phytocannabinoids.
However, substantial literature indicates that HD pathology
develops via multiple pathways that may act synergistically. A
recent report has investigated the gene expression profile in
different animal models of HD compared with striatal gene
expression phenotype of human HD [58]. In such a study, the
authors found differences between the R6/2 and the 3NP
models, showing that the 3NP profile is consistent with neu-
roinflammation, with changes in genes involved in immune
response, response to wounding, defense response, and in-
flammatory response. In our study, with a limited number of
HD-related genes, we also found clear differences between
R6/2 (significant changes in 21 of 84 genes) and 3NP (signif-
icant changes in 3 of 84 genes) (see Supplementary Informa-
tion) models. This result may be explained by the rapid
induction of cell death mechanisms mediated by 3NP, and
the array data may reflect only a small fraction of dysfunc-
tional neurons present at one time. Thus, it will be interesting
to study the effect of CBG on the profile of gene expression in
3NP-lesioned animals before the loss of striatal cells.
Finally, given that the improvement of antioxidant defenses
by CBG, reflected in increased activities of catalase and SOD-
1 and higher levels of GSH, appears to be a key mechanism
for the beneficial effects of this phytocannabinoid in the 3NP
model, we were also interested in investigating whether the
neuroprotective effects of CBG in this pro-oxidant model may
be associated with specific effects on Nrf-2 signaling and/or
on the target genes for this transcription factor, a fact also
proposed for the antioxidant effects of cannabidiol [15]. How-
ever, preliminary immunostaining of Nrf-2 and qRT-PCR
analysis of Nrf-2-dependent genes failed to prove any effect
of CBG at this level (data not shown).
In summary, CBG appears to have a promising neuropro-
tective profile for the treatment of HD, a fact already investi-
gated with other phytocannabinoids separately or in combina-
tion [6–9, 14, 49]. CBG appears to be particularly active
against the mitochondrial dysfunction, calpain activation and
oxidative injury caused by 3NP. It was also active in R6/2
mice, but with only modest effect, so it is possible that it needs
to be combined with another phytocannabinoid in these mice
to enhance its therapeutic effects, in particular with cannabi-
noids having activity at CB1 and/or CB2 receptors, which have
been found to serve as therapeutic targets in these mice [8, 9].
This additional investigation will be critical before proceeding
to clinical studies with CBG in patients with HD.
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Supplementary Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of CBG on PPAR transcriptional activity. STHdhQ7/Q7 (wild-type) and 
STHdhQ111/Q111 (mutant) cells were co-transfected with GAL4-PPAR and GAL4-
luc. Cells were treated with of CBG at the indicated concentrations for 12 h and 
luciferase activity measured in the cell lysates. Fold activation level was 
calculated, taking the control sample as reference. Data are expressed as mean 
± S.D. of at least three independent experiments. *p < 0.05, **p < 0.01 and ***p 
< 0.005 in an unpaired two-tailed Student’s t test. 
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Table 1S. HD array analysis (84 genes) showing their up- or down-regulatory 
responses in the striatum of control and 3NP-lesioned mice treated with CBG or 
vehicle. Values correspond to number of folds that a specific gene is up- 
(positive value) or down-regulated (negative value). 
 
 
3NP vs control 3NP+CBG vs control
Gene Fold Up- or Down-Regulation Gene
Fold Up- or Down-
Regulation Gene
Fold Up- or Down-
Regulation Gene
Fold Up- or Down-
Regulation
Akt1 -1,0396 Kcnc3 1,0098 Akt1 -1,1810 Kcnc3 1,0943
Apoe -1,4804 Lpl 1,0454 Apoe -1,1892 Lpl -1,0140
Aqp1 1,0898 Map3k10 -1,0989 Aqp1 1,1096 Map3k10 1,0210
Arfip2 1,2008 Ncor1 1,1204 Arfip2 -1,0570 Ncor1 1,0718
Atp2b2 -1,2025 Nefl -1,5326 Atp2b2 -1,0792 Nefl -1,2142
Bax -1,0253 Ngef -1,0468 Bax -1,0425 Ngef -1,1096
Bbox1 -1,0762 Ntrk2 1,2431 Bbox1 -1,1647 Ntrk2 1,0570
Bdnf 1,5845 Pacsin1 -1,0324 Bdnf 1,0644 Pacsin1 -1,0425
C3 1,1761 Pgk1 1,0454 C3 1,0792 Pgk1 -1,1408
Calb1 -1,1376 Plcb4 1,0238 Calb1 -1,2226 Plcb4 1,1408
Casp3 1,1925 Plod2 -1,0837 Casp3 -1,3195 Plod2 -1,1647
Casp8 1,3890 Ppargc1a 1,3794 Casp8 1,3566 Ppargc1a 1,1728
Cd44 3,0189 Ppp3ca -1,0253 Cd44 -1,3104 Ppp3ca 1,0353
Cltc 1,1519 Prkcb 1,1050 Cltc -1,1096 Prkcb 1,0644
Cnr1 -1,0042 Prpf40a 1,2518 Cnr1 -1,1173 Prpf40a 1,0281
Creb1 -1,1615 Ptpn11 1,4083 Creb1 1,1567 Ptpn11 1,0792
Crebbp 1,1680 Rab6 1,0673 Crebbp 1,0570 Rab6 1,1647
Dctn1 1,1127 Rcor1 1,0168 Dctn1 1,1487 Rcor1 -1,0281
Dlg4 -1,2449 Rest 1,5845 Dlg4 -1,1408 Rest 1,0210
Eef1a2 -1,0112 Rgs4 -1,2449 Eef1a2 1,0070 Rgs4 -1,1647
Egfr -1,2277 Rilp 1,9106 Egfr -1,1647 Rilp -1,0570
Elmo1 1,2781 Rph3a -1,3717 Elmo1 1,1810 Rph3a -1,0792
Fgf12 1,2260 Rxrb -1,0042 Fgf12 1,0353 Rxrb 1,1567
Gabrd -1,1696 Sgk1 2,7207 Gabrd -1,0570 Sgk1 -1,4142
Gja1 -1,6088 Sin3a 1,0028 Gja1 -1,0353 Sin3a 1,1019
Gjb6 1,2260 Slc14a1 1,8583 Gjb6 1,1567 Slc14a1 1,2311
Gnaq 1,0526 Slc25a4 1,0822 Gnaq -1,0353 Slc25a4 -1,1096
Gpx1 1,2092 Snap25 1,0168 Gpx1 1,2746 Snap25 -1,0140
Grb2 1,1599 Sod1 1,1127 Grb2 1,0353 Sod1 1,0210
Grin2a 1,3794 Sox2 -1,1142 Grin2a 1,1892 Sox2 -1,1019
Grin2b 1,2431 Sp1 -1,1535 Grin2b 1,2058 Sp1 -1,0867
Grm5 -1,0614 Sympk -1,0989 Grm5 1,0070 Sympk 1,0425
Hap1 1,0098 Syn1 1,0098 Hap1 -1,0497 Syn1 1,0570
Hdac1 1,2176 Tac1 1,1439 Hdac1 1,0353 Tac1 1,3472
Hdac2 -1,1142 Tbp 1,1761 Hdac2 -1,1567 Tbp 1,1975
Hip1 1,1599 Tgm2 2,0907 Hip1 1,1408 Tgm2 1,5911
Homer1 -1,1455 Tollip 1,3324 Homer1 1,0281 Tollip 1,0718
Hpca 1,1127 Trp53 1,1599 Hpca 1,0210 Trp53 1,3851
Htt 1,1050 Tubb5 -1,1297 Htt -1,0000 Tubb5 -1,0718
Ift57 1,0526 Zbtb16 1,6178 Ift57 1,1329 Zbtb16 1,0943
Igf1 1,3416 Actb 1,1439 Igf1 1,1251 Actb -1,0644
Itpr1 -1,0541 B2m 1,0310 Itpr1 1,1892 B2m 1,1728
Kcnab1 -1,1142 Gapdh -1,1065 Kcnab1 -1,1647 Gapdh -1,2483
Kcnab2 1,0238 Gusb -1,0253 Kcnab2 1,0353 Gusb 1,0867
Hsp90ab1 -1,0396 Hsp90ab1 1,0425
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Table 2S. HD array analysis (84 genes) showing their up- or down-regulatory 
responses in the striatum of wild-type and R6/2 mice treated with CBG or 
vehicle. Values correspond to number of folds that a specific gene is up- 
(positive value) or down-regulated (negative value). 
 
R6/2 vs wild-type R6/2+CBG vs wild-type
Gene Fold Up- or Down-Regulation Gene
Fold Up- or Down-
Regulation Gene
Fold Up- or Down-
Regulation Gene
Fold Up- or Down-
Regulation
Akt1 1,0733 Kcnc3 -1,1313 Akt1 -1,0483 Kcnc3 -1,1313
Apoe -2,3424 Lpl -1,4722 Apoe -2,5105 Lpl -2,9856
Aqp1 -1,4025 Map3k10 1,0807 Aqp1 -1,5999 Map3k10 -1,0852
Arfip2 -1,0629 Ncor1 1,3967 Arfip2 1,0439 Ncor1 1,0154
Atp2b2 -2,5633 Nefl 1,4459 Atp2b2 -3,0063 Nefl 1,2414
Bax 1,1503 Ngef -1,8251 Bax -1,0556 Ngef -2,1856
Bbox1 2,5883 Ntrk2 1,0958 Bbox1 -1,2995 Ntrk2 -1,1958
Bdnf -1,2209 Pacsin1 -1,6795 Bdnf 1,2414 Pacsin1 -1,4025
C3 -2,6537 Pgk1 1,1423 C3 -3,7529 Pgk1 1,0295
Calb1 1,4969 Plcb4 -1,5562 Calb1 -1,5562 Plcb4 -1,3268
Casp3 1,3491 Plod2 1,7435 Casp3 1,2675 Plod2 -1,1712
Casp8 1,3398 Ppargc1a 1,0014 Casp8 -1,4722 Ppargc1a -1,2041
Cd44 -3,3589 Ppp3ca -3,0063 Cd44 -1,2728 Ppp3ca -2,5456
Cltc 1,0084 Prkcb -1,1631 Cltc -1,1080 Prkcb -2,0820
Cnr1 -3,9945 Prpf40a 1,3491 Cnr1 -4,0784 Prpf40a 1,2243
Creb1 1,1345 Ptpn11 1,1663 Creb1 -1,1392 Ptpn11 -1,1712
Crebbp 1,6609 Rab6 1,3122 Crebbp 1,0585 Rab6 1,3305
Dctn1 -1,8125 Rcor1 2,8521 Dctn1 -1,7630 Rcor1 1,2329
Dlg4 -2,4083 Rest -1,4221 Dlg4 -2,4419 Rest -2,0392
Eef1a2 -1,8895 Rgs4 -3,2898 Eef1a2 -1,6223 Rgs4 -3,2898
Egfr 1,3122 Rilp -1,2816 Egfr -1,2294 Rilp -1,4928
Elmo1 -1,0852 Rph3a -1,5347 Elmo1 -1,8000 Rph3a -1,4520
Fgf12 -1,1157 Rxrb -3,8053 Fgf12 -1,1157 Rxrb -1,8506
Gabrd -7,0031 Sgk1 -1,5889 Gabrd -4,3409 Sgk1 -1,4722
Gja1 -3,3823 Sin3a -2,3751 Gja1 -3,3357 Sin3a -1,8125
Gjb6 -1,2041 Slc14a1 -1,3268 Gjb6 -1,1794 Slc14a1 -1,7876
Gnaq 1,6044 Slc25a4 1,5497 Gnaq 1,1266 Slc25a4 1,3775
Gpx1 1,5178 Snap25 -1,0777 Gpx1 1,0439 Snap25 1,0733
Grb2 1,8050 Sod1 1,9480 Grb2 1,2414 Sod1 1,1034
Grin2a -1,1958 Sox2 -1,1080 Grin2a -1,3454 Sox2 -1,2816
Grin2b -2,1555 Sp1 1,6609 Grin2b -1,8895 Sp1 1,0439
Grm5 1,0367 Sympk -5,4945 Grm5 -1,8251 Sympk -3,3823
Hap1 2,2847 Syn1 1,0882 Hap1 -1,0556 Syn1 1,0882
Hdac1 1,7195 Tac1 1,2159 Hdac1 1,2763 Tac1 -1,3177
Hdac2 2,2532 Tbp 1,5284 Hdac2 1,2852 Tbp 1,1423
Hip1 -1,0338 Tgm2 1,6609 Hip1 -1,8378 Tgm2 1,2763
Homer1 -1,9026 Tollip 1,4459 Homer1 -2,2315 Tollip 1,1663
Hpca -3,0908 Trp53 1,2159 Hpca -4,1068 Trp53 1,1423
Htt -1,6223 Tubb5 -1,1004 Htt -1,9159 Tubb5 -1,0703
Ift57 1,0733 Zbtb16 -1,4722 Ift57 -1,1471 Zbtb16 1,2588
Igf1 -1,8506 Actb -1,9697 Igf1 -1,2294 Actb -1,5889
Itpr1 -2,7856 B2m 1,5497 Itpr1 -2,1705 B2m 1,2329
Kcnab1 -1,5670 Gapdh 1,0367 Kcnab1 -2,5991 Gapdh 1,1111
Kcnab2 1,1503 Gusb 1,1583 Kcnab2 -1,1004 Gusb 1,1991
Hsp90ab1 1,0585 Hsp90ab1 -1,0338
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CHAPTER 2
Evaluation of Sativex in a pilot clinical trial with patients of HD.
All the preclinical data obtained (here and previously) from the different studies exploring the 
potential of different cannabinoid compounds as disease-modifying treatments in animal and 
cellular models of HD supports the evaluation any cannabinoid formulation in the clinical field. The 
data generated so far support more the use of a broad-spectrum cannabinoid or a combination 
of cannabinoids with complementary pharmacological profiles, rather than using a very selective 
cannabinoid. In this Chapter, we present the results of a double-blind, randomized, cross-over, 
placebo-controlled pilot clinical trial with Sativex in patients with HD. Sativex is an already licenced 
medicine in Spain for the treatment of spasticity in patients with MS. The primary endpoint of this 
study was achieved, since the treatment with Sativex was safe and well tolerated. However, it did 
not cause any improvement in motor performance and cognitive and psychiatric measures. Besides, 
no change was observed in the biomarkers examined, except for an increase in CB
2
 expression in 
the patients’ lymphocytes during Sativex-treatment phase, which was interpreted as a possible 
cytoprotective and antiinflamatory response given the functions of this receptor. Additional studies, 
with more subjects and in particular, longer treatment duration are proposed to further evaluate if 
Sativex can produce a clinical benefit in HD patients.
This study was done in collaboration with the group led by Justo García de Yébenes at “Hospital Ramón 
y Cajal”, and in collaboration with the groups led by Manuel Guzmán at “Universidad Complutense” 
and Julián Romero at “Hospital Universitario Fundación Alcorcón”. We participated in the analysis of 
gene expression of different cannabinoid and HD markers in the lymphocytes of HD patients.
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Abstract Huntington’s disease (HD) is a neurodegenera-
tive disease for which there is no curative treatment
available. Given that the endocannabinoid system is
involved in the pathogenesis of HD mouse models, stim-
ulation of specific targets within this signaling system has
been investigated as a promising therapeutic agent in HD.
We conducted a double-blind, randomized, placebo-con-
trolled, cross-over pilot clinical trial with Sativex, a
botanical extract with an equimolecular combination of
delta-9-tetrahydrocannabinol and cannabidiol. Both
Sativex and placebo were dispensed as an oral spray, to
be administered up to 12 sprays/day for 12 weeks. The
primary objective was safety, assessed by the absence of
more severe adverse events (SAE) and no greater deterio-
ration of motor, cognitive, behavioral and functional scales
during the phase of active treatment. Secondary objectives
were clinical improvement of Unified Huntington Disease
Rating Scale scores. Twenty-six patients were randomized
and 24 completed the trial. After ruling-out period and
sequence effects, safety and tolerability were confirmed.
No differences on motor (p = 0.286), cognitive
(p = 0.824), behavioral (p = 1.0) and functional
(p = 0.581) scores were detected during treatment with
Sativex as compared to placebo. No significant molecular
effects were detected on the biomarker analysis. Sativex
is safe and well tolerated in patients with HD, with no SAE
or clinical worsening. No significant symptomatic effects
were detected at the prescribed dosage and for a 12-week
period. Also, no significant molecular changes were
observed on the biomarkers. Future study designs should
consider higher doses, longer treatment periods and/or
alternative cannabinoid combinations.
Clincaltrals.gov identifier: NCT01502046
Keywords Huntington’s disease  Cannabinoid  Sativex 
Clinical trial
Introduction
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder, that progressively affects
cognition, behavior and movement. HD is caused by an
unstable expansion of the CAG trinucleotide repeat in the
Huntingtin (HTT) gene, producing generalized neuronal
degeneration that specially affects the striatum [1–3].
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There is no known neuroprotective therapy available for
HD and current symptomatic treatment is limited. Previous
studies in animal models of HD suggest that cannabinoid-
based treatments might have a neuroprotective effect. The
endocannabinoid system has been proven to confer neu-
roprotection through its direct participation in cellular
survival pathways and in neurogenesis control [4–7]. Given
that the endocannabinoid system is involved in HD
pathogenesis, stimulation of specific targets within this
signaling system has been investigated as a promising
therapeutic strategy that improves deficits in HD models
[8–12]. Some cannabinoids are known to inhibit excito-
toxicity events, oxidative stress and neuroinflammation,
which makes them attractive for the treatment of not only
of HD, but also other neurodegenerative disorders, such as
Alzheimer’s and Parkinson’s disease [13, 14].
There are two major cannabinoid receptor types: the
CB1 receptor, which is widely distributed through many
different regions of the central nervous system, particularly
in the basal ganglia, cortex, hippocampus and cerebellum,
and the CB2 receptor, which is expressed mainly in the
immune system modulating inflammation. Other non-
classic receptors, such as TRPV1 (transient receptor
potential cation channel, subfamily V, member 1) have also
been proposed as potential cannabinoid receptors [15–17].
CB1 receptors progressively lose their functionality from
HD early stages, potentially increasing vulnerability to the
different cytotoxic stimuli related to cellular damage [8,
18], although a recent study has unequivocally demon-
strated that the pool of CB1 receptors that are neuropro-
tective in HD mouse models would be located in neurons
that do not degenerate primarily in HD (i.e. corticostriatal
neurons) [19]. In normal conditions, CB2 receptors are
found at very small levels in the striatum, but an up reg-
ulation can be detected in response to cellular damage.
CB2 activation in glial cells could improve homeostasis in
HD by reducing the cytotoxic influence of reactive
microglial cells and increasing the trophic support provided
by astrocytes [20]. The reduction of oxidative stress caused
by cannabinoids via cannabinoid receptor-independent
mechanisms has also been described [9, 21].
Previous clinical trials with cannabinoids in HD were
based on the change of symptoms, such as chorea and
behavioral alterations. Nabilone, a synthetic cannabinoid
receptor agonist, was investigated in two non-controlled
trials with contradictory results [22, 23]. One of these trials
showed an improvement in hyperkinesis and behavioral
alterations [23], while in the other trial a worsening was
observed [22]. Positive results were found with the same
compound in a cross, double blinded, placebo controlled
trial [24]. CBD (cannabidiol) effects were also studied in
another trial with fifteen HD patients, and although it was
well tolerated, no positive results were obtained [25].
Sativex mouth spray solution is a standardized botanic
extract with an approximately equimolar combination ofD9-
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
(specifically, 2.7 mg THC/2.5 mg CBD per spray) [7, 12,
26]. These two compounds were tested separately in animal
models of striatal damage with positive results [27, 28], and
further studies conducted with a Sativex-like combination of
both phytocannabinoids enhanced these benefits [29].
Although the long-term effects of Sativex use are still
unknown, it is currently approved for the treatment of mul-
tiple-sclerosis associated spasticity inmany countries aswell
as for neuropathic pain in Canada. CBD has shown good
tolerance and low toxicity.Moreover, CBD could counteract
possible adverse effects related to THC chronic use, such as
psychotic alterations [26], a mayor concern in HD. For all
these reasons, we decided to test whether Sativex was an
appropriate medicine for the experimental treatment of HD.
Patients and methods
Patient selection
The study was performed at Ramo´n y Cajal Hospital, Madrid,
Spain. The protocol and consent forms were approved by the
Spanish Agency of Medicines and the hospital’s local
Research Ethical Committee. GW Pharmaceuticals Ltd.
supplied the Sativex and identical placebo vials.
Inclusion criteria
(1) HD patients, older than 18 years and able to understand
the study protocol, to attend the study visits and to provide
written informed consent, (2) Stable baseline medication
for at least 6 weeks prior to randomization, (3) UHDRS-
motor score ranging from 5 to 50, (4) Good cognitive status
(MMSE[25) at the screening visit, with no evidence of
major depression, and no evidence of psychosis.
Exclusion criteria
(1) Pregnant or lactating women, (2) History of drug
addiction, (3) History of psychosis or suicidal ideation, (4)
Diseases of the oral cavity preventing the safe adminis-
tration of the drug, (5) Drug administration contraindicated
according to the summary of product characteristics
(SmPC), (6) Active consumers of marijuana or other can-
nabis-derived products.
Patients
Twenty-six patients were recruited from the Ramo´n y Cajal
Hospital Huntington Disease clinics. A previous selection
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from the Huntington’s disease clinics patient database was
performed according to the inclusion and exclusion criteria
to optimize the screening. Written informed consent was
obtained from all participants.
Outcome measures
Themain objective in the studywas to assess Sativex safety
and tolerability administered to HD patients for 12 weeks.
The primary outcome measurements were the absence of
Severe Adverse Events (SAE) reported during a time frame
of 8 months and the absence of worsening in clinical
symptoms as measured by the motor, cognitive, psychiatric
and functional Unified Huntington’s Disease Rating Scale
(UHDRs) scores, at the end of both treatment periods.
The mUHDRS scale ranges from 0 to 124 [30]. A change
of three points or more in the total mUHDRS score was
considered a clinically relevant effect. Themotor component
of UHDRS scale was sub-divided for analysis purposes in
four items: eye movements, maximal dystonia, maximal
chorea and a sum of the remaining motor items. Cognition
was assessed through cUHDRS (Verbal Fluency, Categori-
cal Fluency and Stroop Interference). Psychiatric changes
were assessed with the Hospital Anxiety and Depression
Scales (HADS), the neuropsychiatric inventory (NPI) and
the behavioral UHDRS scale. Functional component chan-
ges were assessed with the fUHDRS. Relevant clinical
worsening was defined as a change of 10 or more in the
cognitive scales, change of 3 or more in the cUHDRS sub-
scale and a change of 2 or more in the fUHDRS subscale.
To evaluate putative subclinical molecular effects of
cannabinoids we have measured the following biomarkers
measured according to already published standardized pro-
cedures: (1) cerebrospinal fluid (CSF) protein concentrations
including Tau, p-Tau and amyloid b-42 peptide (ab-42) [31];
(2) CSF monoamine levels including 3-methoxy-4-hydrox-
yphenylglycol (MHPG), 3,4-dihydroxyphenylacetic
(DOPAC), tryptophan (Trp), 5-hydroxyindoleacetic acid
(5HIAA) and homovalinic acid (HVA) [32]; (3) plasmamiR-
34b levels [33]; (4) CSF endocannabinoid levels (anan-
damide, AEA; palmitoylethanolamide, PEA; 2-arachi-
donoyglicerol, 2-AG) [34, 35]; (5) CSF Brain-derived
neurotrophic factor (BDNF); (6) sensitivity to toxins (H2O2,
rotenone, kainic acid, quinolinic acid, malonate) in skin
fibroblasts [36] and (7) gene expression of endocannabinoid
system elements in peripheral lymphocytes [37]. The elec-
tion of this panel of analyzes was based on the previous
evidence on their potential as HD activity biomarkers.
Study design
Patients were randomized to either Sativex followed by
placebo (Group A) or placebo followed by Sativex
(Group B). The two treatment blocks lasted 12 weeks each,
separated by a 4-week washout period. The first 4 weeks of
each period were of titration, gradually increasing Sativex
or placebo doses (as specified in the SmPC). Six visits were
carried out on weeks 0 (screening), 4 (randomization and
beginning of the first period of treatment), 16 (end of the
first phase of treatment and beginning of washout period),
20 (beginning of the second period of treatment), 32 (end
of the second period of treatment) and 36 (end of the trial).
Each visit included hematological and biochemical blood
analysis, a 12-lead ECG and urine sampling determining
cannabinoid concentration to check compliance. Patients
were given the option to sign a second informed consent
for CSF donation at visits 3 and 6, both after 12 weeks of
placebo or Sativex administration. Likewise, at the same
visits, the patients were given the option of signing a third
informed consent for donation of skin biopsies that were
used to obtain cultures of fibroblasts to be used in phar-
macological studies [36, 38] (Fig. 1).
Randomization and statistical analysis
Randomization was carried out through a random number
simple table, specifically developed by the Biostatistical
Service at Hospital Ramo´n y Cajal. Patients and clinical
raters were blind to treatment allocation. The placebo used
was a solvent, packed in containers identic to those of the
studied drug. GW Pharma Ltd (Porton Down Science Park,
Salisbury, Wiltshire, SP4 OJQ, UK) provided both placebo
and Sativex. An independent safety committee monitored
all the trial.
The number of patients to be included in the study was
calculated rescaling biomarker variables so as the means
would be 100, assuming that the mean after treatment
would be 85, with a difference in standard deviation of 20.
This would give an effect size of 0.75 with an alpha level
of 0.05 and 10 % power, assuming a 10 % drop-out rate.
According to these data, we estimated that 24 patients were
enough for this proof of concept study. To prevent possible
drop-outs, 2 additional subjects were included.
Changes in clinical scales were calculated comparing
values obtained in the active drug phase with those of the
placebo phase. Results in parametric variables are given as
mean ± standard deviation. Comparison was performed
through paired t. The significance level required was
p\ 0.05. The statistical analysis of adverse effects was
carried out through Chi-square comparison of parameters
corresponding to active drug phase and placebo phase.
Results are given in frequency tables. Comparison of the
responses between the different treatment groups was
performed through paired Student’s t or Wilcoxon test,
depending on the respective variable distribution, and
applying Bonferroni correction for multiple comparisons.
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Following protocol indications, only patients that had
completed the two treatment phases (placebo and active
drug) were included in the study. Sequence period and
treatment effects were evaluated.
Results
Twenty-six patients were recruited from the Ramo´n y Cajal
Hospital Huntington’s Disease clinics, in the disease initial
phase. One patient withdrew from the study before ran-
domization due to a cholelithiasis that required surgical
intervention. Twenty-five patients (14 male) were thus
allocated to treatment over a period of 3 months: 12 to
Sativex followed by placebo, and 13 to placebo followed
by Sativex. The mean age at randomization was 47.6 (SD
12.4; range 26–65 years). The mean age at disease onset
was of 41 (SD 0.5) years. The mean time from disease
onset was of 6.6 years (SD 4.3). The mean number of CAG
repeats in the longest allele was almost 46. Most patients
were under stable symptomatic treatment, with a great
predominance of benzodiazepines (60 %) (Table 1).
The baseline characteristics of both groups were com-
pared in both pre-treatment visits. In the first basal visit,
group B (placebo-Sativex) presented significant lower
scores in eye movements (7 versus 4, p = 0.013) and total
mUHDRS scale (32 versus 20, p = 0.004). Values for
maximal dystonia were on the limit of statistical signifi-
cance (2 versus 1, p = 0.048). Differences between the two
groups in the other assessed components was not statisti-
cally significant, except for interference Stroop which
presented a lower value for the group A (Sativex-placebo)
(18 versus 28, p = 0.045). In the second pre-treatment
visit, significant differences were detected for eye move-
ments (6.5 versus 2, p = 0.013), total mUHDRS (33.5
versus 22, p = 0.003), HADS (14 versus 10, p = 0.006)
and NPI (12 versus 7; p = 0.023). In all cases, the most
unfavorable scores were those belonging to the group
treated with Sativex in the first period and with placebo in
the second one (see Table 1 supplementary material).
Treatment compliance, assessed checking the returned
packages and through the urine test, reached 95.8 %.
McNemar test for paired data confirmed the absence of
statistically significant differences between drug and pla-
cebo tolerability (p = 0.414). A total of 20 patients (80 %)
tolerated the 12 daily Sativex sprays and 22 patients
(88 %) tolerated the 12 daily placebo sprays.
Biomarkers
CSF protein concentrations Changes of CSF protein con-
centrations are a well-documented marker of neurodegen-
eration and reflect neuropathological changes in
Alzheimer’s disease and other neurodegenerative diseases
[39]. Also, Tau and p-Tau are validated markers of neu-
ronal damage. However, we did not find any significant
differences between the patients tretated with Sativex and
the patients who received placebo (Table 2; Fig. 2).
CSF monoamine levels Measurement of monoamine
metabolites can be used to investigate serotonin and cate-
cholamine metabolism, thus providing an indication of the
activity of central monoaminergic neuronal pathways.
Changes in the CSF monoamine metabolite concentrations
have been linked to various disease phenotypes, including
HD, and several psychiatric symptoms, such as depression
and suicidal ideation. Also, it is known that certain medi-
cations have an impact on the CSF metabolite concentra-
tions, reflecting an influence on the monoaminergic
pathways [32]. However, we did not observe any signifi-
cant differences between the placebo and Sativex groups
in any of the monoamine metabolites analyzed (Table 2;
Fig. 2).
Plasma miR-34b levels MicroRNA formation is altered by
mutant huntingtin and microRNAs are present in plasma
and have been proposed as useful biomarkers in HD,
Fig. 1 Study flow chart
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Table 1 Patient demographic and baseline characteristics
Total, N = 25 Group A (Sativex-Placebo) N = 12 Group B (Placebo-Sativex) N = 13
Mean ± SD age, years 47.6 ± 12.4 49.2 ± 11.4 46.1 ± 13.6
Male:female 14:11 7:5 7:6
Age at onset ± SD, years 41.0 ± 10.5 40.7 ± 9.4 41.1 ± 11.8
Caucasian:Latino 24:1 12:0 12:1
Mean ± SD duration, years 6.6 ± 4.3 8.4 ± 4.7 4.8 ± 3.1
Mean CAG ± SD 45.7 ± 3.7 44.9 ± 3.4 46.4 ± 3.9
BMI (kg/m2) 22.0 ± 3.4 21.9 ± 2.9 22.2 ± 4.1
Other medication
Dopamine blockers 6 2 4
Tetrabenazine 6 4 2
Amantadine 1 1 0
Antidepressants 5 3 2
Benzodiacepines 15 8 7
Values are expressed in relation to order of drug administration (mean ± SD)
BMI body mass index, SD standard deviation
Table 2 Biomarker
determinations in patients after
Sativex and placebo treatments
Sativex Placebo P value
CSF protein concentrations
ab-42 (qg/mL) 757.1 (318.9) 655.3 (275.9) 0.258
Tau (qg/mL) 206.4 (91.3) 202.4 (76.0) 0.876
p-Tau (qg/mL) 47.9 (14.9) 50.2 (15.6) 0.627
CSF monoamine levels
MHPG (gg/mL) 14.5 (3.7) 14.5 (3.9) 0.992
DOPAC 9 100 (gg/mL) 0.3 (0.1) 9 100 0.3 (0.2) 9 100 0.876
Trp/10 (gg/mL/10) 588.6 (186.7)/10 621.0 (233.2)/10 0.618
5HIAA (gg/mL) 27.1 (9.3) 27.8 (9.3) 0.804
HVA (gg/mL) 51.0 (19.1) 53.1 (22.1) 0.732
Plasma miR-34b levels 14.5 (1.0) 14.3 (0.91) 0.595
CSF endocannabinoid levels
AEA (pmol/mL) \0.15 \0.15 –
PEA (pmol/mL) 2.5 (0.6) 2.8 (0.9) 0.374
2-AG (pmol/mL) \1 \1 –
CSF BDNF levels 27.7 (8.1) 30.2 (9.5) 0.322
Endocannabinoid gene expression in lymphocytes
CB2 (2-DDCt) 0.00046 (0.00006) 0.00071 (0.00009) \0.005
FAAH (2-DDCt) 0.00169 (0.00023) 0.00227 (0.00049) n.s.
MAGL (2-DDCt) 0.00047 (0.00011) 0.00061 (0.00017) n.s.
ACO2 (2-DDCt) 0.00821 (0.00140) 0.00641 (0.00112) n.s.
UCP2 (2-DDCt) 0.126 (0.018) 0.108 (0.013) n.s.
Values express as mean ± SD
CSF cerebrospinal fluid, miR MicroRNA, BDNF brain derived neurotrophic factor, MHPG 3-methoxy-4-
hydroxyphenylglycol, DOPAC 3,4 dihydroxyphenylacetic acid, Trp tryptophan, 5HIAA 5-hydroxyin-
dolacetic acid, HVA homovanilic acid, AEA anandamide, PEA palmitoylethanolamide, 2-AG 2-arachi-
donoyglycerol, FAAH fatty acid amide hydrolase, MAGL monoacylglycerol lipase, ACO2 aconitase-2,
UCP2 uncoupling protein-2, n.s. non significant
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particullary miR-34b, which is significantly elevated in HD
gene carriers [33]. Hence, miR-34b expression was deter-
mined in plasma from the patients by qRT-PCR after RNA
extraction. However, we did not find any significant dif-
ference between Sativex-treated patients and placebo-
treated patients (Table 2; Fig. 2).
CSF endocannabinoid levels CSF endocannabinoid levels
were determined by liquid chromatography coupled to
mass spectrometry as described previously [34, 35].
Endocannabinoid and PEA levels are known to change in
the brain areas of transgenic mouse models of HD,
reflecting an impaired endocannabinoid system, which is a
hallmark of symptomatic HD [35]. Specifically, an increase
in the CSF levels of putative neuroprotective substances,
such as the endocannabinoid or endocannabinoid-like
compounds, such as AEA, 2-AG and PEA could be con-
sidered as potentially benefitable to subjects treated with
Sativex. On the one hand, 2-AG and AEA levels were
undetectable in all patients tested (less than 1 pmol/mL for
2-AG and less than 0.15 pmol/mL for AEA), thus
Fig. 2 Total monoamine metabolites, ab-42, Tau and p-Tau, BDNF and miR-34b expression levels in Placebo and Sativex groups
J Neurol
123
Results - Chapter  2
105
suggesting that HD may decrease 2-AG and AEA levels in
CSF. This would be in line with the decrease in 2-AG and
AEA levels found in the striatum of symptomatic R6/2
mice compared to wild-type animals [35]. On the other
hand, PEA levels were readily detectable in all cases.
However, no significant differences were observed
between Sativex and placebo-treated patients (Table 2).
CSF BDNF concentration The influence of BDNF, an key
neurotrophin implicated in neuronal survival, has been
widely investigated in HD and low levels of BDNF are
considered key in the pathogenesis of HD in animal models
[40, 41]. An increase in BDNF CSF levels could, therefore,
be considered as a beneficial marker in Sativex-treated
patients. However, we did not find significant differences
between the placebo and the Sativex groups (Table 2;
Fig. 2).
Sensitivity to toxins in skin fibroblasts We investigated the
influence of Sativex and placebo on skin fibroblasts and
its potential for protection against toxic effects of several
agents. Skin fibroblasts, obtained from the patients and
grown in high serum (20 %) as described [36] were
transferred to DMEM supplemented with low serum
(0.2 %). Saline vehicle, 150 lM rotenone, 50 lM H2O [2,
30] 0 lM malonate, 300 lM quinolinic acid or 1.5 mM
kainic acid was subsequently added and cell viability was
measured after 48 h by the MTT method. There were no
significant differences in the sensitivity to the toxins
between cells from Sativex-treated patients and cells from
placebo-treated patients (Table 3).
Gene expression of endocannabinoid system elements in
peripheral lymphocytes Endocannabinoid gene expression
on lymphocytes is known to mirror metabolic changes in
the brain and has been considered as a marker of disease
and a potential tool to gage the action of chemical agents
on the effects of the mutant huntingtin protein [37]. Gene
expression for three key endocannabinoid elements was
measured in lymphocytes of HD patients during the active
(Sativex) and placebo phases. Our data revealed no dif-
ferences in the expression of FAAH and MAGL, the two
major endocannabinoid-degrading enzymes, but an inter-
esting elevation of CB2 receptor gene expression due to the
Sativex treatment (Table 2). In addition to
endocannabinoid elements, we also analyzed lymphocyte
gene expression for two genes encoding proteins involved
in metabolism and oxidative stress, aconitase-2 (ACO2)
and uncoupling protein-2 (UCP2), which have been pre-
viously to be downregulated in HD patients compared to
control subjects [42]. However, we did not find that such
expected downregulation may be counteracted by the
treatment with Sativex in agreement with the lack of
effects on other biomarkers and in the progression of
neurological decline in patients (Fig. 3).
Safety and tolerability
Two SAEs were recorded, both occurring in the same
patient during the placebo phase, and thus, were considered
unrelated to the active treatment. The first SAE consisted
on self-limited microcytic anemia, considered related to the
use of non-steroidal antiinflamatory drugs (NSAIDs) and
resolved after its discontinuation. The second SAE con-
sisted on pregnancy, confirmed with a pregnancy test,
taking place between visits 6 and 7 of the placebo phase.
Both complications were reported as the protocol deman-
ded, and followed until complete resolution.
No SAEs consisting on psychiatric alterations were
detected neither during active Sativex treatment or its
withdrawal. Dizziness or disturbance in attention were the
two most frequent adverse events (AA), with significant
differences between drug and placebo periods, in agree-
ment with other publications. Dizziness and disturbance in
attention were both present in 16 % of patients during drug
treatment period, while no case was reported during pla-
cebo period. The rest of AA showed a similar frequency in
active, placebo, and no-treatment periods (Table 4).
Scores in clinical UHDR scales
Period and sequence effects were discarded, and thus data
from the two periods could be used for the analysis of the
treatment effect. The results showing the differences
between scores recorded in the basal and final visit of each
period, are presented in Table 5. No differences on motor
(p = 0.286), cognitive (p = 0.824), behavioral (p = 1.0)
and functional (p = 0.581) scores were detected during
Table 3 Sensitivity to toxins of
skin fibroblasts from Sativex-
treated and placebo-treated
patients
H2O2 (50 lM) Mal (300 lM) QA (300 lM) KA (1500 lM) Rot (15 lM)
Sativex 89 ± 2* 96 ± 2 98 ± 2 97 ± 3 53 ± 6*
Placebo 89 ± 3* 101 ± 4 101 ± 4 98 ± 52 58 ± 7*
Data are expressed as mean ± SEM
Mal malonate, QA quinolinic acid, KA kainic acid, Rot rotenone
* P\ 0.01 from vehicle incubations
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treatment with Sativex as compared to placebo. Results of
motor scale analysis showed no changes between active
drug and placebo treatments (Table 5; Fig. 4). Individual
evaluation of each of these clinical scales, indicates a non-
significant trend towards improvement with placebo as
compared to Sativex.
Discussion
Sativex was safe and well tolerated in patients with HD.
Neither clinical improvement nor worsening was detected
for any motor, cognitive or psychiatric measures or the
functional situation assessment. A remarkable finding was
Fig. 3 Gene expression
Table 4 Reported adverse events
Sativex, N = 25 Placebo, N = 24 No treatment N = 25 p value
Anxiety 6 (24) 3 (12.5) 5 (20) 0.479
Sleepiness 5 (20) 1 (4.17) 3 (12) 0.102
Dizziness 4 (16) 0 2 (8) 0.045*
Disturbance in attention 4 (16) 0 1 (0) 0.045*
Insomnia 2 (8) 1 (4.17) 3 (12) 0.564
Behavioral changes 1 (4) 3 (12.5) 3 (12) 0.317
Fever 1 (4) 2 (8.33) 2 (8) 0.564
Local infection 4 (16) 1 (4.17) 1 (4) 0.317
Upper respiratory infection 7 (28) 8 (33) 9 (36) 0.317
Diarrhea 6 (24) 3 (12.5) 1 (4) 0.414
Vomits 3 (12) 0 3 (12) 0.083
Headache 4 (16) 4 (16.67) 9 (36) 1
Muscular pain 2 (8) 2 (18.33) 5 (20) 1
Values are expressed as n (%), during the Sativex, placebo and no-treatment periods
* p\ 0.05
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the absence of neuropsychiatric symptoms, a major con-
cern due to their high prevalence in HD. There were no
significant clinical variations, thus suggesting a relevant
therapeutic response. Likewise, the lack of significant
clinical effects of Sativex was associated with a lack of
changes in essentially all the biomarkers examined. The
only exception was an elevation of CB2 receptor gene
expression in peripheral lymphocytes due to the Sativex
treatment. We interpret this elevation as a positive response
elicited by the treatment and possibly aimed at enhancing
the cytoprotective and anti-inflammatory role played by
this cannabinoid receptor type in damaging conditions
existing in HD, as described previously in patients and
experimental models [20, 43]. However, it is possible that a
longer period of treatment may be necessary to allow that
the benefits derived from the activation of the CB2 receptor
may be visible in the progression of the disease in patients.
On the other hand, THC has been previously reported to
increase BDNF levels in the brain of rodents [44] as well as
in the plasma of human volunteers [45], while THC and
CBD have been shown to modulate endocannabinoid
degradation and, therefore, to change endocannabinoid
levels [46, 47]. However, these short-term cannabinoid
actions were not evident in the long-term cannabinoid
treatments that we administered to the patients of our
study.
Our results are in apparent contradiction with those
reported in animal models [48], in which pharmacological
administration of THC to mice expressing human mutant
huntingtin exon 1 (R6/2 mice) exerted a therapeutic effect.
It is likely that the therapeutic potential of cannabinoids in
HD patients should be explored in the earlier phases of the
disease, since progressive loss of CB1 receptors may
attenuate its mechanisms of action [49]. It is possible that
Sativex high tolerability and the absence of clinical
changes in HD symptomatology were related with the use
Table 5 Changes in outcomes
between treatment allocations
Changes during Sativex Changes during Placebo p value
Motor scores
Eye movements 0 (1.9) 0.4 (1.3) 0.238
Maximal dystonia -0.4 (1.6) -0.4 (1.2) 1.000
Maximal chorea 0 (2.2) 0.6 (2.3) 0.405
Remaining items -0.2 (3.4) 1.4 (2.6) 0.678
TMS -0.6 (6.4) 2.0 (5.0) 0.286
Cognitive scores
Verbal fluency 0.6 (5.6) -0.7 (6.6) 0.405
Categorical fluency 11.7 (4.8) 11.6 (5.1) 0.824
Stroop interference 1.6 (6.2) 0.7 (5.5) 0.824
Behavior scores
bUHDRS -2.6 (5.6) -0.1 (8.0) 1.000
HADS -2 (3.5) -0.2 (5.1) 0.405
NPI -2.6 (5.6) -0.1 (7.9) 0.134
Function scores
fUHDRS 2.8 (11.6) 0.3 (1.2) 0.581
Data are presented as mean (SD)
TMS total motor score, bUHDRS behavioral Unified Huntington disease rating scale, HADS Hospital
Anxiety and Depression Scale, NPI neuropsychiatric inventory, fUHDRS functional Unified Huntington
Disease Rating Scale
* P value for the difference between changes in treatment allocations: Sativex treatment vs. placebo
treatment
Fig. 4 TMS
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of the drug in too late disease stages, when the number of
CB1 receptors is highly decreased. In this sense, the use of
cannabinoids in earlier stages could maximize both,
adverse events and clinical response.
In addition, it is likely that our experimental design was
adequate to show safety but not well suited to prove effi-
cacy. Additional studies of longer duration are likely to be
more effective than crossed studies. Also, the use of other
cannabinoids including CB1 and CB2 agonists with dif-
ferent ratios could exert different effects, and so might do
TRPV1 receptor agonists, since the latter do not seem to
disappear with HD progression [12]. The adequate safety
showed in this clinical trial should encourage other studies
with higher cannabinoid doses and longer administration
periods.
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CHAPTER 3
Study of some of the molecular mechanisms involved in the effect of cannabinoid 
compounds in experimental models of HD. 
In this Chapter we wanted to study more deeply some of the possible mechanisms involved in the 
positive effect of phytocannabinoids. In particular, we focused in the antioxidant effect and the 
possible involvement of NRF2 activation and promotion of antioxidant phase II response. To this aim, 
we tested the Sativex-like combination of Δ9-THC and CBD botanical extracts compared with each 
phytocannabinoid used individually in a HD cellular model of conditionally immortalized murine 
striatal neuroblasts (STHdhQ7/Q7 and STHdhQ111/Q111 cells). Firstly, we exposed these cells to agents that 
produced different cytotoxic events that occur in HD brains: glutamate (excitotoxicity), malonate 
(mitochondrial damage) and hydrogen peroxide (oxidative damage). In all cases, we confirmed an 
important extent of cell death, but our results showed that protection with phytocannabinoids was 
only visible against hydrogen peroxide insult. We found that CBD, but mainly Sativex, protected both 
cell lines against H
2
O
2
, although this effect was much more modest in STHdhQ111/Q111 than in STHdhQ7/
Q7 cells. This effect was accompanied by an increase of HO1 gene expression, so next we tested the 
possible involvement of NRF2/ARE pathway in this phytocannabinoid-mediated neuroprotection. 
Our results did not confirm a role of NRF2/ARE in this process, so further research will be needed 
to dissect the potential mechanisms involved in the CBD and Sativex –mediated neuroprotection 
against oxidative damage in striatal cells.
A second specific objective in this chapter consisted in exploring whether endocannabinoids, 
in particular 2-AG, provide some type of tonic protection in HD, using the malonate model. 
Unexpectedly, we observed that inhibiting MAGL, rather than being neuroprotective, aggravated 
striatal damage, whereas the opposite happened with DAGL inhibition. This unexpected result was 
explained through a malonate-induced COX-2 up-regulation which contributes to convert 2-AG in 
prostaglandin-glycerol-esters. Such derivatives were highly neurotoxic. Using in vitro tools, M-213 
cells, we proved that the induction of COX-2 and the generation of the 2-AG oxygenated derivatives, 
as well as that inhibition of COX-2 or the blockade of the targets for these derivatives reduced the 
neurotoxicity.
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Abstract
Different phytocannabinoids have provided neuroprotection in experimental models of Huntington’s disease 
(HD), even the issue has extended to the clinical scenario with the recent development of a trial using 
the phytocannabinoid-based medicine Sativex in HD patients. In the present study, we wanted to further 
investigate some of the molecular mechanisms underlying the positive effects of phytocannabinoids, using 
an in vitro strategy with striatal derived cell lines generated from a knock-in mouse containing homozygous 
huntingtin loci with a humanized exon 1 with either 7 (STHdhQ7/Q7, WT cells) or 111 (STHdhQ111/Q111, HD cells) 
polyglutamine repeats. We first investigated whether botanical extracts enriched in Δ9-tetrahydrocannabinol 
(Δ9-THC-BDS) or cannabidiol (CBD-BDS), as well as their 1:1 combination as in Sativex®, were effective against 
different cytotoxic insults in STHdhQ7/Q7 and STHdhQ111/Q111 cells. We used excitotoxins, mitochondrial toxins, 
or hydrogen peroxide (H
2
O
2
), which resemble those cytotoxic events occurring in HD brains, although our 
data were positive only in the case of cells treated with H
2
O
2
. Thus, in the case of STHdhQ7/Q7 cells, we found 
that CBD-BDS, alone or combined with Δ9-THC-BDS as in Sativex, but not Δ9-THC-BDS, prevented cell death 
after H
2
O
2
-induced oxidative damage. This protection was accompanied by an increase in heme oxygenase-1 
(HO1) an enzyme induced by the activation of the transcription factor NRF2. Then we tried to confirm that 
the treatment of STHdhQ7/Q7 cells with phytocannabinoids enhanced H
2
O
2
-induced NRF2 translocation to the 
nucleus, a response expected at the light of phytocannabinod effects of HO-1 gene expression. However, we 
were not able to confirm such response, even the nuclear translocation of NRF2 appeared to be a little bit lower 
after the treatment with the phytocannabinoids. In general, the responses in gene and protein expression in 
STHdhQ111/Q111 cells were relatively similar compared to STHdhQ7/Q7 cells, although much more moderate. Given 
that these differences did not influence the capability of phytocannabinoids to prevent cell death after H
2
O
2
, 
which resulted to be relatively similar in both types of cells, we assumed that other mechanisms of protection 
should work in the case of STHdhQ111/Q111 cells. In summary, we predict, although additional evidence needs 
to be provided, a possible activation of NRF2-mediated mechanism of neuroprotection by CBD and Sativex, 
but not Δ9-THC, against oxidative damage in striatal neurons. The involvement of other signaling mechanisms 
cannot be ruled out, and further research is needed to elucidate the relevance of this mechanism for a 
cannabinoid-based treatment for HD.
Key words: Phytocannabinoids, Sativex, STHdhQ7/Q7 and STHdhQ111/Q111 cells, NRF2, oxidative stress.
Introduction
 Huntington’s disease (HD) is a fatal  inherited 
neurodegenerative disorder characterized by motor 
impairment, cognitive dysfunction and psychiatric 
illness (Huntington, 2003). The primary cause of 
the disease is a mutation in the huntingtin gene 
consisting of a variable expansion of the CAG triplet 
repeat translated into an abnormal polyglutamine 
tract in the amino-terminal portion of this protein, 
which becomes toxic for specific striatal and cortical 
neuronal subpopulations (THDCRG, 1993).                              
Nowadays, there is no specific pharmacotherapy to 
alleviate motor and cognitive symptoms and/or to 
delay disease progression in HD. Thus, even though a 
few compounds have produced encouraging effects 
in preclinical studies (e.g. minocycline, coenzyme 
Q10, unsaturated fatty acids, inhibitors of histone 
deacetylases), none of them have resulted yet in the 
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development of an effective treatment (Ross et al., 
2014).
A potential therapy that is being deeply evaluated in 
preclinical models of HD is the use of cannabinoid 
compounds. Preclinical studies with cannabinoids 
demonstrated preservation of striatal neurons 
against different cytotoxic stimuli that operate in 
HD pathogenesis (Pazos et al., 2008), effects that 
were exerted through mechanisms of action that 
could involve or not the activation of CB
1
 and/or CB
2
 
receptors. For instance, the positive effects exerted 
by the non-selective phytocannabinoid agonist 
∆9-tetrahydrocannabinol (∆9-THC) in the transgenic 
mouse model of HD R6/2  are likely produced through 
the activation of CB
1
 receptors (Blázquez et al., 2011). 
∆9-THC can also be active at the CB
2
 receptors, as 
selective agonists of this receptor preserved striatal 
neurons in this genetic model (Palazuelos et al., 
2009) and also in malonate-lesioned rats (Sagredo 
et al., 2009), an acute model of HD in which striatal 
damage is produced primarily by apoptosis and glial 
activation/inflammatory events. Selective agonists of 
CB
1
 (Pintor et al., 2006) and CB
2
 receptors (Palazuelos 
et al., 2009) also preserved striatal neurons in in vitro 
or in vivo excitotoxic models. On the other hand, 
cannabinoids with antioxidant profile, e.g. ∆9-THC, 
cannabidiol (CBD) or cannabigerol (CBG) protected 
striatal neurons against toxicity caused by the 
mitochondrial complex II inhibitor 3-nitropropionic 
acid (3NP) that primes calpain activation and 
oxidative injury (Lastres-Becker et al., 2004; Sagredo 
et al., 2007; Valdeolivas et al., 2015). 
These results point to the hypotheses that the 
evaluation of cannabinoids as disease-modifying 
agents in HD patients should be necessarily 
conducted with a broad-spectrum cannabinoid or 
with combinations of various cannabinoids with 
different and complementary pharmacological 
profiles. Sativex is a cannabis-based medicine 
already approved for the treatment of spasticity and 
neuropathic pain in patients with multiple sclerosis 
in many countries (Sastre-Garriga et al., 2011) and 
,in Canada under the Notice of Compliance with 
Conditions (NOC/c) policy as adjunctive analgesic 
treatment in patients with advanced cancer (Johnson 
et al., 2010). It has an appropriate profile for HD; 
it is antioxidant due to the structure of both of its 
components, can activate CB
1
 and CB
2
 receptors 
because of the presence of ∆9-THC, and can also 
exert cannabinoid receptor-independent properties 
due to ∆9-THC and, in particular, to CBD (Fernandez-
Ruiz et al., 2013). This non-psychoactive cannabinoid 
has proved effectiveness against cell death in 
multiple models of brain damage, acting through 
non-cannabinoid receptor based signaling pathways, 
such as the activation of 5-HT
1A
 receptors (Pazos et 
al., 2013), PPARγ nuclear receptors (Scuderi et al., 
2014) and NRF2 transcription factor (Juknat et al., 
2013). Moreover, CBD may counteract the possible 
psychoactive-like side effects related to the chronic 
use of ∆9-THC (Russo & Guy, 2006).
In the last years, we have performed experiments 
with the combination of ∆9-THC and CBD botanical 
extracts present in Sativex in those animal models 
of HD in which individual cannabinoid agonists 
have proved to be effective, with the objective of 
determining whether this mixture is also beneficial 
in these models. We obtained the first data in rats 
subjected to 3NP intoxication, a model in which 
the Sativex-like combination of phytocannabinoids 
preserved striatal neurons from death as the 
individual compounds had done previously (Lastres-
Becker et al., 2004; Sagredo et al., 2007), and this 
effect was, as expected, independent of CB
1
 and CB
2
 
receptors (Sagredo et al., 2011). Next, we conducted 
similar studies in rats lesioned with malonate, an 
acute model in which selective CB
2
 receptor agonists 
had yielded positive results (Sagredo et al., 2009), 
while the blockade of CB
1
 receptors aggravated the 
striatal damage (Lastres-Becker et al., 2003). The 
Sativex®-like combination of phytocannabinoids also 
preserved striatal neurons from death caused by 
malonate and this effect was dependent on both CB
1
 
and CB
2
 receptors (Valdeolivas et al., 2012). These 
positive effects prompted us to extend our research 
to transgenic mouse models of HD, in particular 
the R6/2 mice which are frequently used for the 
evaluation of potential neuroprotective compounds 
that deserve to be studied at the clinical level. We 
found that a daily treatment with Sativex®-like 
combination of phytocannabinoids in R6/2 mice 
improved some motor deficits (Valdeolivas et al., 
2017), whereas it reversed the changes found in 
local metabolic activity in the basal ganglia using 
PET, and in a series of detectable biomarkers 
measured by ex-vivo proton magnetic resonance 
spectroscopy (H+-MRS), which reflect oxidative 
damage, energy failure, excitotoxicity, and other 
events typically found in HD, all of them being 
prognostic for brain integrity/damage (Tsang et 
al., 2006; Pazos et al., 2013).
In the present study, we aimed to further explore 
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the molecular mechanisms by which Sativex is 
neuroprotective in different models of HD using an in 
vitro strategy with striatal derived cell lines generated 
from a knock-in mouse containing homozygous 
huntingtin loci with a humanized exon 1 with either 
7 (STHdhQ7/Q7, WT cells) or 111 (STHdhQ111/Q111 HD 
cells) polyglutamine repeats. Our first objective 
was to quantify possible differences between both 
types of cells in the expression of specific genes 
related to the endocannabinoid signaling and 
other markers of interest for the purpose of our 
study (e.g. inflammatory state, oxidative response, 
neurotrophins, and others). The second objective 
was evaluate the neuroprotective profile of ∆9-THC-
BDS, CBD-BDS and Sativex against three different 
cytotoxic events that occur in the brains of the 
patients: excitotoxicity, mitochondrial damage and 
oxidative stress, all of them reproduced by using 
appropriate neurotoxins. Given the positive effects 
found with CBD and Sativex against oxidative stress-
mediated cell death, our last objective was to explore 
the potential mechanisms involved in this action. 
Thus, we aimed to assess the possible involvement 
of the NRF2-KEAP1/ARE signaling pathway in the 
observed antioxidant effect by non-psychoactive 
cannabinoids.
Materials and methods
Cell culture
Conditionally immortalized striatal neuroblasts 
from wild-type mice (STHdhQ7/Q7 cells), or knock-in 
mice expressing two copies of a mutant huntingtin 
allele (STHdhQ111/Q111 cells), thus expressing 
endogenous levels of full-length huntingtin with 7 
or 111 glutamine repeats respectively, were used. 
These cells are infected with a defective retrovirus 
transducing the temperature-sensitive A58/U19 
large T antigen and geneticin-resistant colonies are 
selected at the permissive temperature of 33ºC, as 
described previously (Trettel et al., 2000). Cells were 
maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 
2mM ultra-glutamine, 1 mM sodium pyruvate, 1% 
penicillin/streptomycin and 400 µg/ml geneticin, 
under a humidified 5% CO
2
 atmosphere at 33ºC. 
Cell viability
Cells were seeded at 38000 cells/cm2 in 24-well 
plates in supplemented-DMEM medium previously 
described (complete medium). After 24h, complete 
medium was replaced by serum-free medium and 
cells were further incubated overnight. Afterwards, 
different conditions were applied depending on 
the cytotoxic agent used. For the mitochondrial 
damage experiment, cells were exposed to 100 
mM malonate prepared in serum-free medium. 
After 5 hours of incubation, cell viability was 
determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) test. For the 
excitotoxicity experiment, serum-free medium was 
replaced by hand-made Locke’s solution (Earle’s 
balanced Salt Solution -EBSS-, 2.3 mM CaCl2, 5mM 
Hepes, 10 µM glycine) and cells were exposed to 10 
mM glutamate for 6h. Then media from each well 
were used to measure lactate deshydrogenase (LDH) 
activity as an index of cell death, using the Cytotox 
96 Non-Radioactive Cytotoxicity Assay Kit (G1780, 
Promega Biotech Ibérica, Madrid, Spain). For the 
oxidative stress experiment, complete medium was 
replaced by DMEM and cells were exposed to 2 
mM hydrogen peroxide. After 2h, LDH activity was 
measured as in the excitotoxicity experiment. In all 
cases, 30 minutes before exposure to the cytotoxic 
agent, cells were treated with botanical extracts 
enriched with either Δ9 -THC, kindly provided by GW 
Pharmaceuticals Ltd., Cambridgeshire, U.K. (Δ9-THC 
botanical extract contains 66.7% Δ9-THC, 0.2% CBD, 
0.8% cannabigerol, 1.1% cannabichromene, and 2.3% 
other phytocannabinoids) or CBD, also provided by 
GW Pharmaceuticals Ltd., Cambridgeshire, U.K. (CBD 
botanical extract contains 62.7% CBD, 3.6% Δ9-THC, 
1.4% cannabigerol, 5.7% cannabichromene, and 
1.8% other phytocannabinoids) or the Sativex-like 
1:1 combination of both. Cannabinoid extracts were 
prepared in Tween-80 – culture medium solution 
(1:10) and always applied at a final concentration of 
0.5 µM. In all experiments, negative control cells (not 
exposed to toxins and treatments, only cannabinoid 
extracts’ vehicle added) and positive control cells 
(exposed to 1% triton X-100, representing 100% of 
cell death) were used. Additional experiments with 
cells only exposed to cannabinoid extracts were done 
(not shown), and cytotoxicity by these compounds at 
the indicated dose was ruled out.
Real-Time qTR-PCR 
Total RNA was isolated using SurePrep™ RNA/Protein 
Purification Kit (Fisher Bioreagents, Fair Lawn, NJ, 
USA). The total amount of RNA was quantified by 
spectrometry at 260 nm, its purity evaluated by 
the 260/280 nm absorbance ratio, and its integrity 
confirmed in agarose gels. cDNA was obtained using 
Quantitec Reverse Transcription Kit (Qiagen, Izasa, 
Results - Chapter 3
116
Madrid, Spain) and samples were kept at -20ºC until 
amplification. Quantitative real-time PCR assays 
were performed using Taqman Gene Expression 
Assays (Applied Biosystems, Foster City, CA, USA), 
in a 7300 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA). References of 
the probes used are shown as follows: KEAP1 
(Mm00497268_m1), NQO1 (Mm01253561_m1), 
HO1 (Mm00516005_m1), iNOS (Mm01309902_m1), 
TNFα (Mm99999068_m1), GLAST (Mm00600697_
m1), GLT-1 (Mm00441457_m1) IGF-1 (Mm00439560_
m1), BDNF (Mm01334042_m1), DARPP32 
(Mm00454892_m1), PPARγ (Mm01184322_m1), 
MAGL (Mm00449274_m1), FAAH (Mm00515684_
m1), CB1 (Mm00432621_s1), GCLC (Mm00802655_
m1), PRDX1 (Mm01621996_s1) and GAPDH 
(Mm99999915_g1). Relative gene expression data 
were determined by the 2−ΔΔCt method. Each value 
was adjusted to GAPDH levels as reference.
Preparation of nuclear and cytosolic extracts
For subcellular fractionation experiments, cells 
were seeded in p100 plates (55000 cells/cm2). After 
24h, complete medium was replaced by serum-free 
medium and, after incubation overnight, cells were 
pre-treated with phytocannabinoids and exposed 
to 0.5 mM hydrogen peroxide for 2.5h. After that, 
cytosolic and nuclear fractions were prepared as 
described elsewhere (Lastres-Becker et al., 2014). 
Briefly, cells were washed with cold PBS, harvested 
in 400 µl of cold Buffer A (20 mM HEPES, pH 7.0, 
0.15 mM EDTA, 0.015 mM EGTA, 10 mM KCl, 1% 
NonidetTM P- 40, 1 mM phenylmethylsulphonyl 
fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, 
1 mM sodium orthovanadate, 1 mg/ml leupeptin) 
and incubated on ice for 30’. Then samples were 
centrifuged 5’ at 500g and the supernatants were 
stored at -80ºC as the cytosolic fraction. The nuclear 
pellet was resuspended carefully in 500 µl of cold 
Buffer B (10 mM HEPES, pH 8.0, 0.1 mM EDTA, 0.1 mM 
NaCl, 25% glycerol, 1 mM phenylmethylsulphonyl 
fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, 
1 mM sodium orthovanadate, 1 mg/ml leupeptin) 
and centrifuged again 5’ at 500g. The supernatant 
was then removed and the nuclear pellets were 
resuspended in Buffer A containing Laemmli SDS 
loading buffer. After sonication, these samples were 
stored at -80ºC as the nuclear fraction. Nuclear and 
cytosolic protein samples were boiled and resolved 
in 10% acrylamide gels (TGX Stain-Free™ FastCast™ 
Acrylamide Kit, Bio-Rad Laboratories, Hercules, CA, 
USA), and then transferred to a PVDF membrane 
(Bio-Rad Laboratories, Hercules, CA, USA) using mini 
Trans-Blot Electrophoretic transfer cell (Bio-Rad 
Laboratories, Hercules, CA, USA). Membranes were 
blocked in 5% non-fat milk and incubated overnight 
at 4°C with the anti- NRF2 (C-20) primary antibody 
(sc-722, Santa Cruz Biotechnology). Incubation 
with anti-α-tubulin (TU-02) (sc-8035, Santa Cruz 
Biotechnology) and anti-laminB (C-20) (sc-6216, 
Santa Cruz Biotechnology) primary antibodies was 
used as a loading control for the cytosolic and nuclear 
fraction, respectively. This was followed by a second 
incubation during 1 hour at room temperature 
with an ECL™ Horseradish Peroxidase-linked whole 
secondary antibody (GE Healthcare UK Limited, 
Buckinghamshire, UK) at a 1:5000 dilution. Reactive 
bands were detected by chemiluminescence with 
the Amersham™ ECL™ Prime Western Blotting 
Detection Reagent (GE Healthcare UK Limited, 
Buckinghamshire, UK). Images were analyzed on 
a ChemiDoc station with Quantity one software 
(Bio-Rad Laboratories, Madrid, Spain). Data were 
calculated as the ratio between the optical densities 
of the specific protein band and the housekeeping 
protein band (α-tubulin or laminB), and they were 
normalized as fold changes over the control group 
for presentation.
Statistical analyses
Data are presented as mean ± SEM. All data were 
analysed by one-way ANOVA followed by the Student-
Newman-Keuls test, or by unpaired Student’s t-test, 
as required, using Graphpad Prism (version 6.0). 
Results
Dysregulation in the expression of genes of interest 
in STHdhQ111/Q111 compared to STHdhQ7/Q7 cells. As 
a first approach to these cell lines, we wanted to 
determine the differences in gene expression in 
STHdhQ111/Q111 cells versus STHdhQ7/Q7 cells in 
endocannabinoid genes, as well as others related to 
cell survival (e.g. neurotrophins) or to the response 
to cytotoxic events such as inflammation, oxidative 
stress, mitochondrial damage and excitotoxicity. 
The results are shown in Figure 1. As expected, 
we observed a decrease in the expression of 
neurotrophins (BDNF and IGF1), which has been 
already described in other HD models and in 
patients (Ferrer et al., 2000; Zuccato & Cattaneo, 
2007). Regarding the cannabinoid system, we found 
an increase in FAAH enzyme, which is also elevated 
in other models of early HD, but decreased at early 
stages and also in human lymphocytes (Battista 
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et al., 2007; Bari et al., 2013). Besides, we found a 
decrease, although not significant, in CB
1
 receptor 
expression that has been widely reported as a 
pathogenic hallmark of the disease (Blazquez et 
al., 2011). We also observed significant differences 
in genes related to  the cellular response to 
oxidative damage, such as NQO1 and Keap-1 and to 
inflammation, such as PPARγ. Of particular interest 
is the huge increase in iNOS found in STHdhQ111/
Q111 cells, nearly 200 times higher than in WT cells, 
which had not been described before. The changes 
observed in the expression of glutamate transporters 
GLT-1 and GLAST are also surprising given that these 
two glutamate transporters are characteristic of glial 
cells (Perego et al., 2000; Plachez et al., 2004). A priori 
all these data made us hypothesize that STHdhQ111/
Q111 cells might be more sensitive to the cytotoxic 
insults that will be described in the following results, 
and likewise could be differently affected by the 
treatment with phytocannabinoids. Unexpectedly, 
our results showed the opposite (see below).
Effects of phytocannabinoid combinations on cell 
death induced by different insults. Next, we aimed to 
determine the potential effects of phytocannabinoids 
on cell death produced by different damaging insults 
that resemble neuropathological events that occur 
in the brains of HD patients. First, we exposed both 
cell lines to malonate, a mitochondrial complex-II 
inhibitor that has been previously used in models 
of neuroinflammation and mitochondrial damage in 
HD. As expected, malonate induced a decrease in cell 
viability in both cell lines (STHdhQ7/Q7 F(4,40)=26.87, 
p<0.005; STHdhQ111/Q111 F(4,39)=15.80, p<0.005) with 
these last cells being apparently more vulnerable to 
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Figure 1. Changes in gene expression in STHdhQ111/Q111 cells 
compared to STHdhQ7/Q7 cells. Values are expressed as means 
± SEM of 3 cases per group. Data were subjected to unpaired 
t-test. *p<0.05, **p<0.01, ***p<0.005 compared to compared 
to STHdhQ7/Q7 cells.
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Figure 2. Viability and cytotoxicity assays of STHdhQ7/Q7 and STHdhQ111/Q111 cells pretreated with phytocannabinoids and exposed to 
malonate and glutamate. Values are expressed as means ± SEM of 8-9 cases per group. Data were subjected to one-way analysis of 
variance, followed by the Student-Newman-Keuls test. a) Relative viability, measured by MTT assay, of STHdhQ7/Q7 and STHdhQ111/Q111 
cells pretreated with either 0.5 µM Δ9-THC, CBD or Sativex for 30’ and exposed to 100 mM malonate for 5h. ***p<0.005 compared to 
control group. b) Relative cytotoxicity, measured by LDH-release assay, of of STHdhQ7/Q7 and STHdhQ111/Q111 cells pretreated with either 
0.5 µM Δ9-THC, CBD or Sativex for 30’ and exposed to 100 mM glutamate for 6h. *p<0.05, **p<0.01 compared to control group.
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this kind of damage (Fig. 2a). Anyway, the treatment 
with none of the phytocannabinoids (Δ9-THC, 
CBD and Sativex) could prevent cell loss. Next, we 
investigated the response of these cells to glutamate 
exposure (Fig. 2b). Glutamate caused cytotoxicity 
in a similar way in both cell lines, although, in 
STHdhQ111/Q111 cells the elevation in cell death was 
not statistically significant (STHdhQ7/Q7 F(4,40)=5.17, 
p<0.01; STHdhQ111/Q111 F(4,39)=2.35, p>0.05), and the 
pre-treatment with phytocannabinoids did not cause 
any effect in cell death in none of these cell lines. 
The third approach consisted on the exposure of the 
cells to hydrogen peroxide (H
2
O
2
) to produce cell 
death through oxidative stress. In this experiment, 
the antioxidant N-acetylcysteine (NAC) was added at 
the same time than phytocannabinoids, as a positive 
control. Although STHdhQ111/Q111 cells showed a 
higher LDH release in basal conditions (data not 
shown), surprisingly, they were much less vulnerable 
to H
2
O
2
 than STHdhQ7/Q7. However, the treatment 
with CBD-BDS and Sativex, but not Δ9-THC-BDS, 
reduced significantly the cytotoxicity (STHdhQ7/Q7 
F(4,40)=26.87, p<0.05 CBD vs H
2
O
2
, p<0.005 Sativex vs 
H
2
O
2
; STHdhQ111/Q111 F(4,39)=15.80, p<0.05), although 
the reversion was not complete as occurred in those 
cells treated with NAC (Fig. 3).
Effect of phytocannabinoids on the expression of 
genes related to NRF2 and antioxidant response. 
After the robust effect exerted by CBD-BDS and 
Sativex, we wanted to further investigate the possible 
mechanisms responsible of this neuroprotective 
action. Although this strong antioxidant profile 
was not unexpected, as CBD has intrinsically more 
antioxidant capacity than Δ9-THC because of its 
chemical structure, the fact that the combination 
of both in the Sativex-like treatment has a higher 
neuroprotective effect suggested that specific 
intracellular signaling mechanisms (e.g. NFR2 
signaling) might be involved. Thus, we repeated the 
same experiment but using a reduced dose and a 
prolonged exposure of H
2
O
2
, with the objective of 
avoiding early cell necrosis. Therefore, cells were 
pre-treated with phytocannabinoids and exposed to 
0.5 mM hydrogen peroxide for 3.5h, and then total 
RNA was extracted to analyze gene expression of 
different enzymes induced by oxidative stress. As 
can be seen in Fig. 4., the expression of antioxidant 
enzymes induced by the activation of NRF2, as well 
as kelch like ECH associated protein 1 (KEAP1), was 
evaluated. Surprisingly, there were no changes in 
gene expression of neither glutamate-cysteine ligase 
catalytic subunit (GCLC) nor peroxiredoxin-1 (PRDX1) 
in none of the cell lines, although the activity of 
these enzymes is directly related to the insult with 
H
2
O
2
. However, the expression of heme oxygenase-1 
(HO1) was significantly increased after the exposure 
to H
2
O
2
 in STHdhQ7/Q7 cells and not affected by the 
treatment with Δ9-THC-BDS (F(4,10)=19.38, p<0.01). 
Moreover, the treatment with CBD-BDS and Sativex 
duplicated the increase in the expression of this 
enzyme, suggesting that an induction of antioxidant 
response may be elicited by the treatment with 
these compounds. In STHdhQ111/Q111 the effect 
was much more moderate and did not reach 
statistical significance, although a similar trend was 
appreciated. Regarding the expression of the enzyme 
NAD(P)H quinone dehydrogenase 1 (NQO1), and the 
repressor of NRF2-dependent transcription KEAP1, 
no changes by the treatment with phytocannabinoids 
were observed. The increase in HO-1 expression 
made us hypothesize that CBD and Sativex could 
exert a neuroprotective effect by inducing the NRF2 
pathway against an oxidative insult.
Effects of phytocannabinoids on NRF2 nuclear 
translocation. In order to confirm the potential action 
STHdhQ7/Q7 H2O2
Co
ntr
ol 2O2H + T
HC
+ C
BD
+ S
ati
ve
x
+ N
AC
0
7
14
***
###
*
###
*** #
***
R
el
at
iv
e 
cy
to
to
xi
ci
ty
(F
ol
d 
ch
an
ge
 o
ve
r 
C
on
tr
ol
)
STHdhQ111/Q111 H2O2
Co
ntr
ol 2O2H + T
HC
+ C
BD
+ S
ati
ve
x
+ N
AC
0
7
14
*** ***
#
***
#
** ###Re
la
tiv
e 
cy
to
to
xi
ci
ty
(F
ol
d 
ch
an
ge
 o
ve
r 
C
on
tr
ol
)
Figure 3. Relative cytotoxicity, measured by LDH-release assay, 
of of STHdhQ7/Q7 and STHdhQ111/Q111 cells pretreated with either 
0.5 µM Δ9-THC, CBD or Sativex for 30’ and exposed to 2mM H
2
O
2
 
for 2h. 1 mM NAC was used as antioxidant control. Values are 
expressed as means ± SEM of 6-12 cases per group. Data were 
subjected to one-way analysis of variance, followed by the 
Student-Newman-Keuls test. *p<0.05, **p<0.01, ***p<0.005 
compared to control group. #p<0.5, ###p<0.005 compared to 
H
2
O
2 
 group.
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of phytocannabinoids on the activation of the NRF2 
pathway, we performed a subcellular fractionation 
and measured the levels of nuclear and cytosolic 
NRF2 protein in both cell lines after the cannabinoid 
pre-treatments and the insult with H
2
O
2
. As shown 
in Fig. 5, hydrogen peroxide clearly induced the 
translocation of NRF2 to the nucleus in STHdhQ7/
Q7 cells (F(1,8)=14.32, p<0.05), but the treatment 
with cannabinoid compounds did not produce any 
additional effect. 
Discussion
 Despite the extensive preclinical research 
performed in the last years to find potential 
treatments for Huntington’s disease, only a few of 
them have shown promising effects to prompt their 
evaluation in clinical trials. Among them, the drugs 
approved for HD patients up to now are focused 
mainly on ameliorating the clinical symptoms (Bates 
et al., 2015). In this context, cannabinoid compounds 
have proved to be a very interesting therapeutic 
option both for the management of symptoms and 
to delay the progression of the disease. For example, 
CB
1
 agonists have shown anti-hyperkinetic and 
thus symptom-relieving effects in acute models of 
excitotoxicity (Lastres-Becker et al., 2002)). Besides, 
phytocannabinoids have been extensively evaluated 
in the last few years to prove their neuroprotective 
potential in different models of the disease. Thus, 
Δ9-THC showed positive results in a mouse model 
of excitotoxicity and in R6/2 transgenic mice 
(Palazuelos et al., 2009) and CBD proved to be highly 
neuroprotective in an acute model of oxidative 
damage (Sagredo et al., 2011). Interestingly, the 1:1 
combination of these two cannabinoids, so-called 
Sativex, has been evaluated in different models of 
the disease with very promising results (Sagredo et 
al., 2011; Valdeolivas et al., 2012; Valdeolivas et al., 
2017). This drug, that has already obtained approval 
for the treatment of spasticity and pain in multiple 
sclerosis in 17 countries, was indeed evaluated in 
a pilot clinical trial with HD patients very recently 
(Lopez-Sendon Moreno et al., 2016). Unfortunately, 
and similarly to other clinical trials with cannabinoids 
such CBD (Consroe et al., 1991), it was safe and well-
tolerated, but did not show any clinical improvement. 
Because of its broad-spectrum profile and the very 
good results obtained in different animal models of 
HD, we consider Sativex a very promising therapeutic 
agent for this disease and have provided preclinical 
evidence that this is the case using neurotoxin-
based models (Sagredo et al., 2011; Valdeolivas et 
al., 2012) and R6/2 mice (Valdeolivas et al., 2017). 
In the present study, we wanted to further explore 
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Figure 4. Changes in gene expression in STHdhQ7/Q7 and STHdhQ111/Q111 cells pretreated with either 0.5 µM Δ9-THC, CBD or Sativex for 
30’ and exposed to 0.5 mM H
2
O
2
 for 3.5h. Values are expressed as means ± SEM of 3 cases per group. Data were subjected to one-
way analysis of variance, followed by the Student-Newman-Keuls test. *p<0.05, ***p<0.005 compared to control group. ##p<0.01 
compared to H
2
O
2 
 group. a) HO1 relative expression. b) NQO1 relative expression. c) GCLC relative expression. d) PRDX1 relative 
expression. e) KEAP1 relative expression.
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the potential molecular mechanisms underlying 
these beneficial effects using an in vitro approach 
and replication of the different cytotoxic stimuli 
that operate in the brains of HD patients. For this 
purpose, we used STHdhQ7/Q7 and STHdhQ111/Q111 cells, 
striatal derived cell lines from knock in transgenic 
HD mice, a model that has been widely used for 
basic research and preclinical drug testing (Blazquez 
et al., 2011; Ruiz et al., 2012). Moreover, we used 
three different approaches that could resemble, as 
in animal models of the disease, different cytotoxic 
events: that is, a model of mitochondrial damage 
and apoptosis (exposure to malonate), a model of 
excitotoxicity (exposure to glutamate) and a model 
of oxidative stress (exposure to H
2
O
2
). We brought 
the cells under the action of these toxic agents, and 
pretreated them with either Δ9-THC-BDS or CBD-BDS 
alone or the Sativex-like combination of them. We 
repeated both manipulations in both cell lines, with 
the purpose of testing if the response to damage by 
the cells or the possible effect of phytocannabinoids 
could be affected by the expression of mutant 
huntingtin. In the first set of experiments, in which 
cells were exposed to the mitochondrial complex II 
inhibitor malonate, we could prove that STHdhQ111/
Q111 cells are more sensitive to mitochondrial damage 
than WT cells, something that has been already 
reported elsewhere (Milakovic & Johnson, 2005). 
Next, we investigated the response to excitotoxicity, 
but, in our hands, we could not observe the higher 
vulnerability of STHdhQ111/Q111 that has been shown 
in previous publications (Blázquez et al., 2011).  This 
could be due to the use in our case of a different agent 
(glutamate instead of NMDA) and also a different 
viability assay (that measures mainly necrotic cell 
death instead of mitochondrial integrity). Anyhow, 
the treatment with phytocannabinoids was not 
able to prevent the cell death caused by neither of 
these agents. In the case of the exposure to oxidative 
damage, we found that STHdhQ111/Q111 cells were 
much less sensitive to this insult than STHdhQ7/Q7. 
This has been reported before (Ribeiro et al., 2013) 
but not at such a high extent, and this unequal 
response could be due to a different dose and time 
of exposure to H
2
O
2
 in our experiment. Another 
explanation for this response would be a reduced 
expression of the Ca2+-binding protein downstream 
regulatory element antagonist modulator (DREAM) 
by STHdhQ111/Q111 cells, which would make them less 
sensitive to this kind of damage, as it was published 
during the time we were conducting our experiments 
(Naranjo et al., 2016). In this case, we did observe an 
protective effect of phytocannabinoids in this model: 
not Δ9-THC-BDS but CBD-BDS and specially Sativex 
were able to prevent cell death, which suggests 
that the combination of these two compounds is 
more effective against this kind of damage than in a 
separate way. Interestingly, this was observed both 
in STHdhQ7/Q7 and STHdhQ111/Q111 cell lines, although 
in the last ones the effect was more modest, 
presumably because the level of damage was lower 
as well by the reasons explained before. The fact that 
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Figure 5. NRF2 protein levels in the cytosol and nucleus of a) STHdhQ7/Q7 and b) STHdhQ111/Q111 cells, pretreated with either 0.5 µM Δ9-
THC, CBD or Sativex for 30’ and exposed to 0.5 mM H
2
O
2
 for 2.5h. Values are expressed as means ± SEM of 5 cases per group. NRF2 
band volumes were normalized to α-tubulin and LaminB as cytosolic and nuclear loading controls, respectively. Data were subjected 
to unpaired t-test (control-cytosol vs control-nucleus, H
2
O
2
-cytosol vs H
2
O
2
-nucleus and so on). *p<0.05 compared to cytosolic protein 
levels.
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CBD and Sativex were more antioxidant than Δ9-THC 
was not surprising for us, being that CBD, because 
of its structure containing two hydroxyl groups, has 
intrinsically more ROS-scavenger activity. However, 
as CBD has been proven recently to induce NRF2-
mediated antioxidant response (Juknat et al., 2013) 
and the activation of this pathway has been proposed 
as a potential therapeutic target for HD (Rotblat et 
al., 2014), we wanted investigate whether this could 
be the mechanism of the neuroprotective effect of 
Sativex in this model.
Therefore, the next step was to evaluate the levels 
of gene expression of some antioxidant enzymes 
induced by NRF2, in both cell lines and in all 
experimental groups. Surprisingly, the expression 
of two antioxidant enzymes typically related to the 
response against H
2
O
2
 damage, GCLC and PRDX1, 
did not change in any cell type, in any experimental 
group in this model. However, we observed a marked 
increase of the enzyme HO1 in STHdhQ7/Q7 cells, that 
was even higher in the cells treated with CBD and 
Sativex. This trend was also observed in the relative 
mRNA levels of NQO1, an enzyme which expression is 
specifically activated by NRF2. Moreover, although no 
significant, we observed a decrease in the expression 
of KEAP-1 in cells exposed to H
2
O
2
, that was reverted 
by the treatment with, again, CBD and Sativex but 
not Δ9-THC. The changes in KEAP-1 must be anyway 
taken with certain caution, as the mechanism by 
which this protein regulates NFR2 does not imply 
changes in KEAP-1 gene expression, but to interact 
directly in the cytoplasm with this transcription 
factor, so changes in KEAP-1 gene expression may be 
a consequence rather than a cause of the changes 
elicited by H
2
O
2
 exposure and/or phytocannabinoid 
treatments. These results suggested that the 
activation of NRF2 signaling pathway could indeed 
be playing a role in the phytocannabinoid-mediated 
protection against ROS. Regarding STHdhQ111/Q111, no 
changes were found in the gene expression of GCLC 
and PRDX1 either, and the mRNA levels of HO-1 
and NQO1 after oxidative damage were very low 
compared to STHdhQ7/Q7 cells. It has been reported 
indeed that mHTT expression leads to an impairment 
of NRF2 signaling in these cells (Jin et al., 2013), 
so we assumed that CBD and Sativex-mediated 
neuroprotection in these cells might be due to the 
activation of additional signaling mechanisms. 
Finally, we aimed to confirm the activation of NRF2 
antioxidant response by assessing the protein levels 
of this transcription factor in the nucleus against 
cytosolic protein levels, in order to show its nuclear 
translocation after an oxidative insult. In STHdhQ7/Q7 
cells, we only observed a significant increase of nuclear 
protein levels in the experimental group exposed to 
hydrogen peroxide, but this change was not clearly 
appreciated in any of the treatment groups, even the 
significance of the differences between the nuclear 
and cytosolic levels of NRF2 disappeared, which may 
suggest that additional mechanisms may be involved 
in the effects of phytocannabinoids and, in particular, 
in the induction of HO-1 expression. In addition, it 
is also important to remark that previous work has 
demonstrated certain non-specific effects for the 
antibodies developed against NRF2, so it is possible 
that this has affected our experimental design.
In conclusion, and considering these preliminary 
data, we cannot confirm that the activation of 
NRF2-mediated antioxidant pathway is the main 
mechanism for the phytocannabinoid-mediated 
neuroprotection against oxidative stress in STHdhQ7/
Q7 cells. It should be noted that the levels of NQO1, 
whose expression is known to be specifically induced 
by the NRF2-KEAP1/ARE pathway, did not change 
significantly in this experiment, despite an increase 
in the expression of HO-1 was absolutely patent. 
However, the expression of this last enzyme, unlike 
NQO1, is reported to be activated by other signaling 
pathways, such as JNK (Lin et al., 2013), PI3K/AKT (Li 
et al., 2014) and p38 (Ning et al., 2002). Therefore, 
the involvement of other mechanisms cannot be 
ruled out, and further experiments are needed 
to elucidate the mechanism of Sativex-mediated 
neuroprotection in this experimental approach.
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The inhibition of 2-arachidonoyl-glycerol (2-AG)
biosynthesis, rather than enhancing striatal damage,
protects striatal neurons from malonate-induced
death: a potential role of cyclooxygenase-2-dependent
metabolism of 2-AG
S Valdeolivas1,2,3,5, MR Pazos1,2,3,5, T Bisogno4, F Piscitelli4, FA Iannotti4, M Allara`4, O Sagredo*,1,2,3,6, V Di Marzo*,4,6
and J Ferna´ndez-Ruiz*,1,2,3,6
The cannabinoid CB2 receptor, which is activated by the endocannabinoid 2-arachidonoyl-glycerol (2-AG), protects striatal
neurons from apoptotic death caused by the local administration of malonate, a rat model of Huntington’s disease (HD). In the
present study, we investigated whether endocannabinoids provide tonic neuroprotection in this HD model, by examining the
effect of O-3841, an inhibitor of diacylglycerol lipases, the enzymes that catalyse 2-AG biosynthesis, and JZL184 or OMDM169,
two inhibitors of 2-AG inactivation by monoacylglycerol lipase (MAGL). The inhibitors were injected in rats with the striatum
lesioned with malonate, and several biochemical and morphological parameters were measured in this brain area. Similar
experiments were also conducted in vitro in cultured M-213 cells, which have the phenotypic characteristics of striatal neurons.
O-3841 produced a significant reduction in the striatal levels of 2-AG in animals lesioned with malonate. However, surprisingly,
the inhibitor attenuated malonate-induced GABA and BDNF deficiencies and the reduction in Nissl staining, as well as the
increase in GFAP immunostaining. In contrast, JZL184 exacerbated malonate-induced striatal damage. Cyclooxygenase-2 (COX-2)
was induced in the striatum 24 h after the lesion simultaneously with other pro-inflammatory responses. The COX-2-derived
2-AG metabolite, prostaglandin E2 glyceryl ester (PGE2-G), exacerbated neurotoxicity, and this effect was antagonized by the
blockade of PGE2-G action with AGN220675. In M-213 cells exposed to malonate, in which COX-2 was also upregulated, JZL184
worsened neurotoxicity, and this effect was attenuated by the COX-2 inhibitor celecoxib or AGN220675. OMDM169 also
worsened neurotoxicity and produced measurable levels of PGE2-G. In conclusion, the inhibition of 2-AG biosynthesis is
neuroprotective in rats lesioned with malonate, possibly through the counteraction of the formation of pro-neuroinflammatory
PGE2-G, formed from COX-2-mediated oxygenation of 2-AG. Accordingly, MAGL inhibition or the administration of PGE2-G
aggravates the malonate toxicity.
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Cannabinoids have been recently proposed as neuroprotect-
ing agents in Huntington’s disease (HD).1–3 HD is an adult-
onset and autosomal-dominant neurodegenerative disorder
characterized by the progressive death of specific neuronal
subpopulations within the striatum and the cerebral cortex.4
HD is caused by a CAG triplet expansion in the gene coding
the protein huntingtin,5 which is toxic for these neuronal
subpopulations, although the mechanism(s) responsible for
this particular preference in neuronal degeneration in HD
remains to be fully identified. An important challenge in HD is
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the development of efficient therapies to halt or slow down
disease progression,6,7 because the therapies investigated to
date have been poorly effective. Compounds likeminocycline,
unsaturated fatty acids, coenzyme Q-10 and inhibitors of
histone deacetylases are presently under clinical investiga-
tion,8 whereas not only certain cannabinoid compounds,
including both CB1 and CB2 receptor agonists, but also
antioxidant phytocannabinoids have been successfully
assayed in preclinical models9–16 and have recently been
applied in the clinical testing.17
The endocannabinoid system, which encompasses not
only CB1 and CB2 receptors but also their endogenous
ligands, the endocannabinoids anandamide and 2-arachido-
noylglycerol (2-AG), and the enzymes for endocannabinoid
biosynthesis and degradation, is subject to dysregulation in
animal models of HD.1,2,18 In particular, a strong correlation
exists between reduced striatal levels of anandamide and
2-AG and locomotor signs of HD in R6/2 mice, genetic model
of HD,19 as well as in 3-nitropropionate-lesioned rats,20 thus
suggesting that impaired biosynthesis or exaggerated
degradation of endocannabinoids might underlie in part the
hyperkinesias typical of this disorder. Although this hypothesis
was supported in part by the beneficial effect of inhibitors of
endocannabinoid degradation,21 it is not known whether the
inhibition of endocannabinoid biosynthesis can worsen HD
signs.
In the present study, we focused on striatal degeneration
generated by the complex II inhibitor malonate, which is
known to result in the death of striatal neurons through
mechanisms that involve mainly the apoptotic machinery.22 In
this model, CB2 receptor agonists protected striatal neurons
from apoptotic death,12 whereas the blockade of CB1
receptors enhanced the magnitude of malonate-induced
lesion.23 Now, we wanted to determine the effects that the
lesion with malonate produces on the striatal endocannabi-
noid levels. In particular, we expected that the inhibition of
diacylglycerol lipases (DAGLs), the enzymes that catalyse the
biosynthesis of 2-AG, with the compound O-3841,24 would
aggravate the effect of this lesion. However, on the basis of
the initial unexpected finding of a neuroprotective effect of this
inhibitor, our study progressed to additional objectives: (i) to
elucidate what type of effect would be produced on the lesion
by the opposite pharmacological manipulation, that is the
blockade of the monoacylglycerol lipase (MAGL) and (ii) to
investigate whether the biotransformation of 2-AG in pros-
taglandin glyceryl esters (PG-Gs) by cyclooxygenase-2
(COX-2) might explain the paradoxical effects found with
O-3841, given that this type of oxygenated derivatives of 2-AG
has been previously related to neurotoxic effects.25 For these
studies, we also used cultured M-213 cells, which share many
phenotypic characteristics with striatal neurons.26
Results
Effects of DAGL inhibition on the striatal degeneration
caused by malonate. The original objective of this study
was to examine the effects of the DAGL inhibitor O-384127
on the striatal damage caused by malonate. As expected, the
local administration of O-3841 produced a significant reduc-
tion in the striatal levels of 2-AG in animals lesioned with
malonate (F(2,17)¼ 4.111, Po0.05), without affecting the
levels of anandamide (Figure 1a). Importantly, unlike other
models of HD,19,20 neither anandamide nor 2-AG was altered
by the lesion of the striatum with malonate. Given the
neuroprotective properties described for 2-AG,28 a reduction
in the levels of this endocannabinoid by O-3841 was
expected to enhance the magnitude of malonate-induced
lesion. However, our data indicate that the inhibitor enhanced
the survival of striatal neurons as could be demonstrated by
its capability to partially attenuate the malonate-induced
deficit in GABA (F(2,15)¼ 12.56, Po0.01; Figure 1b) and
BDNF (F(2,12)¼ 4.04, Po0.05; Figure 1c). It also enhanced
the number of Nissl-stained neurons that had been markedly
reduced by malonate (F(2,18)¼ 26.46, Po0.0001; Figures
1d and e) and attenuated the glial activation caused by this
neurotoxin, as indicated by the reduction in the intensity of
immunostaining for the marker of astrocytes GFAP
(F(2,13)¼ 4.623, Po0.05; Figures 1f and g). Looking at the
representative microphotographs of the three groups under
investigation, it was evident that astrocytes underwent
morphological alterations after the lesion, similar to those
previously reported.29 Such alterations were notably reduced
by the treatment with O-3841 (Figure 1g).
Effects of malonate lesion on COX-2 and other
pro-inflammatory responses and PGE2-G formation. The
above data contrast with the notion that 2-AG is neuro-
protective, although a few studies demonstrated that, under
certain circumstances, 2-AG may be also neurotoxic, in part
through the generation of COX-2-derived metabolites.25 We
examined this possibility by analysing the effects of malonate
on the expression of COX-2 as well as on the levels of one of
the most representative COX-2 derivative of 2-AG, the
PGE2-G. We have also quantitated the expression of other
mediators (e.g., iNOS, PPAR-a, PPAR-g) that have been
reported to have an instrumental role in proinflammatory
events in neurodegenerative disorders.30 Our experiments
revealed that malonate lesion upregulated COX-2 in the
striatum, although this effect was evident only 24-h after the
lesion (F(2,10)¼ 10.17, Po0.01; Figure 2a), and the same
pattern was seen for iNOS (F(2,11)¼ 12.46, Po0.005;
Figure 2b). In agreement with these responses, we found a
reduction in the expression of PPARs (only significant in the
case of PPAR-a: F(2,8)¼ 15.21, Po0.005, but showing a
trend towards a decrease in the case of PPAR-g:
F(2,9)¼ 1,503, ns; see Figures 2c and d), the activation of
which is known to inhibit the expression of these pro-
inflammatory enzymes—an effect that has been related to a
reduction in NFkB signalling.31
The increase in COX-2 expression by malonate might be in
favour of an increased generation of COX-2-derived 2-AG
metabolites. We tried to demonstrate such an increase by
analysing the levels of PGE2-G in the malonate-lesioned
striatum, and, particularly, after the inhibition of MAGL, which
should facilitate the formation of PGE2-G (see below).
Although our method, described here for the first time, was
extremely sensitive (by allowing the quantification of as little
as 50 fmols of PGE2-G), we did not detect any PGE2-G-like
peak after LC-ESI-IT-ToF analysis. This, considering the
average amount of striatal tissue that we analysed, indicates
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that less than 1.9 pmol/g wet tissue weight of PGE2-G are
present in the striatum of malonate-treated rats. However, this
finding does not necessarily imply that PGE2-G was not
formed under our experimental conditions, as the generation
of this compound might be restricted only to those striatal
areas where the lesion is more intense, and hence impossible
to detect when the whole striatum is analysed.
Effects of MAGL inhibition on striatal degeneration
caused by malonate. Next, we investigated whether the
increase in 2-AG levels after MAGL inhibition would produce
the opposite effect to the protection found with DAGL
inhibition. We first worked with the non-covalent MAGL
inhibitor OMDM169,32 but the local administration of this
compound did not produce any significant change in the
levels of 2-AG and anandamide (Figure 3a), and it did not
aggravate the effects of malonate on the striatal parenchyma
measured by Nissl staining (Figure 3b). Therefore, we used
the more potent MAGL inhibitor JZL184, which, compared
with OMDM169, is covalent and also more selective and
elicits an eightfold increase in 2-AG levels.33 The Nissl
staining in the striatal parenchyma revealed some apparent
reduction in the number of stained cells that did not reach
statistical significance (see Figure 3d), but the differences
were evident and statistically significant in the case of GFAP
immunostaining, which was higher in the malonate-lesioned
animals treated with JZL184 (F(2,10)¼ 41.22, Po0.0001;
Figure 3c), thus indicating stronger astrogliosis in the striatal
parenchyma of these animals. We assumed that this
aggravating effect was caused by the biotransformation of
2-AG in PG-Gs despite the fact that, also in this case, we
were unable to detect in vivo generation of PGE2-G. To
further explore this possibility, we decided to inject this 2-AG
derivative directly into the striatum of malonate-lesioned rats
Figure 1 Levels of endocannabinoids (panel a), GABA (panel b), BDNF-mRNA (panel c), number of Nissl-stained cells (panel d and representative microphotographs in
panel e) and GFAP immunostaining (panel f and representative microphotographs in panel g), measured in the striatum of malonate-lesioned rats after DAGL inhibition with
O-3841 (250 ng administered locally) and of their sham-operated controls. See details in the text. Values are means±S.E.M. of 5–7 animals per group. Data were assessed
by one-way analysis of variance followed by the Student–Newman–Keuls test (*Po0.05, **Po0.005 versus controls; #Po0.05 versus the group treated with malonate)
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and found a further reduction in the number of Nissl-stained
cells in the striatal parenchyma that were partially attenuated
by the co-administration of the PGE2-G antagonist
AGN220675 (F(3,15)¼ 28.48, 0o0.0001; Figure 3e).
Induction of COX-2 in response to malonate and effects
of MAGL inhibition in cultured M-213 cells. Given the
difficulties to detect in vivo generation of PG-Gs in malonate-
lesioned rats, we moved to an in vitro strategy using a cell
line, M-213, which recapitulates some phenotypic character-
istics of striatal neurons.26 These cells were sensitive to
malonate, which reduced the number of surviving cells by
more than 50% at 6 h after the addition of the neurotoxin
(Figure 4a). This was paralleled by a marked upregulatory
response (46 fold) in the expression of COX-2 (Figure 4b),
reproducing the same response found in vivo, whereas the
exposure to malonate downregulated the expression of
MAGL and FAAH (Figures 4d and f). Accordingly, the
activities of 2-AG and anandamide-hydrolysing enzymes,
which in neurons are mostly accounted for MAGL and FAAH,
respectively, were reduced (Figure 4c), and the same
happened with the MAGL and FAAH levels (Figures 4e
and g). Malonate did not affect the levels of anandamide and
related N-acylethanolamines in these cells, whereas there
was a trend towards an increase in the levels of 2-AG,
although we were still unable to detect any significant change
in the levels of PGE2-G (Figure 4c). However, the addition of
the MAGL inhibitor OMDM169 to the culture media tended to
reduce the levels of 2-AG (Figure 5a) and allowed to detect
for the first time PGE2-G levels (F(2,8)¼ 17.22, Po0.005;
Figure 5b), precisely in the experimental condition in which
the generation of this 2-AG derivative should be maximal. In
agreement with this, we found an increase in malonate-
induced cell death when 2-AG levels were elevated with
OMDM169 (F(2,14)¼ 243.5, Po0.0001; Figure 5c) and a
trend towards an increase when we used JZL184
(Figure 5d). We also found that the addition of 2-AG per se
enhanced malonate-induced cell death (F(2,15)¼ 130.6,
Po0.0001; Figure 5e). We conducted a pilot
concentration–response study (0.1–50 mM), which showed
that doseso25 mM did not enhance malonate-induced cell
death, whereas a significant potentiating effect was found
with 25 and 50 mM (data not shown).
We next investigated whether the enhancing effect of
MAGL inhibitors on malonate-induced cell death may be
attenuated by the blockade with the PGE2-G antagonist
AGN220675 or by inhibiting COX-2 with celecoxib, which
would provide further evidence of the role of 2-AG biotrans-
formation in the effects investigated in this study. We used for
these experiments the MAGL inhibitor JZL184, which pro-
duced a slight increase in malonate-induced cell death, and
we found that both AGN220675 (F(3,30)¼ 8.605, Po0.005;
Figure 6a) and celecoxib (F(3,21)¼ 30.04, Po0.0001;
Figure 6b; we used two concentrations, 12.5 and 25 mM, both
Figure 2 mRNA levels for COX-2 (a), iNOS (b), PPAR-a (c) and PPAR-g (d) measured in the striatum of malonate-lesioned rats (at 24 or 48 hour after the injection) and of
their sham-operated controls. See details in the text. Values are presented as means±S.E.M. of 4–6 animals per group. Data were assessed by one-way analysis of variance
followed by the Student–Newman–Keuls test (*Po0.05, **Po0.005, ***Po0.0005 versus the other groups; #Po0.05 versus the group treated with malonate)
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equally effective) reduced cell death compared with the effect
found with the combination of malonate and JZL184. We next
tried to obtain a similar result with the direct addition of 2-AG.
We again found that 2-AG was able to enhance malonate-
induced cell death (F(4,29)¼ 36.42, Po0.0001; Figure 6c),
but this response was not altered by the celecoxib-induced
inhibition of COX-2 or by the PGE2-G antagonist AGN220675
(Figure 6c), used at the same concentrations as in the
experiments with JZL184. In addition, higher concentrations
of AGN220675 (1 and 50mM) were ineffective in this case
(data not shown). This latter findingmay be related to the rapid
degradation of 2-AG to arachidonic acid and glycerol in
absence of MAGL inhibition, and the subsequent generation
of prostaglandins, rather than PG-Gs, by the action of COX-1
and, to a smaller extent, COX-2, which would explain the
highest cell death found after the combination of 2-AG
and malonate compared with the cells exposed to malonate
alone (Figure 6c). In fact, this is supported by the observation
that the incubation of these cells with 2-AG at the same
concentration (25mM) as in the above experiment, and also at
a higher concentration (50mM), but in absence of malonate,
increased cell death (more than twofold for 25 mM 2-AG and
almost fourfold for 50 mM 2-AG), and both responses were
significantly enhanced by celecoxib (F(4,31)¼ 26.6,
Po0.0001; Figure 6d). This inhibitor might have blocked the
formation of PGE2-Gs by COX-2 acting on exogenous 2-AG
and enhanced the amount of 2-AG available for arachidonic
acid generation and the action of COX-1, with a subsequent
greater generation of prostaglandins, which would cause cell
death. Indeed, 2-AG hydrolysis is an important source of
arachidonic acid and neuroinflammatory prostaglandins,34
such that genetic or pharmacological inactivation of
2-AG hydrolysis provides beneficial effects in experimental
Parkinsonism34 and Alzheimer’s disease.35
Figure 3 Amounts of endocannabinoids (panel a), number of Nissl-stained cells (panels b, d and e) and GFAP immunostaining (panel c), measured in the striatum of
malonate-lesioned rats after MAGL inhibition with OMDM169 (500 ng administered locally) or JZL184 (4mg/kg weight administered i.p.), or after the administration of PGE2-G
(10mg administered locally) and/or AGN220675 (300 ng administered locally), and of their sham-operated controls. See details in the text. Values are means±S.E.M. of 4–6
animals per group. Data were assessed by one-way analysis of variance followed by the Student–Newman–Keuls test (*Po0.05, **Po0.001, ***Po0.005 versus controls;
#Po0.05 versus the group treated with malonate and PGE2-G)
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Discussion
Previous studies have shown that CB2 receptor-deficient mice
exhibit a greater sensitivity to malonate,12 whereas the
blockade of CB1 receptors with rimonabant also enhanced
the magnitude of striatal degeneration caused by this
neurotoxin in rats.23 In this context, we predicted that the
blockade of 2-AG biosynthesis with the recently developed
DAGL inhibitor O-384127 should also result in a greater
sensitivity to malonate, given the previously reported
neuroprotective effects of 2-AG through its capability to
activate both cannabinoid receptors with similar efficacy.28
Surprisingly, however, the administration of O-3841 to
malonate-lesioned rats, rather than aggravating the striatal
lesion, was accompanied by greater survival of striatal
neurons and by the attenuation of glial activation typically
associated with the malonate lesion.12
These unexpected observations found some support in
recent studies that have demonstrated that 2-AG may also
behave as a neurotoxic factor under special circumstances,
Figure 4 LDH activity (panel a), mRNA levels for COX-2 (panel b), MAGL (panel d) and FAAH (panel f), protein levels of MAGL (panel e) and FAAH (panel g) and levels of
2-AG, PGE2-G, anandamide and related N-acylethanolamines and activities of 2-AG- and anandamide-hydrolysing enzymes (panel c), measured in cultured M-213 cells
treated for 6 h with 40mMmalonate. See details in the text. Values are presented as means±S.E.M. of 5–7 cases per group (except in the measures of enzyme activities and
protein levels that were three cases per group). Data were assessed by the unpaired Student’s t-test (*Po0.05, **Po0.01, ***Po0.005 versus controls)
Figure 5 Amounts of 2-AG (panel a) and PGE2-G (panel b), and LDH activity, measured in cultured M-213 cells treated for 6 h with 40mMmalonate and/or the inhibitors of
MAGL, OMDM169, at 1mM (panel c) or JZL184 at 10 nM (panel d), or with 40 nM malonate and/or 2-AG at 25 mM (panel e). See details in the text. Values are presented as
means±S.E.M. of 4–6 cases per group. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*Po0.05, **Po0.005
versus controls; #Po0.05 versus malonate)
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namely, during the overexpression of COX-2, a key response
in neuroinflammatory events accompany neurodegenera-
tion.36–38 Thus, Sang et al.25 reported that 2-AG may be a
natural substrate of inducible COX-2 enzyme and generate a
series of metabolites, known as PG-Gs,39 the most abundant
of which, PGE2-G, is known to induce excitotoxic damage
25
and to exert pro-inflammatory and hyperalgesic effects.40 In
fact, 2-AG is oxygenated by COX-2 as effectively as
arachidonic acid,25 whereas the oxygenation of anandamide
by this enzyme is slower.41 Therefore, it appears that the key
condition for the activation of this metabolic pathway would be
that COX-2 enzyme is abnormally upregulated in response to
a brain insult. In such situation, there would be an imbalance
between the previously reported neuroprotective effects of
2-AG (mediated by the activation of either CB1, CB2 or other
cannabinoid-related receptors;28,42–44) and its transformation
by COX-2, which would generate potential neurotoxic
metabolites like PGE2-G. Our data support the existence of
this imbalance in our experimental conditions, because we
found an elevated COX-2 gene expression in the malonate-
lesioned striatum compared with controls. We also found a
similar early upregulatory response in other pro-inflammatory
enzyme such as iNOS, which frequently accompanies COX-2
elevation.30 In addition, we observed the expected down-
regulation of PPAR-a and PPAR-g, for which certain canna-
binoids, including 2-AG (see below), have been recently found
to act as agonists.43,45 This may explain the observed
increases in COX-2 and iNOS with the reduction of the
PPAR-dependent inhibitory effect on NFkB signalling, which
in turn is involved in the stimulation of the expression of these
pro-inflammatory enzymes.31 It is important to remark that
the elevation of COX-2 has been already found in neuro-
degenerative disorders including HD,36,46–48 having an instru-
mental role in the pathogenesis,38 so that its reduction through
different strategies (e.g., pharmacological inhibition) may
reduce brain damage.49 Interestingly, 2-AG may represent
an important source of arachidonic acid and neuroinflamma-
tory prostanoids in some of these disorders,34,35 and, there-
fore, the neuroprotective and anti-inflammatory actions of
O-3841 effect could be also explained by the interference with
this mechanism. However, although in the studies in which
2-AG was shown to act as a biosynthetic precursor of
neuroinflammatory prostanoids, MAGL inhibitors produced
neuroprotective and anti-inflammatory effects,34,35 here we
found that MAGL inhibition results in a greater striatal damage
both in vivo and in vitro. Therefore, our findings with O-3841
and JZL184/OMDM169 can only be interpreted by the
interference with, or enhancement of, the generation of
oxygenated derivatives of 2-AG by elevated activity of COX-
2 (see Figure 7 panels A and B, respectively). In other words,
the inhibition of DAGLmight re-establish the balance between
the neuroprotective and neurotoxic mechanisms of 2-AG,
whereas the inhibition of MAGL would enhance this imbal-
ance, which is, in fact, likely to be facilitated under conditions
of reduced expression of this enzyme, as in the present case
(see below).
On these premises, the next objective of our study became
the demonstration that PG-Gs, in particular PGE2-G, are
generated in the striatum in response to malonate, and that
they are reduced by DAGL inhibition and increased after
MAGL inhibition. However, we were unable to find detectable
levels of PGE2-G after these manipulations in vivo, in
Figure 6 LDH activity measured in cultured M-213 cells treated for 6 h with 40mM malonate and/or the inhibitor of MAGL JZL184 at 10 nM in the presence or absence of
PGE2-G antagonist AGN220675 at 25mM (panel a) or the COX-2 inhibitor celecoxib at 12.5mM (panel b), or with 40 nM malonate and/or 2-AG at 25 mM combined with
celecoxib at 12.5 mM or AGN220675 at 25mM (panel c), or treated directly with 2-AG at 25 or 50 mM and/or celecoxib at 12.5mM (panel d). See details in the text. Values are
presented as means±S.E.M. of 6-8 cases per group. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*Po0.05,
**Po0.005, ***Po0.0005 versus controls; #Po0.05 versus malonateþ JZL184; ##Po0.005 versus malonate)
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particular after the lesion with malonate combined with MAGL
inhibition, that is, the experimental conditions in which the
generation of these derivatives would be maximal. On the
basis of the detection limit of our analytical method, we
estimated that an amount of less than 1.9 pmol/g wet tissue
weight of this compound is present in the whole striatum from
both unlesioned and lesioned rats, in agreement with previous
findings indicating that the tissue concentrations of this
compound, for example, in the rat paw, are in the order of
the fmol/g wet tissue weight.40 It is possible that the
generation of this metabolite is restricted to the lesioned cells
within the striatum, then rendering impossible its detection
when the whole striatum needs to be used for biochemical
determinations (see Results section).
Given the difficulties to detect the generation of PG-Gs from
2-AG in our in vivo model, we considered the possibility that
pathways other than COX-2 metabolism of 2-AG may be
involved in the generation of putative pro-inflammatory 2-AG-
derived compounds, or that the neuroprotection shown by
O-3841 was due to its interaction with targets other than
DAGL. An attractive possibility would be the expected
increase in the DAG levels derived from the inhibition of
DAGL, as DAG signalling has been associated with cell
proliferation, differentiation and survival/death decision.50
However, our next experiments provided further evidence in
support of a mechanism involving the generation of PG-Gs
from 2-AG by the action of COX-2. First, we administered
synthetic PGE2-G to malonate-lesioned rats and found an
aggravation of striatal damage that was partially reversed by
the PGE2-G antagonist AGN220675. Secondly, in experi-
ments conducted in vitro with cultured M-213 cells, which also
experience a marked upregulation of COX-2 in response to
malonate, we showed that the increase in endogenous 2-AG
levels derived from MAGL inhibition results in a greater cell
death. This effect appeared to be related to the generation of
PG-Gs as it was reversed by pharmacological manipulations
that either inhibit the formation (e.g., inhibition of COX-2 with
celecoxib) or block the action at its target(s) (e.g.,
AGN220675) of PGE2-G. Indeed, the only experimental
condition in which we were able to detect PGE2-G was in
these cells after the incubation with malonate combined with
the MAGL inhibitor OMDM169, that is, the same experimental
conditions in which cell death was maximal. Notably,
malonate treatment of M-213 cells was accompanied by the
downregulation of MAGL mRNA, protein and enzymatic
activity, that is, another condition that, together with COX-2
upregulation, is expected to favour the formation of PG-Gs.
Another issue arising from our data and deserving some
comments is the role that 2-AG may have in the upregulation
of COX-2 observed here. A recent study51 showed that COX-2
upregulation may be elicited by a loss in the endogenous
inhibition of this enzyme exerted by 2-AG via CB1 receptors.
This was found in the hippocampus under pro-inflammatory
and excitotoxic stimuli both in vivo and in vitro,51 thus
supporting the idea that neuroprotection exerted by 2-AG
through the activation of CB1 receptors might be used also to
prevent the COX-2 elevation typical of several neuroinflam-
matory/neurodegenerative conditions. A priori, this possibility
would be in contrast with our present hypothesis of 2-AG
exerting a neurotoxic, rather than neuroprotective, effect. It is
possible that neuroprotection with 2-AG is the predominant
response when the levels of 2-AG are strongly elevated by the
neurotoxic stimuli, as in the case of traumatic brain injury,44 as
this elevation would allow to prevent, among others, the
upregulation of COX-2. In contrast, in our present case, in
which 2-AG levels remained unaffected by the malonate-
induced lesion, this might have allowed the upregulation of
COX-2 and the subsequent potential transformation of basal
2-AG levels into PG-Gs by the action of this enzyme, thus
supporting the above-mentioned idea of an imbalance
between the neuroprotective and neurotoxic effects of 2-AG.
Interestingly, a follow-up study by the same group52 revealed
that the inhibitory effect by 2-AG of COX-2 expression also
involves the activation of PPAR-g, for which we have found,
under our experimental conditions, a trend towards down-
regulation. This downregulation effect might counteract the
inhibition by 2-AG of COX-2, participate in COX-2 upregula-
tion and facilitate the conversion by this enzyme of 2-AG in
PG-Gs. It is also important to remark that the downregulation
of PPARs observed in the malonate-lesioned rats would be
another factor, in addition to elevated levels of COX-2,
aggravating the imbalance between the neuroprotective and
neurotoxic effects of 2-AG, as these nuclear receptors have
been involved in part of the neuroprotective actions of
2-AG,43,45 which would then be lost in malonate-lesioned rats.
In summary, the inhibition of 2-AG biosynthesis is accom-
panied by neuroprotection in rats lesioned withmalonate. This
effect seems to be related to a potential inhibition of certain
pro-neuroinflammatory actions of 2-AG, particularly those
involving its transformation into oxygenated metabolites by
COX-2, an enzyme that was found here to be elevated in
Figure 7 Schematic overview of possible mechanisms explaining the effect
of 2-AG following malonate lesion and after MAGL (panel a) or DAGL (panel b)
inhibition
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the striatum after the lesion with malonate. In contrast,
MAGL inhibition or the administration of PGE2-G in vivo
aggravated the malonate toxicity, and these effects were
reproduced in cultured M-213 cells in which upregulation of
COX-2 was also elicited by malonate.
Materials and methods
Animals, treatments and sampling. Male Sprague–
Dawley rats were housed in a room with controlled
photoperiod (08 : 00–20 : 00 light) and temperature
(22±1 1C). They had free access to standard food and
water and were used at an adult age (3-month old; 300–350 g
weight) for experimental purposes, all conducted in an
attempt to minimize animal pain and discomfort, and
following local and European rules (directive 86/609/EEC).
Rats were injected stereotaxically (coordinates: þ 0.8mm
anterior, þ 2.9mm lateral from the bregma, � 4.5mm ventral
from the dura mater) into the left striatum with 2M malonate
(dissolved in PBS 0.1M, pH¼ 7.4) in a volume of 1 ml or were
sham operated in the same left striatum but with no injection
of the toxin. The contralateral striatum of each animal always
remained unaffected, allowing analyses performed in this
animal model lead to data frequently expressed as percen-
tage of the lesioned side over the corresponding non-
lesioned side. Animals were used for these experimental
analyses 48 h later, except in the case of the time–course
analysis of gene expression for COX-2, inducible nitric oxide
synthase (iNOS) and peroxisome-proliferator activated
receptors (PPAR) for which animals were sacrificed at 24
and 48 h after the lesion.
O-3841 (octadec-9-enoic acid 1-methoxymethyl-2-(fluoro-
methyl-phosphinoyloxy)-ethyl ester), a kind gift by Dr. A
Mahadevan, Organix, Woburn, Massachussets, was synthe-
sized as previously described.27 The compound was
dissolved in dimethylsulfoxide (DMSO) and diluted in 0.1M
PBS (pH¼ 7.4) for administration (final concentration of
DMSOo1%). As this compound is not expected to cross the
blood–brain barrier, it was locally administered 30min before
the administration of malonate. Each animal received a
unique administration of 250 ng of O-3841 in a volume of
1ml. In additional experiments, 500 ng of OMDM169, synthe-
sized as previously described,32 10 mg of prostaglandin
E2-glycerol ester (PGE2-G; purchased from Cayman
Chemical, Ann Arbor, Michigan, USA) and 300ng of
AGN220675 (generously provided by Dr. Woodward, Allergan,
Irvine, CA, USA), prepared in 5% DMSO-saline, were also
administered following the same procedure as in the case of
O-3841. In another experiment, JZL184 (purchased from
Tocris Bioscience, Bristol, UK, and dissolved in DMSO-
Tween 80-saline, 1 : 1 : 18) was administered to malonate-
lesioned rats at the dose of 4mg/kg weight in two injections,
30min before and 2 h after the intrastriatal injection of
malonate, following our previously published procedure.12
Malonate-lesioned animals, administered with the
corresponding vehicle for all treatments (malonate group),
as well as sham-operated animals (control group), were
always included for each pharmacological experiment.
Depending on the experiment, animals were killed 24–48 h
after the administration of malonate, and their brains were
rapidly removed and frozen in 2-methylbutane, cooled in dry
ice and stored until evaluation of neurochemical parameters
indicating the degree of malonate-induced striatal injury.
Some animals from each experimental group were perfused
with 10% formalin, and their brains were post fixed during 3 h,
cryoprotected and stored at � 20 1C before being sliced in a
vibratome. Thismaterial was used for histological analyses. In
a separate group of animals (only in the experiments with the
DAGL inhibitor O-3841 or the MAGL inhibitor OMDM169),
brains were dissected before freezing and their striata were
weighed, frozen on dry ice and stored in eppendorf tubes at
� 80 1C until lipid extraction and analysis of endocannabi-
noids and related compounds (PGE2-G or N-acylethanol-
amines). The entire procedure took less than 5min, which is
significantly less than the amount of time required for
postmortem generation of 2-AG, arachidonoylethanolamide
(anandamide) or related compounds. Finally, in another
separate experiment, malonate-injected and sham-operated
rats were decapitated twice after the formation of the lesion
(24 and 48h). Their brains were quickly and carefully removed,
the striata dissected and frozen for qRT-PCR analysis.
Cell culture. M-213-2O cells were a generous gift from Dr.
WJ Freed (National Institute on Drug Abuse, Bethesda, MD,
USA; see 26). Cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 2mM ultra-glutamine, 1% non-essential
amino acids and 1% penicillin/streptomycin (LONZA,
Verviers, Belgium) and under a humidified 5% CO2 atmo-
sphere at 37 1C. For cytotoxicity experiments, cells were
seeded at 50000 cells/cm2 in 24-well plates and maintained
under a humidified atmosphere (5% CO2) at 37 1C overnight.
Afterwards, normal medium was replaced by serum-free
medium and cells were exposed to either OMDM169 (1 mM),
JZL184 (10 nM), 2-AG (25 and 50 mM; purchased from Tocris
Bioscience, Bristol, UK), celecoxib (12.5 or 25 mM; purchased
from Sigma-Aldrich, Madrid, Spain) or AGN220675 (25 mM)
added from more-concentrated solutions (prepared in serum-
free medium and containing low amounts of DMSO) to obtain
these final concentrations (final DMSO was alwayso0.1%).
Thirty min later, cells were exposed to malonate for 6 h,
added from a solution prepared in a serum-free medium to
obtain a final concentration of 40mM in the wells. Control
cells were maintained in the serum-free medium, but
were not exposed to malonate or the different treatments.
After malonate exposure, media from each well were used to
measure lactate deshydrogenase (LDH) activity as an index
of cell death, using the CytoTox 96 Non-Radioactive
Cytotoxicity Assay Kit (G1780, Promega Biotech Ibe´rica,
Madrid, Spain). In all experiments, the data of LDH activity
were compared with the values obtained in a positive control
with 1% Triton X-100 (Sigma-Aldrich, Madrid, Spain) that
was taken as 100% of cell death. Compared with the Triton
X-100-exposed cells, control cells (not exposed to malonate)
accounted for a 10–20% of cell death, whereas malonate
accounted for a 60–80%. For graphical presentation, the
data in malonate-exposed cells (with or without the different
additional treatments) were always expressed as the
percentage over the data in the control cells (not exposed
to malonate).
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Analysis of endocannabinoid levels. Tissues or cells
were homogenized in 5 volume of chloroform/methanol/
Tris–HCl 50mM (2 : 1 : 1) containing 10 pmol of d8-ananda-
mide, d4-palmitoylethanolamide (PEA), d4-oleylethanolamide
(OEA) and d5-2-AG. Deuterated standards were synthesized
from d8 arachidonic acid and ethanolamine or glycerol, or
from d4-ethanolamine and palmitic or oleic acid, as described
(53,54 respectively). Homogenates were centrifuged at
13 000g for 16min (4 1C), and the aqueous phase plus
debris were collected and extracted again twice with 1
volume of chloroform. The organic phases from the three
extractions were pooled and the organic solvents evaporated
in a rotating evaporator. Lyophilized extracts were resus-
pended in chloroform/methanol 99 : 1 by volume. The
solutions were then purified by open-bed chromatography
on silica as described.54 Fractions eluted with chloroform/
methanol 9 : 1 by volume. (containing anandamide, 2-AG,
OEA and PEA) were collected and the excess solvent
evaporated with a rotating evaporator, and aliquots were
analysed by isotope dilution liquid chromatography/atmo-
spheric pressure chemical ionization/mass spectrometry
(LC-APCI–MS) carried out under conditions described
previously,55 and allowing the separations of 2-AG, ananda-
mide, OEA and PEA. MS detection was carried out in the
selected ion-monitoring mode using m/z values of 356 and
348 (molecular ion þ 1 for deuterated and undeuterated
anandamide), 384.35 and 379.35 (molecular ion þ 1 for
deuterated and undeuterated 2-AG), 304 and 300 (molecular
ion þ 1 for deuterated and undeuterated PEA) and 330 and
326 (molecular ion þ 1 for deuterated and undeuterated
OEA). The amounts of endocannabinoids and related
N-acylethanolamines were expressed as pmols/mg of lipids
extracted. An amount of 1 mg of extracted lipids corresponds
to B0.010–0.015 g of wet tissue weight.
Method for the extraction, purification and quantification
of PGE2-G. Tissues and cells were homogenized in 5
volume of acetone containing 25 pmol of d4-PGE2-G (a kind
gift by Dr. DF Woodward, Allergan, Irvine, CA, USA).
Homogenates were centrifuged at 13 000 g for 5min (4 1C),
and the debris was extracted again four times with 1 volume
of acetone. The organic phases from the five extractions
were pooled and the organic solvents evaporated in a
rotating evaporator. Lyophilized extracts were resuspended
in chloroform/methanol 99 : 1 by volume. The solutions were
then purified by open-bed chromatography on silica using a
gradient elution of chloroform/methanol to separate different
class of lipids. Fractions eluted with chloroform/methanol 7 : 3
by volume. (containing PGE2-G) were collected and the
excess solvent evaporated with a rotating evaporator, and
aliquots were analyzed by Liquid Chromatography-
Electrospray-Ion Trap-Time of Flight (LC-ESI-IT-ToF) mass
spectrometry. An IT-ToF mass spectrometer (Shimadzu)
was used in conjunction with an LC-20AB (Shimadzu). LC
analysis was performed in the isocratic mode using a
DiscoveryC18 column (15 cm� 2.1mm, 5 mm) and metha-
nol/water/acetic acid (53 : 47 : 0.05 by volume.) as mobile
phase with a flow rate of 0.15ml/min. Identification of
PGE2-G (retention time 22.5min) was carried out using ESI
ionization in the positive mode with nebulizing gas flow of
1.5ml/min and a curved desolvation line temperature of
250 1C. PGE2-G quantification was performed by isotope
dilution by using m/z values of 453.2766 and 449.2515,
corresponding to the sodium adduct of the molecular ion
(Mþ 23)þ for deuterated and undeuterated PGE2-G, respec-
tively. The full recovery of PGE2-G from tissue due to the
analytical procedure reported above was 44.9±9.1. The LC-
ESI-IT-ToF method described here for the first time is
specific and sensitive with a limit of detection (defined as
the concentration at which the signal/noise ratio is greater
than 3 : 1) of 25 fmol. Moreover, the ratio between the
(Mþ 23)þ peak areas of undeuterated (0.025–20pmol)
versus. deuterated (1 pmol) PGE2-G varied linearly with the
amount of undeuterated PGE2-G. The quantification limit of
PGE2-G was 50 fmol.
56
HPLC determination. Brain coronal slices (around 500mm
thick) were made at the level of the striatum.57 Subsequently,
this structure was dissected and homogenized in 20–40
volumes of cold 150mM potassium phosphate buffer, pH 6.8,
and distributed into two aliquots, one to be used for the
analysis of protein concentration.58 The other aliquot was
used for the measurement of GABA contents by HPLC
coupled to electrochemical detection.11 It was diluted (½)
with 0.4N perchloric acid containing 0.4mM sodium dis-
ulphite, 0.90mM EDTA and b-aminobutirate as internal
standard. Afterwards, samples were centrifuged for 3min
(15000g) and the supernatants subjected to a previous
derivatization process with o-phthaldehide (OPA)-sulphite
solution (14.9mM OPA, 45.4mM sodium sulphite and 4.5%
ethanol in 327mM borate buffer, pH 10.4; see details in 11),
previous to their injection into the HPLC system. This
consisted of the following elements. The pump was an
isocratic Spectra-Physics 8810. The column was an RP-18
(Spherisorb ODS-2; 150mm, 4.6mm, 5 mm particle size;
Waters, Massachusetts, USA). The mobile phase, previously
filtered and degassed, consisted of 0.06M sodium dihydrogen
phosphate, 0.06mM EDTA and 20-30% methanol
(pH 4.4). The flow rate was 0.8ml/min. The effluent was
monitored with a Metrohm bioanalytical system ampero-
metric detector using a glassy carbon electrode. The
potential was 0.85V relative to an Ag/AgCl reference
electrode with a sensitivity of 50 nA (approx. 2 ng per
sample). The signal was recorded on a Spectra-Physics
4290 integrator. The results were obtained from the peaks
and calculated by comparison with the area under the
corresponding internal standard peak. Values were
expressed as mg/mg of protein.
Histological analyses. Fixed brains were sliced (35mm-
thick sections) in a vibratome. Free-floating sections
obtained from each brain were incubated with a monoclonal
anti-GFAP-Cy3 conjugate antibody (1 : 500, Sigma-Aldrich,
Madrid, Spain) 24 h at room temperature. Following exten-
sive washing, the brain sections were mounted on glass
slides using the Vectashield Mounting Medium (Vector
Laboratories, Burlingame, USA). In addition, the Hoescht
staining was used for nuclear counterstaining. Adjacent
sections to those used in the immunohistochemical analysis
were used for Nissl staining, which allowed for the
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determination of the number of cells after the different
treatments done. A Nikon Eclipse 90i confocal microscope
and a Nikon DXM 1200F camera were used for observation
and photography, and all image processing techniques were
performed using ImageJ, the software developed and freely
distributed by the US National Institutes of Health (Bethesda.
MD, USA).
Real time qRT-PCR analysis. Total RNA was isolated from
lesioned or non-lesioned rat striata, or from cultured cells,
using the RNATidy reagent (AppliChem., Cheshire, CT,
USA). The total amount of RNA extracted was quantitated by
spectrometry at 260 nm, and its purity was evaluated by the
ratio between the absorbance values at 260 and 280nm,
whereas its integrity was confirmed in agarose gels. After the
removal of genomic DNA (to eliminate DNA contamination),
single-stranded complementary DNA was synthesized from
1mg of total RNA using a commerical kit (Rneasy Mini
Quantitect Reverse Transcription, Qiagen, Izasa, Madrid,
Spain). The reaction mixture was kept frozen at  20 1C until
enzymatic amplification. Quantitative real-time PCR assays
were performed using TaqMan Gene Expression Assays
(Applied Biosystems, Foster City, CA, USA) to quantify
mRNA levels for COX-2 (reference: Rn01483828_m1),
BDNF (reference: Rn01484928_m1), iNOS (reference:
Rn00561646_m1), PPAR-a (reference: Rn00566193_m1),
PPAR-g (reference: Rn00440945_m1), MAGL (reference:
Rn00593297_m1) and FAAH (reference: Rn00577086_m1),
using b-actin expression (reference: Rn00667869_m1) as an
endogenous control gene for normalization. The PCR assay
was performed using the 7300 Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA), and the
threshold cycle (Ct) was calculated by the instrument’s
software (7300 Fast System, Applied Biosystems, Foster
City, CA, USA).
Enzyme assays. 2-AG and anandamide hydrolysing activ-
ities were measured in cells after malonate treatment as
described above for PGE2-G measurement. In particular,
2-AG hydrolysis, which is mostly accounted for at least 80%
by MAGL in neurons,59 was measured by incubating the
10000 g cytosolic fraction (70–100 mg/sample) of cells in
Tris-HCl 50mM, at pH 7.0 at 37 1C for 20min, with synthetic
2-arachidonoyl-(3H)-glycerol (40Ci/mmol, ARC St. Louis,
MO, USA) properly diluted with 2-AG (Cayman Chemicals,
Ann Arbor, MI, USA) to the final concentration of 50 mM. After
incubation, the amount of [3H]-glycerol produced was
measured by scintillation counting of the aqueous phase
after extraction of the incubation mixture with 2 volumes of
CHCl3/CH3OH 1 : 1 (by volume). Anandamide hydrolysis,
which is almost uniquely accounted for FAAH in neurons,
was measured by incubating the 10 000 g membrane fraction
(70–100mg/sample) of tissues in Tris-HCl 50mM, at pH 9.0–
10.00 at 37 1C for 30min, with synthetic N-arachidonoyl-
[14C]-ethanolamine (55mCi/mmol, ARC St. Louis, MO, USA)
properly diluted with anandamide (Tocris Bioscience, Avon-
mouth, Bristol, UK) to the final concentration of 10 mM. After
incubation, the amount of [14C]-ethanolamine produced was
measured by scintillation counting of the aqueous phase
after extraction of the incubation mixture with 2 volumes of
CHCl3/CH3OH 1 : 1 (by volume). In both cases, values were
expressed as pmol of product formed/mg of protein in
1 minute of incubation.
Western blot analysis. Cultured cells (approximately
106/sample), exposed or not to 40mM malonate for 6 h,
were collected and washed twice in cold PBS and lysed on
ice using the RIPA lysis solution. Lysates were maintained in
ice for 20min before a centrifugation of 15min at 15 000g.
Supernatants were recovered and quantified by Bio-Rad
DC Protein Assay Kit (Bio-Rad, Segrate, MI, Italy). Subse-
quently, 40–50 mg of lysates were boiled for 5min in the
Laemmli SDS loading buffer and loaded on precast
polyacrylamide gels (4–12% gradient; Bolt Bis-Tris Plus
gels; Life Technologies, Milan, Italy) and then transferred to a
PVDF membrane. Filters were incubated overnight at 4 1C
with the following antibodies: mouse anti-FAAH antibody
(1 mg/ml; from Sigma-Aldrich Milan, Italy; batch number:
11011-4H8) or rabbit anti-MAGL (1 : 200; Cayman Chemical,
Ann Abor MI, USA). An anti a-tubulin antibody (1 : 5000;
Sigma-Aldrich Milan, Italy) was used to check for equal
protein loading. Reactive bands were detected by chemilu-
minescence (ECL or ECL-plus; Biorad, Segrate, MI, Italy).
Images were analysed on a ChemiDoc station with Quanti-
tyone software (Bio-Rad, Segrate, MI, Italy). Data were
calculated as the ratio between the optical densities of the
protein and a-tubulin, but they were normalized as a
percentage over the control group for presentation.
Statistical analyses. All data were assessed by one-way
ANOVA followed by the Student–Newman–Keuls test, or by
the unpaired Student’s t-test, as required, using the
GraphPad software (version 4.0).
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Neurodegenerative diseases can 
certainly be considered as emerging diseases 
in the 21st century. The progressive increase in 
human life span occurring in the last decades, 
in particular in developed countries, have led 
to the emergence of disorders that involve the 
progressive and unstoppable degeneration of 
certain parts of the nervous system resulting 
in important physical and cognitive inabilities. 
In parallel with the increase in the prevalence 
of neurodegenerative disorders in the world 
population, it is necessary to progress in the 
knowledge of these disorders and, in particular, 
in the development of new therapies that can 
delay the progression of these devastating 
illnesses. 
Huntington’s disease, despite having a known 
origin (a single mutation in the HTT gene that 
leads to a protein with an abnormally long poly-
glutamine tract), is not different from other 
neurodegenerative disorders in terms of aging 
influence and brain atrophy. The degeneration 
of basal ganglia and cerebral cortex results not 
only in motor symptoms, but cognitive decline 
and psychiatric problems as well. The prognosis 
of these patients is really poor, as to date 
there is no cure and the treatments available 
are merely palliative (e.g. antidepressants 
and benzodiacepines for the control of 
psychiatric issues). For the management of 
choreic movements, tetrabenazine (a vesicular 
monoamine transporter type 2 inhibitor) is the 
only treatment available (Kenney et al., 2007). 
Its derivative deutetrabenazine, which has a 
longer half-life and reduced metabolic variability, 
is under clinical evaluation (Huntington Study et 
al., 2016). However,  beyond the management 
of symptoms, there is an urgent need to find a 
therapy that can delay the progression of the 
disease. In this context, only pridopidine (a 
dopamine stabilizer) has provided a weak hope, 
as it showed certain ability to improve Total 
Functional Capacity, which may be an indirect 
indicator of disease progression, in patients 
compared to placebo, in a phase II clinical trial 
(Shannon, 2016), although it did not show 
improvement in any other parameter evaluated.
Pharmacological manipulation of the ECS 
may have an impact in both motor and cognitive 
symptoms as well as in disease progression 
in HD. As explained in the Introduction, HD 
patients show alterations in various components 
of this system during the development of the 
disease (Glass et al., 200; Palazuelos et al., 
2009). Moreover, several preclinical studies 
conducted during the last years have shown that 
certain cannabinoid compounds are capable 
of attenuating cytotoxic processes involved 
in the neuropathology of the disease, such as 
oxidative, inflammatory and excitotoxic injury, 
thus improving neuronal survival (reviewed 
in Fernández-Ruiz et al., 2015). All these data 
has generated a hope on the potential of 
cannabinoids as disease modifiers in HD.
As explained in previous sections, not only CB
1
 
(Pintor et al., 2006; Blázquez et al., 2011) and 
CB
2
 agonists (Sagredo et al., 2009, Palazuelos 
et al., 2009) have shown efficacy in preclinical 
models of the disease. The use of antioxidant 
cannabinoids (Sagredo et al., 2011) and inhibitors 
of endocannabinoid degrading enzymes (Lastres-
Becker et al., 2003) have also been tested with 
positive results in different HD experimental 
models. Given the multiple dysregulation of 
the endocannabinoid system in HD subjects, 
the multi-target capability of cannabinoids 
(acting by cannabinoid receptor dependent and 
independent mechanisms), and the action on 
different pathways separately by cannabinoids 
in different experimental approaches, the best 
pharmacological strategy would be the use of 
a broad-spectrum treatment, with only one 
cannabinoid having multiple sites of action or 
combining various cannabinoid compounds 
active at  different neuroprotective mechanisms 
of action. The purpose of this multi-target 
strategy would be to act at the  greatest number 
of pathological events that occur in the disease.
With this purpose, the pharmacological 
evaluations performed in this Doctoral Thesis 
have been designed to point towards three 
directions: first, the use of different experimental 
models that can resemble most of the cytotoxic 
events of the pathology; second, the validation 
of a cannabinoid medicine that has already been 
approved for other prescriptions (Sativex for the 
treatment of spasticity in multiple sclerosis), and 
that owns the desired broad-spectrum profile; 
third, the study of cannabinoid compounds that 
have barely been investigated, such as CBG, 
and whose pharmacological profile, as happens 
with CBD, is different from classic cannabinoids, 
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being devoid of psychoactive effects, and having 
interest for medical development.
As reported in Chapter 1, we have demonstrated 
that the broad-spectrum strategy has a good 
neuroprotective potential in this disease. The 
Sativex-like combination of phytocannabinoids 
attenuated neuronal loss and glial activation 
in the malonate model of HD, characterized by 
inflammatory and apoptotic damage (Valdeolivas 
et al., 2012), and improved some motor deficits 
and brain metabolic alterations in R6/2 transgenic 
mice (Valdeolivas et al., 2017). These results can 
be added to the ones obtained in the previously 
published study with this phytocannabinoid 
formulation in the 3NP model, which is 
characterized by oxidative stress and calpain 
activation (Sagredo et al., 2011). Moreover, we 
could also demonstrate that the neuroprotective 
effect of Sativex was exerted by the activation 
of CB
1
 and CB
2
 receptors in the case of the 
malonate model, whereas Sativex apparently 
worked by  cannabinoid receptor-independent 
mechanisms (although the possibility of a role 
of PPARs in this model cannot be ruled out) in 
the case of the 3NP-lesioned animals, which 
supports our idea of a multi-target strategy. 
The mechanism(s) involved in the beneficial 
effects of Sativex in R6/2 mice was(were) not 
investigated in this work, but previous work in 
which our group has participated, demonstrated 
that both CB
1
 and CB
2
 receptor appear to be 
involved. It is important to remark that the 
same formulation provided beneficial effects in 
three different models in which striatal damage 
was predominantly caused by one specific 
cytotoxic insult, then stressing the pleiotrophic 
properties of cannabinoids and their suitability 
to be used as neuroprotective agents. We 
wanted to maintain the same approach in 
the evaluation of CBG, so we investigated this 
non-psychoactive phytocannabinoid in the 
model of mice lesioned with 3NP and in the 
R6/2 model, and in both cases the treatment 
with this phytocannabinoid attenuated some 
of their characteristic neurological deficits and 
histopathological signs (Valdeolivas et al., 2015). 
CBG has a low affinity for cannabinoid receptors, 
but we showed its capability to activate PPARγ 
receptors instead, so we suggest that this 
could be one of the mechanisms involved in 
the neuroprotective effects of this compound 
in these two models, and, by extension, this 
may be also one of the active mechanisms, as 
mentioned before, in the effects of Sativex, 
which also contains a cannabinoid receptor-
independent phytocannabinoid as CBD, in 3NP-
lesioned rats (Sagredo et al., 2011). Therefore, 
we can conclude that the phytocannabinoids 
evaluated are able to provide neuroprotection 
against oxidative stress, inflammation, apoptotic 
processes and mitochondrial damage, and 
that different molecular targets implicated in 
these effects, including CB
1
 and CB
2
 receptors, 
antioxidant responses and may be PPAR 
receptors. This represents an important 
advantage for the development of novel 
neuroprotective therapies with cannabinoids 
in comparison with current strategies which 
are based on very selective compounds active 
exclusively on only one of these cytotoxic 
insults. Considering these results, we suggest 
that focusing not only in CB
1
 receptors, which 
are lost very early in the disease, but also in 
other endocannabinoid-related targets active 
on pathogenic events such as oxidative damage, 
inflammation and gliosis, would be a good 
strategy for developing cannabinoid compounds 
as a novel therapy useful to alleviate symptoms 
and delay disease progression in HD. For the 
future, we assume that a further evaluation 
of CBD and CBG is highly justified, since these 
non-classic phytocannabinoids, besides being 
potent antioxidants, can act on different, even 
complementary targets; some of them would be 
NRF2, NFκB, PPARγ and 5HT
1A
 activation and the 
inhibition of FAAH in the case of CBD (Bisogno 
et al., 2001; Esposito et al., 2006; O’Sullivan & 
Kendall, 2010; Fernández-Ruiz et al., 2013), and 
TRPV1, TRPA1 and PPARγ activation and 5HT
1A
 
inhibition in the case of CBG (Borrelli et al., 
2014; Granja et al., 2012; Cascio et al., 2010). 
This completely fits with the idea of developing 
broad-spectrum therapies against the multiple 
cytotoxic mechanisms operating in HD. 
 After the different preclinical evidences 
provided, the clinical evaluation of Sativex as 
a neuroprotective therapy in HD patients was 
highly justified. Sativex  has a promising broad-
spectrum profile, has been already approved 
for other indications (as explained in the 
Introduction) and appears to be safe with no 
relevant  psychoactive side-effects despite the 
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presence of ∆9-THC. In Chapter 2, we present 
the results of a double-blind, randomized, 
cross-over, placebo controlled, pilot trial with 
Sativex in a small cohort of HD patients (Chapter 
II, Lopez-Sendon Moreno et al., 2016). The 
primary endpoint of this study, which was the 
safety and tolerability of the compound, was 
fully achieved (only 2 SAEs were reported, both 
drug-unrelated), and no psychoactive effects 
were detected. However, there was no clinical 
response in the arms treated with Sativex, in 
parallel with the absence of changes in the 
biomarkers analyzed, except an increase of CB
2
 
in the lymphocytes of Sativex-treated subjects. 
Although the primary endpoint of the study 
was reached, the treatment with Sativex did not 
offer the clinical benefits expected according 
to the data obtained in the preclinical models. 
We believe that this lack of efficacy is directly 
related to an excessively short time for the 
active treatment, which could be prevented in 
future studies with some changes in the study 
design. As stated in the paper (López-Sendón 
et al., 2016), a new study with presymptomatic 
subjects should be considered, as in this stage 
the loss of CB
1
 receptors is still not relevant and 
Sativex could thus be more effective delaying the 
onset of motor symptoms. Moreover, although 
cross over is a well design for a pilot study, it 
renders a high placebo effect and the wash 
out period might not be long enough to make 
a clear deference between arms. We would 
also need to extend the period of treatment to 
attenuate this placebo effect and to enhance 
the possibilities for Sativex to be active.An 
analogous situation was reported before in a 
clinical trial with creatine (Tabrizi et al., 2003), 
also failed and in which the treatment duration 
was one year. Authors suggested that this short 
treatment period could be the main factor for 
its lack of efficacy. Therefore, we would suggest 
performing a parallel study with a longer 
treatment duration. In addition to these changes, 
an increase in the dose should be considered, 
as the highest dose applied did not render any 
psychoactive effect, and the establishment of a 
fixed instead of a variable dosing scheme might 
offer more robust results. It is important also to 
highlight that the increase in the expression of 
CB
2
 receptors, although yet unexplained, might 
be attributed to a protective response, as found 
in postmortem samples from HD patients and 
from experimental models, a fact that also occurs 
in other neurodegenerative disorders (Ashton 
& Glass, 2007; Aso & Ferrer, 2016). In addition, 
the activation of CB
2
 receptors by selective and 
non-selective cannabinoids has proven to be 
neuroprotective in inflammatory and excitotoxic 
models of the disease (Palazuelos et al., 2009; 
Sagredo et al., 2009), and Sativex is active 
at the CB
2
 receptors Therefore, a prolonged 
treatment scheme with Sativex could facilitate 
the appearance of positive effects related to 
CB
2
 activation. Lastly,  besides a higher dose of 
Sativex, we propose the use of other cannabinoid 
combinations that are not only cannabinoid 
receptor –mediated. The positive results offered 
by CBG in preclinical studies and the preclinical 
evidences of a protective effect of cannabinoids 
able to act at TRPV1 and PPARγ receptors, 
among other additional targets, in HD models, 
support the evaluation of new combinations of 
cannabinoids. 
In the last Chapter of this Thesis, we 
wanted to further study the mechanisms 
that could underlie the positive effects of 
cannabinoids as neuroprotectant observed in 
animal models of HD. We used first STHdhQ7/
Q7 and STHdhQ111/Q111 cells, in order to study 
the effect of mHTT on the cellular response 
against excitotoxic, mitochondrial and oxidative 
damage, although we focused on the last 
one. First, we were surprised to observe that 
STHdhQ111/Q111 cells were less vulnerable to H
2
O
2
. 
A possible explanation to this result could be a 
reduced expression of the Ca2+-binding protein 
DREAM by STHdhQ111/Q111 cells triggered by the 
presence of mHTT, which would make them 
less sensitive to this kind of damage, as shown 
by other authors during the time we were 
conducting our experiment (Naranjo et al., 2016). 
Dysregulation in Ca2+ homeostasis is a key  event 
for neurodegeneration in HD, so the reduced 
expression of this factor in mutant cells could 
be interpreted as an endogenous protective 
mechanism against oxidation. In this model, 
CBD, but particularly in the form of Sativex-like 
combination of phytocannabinoids, afforded 
neuroprotection against H
2
O
2
 exposure. This 
effect was equally significant in both cell lines, 
but it was much more moderate in STHdhQ111/Q111 
than in STHdhQ7/Q7 cells. This positive effect in 
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STHdhQ7/Q7 cells, which are wild type neuroblasts, 
means that these results can be applied not 
only to HD, but also to other neurodegenerative 
diseases in which mHTT is not involved. 
Therefore, we could prove Sativex and CBD 
are highly effective protecting neurons against 
oxidative insults, a fact that has been frequently 
claimed (Borges et al., 2013; Rajan et al., 2016; 
Hosseinzadeh et al., 2016). This neuroprotection 
correlated with a clearly enhanced expression of 
the phase II (inducible) antioxidant enzyme HO-
1, so we tried to prove if the activation of the 
NRF2/ARE pathway, which is currently widely 
investigated in neurodegeneration (Calkins et 
al., 2009; Johnson & Johnson, 2015) was the 
main responsible of this neuroprotective effect. 
Unfortunately,  we could not completely prove 
this involvement, but it is important to highlight 
that these data are preliminary and that further 
experiments will be needed to confirm if Sativex 
activates NRF2-mediated gene transcription 
and/or if other pathways are involved, such 
as the  NFkB as has been reported with CBD 
(Esposito et al., 2006) or others in which the 
activity of HO-1 is also increased, such as JNK 
(Lin et al., 2013), PI3K/AKT (Li et al., 2014) and 
p38 (Ning et al., 2002).
Lastly, although the pharmacological 
manipulation of the endocannabinoid system 
has provided promising results as a novel 
neuroprotective therapy in preclinical studies 
of HD and has demonstrated to be safe in HD 
patients, there exist some circumstances that 
may alter such beneficial effects. In the last 
publication of this Thesis, presented in Chapter 
3, we have addressed this “dark face” of the 
endocannabinoid system that sometimes has 
been found to have a dual activity at different 
processes (Fowler et al., 2010). Examples of this 
duality can be found in the anticonvulsant effects 
of different cannabinoids, in particular those 
active at the CB
1
 receptor, which may behave as 
anticonvulsant or proconvulsant depending on 
the neuronal site in which the receptor is located, 
e.g. anticonvulsant when acting at CB
1
 receptors 
located in glutamatergic neurons, proconvulsant 
if these receptor are located in GABAergic 
neurons. A similar situation happens with the 
protective/proapoptotic effects of cannabinoids 
which depend on the cellular context, so they can 
protect/preserve healthy neurons, as it has been 
investigated in this Doctoral Thesis, but they 
can also activate the apoptosis of tumoral cells. 
Moving to the work conducted in this thesis, we 
have obtained experimental evidence showing 
that the alteration of the endocannabinoid 
tone may have positive or deleterious effects 
depending on the context. . It is important to 
remark that, speaking on the pharmacological 
manipulation of this system, acting on CB
1
 
receptors in this pathology may not exert a 
very potent effect, since these receptors are 
downregulated from initial stages of the disease 
and the striatal neurons in which these receptors 
are more highly expressed are the ones more 
vulnerable to neurodegeneration. Therefore, 
maybe the treatment with CB
1
 agonists would 
only provide a significant effect during pre-
symptomatic, early stages of the disease. 
However, a recent study suggests that a small 
pool of CB
1
 receptors, located in corticostriatal 
projections of glutamatergic neurons and 
not in MSNs as expected, are the target of 
the neuroprotective effect of cannabinoids 
(Chiarlone et al., 2014), which represents a good 
news. On the contrary, targeting the elevation of 
CB
2
 has shown very positive effects in different 
models, both of inflammation, glial activation and 
excitotoxicity, as explained previously (Sagredo 
et al., 2009, Palazuelos et al., 2009). Moreover, 
the enhancement of 2-AG and AEA levels has 
proven anti-inflammatory effects in various 
models of neurodegeneration (see Turcotte 
et al., 2015 for review). These data, together 
with the changes in FAAH levels observed in HD 
postmortem brain tissue (Battista et al., 2007) 
and in animal models (Blázquez et al., 2011) 
which ran in opposite directions, prompted us 
to evaluate consequences of the variation in 
2-AG levels elicited by the inhibition of DAGL 
and MAGL enzymes in the malonate model of 
HD, an aspect that has not been significantly 
investigated in this disease. Despite what we 
expected, inhibition of 2-AG biosynthesis with 
a DAGL inhibitor prevented the damage by 
malonate, and on the contrary, the inhibition of 
its degradation with a MAGL inhibitor enhanced 
striatal damage in this model. These effects were 
completely independent on the activation of 
CB
1
/CB
2
 receptors (the protective targets of the 
endocannabinoid system), and they seemed to 
be related to a proinflammatory action of 2-AG 
that involves its transformation into oxygenated 
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metabolites by the enzyme COX-2 (which is also 
elevated in this model), named prostaglandin 
glyceryl esters (PG-Gs), which have been related 
to aggravation of inflammatory and excitotoxic 
processes in other experimental models (Sang 
et al., 2007; Hu et al., 2008). In this context, 
recent reports suggest the use of “substrate-
selective” COX-2 inhibitors (SSCIs), which inhibit 
endocannabinoid inactivation without affecting 
prostaglandin generation from arachidonic 
acid, to avoid the neurotoxic effects exerted 
by the increase of endocannabinoid levels and 
their conversion to oxygenated metabolites 
observed in certain circumstances (Hermanson 
et al., 2014). Therefore, certain caution must be 
taken when considering the modulation of the 
endocannabinoid system in neurodegenerative 
disorders, since elements of this system may 
experience dysregulation and trying to target 
many of them at the same time could facilitate 
the occurrence of unexpected harmful effects.
 As an overall conclusion, the results 
shown in this Thesis allow us to confirm that 
the treatment with phytocannabinoids is 
neuroprotective in different preclinical models 
of HD. This has led to the evaluation of Sativex 
in a small group of HD patients that proved 
to be safe and well-tolerated, but did not 
offer any clinical improvement. Hence, more 
research must be done to unveil the multiple 
mechanisms involved in the neuroprotective 
effects of cannabinoid compounds in HD. 
We also propose the evaluation of new 
phytocannabinoid combinations in preclinical 
models and in the clinical field, in order to 
develop multitarget therapies that can limit the 
multiple neuropathological processes involved 
in the disease. Moreover, we also suggest a 
cautious approach when manipulating the 
endocannabinoid system in this disease, since 
under certain circumstances the enhancement 
of the endocannabinoid tone might have 
deleterious effects, and this might be one of 
the causes for the lack of positive effects with 
cannabinoid formulations in preclinical and 
clinical testing.
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The results obtained in this Doctoral Thesis allow us to conclude that:
 1. CBG protects striatal neurons and improves neurological decline  in the 3NP model of acute 
striatal oxidative damage, by acting specifically on improving antioxidant defenses and reducing 
glial reactivity, and these effects are exerted by cannabinoid receptor-independent mechanisms, 
presumably by acting at the PPARs.
 2. CBG also exerts neuroprotection in the transgenic R6/2 model, in this case, by reducing the 
accumulation of huntingtin aggregates and acting positively on specific neurotrophins and specific 
genes related to HD transcriptional dysregulation. Again the effects are cannabinoid receptor-
independent. 
 3. The Sativex-like combination of phytocannabinoid botanical extracts protects striatal cells 
in the malonate model of acute inflammatory and apoptotic damage, acting specifically on limiting 
glial reactivity and improving neurotrophic support. This effect involves the activation of both CB
1
 
and CB
2
 receptors. 
 4. The Sativex-like combination of phytocannabinoid botanical extracts also improves some 
motor deficits and corrects the metabolic deficiencies and prognostic markers related to energy 
deficit and mitochondrial failure in the R6/2 transgenic model of HD.
 5. Sativex is safe and well-tolerated in HD patients as shown in a pilot Phase II clinical trial 
conducted in a cohort of early symptomatic HD patients.
 6. However, Sativex did not exert any clinical benefit in motor and cognitive scales and also 
in different biomarkers, other than an elevation in the levels of CB
2
 receptors that could be an 
endogenous protective response. The short time used for the active treatment in this clinical trial 
suggests the need to consider longer periods of treatment in future clinical studies.
 7. Using in vitro strategies (STHdhQ7/Q7 and STHdhQ111/Q111 cells), we could demonstrate that 
the protective effects of CBD against oxidative damage in the form of botanical extract, alone or 
combined with Δ9-THC as in Sativex, may involve a certain activation of the NRF2 signaling, although 
the contribution of additional cellular mechanisms appears to be necessary.
 8. Contrarily to the expected result, STHdhQ111/Q111 cells are not more vulnerable to the 
oxidative insult, and the contribution of NRF2 signaling in these cells is rather limited. 
 9. The inhibition of 2-AG biosynthesis in malonate-lesioned rats, contrarily to the expected 
result, preserves striatal neurons from death, whereas the inhibition of 2-AG degradation aggravates 
striatal damage.
 10. Using this in vivo model and also an in vitro strategy (M-213 cells), we could demonstrate 
that such unexpected result was facilitated by the up-regulation of COX-2 enzyme, the increase in 
2-AG availability, and its transformation by this enzyme into prostaglandin-glyceryl-esters, which are 
highly neurotoxic.
148
REFERENCES
149
150
References
151
Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L.A., 
Pertwee, R.G. & Makriyannis, A. (1994) (R)-
methanandamide: a chiral novel anandamide 
possessing higher potency and metabolic 
stability. J Med Chem, 37, 1889-1893.
Abadji, V., Lucas-Lenard, J.M., Chin, C. & Kendall, D.A. 
(1999) Involvement of the carboxyl terminus of 
the third intracellular loop of the cannabinoid 
CB1 receptor in constitutive activation of Gs. J 
Neurochem, 72, 2032-2038.
Adanyeguh, I.M., Rinaldi, D., Henry, P.G., Caillet, S., 
Valabregue, R., Durr, A. & Mochel, F. (2015) 
Triheptanoin improves brain energy metabolism 
in patients with Huntington disease. Neurology, 
84, 490-495.
Aguado, T., Monory, K., Palazuelos, J., Stella, N., Cravatt, 
B., Lutz, B., Marsicano, G., Kokaia, Z., Guzman, M. 
& Galve-Roperh, I. (2005) The endocannabinoid 
system drives neural progenitor proliferation. 
FASEB J, 19, 1704-1706.
Albin, R.L., Reiner, A., Anderson, K.D., Penney, J.B. & 
Young, A.B. (1990) Striatal and nigral neuron 
subpopulations in rigid Huntington’s disease: 
implications for the functional anatomy of chorea 
and rigidity-akinesia. Ann Neurol, 27, 357-365.
Alexander, S.P. (2015) Common receptors for 
endocannabinoid-like mediators and plant 
cannabinoids. In Di Marzo, V., Wang, J. (eds) The 
Endocannabinoidome. Elsevier, pp. 153-175.
Andre, V.M., Cepeda, C. & Levine, M.S. (2010) Dopamine 
and glutamate in Huntington’s disease: A 
balancing act. CNS Neurosci Ther, 16, 163-178.
Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. & 
Finkbeiner, S. (2004) Inclusion body formation 
reduces levels of mutant huntingtin and the risk 
of neuronal death. Nature, 431, 805-810.
Ashton, J.C. & Glass, M. (2007) The cannabinoid CB2 
receptor as a target for inflammation-dependent 
neurodegeneration. Curr Neuropharmacol, 5, 73-
80.
Aso, E. & Ferrer, I. (2014) Cannabinoids for treatment of 
Alzheimer’s disease: moving toward the clinic. 
Front Pharmacol, 5, 37.
Aso, E. & Ferrer, I. (2016) CB2 Cannabinoid Receptor As 
Potential Target against Alzheimer’s Disease. 
Front Neurosci, 10, 243.
Atwood, B.K. & Mackie, K. (2010) CB2: a cannabinoid 
receptor with an identity crisis. Br J Pharmacol, 
160, 467-479.
Badowski, M.E. & Perez, S.E. (2016) Clinical utility of 
dronabinol in the treatment of weight loss 
associated with HIV and AIDS. HIV AIDS (Auckl), 
8, 37-45.
Balenga, N.A., Martinez-Pinilla, E., Kargl, J., Schroder, R., 
Peinhaupt, M., Platzer, W., Balint, Z., Zamarbide, 
M., Dopeso-Reyes, I.G., Ricobaraza, A., Perez-Ortiz, 
J.M., Kostenis, E., Waldhoer, M., Heinemann, A. & 
Franco, R. (2014) Heteromerization of GPR55 and 
cannabinoid CB2 receptors modulates signalling. 
Br J Pharmacol, 171, 5387-5406.
Bari, M., Battista, N., Valenza, M., Mastrangelo, N., 
Malaponti, M., Catanzaro, G., Centonze, D., 
Finazzi-Agro, A., Cattaneo, E. & Maccarrone, M. 
(2013) In vitro and in vivo models of Huntington’s 
disease show alterations in the endocannabinoid 
system. FEBS J, 280, 3376-3388.
Battista, N., Bari, M., Tarditi, A., Mariotti, C., Bachoud-
Levi, A.C., Zuccato, C., Finazzi-Agro, A., Genitrini, 
S., Peschanski, M., Di Donato, S., Cattaneo, E. 
& Maccarrone, M. (2007) Severe deficiency of 
the fatty acid amide hydrolase (FAAH) activity 
segregates with the Huntington’s disease 
mutation in peripheral lymphocytes. Neurobiol 
Dis, 27, 108-116.
Bates, G.P., Dorsey, R., Gusella, J.F., Hayden, M.R., Kay, 
C., Leavitt, B.R., Nance, M., Ross, C.A., Scahill, 
R.I., Wetzel, R., Wild, E.J. & Tabrizi, S.J. (2015) 
Huntington disease. Nat Rev Dis Primers, 1, 
15005.
Beal, M.F., Ferrante, R.J., Swartz, K.J. & Kowall, N.W. (1991) 
Chronic quinolinic acid lesions in rats closely 
resemble Huntington’s disease. J Neurosci, 11, 
1649-1659.
Beal, M.F., Hyman, B.T. & Koroshetz, W. (1993) Do defects 
in mitochondrial energy metabolism underlie 
the pathology of neurodegenerative diseases? 
Trends Neurosci, 16, 125-131.
Benard, G., Massa, F., Puente, N., Lourenco, J., Bellocchio, L., 
Soria-Gomez, E., Matias, I., Delamarre, A., Metna-
Laurent, M., Cannich, A., Hebert-Chatelain, E., 
Mulle, C., Ortega-Gutierrez, S., Martin-Fontecha, 
M., Klugmann, M., Guggenhuber, S., Lutz, B., 
Gertsch, J., Chaouloff, F., Lopez-Rodriguez, M.L., 
Grandes, P., Rossignol, R. & Marsicano, G. (2012) 
Mitochondrial CB(1) receptors regulate neuronal 
energy metabolism. Nat Neurosci, 15, 558-564.
Benito, C., Nunez, E., Tolon, R.M., Carrier, E.J., Rabano, 
A., Hillard, C.J. & Romero, J. (2003) Cannabinoid 
CB2 receptors and fatty acid amide hydrolase 
are selectively overexpressed in neuritic plaque-
associated glia in Alzheimer’s disease brains. J 
Neurosci, 23, 11136-11141.
Bisogno, T., Berrendero, F., Ambrosino, G., Cebeira, 
M., Ramos, J.A., Fernandez-Ruiz, J.J. & Di 
Marzo, V. (1999) Brain regional distribution 
of endocannabinoids: implications for their 
biosynthesis and biological function. Biochem 
Biophys Res Commun, 256, 377-380.
References
152
Bisogno, T., Martire, A., Petrosino, S., Popoli, P. & Di 
Marzo, V. (2008) Symptom-related changes of 
endocannabinoid and palmitoylethanolamide 
levels in brain areas of R6/2 mice, a transgenic 
model of Huntington’s disease. Neurochem Int, 
52, 307-313.
Blazquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, 
M.R., Resel, E., Palazuelos, J., Julien, B., Salazar, 
M., Borner, C., Benito, C., Carrasco, C., Diez-
Zaera, M., Paoletti, P., Diaz-Hernandez, M., Ruiz, 
C., Sendtner, M., Lucas, J.J., de Yebenes, J.G., 
Marsicano, G., Monory, K., Lutz, B., Romero, J., 
Alberch, J., Gines, S., Kraus, J., Fernandez-Ruiz, 
J., Galve-Roperh, I. & Guzman, M. (2011) Loss 
of striatal type 1 cannabinoid receptors is a key 
pathogenic factor in Huntington’s disease. Brain, 
134, 119-136.
Borges, R.S., Batista, J., Jr., Viana, R.B., Baetas, A.C., 
Orestes, E., Andrade, M.A., Honorio, K.M. & da 
Silva, A.B. (2013) Understanding the molecular 
aspects of tetrahydrocannabinol and cannabidiol 
as antioxidants. Molecules, 18, 12663-12674.
Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., 
Coppola, D., De Petrocellis, L., Buono, L., Orlando, 
P. & Izzo, A.A. (2014) Colon carcinogenesis is 
inhibited by the TRPM8 antagonist cannabigerol, a 
Cannabis-derived non-psychotropic cannabinoid. 
Carcinogenesis, 35, 2787-2797.
Bouchard, J., Truong, J., Bouchard, K., Dunkelberger, 
D., Desrayaud, S., Moussaoui, S., Tabrizi, S.J., 
Stella, N. & Muchowski, P.J. (2012) Cannabinoid 
receptor 2 signaling in peripheral immune cells 
modulates disease onset and severity in mouse 
models of Huntington’s disease. J Neurosci, 32, 
18259-18268.
Browne, S.E. & Beal, M.F. (2006) Oxidative damage in 
Huntington’s disease pathogenesis. Antioxid 
Redox Signal, 8, 2061-2073.
Brusco, A., Tagliaferro, P., Saez, T. & Onaivi, E.S. (2008) 
Postsynaptic localization of CB2 cannabinoid 
receptors in the rat hippocampus. Synapse, 62, 
944-949.
Cabral, G.A. & Griffin-Thomas, L. (2009) Emerging role of the 
cannabinoid receptor CB2 in immune regulation: 
therapeutic prospects for neuroinflammation. 
Expert Rev Mol Med, 11, e3.
Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V. & Di Filippo, 
M. (2014) Direct and indirect pathways of basal 
ganglia: a critical reappraisal. Nat Neurosci, 17, 
1022-1030.
Callen, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, 
D., Cortes, A., Mallol, J., Casado, V., Lanciego, J.L., 
Franco, R., Lluis, C., Canela, E.I. & McCormick, P.J. 
(2012) Cannabinoid receptors CB1 and CB2 form 
functional heteromers in brain. J Biol Chem, 287, 
20851-20865.
Carriba, P., Ortiz, O., Patkar, K., Justinova, Z., Stroik, J., 
Themann, A., Muller, C., Woods, A.S., Hope, 
B.T., Ciruela, F., Casado, V., Canela, E.I., Lluis, C., 
Goldberg, S.R., Moratalla, R., Franco, R. & Ferre, 
S. (2007) Striatal adenosine A2A and cannabinoid 
CB1 receptors form functional heteromeric 
complexes that mediate the motor effects of 
cannabinoids. Neuropsychopharmacology, 32, 
2249-2259.
Cascio, M.G., Gauson, L.A., Stevenson, L.A., Ross, R.A. 
& Pertwee, R.G. (2010) Evidence that the plant 
cannabinoid cannabigerol is a highly potent 
alpha2-adrenoceptor agonist and moderately 
potent 5HT1A receptor antagonist. Br J 
Pharmacol, 159, 129-141.
Castillo, P.E., Younts, T.J., Chavez, A.E. & Hashimotodani, 
Y. (2012) Endocannabinoid signaling and synaptic 
function. Neuron, 76, 70-81.
Cattaneo, E., Zuccato, C. & Tartari, M. (2005) Normal 
huntingtin function: an alternative approach to 
Huntington’s disease. Nat Rev Neurosci, 6, 919-
930.
Cicchetti, F. & Parent, A. (1996) Striatal interneurons in 
Huntington’s disease: selective increase in the 
density of calretinin-immunoreactive medium-
sized neurons. Mov Disord, 11, 619-626.
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., 
Sandyk, R., Kennedy, K. & Schram, K. (1991) 
Controlled clinical trial of cannabidiol in 
Huntington’s disease. Pharmacol Biochem Behav, 
40, 701-708.
Conti, S., Costa, B., Colleoni, M., Parolaro, D. & 
Giagnoni, G. (2002) Antiinflammatory action of 
endocannabinoid palmitoylethanolamide and 
the synthetic cannabinoid nabilone in a model 
of acute inflammation in the rat. Br J Pharmacol, 
135, 181-187.
Costa, B. (2007) On the pharmacological properties 
of Delta9-tetrahydrocannabinol (THC). Chem 
Biodivers, 4, 1664-1677.
Covelo, A. & Araque, A. (2016) Lateral regulation of synaptic 
transmission by astrocytes. Neuroscience, 323, 
62-66.
Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., 
Lerner, R.A. & Gilula, N.B. (1996) Molecular 
characterization of an enzyme that degrades 
neuromodulatory fatty-acid amides. Nature, 384, 
83-87.
Crotti, A. & Glass, C.K. (2015) The choreography of 
neuroinflammation in Huntington’s disease. 
Trends Immunol, 36, 364-373.
Croxford, J.L. & Yamamura, T. (2005) Cannabinoids and 
References
153
the immune system: potential for the treatment 
of inflammatory diseases? J Neuroimmunol, 166, 
3-18.
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., 
Tanese, N. & Krainc, D. (2006) Transcriptional 
repression of PGC-1alpha by mutant huntingtin 
leads to mitochondrial dysfunction and 
neurodegeneration. Cell, 127, 59-69.
Curtis, A., Mitchell, I., Patel, S., Ives, N. & Rickards, H. (2009) 
A pilot study using nabilone for symptomatic 
treatment in Huntington’s disease. Mov Disord, 
24, 2254-2259.
Curtis, A. & Rickards, H. (2006) Nabilone could treat 
chorea and irritability in Huntington’s disease. J 
Neuropsychiatry Clin Neurosci, 18, 553-554.
Chavez, A.E., Chiu, C.Q. & Castillo, P.E. (2010) TRPV1 
activation by endogenous anandamide triggers 
postsynaptic long-term depression in dentate 
gyrus. Nat Neurosci, 13, 1511-1518.
Chiarlone, A., Bellocchio, L., Blazquez, C., Resel, E., Soria-
Gomez, E., Cannich, A., Ferrero, J.J., Sagredo, 
O., Benito, C., Romero, J., Sanchez-Prieto, J., 
Lutz, B., Fernandez-Ruiz, J., Galve-Roperh, I. & 
Guzman, M. (2014) A restricted population of 
CB1 cannabinoid receptors with neuroprotective 
activity. Proc Natl Acad Sci U S A, 111, 8257-8262.
Chiodi, V., Uchigashima, M., Beggiato, S., Ferrante, A., 
Armida, M., Martire, A., Potenza, R.L., Ferraro, 
L., Tanganelli, S., Watanabe, M., Domenici, M.R. 
& Popoli, P. (2012) Unbalance of CB1 receptors 
expressed in GABAergic and glutamatergic 
neurons in a transgenic mouse model of 
Huntington’s disease. Neurobiol Dis, 45, 983-991.
D’Ambra, T.E., Estep, K.G., Bell, M.R., Eissenstat, M.A., 
Josef, K.A., Ward, S.J., Haycock, D.A., Baizman, 
E.R., Casiano, F.M., Beglin, N.C. & et al. (1992) 
Conformationally restrained analogues of 
pravadoline: nanomolar potent, enantioselective, 
(aminoalkyl)indole agonists of the cannabinoid 
receptor. J Med Chem, 35, 124-135.
de la Monte, S.M., Vonsattel, J.P. & Richardson, E.P., Jr. 
(1988) Morphometric demonstration of atrophic 
changes in the cerebral cortex, white matter, 
and neostriatum in Huntington’s disease. J 
Neuropathol Exp Neurol, 47, 516-525.
De Petrocellis, L., Ligresti, A., Moriello, A.S., Allara, M., 
Bisogno, T., Petrosino, S., Stott, C.G. & Di Marzo, V. 
(2011) Effects of cannabinoids and cannabinoid-
enriched Cannabis extracts on TRP channels 
and endocannabinoid metabolic enzymes. Br J 
Pharmacol, 163, 1479-1494.
den Boon, F.S., Chameau, P., Schaafsma-Zhao, Q., 
van Aken, W., Bari, M., Oddi, S., Kruse, C.G., 
Maccarrone, M., Wadman, W.J. & Werkman, 
T.R. (2012) Excitability of prefrontal cortical 
pyramidal neurons is modulated by activation of 
intracellular type-2 cannabinoid receptors. Proc 
Natl Acad Sci U S A, 109, 3534-3539.
Devane, W.A., Dysarz, F.A., 3rd, Johnson, M.R., Melvin, 
L.S. & Howlett, A.C. (1988) Determination and 
characterization of a cannabinoid receptor in rat 
brain. Mol Pharmacol, 34, 605-613.
Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., 
Stevenson, L.A., Griffin, G., Gibson, D., 
Mandelbaum, A., Etinger, A. & Mechoulam, 
R. (1992) Isolation and structure of a brain 
constituent that binds to the cannabinoid 
receptor. Science, 258, 1946-1949.
Devinsky, O., Marsh, E. & Friedman, D. (2016) Cannabidiol 
in patients with treatment-resistant epilepsy - 
Authors’ reply. Lancet Neurol, 15, 545-546.
Di Marzo, V. (2009) The endocannabinoid system: 
its general strategy of action, tools for its 
pharmacological manipulation and potential 
therapeutic exploitation. Pharmacol Res, 60, 77-
84.
Di Marzo, V., Bisogno, T., De Petrocellis, L., Brandi, I., 
Jefferson, R.G., Winckler, R.L., Davis, J.B., Dasse, 
O., Mahadevan, A., Razdan, R.K. & Martin, 
B.R. (2001) Highly selective CB(1) cannabinoid 
receptor ligands and novel CB(1)/VR(1) vanilloid 
receptor “hybrid” ligands. Biochem Biophys Res 
Commun, 281, 444-451.
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, 
G., Schwartz, J.C. & Piomelli, D. (1994) Formation 
and inactivation of endogenous cannabinoid 
anandamide in central neurons. Nature, 372, 
686-691.
Di Prospero, N.A. & Tagle, D.A. (2000) Normal and mutant 
huntingtin: partners in crime. Nat Med, 6, 1208-
1209.
Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, 
I., Sensi, S.L., Kathuria, S. & Piomelli, D. (2002) 
Brain monoglyceride lipase participating in 
endocannabinoid inactivation. Proc Natl Acad Sci 
U S A, 99, 10819-10824.
Dobson, L., Trager, U., Farmer, R., Hayardeny, L., Loupe, P., 
Hayden, M.R. & Tabrizi, S.J. (2016) Laquinimod 
dampens hyperactive cytokine production in 
Huntington’s disease patient myeloid cells. J 
Neurochem, 137, 782-794.
Docagne, F., Muneton, V., Clemente, D., Ali, C., Loria, F., 
Correa, F., Hernangomez, M., Mestre, L., Vivien, 
D. & Guaza, C. (2007) Excitotoxicity in a chronic 
model of multiple sclerosis: Neuroprotective 
effects of cannabinoids through CB1 and CB2 
receptor activation. Mol Cell Neurosci, 34, 551-
561.
References
154
Dong, Y. & Benveniste, E.N. (2001) Immune function of 
astrocytes. Glia, 36, 180-190.
Dow-Edwards, D. & Silva, L. (2017) Endocannabinoids in 
brain plasticity: Cortical maturation, HPA axis 
function and behavior. Brain Res, 1654, 157-164.
Dowie, M.J., Grimsey, N.L., Hoffman, T., Faull, R.L. & Glass, 
M. (2014) Cannabinoid receptor CB2 is expressed 
on vascular cells, but not astroglial cells in the 
post-mortem human Huntington’s disease brain. 
J Chem Neuroanat, 59-60, 62-71.
Dudok, B., Barna, L., Ledri, M., Szabo, S.I., Szabadits, E., 
Pinter, B., Woodhams, S.G., Henstridge, C.M., 
Balla, G.Y., Nyilas, R., Varga, C., Lee, S.H., Matolcsi, 
M., Cervenak, J., Kacskovics, I., Watanabe, M., 
Sagheddu, C., Melis, M., Pistis, M., Soltesz, I. 
& Katona, I. (2015) Cell-specific STORM super-
resolution imaging reveals nanoscale organization 
of cannabinoid signaling. Nat Neurosci, 18, 75-86.
Duyao, M., Ambrose, C., Myers, R., Novelletto, A., 
Persichetti, F., Frontali, M., Folstein, S., Ross, C., 
Franz, M., Abbott, M. & et al. (1993) Trinucleotide 
repeat length instability and age of onset in 
Huntington’s disease. Nat Genet, 4, 387-392.
Duyao, M.P., Auerbach, A.B., Ryan, A., Persichetti, F., 
Barnes, G.T., McNeil, S.M., Ge, P., Vonsattel, 
J.P., Gusella, J.F., Joyner, A.L. & et al. (1995) 
Inactivation of the mouse Huntington’s disease 
gene homolog Hdh. Science, 269, 407-410.
Egertova, M., Cravatt, B.F. & Elphick, M.R. (2003) 
Comparative analysis of fatty acid amide hydrolase 
and cb(1) cannabinoid receptor expression in 
the mouse brain: evidence of a widespread role 
for fatty acid amide hydrolase in regulation of 
endocannabinoid signaling. Neuroscience, 119, 
481-496.
Elphick, M.R. (2012) The evolution and comparative 
neurobiology of endocannabinoid signalling. 
Philos Trans R Soc Lond B Biol Sci, 367, 3201-3215.
Esposito, G., De Filippis, D., Steardo, L., Scuderi, C., 
Savani, C., Cuomo, V. & Iuvone, T. (2006) CB1 
receptor selective activation inhibits beta-
amyloid-induced iNOS protein expression in 
C6 cells and subsequently blunts tau protein 
hyperphosphorylation in co-cultured neurons. 
Neurosci Lett, 404, 342-346.
Estrada Sanchez, A.M., Mejia-Toiber, J. & Massieu, L. (2008) 
Excitotoxic neuronal death and the pathogenesis 
of Huntington’s disease. Arch Med Res, 39, 265-
276.
Evans, S.J., Douglas, I., Rawlins, M.D., Wexler, N.S., 
Tabrizi, S.J. & Smeeth, L. (2013) Prevalence of 
adult Huntington’s disease in the UK based on 
diagnoses recorded in general practice records. J 
Neurol Neurosurg Psychiatry, 84, 1156-1160.
Feigenbaum, J.J., Bergmann, F., Richmond, S.A., 
Mechoulam, R., Nadler, V., Kloog, Y. & Sokolovsky, 
M. (1989) Nonpsychotropic cannabinoid acts 
as a functional N-methyl-D-aspartate receptor 
blocker. Proc Natl Acad Sci U S A, 86, 9584-9587.
Felder, C.C., Nielsen, A., Briley, E.M., Palkovits, M., Priller, 
J., Axelrod, J., Nguyen, D.N., Richardson, J.M., 
Riggin, R.M., Koppel, G.A., Paul, S.M. & Becker, 
G.W. (1996) Isolation and measurement of the 
endogenous cannabinoid receptor agonist, 
anandamide, in brain and peripheral tissues of 
human and rat. FEBS Lett, 393, 231-235.
Fernandez-Ruiz, J., Pazos, M.R., Garcia-Arencibia, M., 
Sagredo, O. & Ramos, J.A. (2008) Role of 
CB2 receptors in neuroprotective effects of 
cannabinoids. Mol Cell Endocrinol, 286, S91-96.
Fernandez-Ruiz, J. (2009) The endocannabinoid system as 
a target for the treatment of motor dysfunction. 
Br J Pharmacol, 156, 1029-1040.
Fernandez-Ruiz, J., Garcia, C., Sagredo, O., Gomez-Ruiz, 
M. & de Lago, E. (2010) The endocannabinoid 
system as a target for the treatment of neuronal 
damage. Expert Opin Ther Targets, 14, 387-404.
Fernandez-Ruiz, J., Moreno-Martet, M., Rodriguez-
Cueto, C., Palomo-Garo, C., Gomez-Canas, M., 
Valdeolivas, S., Guaza, C., Romero, J., Guzman, M., 
Mechoulam, R. & Ramos, J.A. (2011) Prospects for 
cannabinoid therapies in basal ganglia disorders. 
Br J Pharmacol, 163, 1365-1378.
Fernandez-Ruiz, J., Romero, J. & Ramos, J.A. (2015) 
Endocannabinoids and Neurodegenerative 
Disorders: Parkinson’s Disease, Huntington’s 
Chorea, Alzheimer’s Disease, and Others. Handb 
Exp Pharmacol, 231, 233-259.
Ferrante, R.J., Beal, M.F., Kowall, N.W., Richardson, 
E.P., Jr. & Martin, J.B. (1987) Sparing of 
acetylcholinesterase-containing striatal neurons 
in Huntington’s disease. Brain Res, 411, 162-166.
Ferrante, R.J., Kowall, N.W., Beal, M.F., Richardson, E.P., Jr., 
Bird, E.D. & Martin, J.B. (1985) Selective sparing 
of a class of striatal neurons in Huntington’s 
disease. Science, 230, 561-563.
Fisher, E.R. & Hayden, M.R. (2014) Multisource 
ascertainment of Huntington disease in Canada: 
prevalence and population at risk. Mov Disord, 
29, 105-114.
Franco, R., Martinez-Pinilla, E., Ricobaraza, A. & McCormick, 
P.J. (2013) Challenges in the development of 
heteromer-GPCR-based drugs. Prog Mol Biol 
Transl Sci, 117, 143-162.
Frost, B. & Diamond, M.I. (2010) Prion-like mechanisms in 
neurodegenerative diseases. Nat Rev Neurosci, 
11, 155-159.
References
155
Fusco, F.R., Chen, Q., Lamoreaux, W.J., Figueredo-
Cardenas, G., Jiao, Y., Coffman, J.A., Surmeier, 
D.J., Honig, M.G., Carlock, L.R. & Reiner, A. (1999) 
Cellular localization of huntingtin in striatal and 
cortical neurons in rats: lack of correlation with 
neuronal vulnerability in Huntington’s disease. J 
Neurosci, 19, 1189-1202.
Gabrielli, M., Battista, N., Riganti, L., Prada, I., Antonucci, 
F., Cantone, L., Matteoli, M., Maccarrone, M. & 
Verderio, C. (2015) Active endocannabinoids are 
secreted on extracellular membrane vesicles. 
EMBO Rep, 16, 213-220.
Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, 
D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, 
G. & Casellas, P. (1995) Expression of central 
and peripheral cannabinoid receptors in human 
immune tissues and leukocyte subpopulations. 
Eur J Biochem, 232, 54-61.
Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., 
Velasco, G. & Guzman, M. (2002) Mechanism of 
extracellular signal-regulated kinase activation by 
the CB(1) cannabinoid receptor. Mol Pharmacol, 
62, 1385-1392.
Gaoni, Y. & Mechoulam, R. (1964) Isolation, structure, 
and partial synthesis of an active constituent of 
hashish. J. Am. Chem. Soc., 86, 1646-1647.
Garcia, M.C., Cinquina, V., Palomo-Garo, C., Rabano, A. 
& Fernandez-Ruiz, J. (2015) Identification of 
CB(2) receptors in human nigral neurons that 
degenerate in Parkinson’s disease. Neurosci Lett, 
587, 1-4.
Gatley, S.J., Gifford, A.N., Volkow, N.D., Lan, R. & 
Makriyannis, A. (1996) 123I-labeled AM251: 
a radioiodinated ligand which binds in vivo to 
mouse brain cannabinoid CB1 receptors. Eur J 
Pharmacol, 307, 331-338.
Gatta-Cherifi, B. & Cota, D. (2015) Endocannabinoids and 
Metabolic Disorders. Handb Exp Pharmacol, 231, 
367-391.
Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, 
J.P., Rangone, H., Cordelieres, F.P., De Mey, 
J., MacDonald, M.E., Lessmann, V., Humbert, 
S. & Saudou, F. (2004) Huntingtin controls 
neurotrophic support and survival of neurons 
by enhancing BDNF vesicular transport along 
microtubules. Cell, 118, 127-138.
Gerard, C.M., Mollereau, C., Vassart, G. & Parmentier, 
M. (1991) Molecular cloning of a human 
cannabinoid receptor which is also expressed in 
testis. Biochem J, 279 ( Pt 1), 129-134.
Gil-Mohapel, J., Brocardo, P.S. & Christie, B.R. (2014) The 
role of oxidative stress in Huntington’s disease: 
are antioxidants good therapeutic candidates? 
Curr Drug Targets, 15, 454-468.
Giuffrida, A., Desarnaud, F. & Piomelli, D. (2000) 
Endogenous cannabinoid signaling and 
psychomotor disorders. Prostaglandins Other 
Lipid Mediat, 61, 63-70.
Glaser, S.T., Kaczocha, M. & Deutsch, D.G. (2005) 
Anandamide transport: a critical review. Life Sci, 
77, 1584-1604
Glass, M., Dragunow, M. & Faull, R.L. (2000) The pattern 
of neurodegeneration in Huntington’s disease: 
a comparative study of cannabinoid, dopamine, 
adenosine and GABA(A) receptor alterations in 
the human basal ganglia in Huntington’s disease. 
Neuroscience, 97, 505-519.
Granja, A.G., Carrillo-Salinas, F., Pagani, A., Gomez-Canas, 
M., Negri, R., Navarrete, C., Mecha, M., Mestre, L., 
Fiebich, B.L., Cantarero, I., Calzado, M.A., Bellido, 
M.L., Fernandez-Ruiz, J., Appendino, G., Guaza, 
C. & Munoz, E. (2012) A cannabigerol quinone 
alleviates neuroinflammation in a chronic model 
of multiple sclerosis. J Neuroimmune Pharmacol, 
7, 1002-1016.
Graveland, G.A., Williams, R.S. & DiFiglia, M. (1985) 
Evidence for degenerative and regenerative 
changes in neostriatal spiny neurons in 
Huntington’s disease. Science, 227, 770-773.
Group, H.S., Frank, S., Testa, C.M., Stamler, D., Kayson, 
E., et al. (2016) Effect of Deutetrabenazine on 
Chorea Among Patients With Huntington Disease: 
A Randomized Clinical Trial. JAMA, 316, 40-50.
Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, 
J.M. & Schapira, A.H. (1996) Mitochondrial defect 
in Huntington’s disease caudate nucleus. Ann 
Neurol, 39, 385-389.
Guzman, M., Galve-Roperh, I. & Sanchez, C. (2001) 
Ceramide: a new second messenger of 
cannabinoid action. Trends Pharmacol Sci, 22, 
19-22.
Hampson, A.J., Bornheim, L.M., Scanziani, M., Yost, C.S., 
Gray, A.T., Hansen, B.M., Leonoudakis, D.J. & 
Bickler, P.E. (1998) Dual effects of anandamide 
on NMDA receptor-mediated responses and 
neurotransmission. J Neurochem, 70, 671-676.
Han, I., You, Y., Kordower, J.H., Brady, S.T. & Morfini, G.A. 
(2010) Differential vulnerability of neurons in 
Huntington’s disease: the role of cell type-specific 
features. J Neurochem, 113, 1073-1091.
Hansen, K.B., Rosenkilde, M.M., Knop, F.K., Wellner, N., 
Diep, T.A., Rehfeld, J.F., Andersen, U.B., Holst, 
J.J. & Hansen, H.S. (2011) 2-Oleoyl glycerol is 
a GPR119 agonist and signals GLP-1 release in 
humans. J Clin Endocrinol Metab, 96, E1409-
1417.
Hedreen, J.C., Peyser, C.E., Folstein, S.E. & Ross, C.A. (1991) 
References
156
Neuronal loss in layers V and VI of cerebral cortex 
in Huntington’s disease. Neurosci Lett, 133, 257-
261.
Henstridge, C.M., Balenga, N.A., Schroder, R., Kargl, J.K., 
Platzer, W., Martini, L., Arthur, S., Penman, J., 
Whistler, J.L., Kostenis, E., Waldhoer, M. & Irving, 
A.J. (2010) GPR55 ligands promote receptor 
coupling to multiple signalling pathways. Br J 
Pharmacol, 160, 604-614.
Herkenham, M., Groen, B.G., Lynn, A.B., De Costa, B.R. 
& Richfield, E.K. (1991) Neuronal localization of 
cannabinoid receptors and second messengers in 
mutant mouse cerebellum. Brain Res, 552, 301-
310.
Hillard, C.J. (2008) Role of cannabinoids and 
endocannabinoids in cerebral ischemia. Curr 
Pharm Des, 14, 2347-2361.
Hillard, C.J., Manna, S., Greenberg, M.J., DiCamelli, R., 
Ross, R.A., Stevenson, L.A., Murphy, V., Pertwee, 
R.G. & Campbell, W.B. (1999) Synthesis and 
characterization of potent and selective agonists 
of the neuronal cannabinoid receptor (CB1). J 
Pharmacol Exp Ther, 289, 1427-1433.
Ho, W.S., Barrett, D.A. & Randall, M.D. (2008) ‘Entourage’ 
effects of N-palmitoylethanolamide and 
N-oleoylethanolamide on vasorelaxation to 
anandamide occur through TRPV1 receptors. Br 
J Pharmacol, 155, 837-846.
Hong, S., Dissing-Olesen, L. & Stevens, B. (2016) New 
insights on the role of microglia in synaptic 
pruning in health and disease. Curr Opin 
Neurobiol, 36, 128-134.
Horne, E.A., Coy, J., Swinney, K., Fung, S., Cherry, A.E., 
Marrs, W.R., Naydenov, A.V., Lin, Y.H., Sun, 
X., Keene, C.D., Grouzmann, E., Muchowski, 
P., Bates, G.P., Mackie, K. & Stella, N. (2013) 
Downregulation of cannabinoid receptor 1 from 
neuropeptide Y interneurons in the basal ganglia 
of patients with Huntington’s disease and mouse 
models. Eur J Neurosci, 37, 429-440.
Hosseinzadeh, M., Nikseresht, S., Khodagholi, F., Naderi, 
N. & Maghsoudi, N. (2016) Cannabidiol Post-
Treatment Alleviates Rat Epileptic-Related 
Behaviors and Activates Hippocampal Cell 
Autophagy Pathway Along with Antioxidant 
Defense in Chronic Phase of Pilocarpine-Induced 
Seizure. J Mol Neurosci, 58, 432-440.
Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, 
P., Devane, W.A., Felder, C.C., Herkenham, 
M., Mackie, K., Martin, B.R., Mechoulam, R. 
& Pertwee, R.G. (2002) International Union 
of Pharmacology. XXVII. Classification of 
cannabinoid receptors. Pharmacol Rev, 54, 161-
202.
Howlett, A.C., Johnson, M.R., Melvin, L.S. & Milne, G.M. 
(1988) Nonclassical cannabinoid analgetics 
inhibit adenylate cyclase: development of a 
cannabinoid receptor model. Mol Pharmacol, 33, 
297-302.
Hua, T., Vemuri, K., Pu, M., Qu, L., Han, G.W., Wu, Y., Zhao, 
S., Shui, W., Li, S., Korde, A., Laprairie, R.B., Stahl, 
E.L., Ho, J.H., Zvonok, N., Zhou, H., Kufareva, I., 
Wu, B., Zhao, Q., Hanson, M.A., Bohn, L.M., 
Makriyannis, A., Stevens, R.C. & Liu, Z.J. (2016) 
Crystal Structure of the Human Cannabinoid 
Receptor CB1. Cell, 167, 750-762 e714.
Huffman, J.W. (2005) CB2 receptor ligands. Mini Rev Med 
Chem, 5, 641-649.
Huntington, G. (2003) On chorea. George Huntington, 
M.D. J Neuropsychiatry Clin Neurosci, 15, 109-
112.
Hussain, S.A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., 
Lay, J., Hung, P., Lerner, J.T. & Sankar, R. (2015) 
Perceived efficacy of cannabidiol-enriched 
cannabis extracts for treatment of pediatric 
epilepsy: A potential role for infantile spasms and 
Lennox-Gastaut syndrome. Epilepsy Behav, 47, 
138-141.
Imperatore, R., Palomba, L., Morello, G., Spiezio, A.D., 
Piscitelli, F., Marzo, V.D. & Cristino, L. (2016) 
Formation of OX-1R/CB1R heteromeric complexes 
in embryonic mouse hypothalamic cells: Effect 
on intracellular calcium, 2-arachidonoyl-
glycerol biosynthesis and ERK phosphorylation. 
Pharmacol Res, 111, 600-609.
Jiang, H., Poirier, M.A., Liang, Y., Pei, Z., Weiskittel, C.E., 
Smith, W.W., DeFranco, D.B. & Ross, C.A. (2006) 
Depletion of CBP is directly linked with cellular 
toxicity caused by mutant huntingtin. Neurobiol 
Dis, 23, 543-551.
Johnson, J.R., Lossignol, D., Burnell-Nugent, M. & Fallon, 
M.T. (2013) An open-label extension study to 
investigate the long-term safety and tolerability 
of THC/CBD oromucosal spray and oromucosal 
THC spray in patients with terminal cancer-related 
pain refractory to strong opioid analgesics. J Pain 
Symptom Manage, 46, 207-218.
Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J.T., Li, 
L., Karsak, M., Zimmer, A., Mallat, A. & Lotersztajn, 
S. (2005) Antifibrogenic role of the cannabinoid 
receptor CB2 in the liver. Gastroenterology, 128, 
742-755.
Kenney, C., Hunter, C. & Jankovic, J. (2007) Long-term 
tolerability of tetrabenazine in the treatment of 
hyperkinetic movement disorders. Mov Disord, 
22, 193-197.
Kerkis, I., Haddad, M.S., Valverde, C.W. & Glosman, S. 
(2015) Neural and mesenchymal stem cells in 
References
157
animal models of Huntington’s disease: past 
experiences and future challenges. Stem Cell Res 
Ther, 6, 232.
Kirilly, E., Gonda, X. & Bagdy, G. (2012) CB1 receptor 
antagonists: new discoveries leading to new 
perspectives. Acta Physiol (Oxf), 205, 41-60.
Kondo, S., Kondo, H., Nakane, S., Kodaka, T., 
Tokumura, A., Waku, K. & Sugiura, T. (1998) 
2-Arachidonoylglycerol, an endogenous 
cannabinoid receptor agonist: identification as 
one of the major species of monoacylglycerols in 
various rat tissues, and evidence for its generation 
through CA2+-dependent and -independent 
mechanisms. FEBS Lett, 429, 152-156.
Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E.V., Mazur, 
C., McAlonis, M.M., Pytel, K.A., Artates, J.W., 
Weiss, A., Cheng, S.H., Shihabuddin, L.S., Hung, 
G., Bennett, C.F. & Cleveland, D.W. (2012) 
Sustained therapeutic reversal of Huntington’s 
disease by transient repression of huntingtin 
synthesis. Neuron, 74, 1031-1044.
Lanciego, J.L., Barroso-Chinea, P., Rico, A.J., Conte-Perales, 
L., Callen, L., Roda, E., Gomez-Bautista, V., Lopez, 
I.P., Lluis, C., Labandeira-Garcia, J.L. & Franco, 
R. (2011) Expression of the mRNA coding the 
cannabinoid receptor 2 in the pallidal complex of 
Macaca fascicularis. J Psychopharmacol, 25, 97-
104.
Lastres-Becker, I., de Miguel, R., De Petrocellis, L., 
Makriyannis, A., Di Marzo, V. & Fernandez-
Ruiz, J. (2003) Compounds acting at the 
endocannabinoid and/or endovanilloid systems 
reduce hyperkinesia in a rat model of Huntington’s 
disease. J Neurochem, 84, 1097-1109.
Lastres-Becker, I., Gomez, M., De Miguel, R., Ramos, J.A. 
& Fernandez-Ruiz, J. (2002a) Loss of cannabinoid 
CB(1) receptors in the basal ganglia in the 
late akinetic phase of rats with experimental 
Huntington’s disease. Neurotox Res, 4, 601-608.
Lastres-Becker, I., Hansen, H.H., Berrendero, F., De Miguel, 
R., Perez-Rosado, A., Manzanares, J., Ramos, J.A. 
& Fernandez-Ruiz, J. (2002b) Alleviation of motor 
hyperactivity and neurochemical deficits by 
endocannabinoid uptake inhibition in a rat model 
of Huntington’s disease. Synapse, 44, 23-35.
Lauckner, J.E., Hille, B. & Mackie, K. (2005) The cannabinoid 
agonist WIN55,212-2 increases intracellular 
calcium via CB1 receptor coupling to Gq/11 G 
proteins. Proc Natl Acad Sci U S A, 102, 19144-
19149.
Laviolette, S.R. & Grace, A.A. (2006) The roles of 
cannabinoid and dopamine receptor systems in 
neural emotional learning circuits: implications 
for schizophrenia and addiction. Cell Mol Life Sci, 
63, 1597-1613.
Lawrence, D.K. & Gill, E.W. (1975) The effects of delta1-
tetrahydrocannabinol and other cannabinoids 
on spin-labeled liposomes and their relationship 
to mechanisms of general anesthesia. Mol 
Pharmacol, 11, 595-602.
Lee, J.M., Ramos, E.M., Lee, J.H., Gillis, T., Mysore, 
J.S., Hayden, M.R., Warby, S.C., Morrison, P., 
Nance, M., Ross, C.A., Margolis, R.L., Squitieri, 
F., Orobello, S., Di Donato, S., Gomez-Tortosa, 
E., Ayuso, C., Suchowersky, O., Trent, R.J., 
McCusker, E., Novelletto, A., Frontali, M., Jones, 
R., Ashizawa, T., Frank, S., Saint-Hilaire, M.H., 
Hersch, S.M., Rosas, H.D., Lucente, D., Harrison, 
M.B., Zanko, A., Abramson, R.K., Marder, K., 
Sequeiros, J., Paulsen, J.S., Group, P.-H.s.o.t.H.S., 
Landwehrmeyer, G.B., Network, R.s.o.t.E.H.s.D., 
Myers, R.H., Group, H.-M.S., MacDonald, M.E., 
Gusella, J.F. & HSG, C.s.o.t. (2012) CAG repeat 
expansion in Huntington disease determines age 
at onset in a fully dominant fashion. Neurology, 
78, 690-695.
Lee, T.T., Hill, M.N. & Lee, F.S. (2016) Developmental 
regulation of fear learning and anxiety behavior 
by endocannabinoids. Genes Brain Behav, 15, 
108-124.
Leung, D., Saghatelian, A., Simon, G.M. & Cravatt, B.F. (2006) 
Inactivation of N-acyl phosphatidylethanolamine 
phospholipase D reveals multiple mechanisms 
for the biosynthesis of endocannabinoids. 
Biochemistry, 45, 4720-4726.
Leung, K., Elmes, M.W., Glaser, S.T., Deutsch, D.G. 
& Kaczocha, M. (2013) Role of FAAH-like 
anandamide transporter in anandamide 
inactivation. PLoS One, 8, e79355.
Ligresti, A., De Petrocellis, L. & Di Marzo, V. (2016) From 
Phytocannabinoids to Cannabinoid Receptors 
and Endocannabinoids: Pleiotropic Physiological 
and Pathological Roles Through Complex 
Pharmacology. Physiol Rev, 96, 1593-1659.
Lippiello, P., Balestrini, S., Leo, A., Coppola, A., Citraro, R., 
Elia, M., Russo, E. & De Sarro, G. (2016) From 
Cannabis to Cannabidiol to Treat Epilepsy, Where 
Are We? Curr Pharm Des, 22, 6426-6433.
Liu, J., Gao, B., Mirshahi, F., Sanyal, A.J., Khanolkar, A.D., 
Makriyannis, A. & Kunos, G. (2000) Functional 
CB1 cannabinoid receptors in human vascular 
endothelial cells. Biochem J, 346 Pt 3, 835-840.
Liu, J., Wang, L., Harvey-White, J., Huang, B.X., Kim, H.Y., 
Luquet, S., Palmiter, R.D., Krystal, G., Rai, R., 
Mahadevan, A., Razdan, R.K. & Kunos, G. (2008) 
Multiple pathways involved in the biosynthesis of 
anandamide. Neuropharmacology, 54, 1-7.
Lopez-Sendon Moreno, J.L., Garcia Caldentey, J., Trigo 
Cubillo, P., Ruiz Romero, C., Garcia Ribas, G., 
Alonso Arias, M.A., Garcia de Yebenes, M.J., 
References
158
Tolon, R.M., Galve-Roperh, I., Sagredo, O., 
Valdeolivas, S., Resel, E., Ortega-Gutierrez, 
S., Garcia-Bermejo, M.L., Fernandez Ruiz, J., 
Guzman, M. & Garcia de Yebenes Prous, J. (2016) 
A double-blind, randomized, cross-over, placebo-
controlled, pilot trial with Sativex in Huntington’s 
disease. J Neurol, 263, 1390-1400.
Lynn, A.B. & Herkenham, M. (1994) Localization of 
cannabinoid receptors and nonsaturable high-
density cannabinoid binding sites in peripheral 
tissues of the rat: implications for receptor-
mediated immune modulation by cannabinoids. 
J Pharmacol Exp Ther, 268, 1612-1623.
Maccarrone, M., Bab, I., Biro, T., Cabral, G.A., Dey, S.K., 
Di Marzo, V., Konje, J.C., Kunos, G., Mechoulam, 
R., Pacher, P., Sharkey, K.A. & Zimmer, A. (2015) 
Endocannabinoid signaling at the periphery: 50 
years after THC. Trends Pharmacol Sci, 36, 277-
296.
Maccarrone, M., Cartoni, A., Parolaro, D., Margonelli, A., 
Massi, P., Bari, M., Battista, N. & Finazzi-Agro, 
A. (2002) Cannabimimetic activity, binding, and 
degradation of stearoylethanolamide within the 
mouse central nervous system. Mol Cell Neurosci, 
21, 126-140.
Mackie, K. (2005) Distribution of cannabinoid receptors 
in the central and peripheral nervous system. 
Handb Exp Pharmacol, 299-325.
Maldonado, R., Banos, J.E. & Cabanero, D. (2016) The 
endocannabinoid system and neuropathic pain. 
Pain, 157 Suppl 1, S23-32.
Manev, H., Favaron, M., Guidotti, A. & Costa, E. (1989) 
Delayed increase of Ca2+ influx elicited 
by glutamate: role in neuronal death. Mol 
Pharmacol, 36, 106-112.
Maroof, N., Pardon, M.C. & Kendall, D.A. (2013) 
Endocannabinoid signalling in Alzheimer’s 
disease. Biochem Soc Trans, 41, 1583-1587.
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. 
& Bonner, T.I. (1990) Structure of a cannabinoid 
receptor and functional expression of the cloned 
cDNA. Nature, 346, 561-564.
May, M.B. & Glode, A.E. (2016) Dronabinol for 
chemotherapy-induced nausea and vomiting 
unresponsive to antiemetics. Cancer Manag Res, 
8, 49-55.
McCaw, E.A., Hu, H., Gomez, G.T., Hebb, A.L., Kelly, M.E. 
& Denovan-Wright, E.M. (2004) Structure, 
expression and regulation of the cannabinoid 
receptor gene (CB1) in Huntington’s disease 
transgenic mice. Eur J Biochem, 271, 4909-4920.
McHugh, D., Page, J., Dunn, E. & Bradshaw, H.B. 
(2012) Delta(9) -Tetrahydrocannabinol and 
N-arachidonyl glycine are full agonists at GPR18 
receptors and induce migration in human 
endometrial HEC-1B cells. Br J Pharmacol, 165, 
2414-2424.
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., 
Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, 
S., Martin, B.R., Compton, D.R. & et al. (1995) 
Identification of an endogenous 2-monoglyceride, 
present in canine gut, that binds to cannabinoid 
receptors. Biochem Pharmacol, 50, 83-90.
Mechoulam, R. & Shvo, Y. (1963) Hashish. I. The structure 
of cannabidiol. Tetrahedron, 19, 2073-2078.
Molina-Holgado, E., Vela, J.M., Arevalo-Martin, A., Almazan, 
G., Molina-Holgado, F., Borrell, J. & Guaza, C. 
(2002) Cannabinoids promote oligodendrocyte 
progenitor survival: involvement of cannabinoid 
receptors and phosphatidylinositol-3 kinase/Akt 
signaling. J Neurosci, 22, 9742-9753.
Montero, C., Campillo, N.E., Goya, P. & Paez, J.A. (2005) 
Homology models of the cannabinoid CB1 and 
CB2 receptors. A docking analysis study. Eur J 
Med Chem, 40, 75-83.
Morales, P., Goya, P., Jagerovic, N. & Hernandez-Folgado, 
L. (2016) Allosteric modulators of the CB1 
cannabinoid receptor: a structural update review. 
Cannabis and Cannabinoid Research, 1, 22-30.
More, S.V. & Choi, D.K. (2015) Promising cannabinoid-
based therapies for Parkinson’s disease: 
motor symptoms to neuroprotection. Mol 
Neurodegener, 10, 17.
Morera-Herreras, T., Miguelez, C., Aristieta, A., Torrecilla, 
M., Ruiz-Ortega, J.A. & Ugedo, L. (2016) 
Cannabinoids and motor control of the basal 
ganglia: therapeutic potential in movement 
disorders. In Meccariello, R., Chianese, R. (eds) 
Cannabinoids in Health and Disease. InTech, pp. 
59-92.
Morreale, M.K. (2015) Huntington’s disease: looking 
beyond the movement disorder. Adv Psychosom 
Med, 34, 135-142.
Muller-Vahl, K.R. (2013) Treatment of Tourette syndrome 
with cannabinoids. Behav Neurol, 27, 119-124.
Muller-Vahl, K.R., Schneider, U. & Emrich, H.M. (1999) 
Nabilone increases choreatic movements in 
Huntington’s disease. Mov Disord, 14, 1038-1040.
Munro, S., Thomas, K.L. & Abu-Shaar, M. (1993) Molecular 
characterization of a peripheral receptor for 
cannabinoids. Nature, 365, 61-65.
Naranjo, J.R., Zhang, H., Villar, D., Gonzalez, P., Dopazo, 
X.M., Moron-Oset, J., Higueras, E., Oliveros, J.C., 
Arrabal, M.D., Prieto, A., Cercos, P., Gonzalez, 
T., De la Cruz, A., Casado-Vela, J., Rabano, A., 
Valenzuela, C., Gutierrez-Rodriguez, M., Li, J.Y. 
References
159
& Mellstrom, B. (2016) Activating transcription 
factor 6 derepression mediates neuroprotection 
in Huntington disease. J Clin Invest, 126, 627-638.
Navarrete, M., Diez, A. & Araque, A. (2014) Astrocytes in 
endocannabinoid signalling. Philos Trans R Soc 
Lond B Biol Sci, 369, 20130599.
Neumeister, A., Seidel, J., Ragen, B.J. & Pietrzak, R.H. 
(2015) Translational evidence for a role 
of endocannabinoids in the etiology and 
treatment of posttraumatic stress disorder. 
Psychoneuroendocrinology, 51, 577-584.
Nunez, E., Benito, C., Pazos, M.R., Barbachano, A., Fajardo, 
O., Gonzalez, S., Tolon, R.M. & Romero, J. (2004) 
Cannabinoid CB2 receptors are expressed by 
perivascular microglial cells in the human brain: 
an immunohistochemical study. Synapse, 53, 
208-213.
O’Sullivan, S.E. (2016) An update on PPAR activation by 
cannabinoids. Br J Pharmacol, 173, 1899-1910.
Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., 
Wright, K., Tam, J., Attar-Namdar, M., Kram, V., 
Shohami, E., Mechoulam, R., Zimmer, A. & Bab, 
I. (2006) Peripheral cannabinoid receptor, CB2, 
regulates bone mass. Proc Natl Acad Sci U S A, 
103, 696-701.
Ostadhadi, S., Rahmatollahi, M., Dehpour, A.R. & Rahimian, 
R. (2015) Therapeutic potential of cannabinoids 
in counteracting chemotherapy-induced adverse 
effects: an exploratory review. Phytother Res, 29, 
332-338.
Ottani, A. & Giuliani, D. (2001) Hu 210: a potent tool for 
investigations of the cannabinoid system. CNS 
Drug Rev, 7, 131-145.
Overton, H.A., Babbs, A.J., Doel, S.M., Fyfe, M.C., 
Gardner, L.S., Griffin, G., Jackson, H.C., Procter, 
M.J., Rasamison, C.M., Tang-Christensen, M., 
Widdowson, P.S., Williams, G.M. & Reynet, C. 
(2006) Deorphanization of a G protein-coupled 
receptor for oleoylethanolamide and its use 
in the discovery of small-molecule hypophagic 
agents. Cell Metab, 3, 167-175.
Pacher, P., Batkai, S. & Kunos, G. (2006) The 
endocannabinoid system as an emerging target 
of pharmacotherapy. Pharmacol Rev, 58, 389-
462.
Pagotto, U., Marsicano, G., Cota, D., Lutz, B. & Pasquali, R. 
(2006) The emerging role of the endocannabinoid 
system in endocrine regulation and energy 
balance. Endocr Rev, 27, 73-100.
Palazuelos, J., Aguado, T., Pazos, M.R., Julien, B., Carrasco, 
C., Resel, E., Sagredo, O., Benito, C., Romero, 
J., Azcoitia, I., Fernandez-Ruiz, J., Guzman, 
M. & Galve-Roperh, I. (2009) Microglial CB2 
cannabinoid receptors are neuroprotective in 
Huntington’s disease excitotoxicity. Brain, 132, 
3152-3164.
Patti, F., Messina, S., Solaro, C., Amato, M.P., Bergamaschi, 
R., Bonavita, S., Bruno Bossio, R., Brescia Morra, 
V., Costantino, G.F., Cavalla, P., Centonze, D., 
Comi, G., Cottone, S., Danni, M., Francia, A., 
Gajofatto, A., Gasperini, C., Ghezzi, A., Iudice, A., 
Lus, G., Maniscalco, G.T., Marrosu, M.G., Matta, 
M., Mirabella, M., Montanari, E., Pozzilli, C., 
Rovaris, M., Sessa, E., Spitaleri, D., Trojano, M., 
Valentino, P., Zappia, M. & group, S.F.s. (2016) 
Efficacy and safety of cannabinoid oromucosal 
spray for multiple sclerosis spasticity. J Neurol 
Neurosurg Psychiatry, 87, 944-951.
Peavy, G.M., Jacobson, M.W., Goldstein, J.L., Hamilton, 
J.M., Kane, A., Gamst, A.C., Lessig, S.L., Lee, J.C. & 
Corey-Bloom, J. (2010) Cognitive and functional 
decline in Huntington’s disease: dementia criteria 
revisited. Mov Disord, 25, 1163-1169.
Pertwee, R.G. (2010) Receptors and channels targeted 
by synthetic cannabinoid receptor agonists and 
antagonists. Curr Med Chem, 17, 1360-1381.
Pidgeon, C. & Rickards, H. (2013) The pathophysiology 
and pharmacological treatment of Huntington 
disease. Behav Neurol, 26, 245-253.
Pinna, A., Bonaventura, J., Farre, D., Sanchez, M., Simola, 
N., Mallol, J., Lluis, C., Costa, G., Baqi, Y., Muller, 
C.E., Cortes, A., McCormick, P., Canela, E.I., 
Martinez-Pinilla, E., Lanciego, J.L., Casado, V., 
Armentero, M.T. & Franco, R. (2014) L-DOPA 
disrupts adenosine A(2A)-cannabinoid CB(1)-
dopamine D(2) receptor heteromer cross-
talk in the striatum of hemiparkinsonian rats: 
biochemical and behavioral studies. Exp Neurol, 
253, 180-191.
Pintor, A., Tebano, M.T., Martire, A., Grieco, R., Galluzzo, 
M., Scattoni, M.L., Pezzola, A., Coccurello, R., 
Felici, F., Cuomo, V., Piomelli, D., Calamandrei, 
G. & Popoli, P. (2006) The cannabinoid receptor 
agonist WIN 55,212-2 attenuates the effects 
induced by quinolinic acid in the rat striatum. 
Neuropharmacology, 51, 1004-1012.
Piomelli, D. (2003) The molecular logic of endocannabinoid 
signalling. Nat Rev Neurosci, 4, 873-884.
Pisanti, S., Malfitano, A.M., Ciaglia, E., Lamberti, A., Ranieri, 
R., Cuomo, G., Abate, M., Faggiana, G., Proto, 
M.C., Fiore, D., Laezza, C. & Bifulco, M. (2017) 
Cannabidiol: State of the art and new challenges 
for therapeutic applications. Pharmacol Ther.
Prospero-Garcia, O., Amancio-Belmont, O., Becerril 
Melendez, A.L., Ruiz-Contreras, A.E. & Mendez-
Diaz, M. (2016) Endocannabinoids and sleep. 
Neurosci Biobehav Rev, 71, 671-679.
References
160
Pryce, G. & Baker, D. (2012) Potential control of multiple 
sclerosis by cannabis and the endocannabinoid 
system. CNS Neurol Disord Drug Targets, 11, 624-
641.
Pryce, G. & Baker, D. (2015) Endocannabinoids in Multiple 
Sclerosis and Amyotrophic Lateral Sclerosis. 
Handb Exp Pharmacol, 231, 213-231.
Rajan, T.S., Giacoppo, S., Iori, R., De Nicola, G.R., Grassi, 
G., Pollastro, F., Bramanti, P. & Mazzon, E. (2016) 
Anti-inflammatory and antioxidant effects of a 
combination of cannabidiol and moringin in LPS-
stimulated macrophages. Fitoterapia, 112, 104-
115.
Ransohoff, R.M. & Perry, V.H. (2009) Microglial physiology: 
unique stimuli, specialized responses. Annu Rev 
Immunol, 27, 119-145.
Rawls, S.M. & Benamar, K. (2011) Effects of opioids, 
cannabinoids, and vanilloids on body 
temperature. Front Biosci (Schol Ed), 3, 822-845.
Reiner, A., Albin, R.L., Anderson, K.D., D’Amato, C.J., 
Penney, J.B. & Young, A.B. (1988) Differential 
loss of striatal projection neurons in Huntington 
disease. Proc Natl Acad Sci U S A, 85, 5733-5737.
Reiner, A., Dragatsis, I., Zeitlin, S. & Goldowitz, D. 
(2003) Wild-type huntingtin plays a role in 
brain development and neuronal survival. Mol 
Neurobiol, 28, 259-276.
Rigamonti, D., Bauer, J.H., De-Fraja, C., Conti, L., Sipione, 
S., Sciorati, C., Clementi, E., Hackam, A., Hayden, 
M.R., Li, Y., Cooper, J.K., Ross, C.A., Govoni, S., 
Vincenz, C. & Cattaneo, E. (2000) Wild-type 
huntingtin protects from apoptosis upstream of 
caspase-3. J Neurosci, 20, 3705-3713.
Rinaldi-Carmona, M., Barth, F., Congy, C., Martinez, S., 
Oustric, D., Perio, A., Poncelet, M., Maruani, J., 
Arnone, M., Finance, O., Soubrie, P. & Le Fur, G. 
(2004) SR147778 [5-(4-bromophenyl)-1-(2,4-
dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-
pyrazole-3 -carboxamide], a new potent and 
selective antagonist of the CB1 cannabinoid 
receptor: biochemical and pharmacological 
characterization. J Pharmacol Exp Ther, 310, 905-
914.
Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., 
Calandra, B., Congy, C., Martinez, S., Maruani, J., 
Neliat, G., Caput, D. & et al. (1994) SR141716A, 
a potent and selective antagonist of the brain 
cannabinoid receptor. FEBS Lett, 350, 240-244.
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.M., 
Casellas, P., Congy, C., Oustric, D., Sarran, M., 
Bouaboula, M., Calandra, B., Portier, M., Shire, 
D., Breliere, J.C. & Le Fur, G.L. (1998) SR 144528, 
the first potent and selective antagonist of the 
CB2 cannabinoid receptor. J Pharmacol Exp Ther, 
284, 644-650.
Rock, E.M. & Parker, L.A. (2016) Cannabinoids As Potential 
Treatment for Chemotherapy-Induced Nausea 
and Vomiting. Front Pharmacol, 7, 221.
Rocha, N.P., Ribeiro, F.M., Furr-Stimming, E. & Teixeira, 
A.L. (2016) Neuroimmunology of Huntington’s 
Disease: Revisiting Evidence from Human Studies. 
Mediators Inflamm, 2016, 8653132.
Rodriguez-Cueto, C., Benito, C., Fernandez-Ruiz, J., 
Romero, J., Hernandez-Galvez, M. & Gomez-Ruiz, 
M. (2014) Changes in CB(1) and CB(2) receptors in 
the post-mortem cerebellum of humans affected 
by spinocerebellar ataxias. Br J Pharmacol, 171, 
1472-1489.
Romero-Sandoval, E.A., Asbill, S., Paige, C.A. & Byrd-Glover, 
K. (2015) Peripherally Restricted Cannabinoids 
for the Treatment of Pain. Pharmacotherapy, 35, 
917-925.
Rosenberg, E.C., Patra, P.H. & Whalley, B.J. (2017) 
Therapeutic effects of cannabinoids in animal 
models of seizures, epilepsy, epileptogenesis, 
and epilepsy-related neuroprotection. Epilepsy 
Behav.
Ross, C.A., Aylward, E.H., Wild, E.J., Langbehn, D.R., Long, 
J.D., Warner, J.H., Scahill, R.I., Leavitt, B.R., Stout, 
J.C., Paulsen, J.S., Reilmann, R., Unschuld, P.G., 
Wexler, A., Margolis, R.L. & Tabrizi, S.J. (2014) 
Huntington disease: natural history, biomarkers 
and prospects for therapeutics. Nat Rev Neurol, 
10, 204-216.
Ross, H.R., Napier, I. & Connor, M. (2008) Inhibition of 
recombinant human T-type calcium channels by 
Delta9-tetrahydrocannabinol and cannabidiol. J 
Biol Chem, 283, 16124-16134.
Rubino, T., Zamberletti, E. & Parolaro, D. (2015) 
Endocannabinoids and Mental Disorders. Handb 
Exp Pharmacol, 231, 261-283.
Rueda, D., Galve-Roperh, I., Haro, A. & Guzman, M. (2000) 
The CB(1) cannabinoid receptor is coupled to 
the activation of c-Jun N-terminal kinase. Mol 
Pharmacol, 58, 814-820.
Russo, M., Naro, A., Leo, A., Sessa, E., D’Aleo, G., Bramanti, 
P. & Calabro, R.S. (2016) Evaluating Sativex(R) 
in Neuropathic Pain Management: A Clinical 
and Neurophysiological Assessment in Multiple 
Sclerosis. Pain Med, 17, 1145-1154.
Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, 
N.O., Leonova, J., Elebring, T., Nilsson, K., Drmota, 
T. & Greasley, P.J. (2007) The orphan receptor 
GPR55 is a novel cannabinoid receptor. Br J 
Pharmacol, 152, 1092-1101.
Sagredo, O., Gonzalez, S., Aroyo, I., Pazos, M.R., Benito, 
C., Lastres-Becker, I., Romero, J.P., Tolon, R.M., 
References
161
Mechoulam, R., Brouillet, E., Romero, J. & 
Fernandez-Ruiz, J. (2009) Cannabinoid CB2 
receptor agonists protect the striatum against 
malonate toxicity: relevance for Huntington’s 
disease. Glia, 57, 1154-1167.
Sagredo, O., Pazos, M.R., Satta, V., Ramos, J.A., Pertwee, 
R.G. & Fernandez-Ruiz, J. (2011) Neuroprotective 
effects of phytocannabinoid-based medicines in 
experimental models of Huntington’s disease. J 
Neurosci Res, 89, 1509-1518.
Sagredo, O., Pazos, M.R., Valdeolivas, S. & Fernandez-Ruiz, 
J. (2012) Cannabinoids: novel medicines for the 
treatment of Huntington’s disease. Recent Pat 
CNS Drug Discov, 7, 41-48.
Sang, N., Zhang, J. & Chen, C. (2007) COX-2 oxidative 
metabolite of endocannabinoid 2-AG enhances 
excitatory glutamatergic synaptic transmission 
and induces neurotoxicity. J Neurochem, 102, 
1966-1977.
Savinainen, J.R., Saario, S.M. & Laitinen, J.T. (2012) The 
serine hydrolases MAGL, ABHD6 and ABHD12 
as guardians of 2-arachidonoylglycerol signalling 
through cannabinoid receptors. Acta Physiol 
(Oxf), 204, 267-276.
Schatz, A.R., Lee, M., Condie, R.B., Pulaski, J.T. & Kaminski, 
N.E. (1997) Cannabinoid receptors CB1 and CB2: 
a characterization of expression and adenylate 
cyclase modulation within the immune system. 
Toxicol Appl Pharmacol, 142, 278-287.
Schwarcz, R., Guidetti, P., Sathyasaikumar, K.V. & 
Muchowski, P.J. (2010) Of mice, rats and men: 
Revisiting the quinolinic acid hypothesis of 
Huntington’s disease. Prog Neurobiol, 90, 230-
245.
Shannon, K.M. (2016) Pridopidine for the treatment of 
Huntington’s disease. Expert Opin Investig Drugs, 
25, 485-492.
Shmist, Y.A., Goncharov, I., Eichler, M., Shneyvays, V., 
Isaac, A., Vogel, Z. & Shainberg, A. (2006) Delta-9-
tetrahydrocannabinol protects cardiac cells from 
hypoxia via CB2 receptor activation and nitric 
oxide production. Mol Cell Biochem, 283, 75-83.
Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M. & 
Mechoulam, R. (2011) Endocannabinoids and 
traumatic brain injury. Br J Pharmacol, 163, 1402-
1410.
Smith, R., Brundin, P. & Li, J.Y. (2005) Synaptic dysfunction 
in Huntington’s disease: a new perspective. Cell 
Mol Life Sci, 62, 1901-1912.
Southwell, A.L., Franciosi, S., Villanueva, E.B., Xie, Y., Winter, 
L.A., Veeraraghavan, J., Jonason, A., Felczak, B., 
Zhang, W., Kovalik, V., Waltl, S., Hall, G., Pouladi, 
M.A., Smith, E.S., Bowers, W.J., Zauderer, M. 
& Hayden, M.R. (2015) Anti-semaphorin 4D 
immunotherapy ameliorates neuropathology 
and some cognitive impairment in the YAC128 
mouse model of Huntington disease. Neurobiol 
Dis, 76, 46-56.
Stefano, G.B., Bilfinger, T.V., Rialas, C.M. & Deutsch, 
D.G. (2000) 2-arachidonyl-glycerol stimulates 
nitric oxide release from human immune and 
vascular tissues and invertebrate immunocytes 
by cannabinoid receptor 1. Pharmacol Res, 42, 
317-322.
Stempel, A.V., Stumpf, A., Zhang, H.Y., Ozdogan, T., 
Pannasch, U., Theis, A.K., Otte, D.M., Wojtalla, A., 
Racz, I., Ponomarenko, A., Xi, Z.X., Zimmer, A. & 
Schmitz, D. (2016) Cannabinoid Type 2 Receptors 
Mediate a Cell Type-Specific Plasticity in the 
Hippocampus. Neuron, 90, 795-809.
Strong, T.V., Tagle, D.A., Valdes, J.M., Elmer, L.W., Boehm, 
K., Swaroop, M., Kaatz, K.W., Collins, F.S. & Albin, 
R.L. (1993) Widespread expression of the human 
and rat Huntington’s disease gene in brain and 
nonneural tissues. Nat Genet, 5, 259-265.
Sun, Y. & Bennett, A. (2007) Cannabinoids: a new group of 
agonists of PPARs. PPAR Res, 2007, 23513.
Sussmuth, S.D., Haider, S., Landwehrmeyer, G.B., Farmer, 
R., Frost, C., Tripepi, G., Andersen, C.A., Di 
Bacco, M., Lamanna, C., Diodato, E., Massai, L., 
Diamanti, D., Mori, E., Magnoni, L., Dreyhaupt, 
J., Schiefele, K., Craufurd, D., Saft, C., Rudzinska, 
M., Ryglewicz, D., Orth, M., Brzozy, S., Baran, 
A., Pollio, G., Andre, R., Tabrizi, S.J., Darpo, B., 
Westerberg, G. & Consortium, P. (2015) An 
exploratory double-blind, randomized clinical 
trial with selisistat, a SirT1 inhibitor, in patients 
with Huntington’s disease. Br J Clin Pharmacol, 
79, 465-476.
THDCRG (1993)  A novel gene containing a trinucleotide 
repeat that is expanded and unstable on 
Huntington’s disease chromosomes. The 
Huntington’s Disease Collaborative Research 
Group. Cell, 72, 971-983.
Thompson, J.C., Harris, J., Sollom, A.C., Stopford, C.L., 
Howard, E., Snowden, J.S. & Craufurd, D. (2012) 
Longitudinal evaluation of neuropsychiatric 
symptoms in Huntington’s disease. J 
Neuropsychiatry Clin Neurosci, 24, 53-60.
Topol, E.J., Bousser, M.G., Fox, K.A., Creager, M.A., Despres, 
J.P., Easton, J.D., Hamm, C.W., Montalescot, G., 
Steg, P.G., Pearson, T.A., Cohen, E., Gaudin, C., 
Job, B., Murphy, J.H., Bhatt, D.L. & Investigators, 
C. (2010) Rimonabant for prevention of 
cardiovascular events (CRESCENDO): a 
randomised, multicentre, placebo-controlled 
trial. Lancet, 376, 517-523.
Toth, A., Blumberg, P.M. & Boczan, J. (2009) Anandamide 
References
162
and the vanilloid receptor (TRPV1). Vitam Horm, 
81, 389-419.
Tsang, C.C. & Giudice, M.G. (2016) Nabilone for the 
Management of Pain. Pharmacotherapy, 36, 273-
286.
Turu, G. & Hunyady, L. (2010) Signal transduction of the 
CB1 cannabinoid receptor. J Mol Endocrinol, 44, 
75-85.
Valdeolivas, S., Satta, V., Pertwee, R.G., Fernandez-Ruiz, 
J. & Sagredo, O. (2012) Sativex-like combination 
of phytocannabinoids is neuroprotective in 
malonate-lesioned rats, an inflammatory model 
of Huntington’s disease: role of CB1 and CB2 
receptors. ACS Chem Neurosci, 3, 400-406.
Valdeolivas, S., Pazos, M.R., Bisogno, T., Piscitelli, F., 
Iannotti, F.A., Allara, M., Sagredo, O., Di Marzo, 
V. & Fernandez-Ruiz, J. (2013) The inhibition of 
2-arachidonoyl-glycerol (2-AG) biosynthesis, 
rather than enhancing striatal damage, protects 
striatal neurons from malonate-induced death: 
a potential role of cyclooxygenase-2-dependent 
metabolism of 2-AG. Cell Death Dis, 4, e862.
Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M.L., 
Munoz, E. & Sagredo, O. (2015) Neuroprotective 
properties of cannabigerol in Huntington’s disease: 
studies in R6/2 mice and 3-nitropropionate-
lesioned mice. Neurotherapeutics, 12, 185-199.
Valdeolivas, S., Sagredo, O., Delgado, M., Pozo, M.A. & 
Fernandez-Ruiz, J. (2017) Effects of a Sativex-Like 
Combination of Phytocannabinoids on Disease 
Progression in R6/2 Mice, an Experimental Model 
of Huntington’s Disease. Int J Mol Sci, 18.
van Dellen, A., Grote, H.E. & Hannan, A.J. (2005) Gene-
environment interactions, neuronal dysfunction 
and pathological plasticity in Huntington’s 
disease. Clin Exp Pharmacol Physiol, 32, 1007-
1019.
van der Burg, J.M., Bjorkqvist, M. & Brundin, P. (2009) 
Beyond the brain: widespread pathology in 
Huntington’s disease. Lancet Neurol, 8, 765-774.
Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., 
Urbani, P., Mackie, K., Stella, N., Makriyannis, A., 
Piomelli, D., Davison, J.S., Marnett, L.J., Di Marzo, 
V., Pittman, Q.J., Patel, K.D. & Sharkey, K.A. (2005) 
Identification and functional characterization of 
brainstem cannabinoid CB2 receptors. Science, 
310, 329-332.
Vinals, X., Moreno, E., Lanfumey, L., Cordomi, A., Pastor, 
A., de La Torre, R., Gasperini, P., Navarro, G., 
Howell, L.A., Pardo, L., Lluis, C., Canela, E.I., 
McCormick, P.J., Maldonado, R. & Robledo, 
P. (2015) Cognitive Impairment Induced by 
Delta9-tetrahydrocannabinol Occurs through 
Heteromers between Cannabinoid CB1 and 
Serotonin 5-HT2A Receptors. PLoS Biol, 13, 
e1002194.
Vonsattel, J.P., Keller, C. & Del Pilar Amaya, M. (2008) 
Neuropathology of Huntington’s disease. Handb 
Clin Neurol, 89, 599-618.
Wager-Miller, J., Westenbroek, R. & Mackie, K. (2002) 
Dimerization of G protein-coupled receptors: CB1 
cannabinoid receptors as an example. Chem Phys 
Lipids, 121, 83-89.
Waldvogel, H.J., Kim, E.H., Tippett, L.J., Vonsattel, J.P. 
& Faull, R.L. (2015) The Neuropathology of 
Huntington’s Disease. Curr Top Behav Neurosci, 
22, 33-80.
Ware, M.A., Daeninck, P. & Maida, V. (2008) A review of 
nabilone in the treatment of chemotherapy-
induced nausea and vomiting. Ther Clin Risk 
Manag, 4, 99-107.
Wilson, J.M., Ogden, A.M., Loomis, S., Gilmour, G., Baucum, 
A.J., 2nd, Belecky-Adams, T.L. & Merchant, K.M. 
(2015) Phosphodiesterase 10A inhibitor, MP-
10 (PF-2545920), produces greater induction of 
c-Fos in dopamine D2 neurons than in D1 neurons 
in the neostriatum. Neuropharmacology, 99, 
379-386.
Woodward, D.F., Carling, R.W., Cornell, C.L., Fliri, H.G., 
Martos, J.L., Pettit, S.N., Liang, Y. & Wang, J.W. 
(2008) The pharmacology and therapeutic 
relevance of endocannabinoid derived cyclo-
oxygenase (COX)-2 products. Pharmacol Ther, 
120, 71-80.
Wright, K.L., Duncan, M. & Sharkey, K.A. (2008) Cannabinoid 
CB2 receptors in the gastrointestinal tract: a 
regulatory system in states of inflammation. Br J 
Pharmacol, 153, 263-270.
Xiong, W., Hosoi, M., Koo, B.N. & Zhang, L. (2008) 
Anandamide inhibition of 5-HT3A receptors 
varies with receptor density and desensitization. 
Mol Pharmacol, 73, 314-322.
Zeron, M.M., Chen, N., Moshaver, A., Lee, A.T., Wellington, 
C.L., Hayden, M.R. & Raymond, L.A. (2001) 
Mutant huntingtin enhances excitotoxic cell 
death. Mol Cell Neurosci, 17, 41-53.
Zeron, M.M., Hansson, O., Chen, N., Wellington, C.L., 
Leavitt, B.R., Brundin, P., Hayden, M.R. & 
Raymond, L.A. (2002) Increased sensitivity 
to N-methyl-D-aspartate receptor-mediated 
excitotoxicity in a mouse model of Huntington’s 
disease. Neuron, 33, 849-860.
Zoratti, C., Kipmen-Korgun, D., Osibow, K., Malli, R. & Graier, 
W.F. (2003) Anandamide initiates Ca(2+) signaling 
via CB2 receptor linked to phospholipase C in calf 
pulmonary endothelial cells. Br J Pharmacol, 140, 
1351-1362.
References
163
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, 
M., Conti, L., Cataudella, T., Leavitt, B.R., Hayden, 
M.R., Timmusk, T., Rigamonti, D. & Cattaneo, E. 
(2003) Huntingtin interacts with REST/NRSF to 
modulate the transcription of NRSE-controlled 
neuronal genes. Nat Genet, 35, 76-83.
Zuccato, C., Valenza, M. & Cattaneo, E. (2010) Molecular 
mechanisms and potential therapeutical targets 
in Huntington’s disease. Physiol Rev, 90, 905-981.
Zygmunt, P.M., Ermund, A., Movahed, P., Andersson, D.A., 
Simonsen, C., Jonsson, B.A., Blomgren, A., Birnir, 
B., Bevan, S., Eschalier, A., Mallet, C., Gomis, 
A. & Hogestatt, E.D. (2013) Monoacylglycerols 
activate TRPV1--a link between phospholipase C 
and TRPV1. PLoS One, 8, e81618.
164


